{"nodes": [{"key": "0", "attributes": {"color": "#FA7371", "label": "Global mapping of randomised trials related articles published in high-impact-factor medical journals: a cross-sectional analysis", "size": null, "x": -108.73834228515625, "y": -76.59327697753906}}, {"key": "1", "attributes": {"color": "#FA7371", "label": "The Lancet Handbook of essential concepts in clinical research", "size": null, "x": -108.23979949951172, "y": -78.93961334228516}}, {"key": "2", "attributes": {"color": "#FA7371", "label": "Getting the methods right--the foundation of patient-centered outcomes research", "size": null, "x": -107.02237701416016, "y": -76.37246704101562}}, {"key": "3", "attributes": {"color": "#FA7371", "label": "Randomised controlled trials: a user's guide. London: BMJ Books", "size": null, "x": -109.78813171386719, "y": -77.67677307128906}}, {"key": "4", "attributes": {"color": "#FA7371", "label": "Improving the quality of reporting of randomized controlled trials. The CONSORT statement", "size": null, "x": -110.49620819091797, "y": -77.12555694580078}}, {"key": "5", "attributes": {"color": "#FA7371", "label": "Bibliometric analysis of the literature of randomized controlled trials", "size": null, "x": -107.27767181396484, "y": -76.94145965576172}}, {"key": "6", "attributes": {"color": "#FA7371", "label": "Why do we need some large, simple randomized trials", "size": null, "x": -109.47235870361328, "y": -78.27178192138672}}, {"key": "7", "attributes": {"color": "#FA7371", "label": "Development, and Translation, Board on Health Sciences Policy, Institute of Medicine. Large simple trials and knowledge generation in a learning health system: workshop summary", "size": null, "x": -106.32196807861328, "y": -76.68402862548828}}, {"key": "8", "attributes": {"color": "#FA7371", "label": "Evidence based medicine: what it is and what it isn't", "size": null, "x": -108.83792114257812, "y": -75.82538604736328}}, {"key": "9", "attributes": {"color": "#FA7371", "label": "Trial reporting in ClinicalTrials.gov -the final rule", "size": null, "x": -107.93448638916016, "y": -75.24658203125}}, {"key": "10", "attributes": {"color": "#FA7371", "label": "Trial registration at ClinicalTrials.gov between", "size": null, "x": -106.9317855834961, "y": -78.34965515136719}}, {"key": "11", "attributes": {"color": "#FA7371", "label": "Sharing clinical trial data: a proposal from the International Committee of Medical Journal Editors", "size": null, "x": -109.0017318725586, "y": -78.33151245117188}}, {"key": "12", "attributes": {"color": "#FA7371", "label": "Data sharing and reanalysis of randomized controlled trials in leading biomedical journals with a full data sharing policy: survey of studies published in The BMJ and PLOS Medicine", "size": null, "x": -108.74995422363281, "y": -77.39566040039062}}, {"key": "13", "attributes": {"color": "#FA7371", "label": "The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials", "size": null, "x": -106.8694076538086, "y": -76.77735137939453}}, {"key": "14", "attributes": {"color": "#FA7371", "label": "CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials", "size": null, "x": -110.35858154296875, "y": -75.57077026367188}}, {"key": "15", "attributes": {"color": "#FA7371", "label": "SPIRIT 2013 statement: defining standard protocol items for clinical trials", "size": null, "x": -107.2977294921875, "y": -77.43501281738281}}, {"key": "16", "attributes": {"color": "#FA7371", "label": "Are citations from clinical trials evidence of higher impact research? An analysis of ClinicalTrials", "size": null, "x": -109.58086395263672, "y": -76.5716323852539}}, {"key": "17", "attributes": {"color": "#FA7371", "label": "Measuring the impact of methodological research: a framework and methods to identify evidence of impact", "size": null, "x": -107.76783752441406, "y": -75.65345764160156}}, {"key": "18", "attributes": {"color": "#FA7371", "label": "Reporting quality of randomised controlled trial abstracts among highimpact general medical journals: a review and analysis", "size": null, "x": -109.62689971923828, "y": -75.3868408203125}}, {"key": "19", "attributes": {"color": "#FA7371", "label": "Assessment of adherence to the CONSORT statement for quality of reports on randomized controlled trial abstracts from four high-impact general medical journals", "size": null, "x": -109.31803894042969, "y": -76.38819885253906}}, {"key": "20", "attributes": {"color": "#FA7371", "label": "Reporting of sample size calculation in randomised controlled trials: review", "size": null, "x": -108.274658203125, "y": -78.66377258300781}}, {"key": "21", "attributes": {"color": "#FA7371", "label": "Reporting and interpretation of SF-36 outcomes in randomised trials: systematic review", "size": null, "x": -107.54048919677734, "y": -75.06737518310547}}, {"key": "22", "attributes": {"color": "#FA7371", "label": "Reporting of safety results in published reports of randomized controlled trials", "size": null, "x": -109.384765625, "y": -75.86680603027344}}, {"key": "23", "attributes": {"color": "#FA7371", "label": "Randomized trials are frequently fragmented in multiple secondary publications", "size": null, "x": -107.9925537109375, "y": -75.4620361328125}}, {"key": "24", "attributes": {"color": "#FA7371", "label": "Public availability of published research data in high-impact journals", "size": null, "x": -109.04768371582031, "y": -76.12809753417969}}, {"key": "25", "attributes": {"color": "#FA7371", "label": "Comparison of registered and published primary outcomes in randomized controlled trials", "size": null, "x": -106.84020233154297, "y": -77.45556640625}}, {"key": "26", "attributes": {"color": "#FA7371", "label": "Falsified papers in high-impact journals were slow to retract and indistinguishable from nonfraudulent papers", "size": null, "x": -108.86288452148438, "y": -75.08145904541016}}, {"key": "27", "attributes": {"color": "#FA7371", "label": "Magnitude of effects in clinical trials published in high-impact general medical journals", "size": null, "x": -106.50780487060547, "y": -76.05906677246094}}, {"key": "28", "attributes": {"color": "#FA7371", "label": "Contradicted and initially stronger effects in highly cited clinical research", "size": null, "x": -107.18046569824219, "y": -76.52647399902344}}, {"key": "29", "attributes": {"color": "#FA7371", "label": "Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey", "size": null, "x": -110.40869903564453, "y": -75.96431732177734}}, {"key": "30", "attributes": {"color": "#FA7371", "label": "Measuring research: what everyone needs to knowÂ®", "size": null, "x": -108.47699737548828, "y": -75.3055419921875}}, {"key": "31", "attributes": {"color": "#FA7371", "label": "Global collaborative networks on meta-analyses of randomized trials published in high impact factor medical journals: a social network analysis", "size": null, "x": -108.41761016845703, "y": -76.02220153808594}}, {"key": "32", "attributes": {"color": "#FA7371", "label": "Visual insights: a practical guide to making sense of data", "size": null, "x": -109.60149383544922, "y": -74.78227233886719}}, {"key": "33", "attributes": {"color": "#FA7371", "label": "Pajek 1.28. Program for large network analysis", "size": null, "x": -108.23372650146484, "y": -77.59028625488281}}, {"key": "34", "attributes": {"color": "#FA7371", "label": "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement", "size": null, "x": -107.8263931274414, "y": -76.48333740234375}}, {"key": "35", "attributes": {"color": "#FA7371", "label": "Statistical methods for assessing agreement between two methods of clinical measurement", "size": null, "x": -108.0919189453125, "y": -75.0562515258789}}, {"key": "36", "attributes": {"color": "#FA7371", "label": "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus", "size": null, "x": -107.48278045654297, "y": -75.96945190429688}}, {"key": "37", "attributes": {"color": "#FA7371", "label": "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)", "size": null, "x": -107.62926483154297, "y": -75.83139038085938}}, {"key": "38", "attributes": {"color": "#FA7371", "label": "Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin", "size": null, "x": -107.0332260131836, "y": -78.00275421142578}}, {"key": "39", "attributes": {"color": "#FA7371", "label": "Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance", "size": null, "x": -107.9721908569336, "y": -76.1236343383789}}, {"key": "40", "attributes": {"color": "#FA7371", "label": "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)", "size": null, "x": -107.76707458496094, "y": -74.81729125976562}}, {"key": "41", "attributes": {"color": "#FA7371", "label": "Action to Control Cardiovascular Risk in Diabetes Study Group", "size": null, "x": -107.92514038085938, "y": -76.53829193115234}}, {"key": "42", "attributes": {"color": "#FA7371", "label": "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial", "size": null, "x": -108.18406677246094, "y": -77.92188262939453}}, {"key": "43", "attributes": {"color": "#FA7371", "label": "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group", "size": null, "x": -108.71292114257812, "y": -74.58747863769531}}, {"key": "44", "attributes": {"color": "#FA7371", "label": "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma", "size": null, "x": -107.37537384033203, "y": -76.40472412109375}}, {"key": "45", "attributes": {"color": "#FA7371", "label": "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer", "size": null, "x": -106.41040802001953, "y": -77.11016845703125}}, {"key": "46", "attributes": {"color": "#FA7371", "label": "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2", "size": null, "x": -109.36915588378906, "y": -76.6488265991211}}, {"key": "47", "attributes": {"color": "#FA7371", "label": "Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study", "size": null, "x": -110.23178100585938, "y": -74.89453887939453}}, {"key": "48", "attributes": {"color": "#FA7371", "label": "Improved survival with ipilimumab in patients with metastatic melanoma", "size": null, "x": -108.84339141845703, "y": -75.96752166748047}}, {"key": "49", "attributes": {"color": "#FA7371", "label": "Improved survival with vemurafenib in melanoma with BRAF V600E mutation", "size": null, "x": -109.21930694580078, "y": -78.6970443725586}}, {"key": "50", "attributes": {"color": "#FA7371", "label": "Sorafenib in advanced hepatocellular carcinoma", "size": null, "x": -109.183837890625, "y": -74.7077865600586}}, {"key": "51", "attributes": {"color": "#FA7371", "label": "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)", "size": null, "x": -111.1982192993164, "y": -77.55049896240234}}, {"key": "52", "attributes": {"color": "#FA7371", "label": "Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia", "size": null, "x": -110.49158477783203, "y": -76.38848114013672}}, {"key": "53", "attributes": {"color": "#FA7371", "label": "The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators", "size": null, "x": -109.25389099121094, "y": -75.33663940429688}}, {"key": "54", "attributes": {"color": "#FA7371", "label": "Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: a randomised placebo-controlled trial", "size": null, "x": -108.5004653930664, "y": -78.13107299804688}}, {"key": "55", "attributes": {"color": "#FA7371", "label": "Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients", "size": null, "x": -108.09070587158203, "y": -74.72352600097656}}, {"key": "56", "attributes": {"color": "#FA7371", "label": "The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators", "size": null, "x": -109.93316650390625, "y": -77.742919921875}}, {"key": "57", "attributes": {"color": "#FA7371", "label": "Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial", "size": null, "x": -107.67032623291016, "y": -78.05694580078125}}, {"key": "58", "attributes": {"color": "#FA7371", "label": "Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy", "size": null, "x": -107.31804656982422, "y": -75.55254364013672}}, {"key": "59", "attributes": {"color": "#FA7371", "label": "The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group", "size": null, "x": -107.01995086669922, "y": -76.88972473144531}}, {"key": "60", "attributes": {"color": "#FA7371", "label": "National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke", "size": null, "x": -110.26454162597656, "y": -77.46688842773438}}, {"key": "61", "attributes": {"color": "#FA7371", "label": "Dabigatran versus warfarin in patients with atrial fibrillation", "size": null, "x": -108.29986572265625, "y": -76.31282043457031}}, {"key": "62", "attributes": {"color": "#FA7371", "label": "Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation", "size": null, "x": -110.42928314208984, "y": -75.30589294433594}}, {"key": "63", "attributes": {"color": "#FA7371", "label": "A randomised. blinded. trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)", "size": null, "x": -108.59151458740234, "y": -78.46566009521484}}, {"key": "64", "attributes": {"color": "#FA7371", "label": "Mapping of available health research and development data: what's there, what's missing, and what role is there for a global observatory?", "size": null, "x": -108.99609375, "y": -76.94831085205078}}, {"key": "65", "attributes": {"color": "#FA7371", "label": "The anatomy of medical research: US and international comparisons", "size": null, "x": -109.2921142578125, "y": -77.68543243408203}}, {"key": "66", "attributes": {"color": "#FA7371", "label": "Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom", "size": null, "x": -109.0260009765625, "y": -75.45152282714844}}, {"key": "67", "attributes": {"color": "#FA7371", "label": "Ethical issues in the design and conduct of clinical trials in developing countries", "size": null, "x": -106.82421875, "y": -75.644775390625}}, {"key": "68", "attributes": {"color": "#FA7371", "label": "Randomised trials in developing countries", "size": null, "x": -109.2174301147461, "y": -75.00390625}}, {"key": "69", "attributes": {"color": "#FA7371", "label": "When will clinical trials finally reflect diversity?", "size": null, "x": -108.76629638671875, "y": -77.0497817993164}}, {"key": "70", "attributes": {"color": "#FA7371", "label": "Under-representation of developing countries in the research literature: ethical issues arising from a survey of five leading medical journals", "size": null, "x": -108.9403305053711, "y": -74.7333984375}}, {"key": "71", "attributes": {"color": "#FA7371", "label": "Citation classics in systematic reviews and meta-analyses: who wrote the top 100 most cited articles?", "size": null, "x": -109.4682388305664, "y": -77.95628356933594}}, {"key": "72", "attributes": {"color": "#FA7371", "label": "A mapping of 115,000 randomized trials revealed a mismatch between research effort and health needs in non-high-income regions", "size": null, "x": -108.79817199707031, "y": -77.93563842773438}}, {"key": "73", "attributes": {"color": "#FA7371", "label": "Association between randomised trial evidence and global burden of disease: cross sectional study (Epidemiological Study of Randomized Trials--ESORT)", "size": null, "x": -108.07506561279297, "y": -78.01115417480469}}, {"key": "74", "attributes": {"color": "#FA7371", "label": "Does the development of new medicinal products in the European Union address global and regional health concerns?", "size": null, "x": -106.3115234375, "y": -78.11042022705078}}, {"key": "75", "attributes": {"color": "#FA7371", "label": "Relation between burden of disease and randomised evidence in sub-Saharan Africa: survey ofresearch", "size": null, "x": -107.4228744506836, "y": -77.70551300048828}}, {"key": "76", "attributes": {"color": "#FA7371", "label": "Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study", "size": null, "x": -109.77162170410156, "y": -74.40927124023438}}, {"key": "77", "attributes": {"color": "#FA7371", "label": "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study", "size": null, "x": -110.13154602050781, "y": -78.22611236572266}}, {"key": "78", "attributes": {"color": "#FA7371", "label": "Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors", "size": null, "x": -106.55335235595703, "y": -77.50218200683594}}, {"key": "79", "attributes": {"color": "#FA7371", "label": "How to increase value and reduce waste when research priorities are set", "size": null, "x": -109.8900375366211, "y": -76.24905395507812}}, {"key": "80", "attributes": {"color": "#FA7371", "label": "Increasing value and reducing waste in biomedical research: who's listening?", "size": null, "x": -107.85142517089844, "y": -77.43638610839844}}, {"key": "81", "attributes": {"color": "#FA7371", "label": "Vicious circles of gender bias, lower positions, and lower performance: gender differences in scholarly productivity and impact", "size": null, "x": -108.1663818359375, "y": -76.88311767578125}}, {"key": "82", "attributes": {"color": "#FA7371", "label": "The gendered system of academic publishing", "size": null, "x": -108.72273254394531, "y": -76.23275756835938}}, {"key": "83", "attributes": {"color": "#FA7371", "label": "Gender bias in academia", "size": null, "x": -107.9451904296875, "y": -75.95791625976562}}, {"key": "84", "attributes": {"color": "#FA7371", "label": "Trends and comparison of female first authorship in high impact medical journals: observational study", "size": null, "x": -110.5501937866211, "y": -75.8197250366211}}, {"key": "85", "attributes": {"color": "#FA7371", "label": "Words and co-words as indicators of intellectual organization", "size": null, "x": -106.42251586914062, "y": -75.4387435913086}}, {"key": "86", "attributes": {"color": "#FA7371", "label": "Why words and co-words cannot map the development of the sciences", "size": null, "x": -110.0743179321289, "y": -76.90888214111328}}, {"key": "87", "attributes": {"color": "#FA7371", "label": "How citation distortions create unfounded authority: analysis of a citation network", "size": null, "x": -108.62151336669922, "y": -76.62852478027344}}, {"key": "88", "attributes": {"color": "#FA7371", "label": "Self-citation is the hallmark of productive authors, of any gender", "size": null, "x": -109.40487670898438, "y": -77.1526870727539}}, {"key": "89", "attributes": {"color": "#FA7371", "label": "Reporting Bias Group. Systematic review of the empirical evidence of study publication bias and outcome reporting bias -an updated review", "size": null, "x": -110.5896987915039, "y": -76.97981262207031}}, {"key": "90", "attributes": {"color": "#FA7371", "label": "Association of the FDA Amendment Act with trial registration, publication, and outcome reporting", "size": null, "x": -110.20634460449219, "y": -76.10086059570312}}, {"key": "91", "attributes": {"color": "#FA7371", "label": "COMPare: a prospective cohort study correcting and monitoring 58 misreported trials in real time", "size": null, "x": -107.74556732177734, "y": -78.64575958251953}}, {"key": "92", "attributes": {"color": "#FA7371", "label": "COMPare: Qualitative analysis of researchers' responses to critical correspondence on a cohort of 58 misreported trials", "size": null, "x": -109.81102752685547, "y": -75.87590026855469}}, {"key": "93", "attributes": {"color": "#FA7371", "label": "Reporting of statistically significant results at ClinicalTrials.gov for completed superiority randomized controlled trials", "size": null, "x": -107.94319915771484, "y": -76.68682098388672}}, {"key": "94", "attributes": {"color": "#FA7371", "label": "Evolution of poor reporting and inadequate methods over time in 20 920 randomised controlled trials included in Cochrane reviews: research on research study", "size": null, "x": -107.2146224975586, "y": -78.13761138916016}}, {"key": "95", "attributes": {"color": "#FA7371", "label": "Reporting of results in ClinicalTrials.gov and high-impact journals", "size": null, "x": -108.9930191040039, "y": -77.92182159423828}}, {"key": "96", "attributes": {"color": "#FA7371", "label": "feasibility of using realworld data to replicate clinical trial evidence", "size": null, "x": -110.89588165283203, "y": -77.44648742675781}}, {"key": "97", "attributes": {"color": "#FA7371", "label": "Reproducible research practices, transparency, and open access data in the biomedical literature", "size": null, "x": -109.93413543701172, "y": -76.0171127319336}}, {"key": "98", "attributes": {"color": "#FA7371", "label": "meta-research: evaluation and improvement of research methods and practices", "size": null, "x": -107.56838989257812, "y": -77.01734924316406}}, {"key": "99", "attributes": {"color": "#FA7371", "label": "Publisher's Note", "size": null, "x": -110.87369537353516, "y": -77.29061126708984}}, {"key": "100", "attributes": {"color": "#FA7371", "label": "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations", "size": null, "x": -110.02460479736328, "y": -78.66972351074219}}, {"key": "101", "attributes": {"color": "#2B0F74", "label": "Do journals and corporate sponsors back certain views in topics where disagreement prevails?", "size": null, "x": -172.42141723632812, "y": 107.80603790283203}}, {"key": "102", "attributes": {"color": "#2B0F74", "label": "Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease", "size": null, "x": -173.11361694335938, "y": 107.80664825439453}}, {"key": "103", "attributes": {"color": "#2B0F74", "label": "Abandon statistical significance", "size": null, "x": -171.5126953125, "y": 108.32726287841797}}, {"key": "104", "attributes": {"color": "#2B0F74", "label": "Information search tactics", "size": null, "x": -173.03614807128906, "y": 109.03929138183594}}, {"key": "105", "attributes": {"color": "#2B0F74", "label": "From Trust me -I am a Doctor", "size": null, "x": -172.7599334716797, "y": 106.79972076416016}}, {"key": "106", "attributes": {"color": "#2B0F74", "label": "Statin wars: Have we been misled about the evidence? A narrative review", "size": null, "x": -172.42910766601562, "y": 107.3725357055664}}, {"key": "107", "attributes": {"color": "#2B0F74", "label": "Scientific inquiry into rhinosinusitis: Who is receiving funding from the National Institutes of Health?", "size": null, "x": -173.15147399902344, "y": 108.23003387451172}}, {"key": "108", "attributes": {"color": "#2B0F74", "label": "Statins and the BMJ", "size": null, "x": -172.08433532714844, "y": 108.56977844238281}}, {"key": "109", "attributes": {"color": "#2B0F74", "label": "The turn: Integration of information seeking and retrieval in context", "size": null, "x": -171.19412231445312, "y": 108.1429214477539}}, {"key": "110", "attributes": {"color": "#2B0F74", "label": "Daekningsgraden i Science Citation Index af dansk sundhedsvidenskabelig forskning 1998", "size": null, "x": -172.0773468017578, "y": 107.80924987792969}}, {"key": "111", "attributes": {"color": "#2B0F74", "label": "How do we index? A report of some ASLIB informatics group activity", "size": null, "x": -171.4011688232422, "y": 107.37620544433594}}, {"key": "112", "attributes": {"color": "#2B0F74", "label": "Mind the gap? Quantifying interlinkages between two traditions in migration literature", "size": null, "x": -172.456298828125, "y": 108.20149993896484}}, {"key": "113", "attributes": {"color": "#2B0F74", "label": "Varning fÃ¶r simvastatin 80 mg", "size": null, "x": -171.95761108398438, "y": 107.04788208007812}}, {"key": "114", "attributes": {"color": "#2B0F74", "label": "Conflict of interest disclosure and polarization of scientific communities", "size": null, "x": -171.11692810058594, "y": 107.80887603759766}}, {"key": "115", "attributes": {"color": "#2B0F74", "label": "Statins for primary prevention: The debate is intense, but the data are weak", "size": null, "x": -173.36239624023438, "y": 108.48680877685547}}, {"key": "116", "attributes": {"color": "#2B0F74", "label": "Becoming metric-wise: A bibliometric guide for researchers", "size": null, "x": -173.09408569335938, "y": 107.00824737548828}}, {"key": "117", "attributes": {"color": "#2B0F74", "label": "Null hypothesis significance tests: A mix-up of two different theories-the basis for widespread confusion and numerous misinterpretations", "size": null, "x": -172.45616149902344, "y": 106.84600067138672}}, {"key": "118", "attributes": {"color": "#2B0F74", "label": "Document representation and indexer consistency", "size": null, "x": -172.18173217773438, "y": 107.42042541503906}}, {"key": "119", "attributes": {"color": "#2B0F74", "label": "From abstract to impact in cardiovascular research: Factors predicting publication and citation", "size": null, "x": -172.69383239746094, "y": 108.9120101928711}}, {"key": "120", "attributes": {"color": "#AB6850", "label": "A Simplified Bayesian Analysis Method for Vaccine Efficacy", "size": null, "x": 76.5378189086914, "y": -197.1485137939453}}, {"key": "121", "attributes": {"color": "#AB6850", "label": "Design and analysis of vaccine studies", "size": null, "x": 76.92019653320312, "y": -198.1344757080078}}, {"key": "122", "attributes": {"color": "#AB6850", "label": "Bias reduction for risk ratio and vaccine effect estimators", "size": null, "x": 75.95002746582031, "y": -196.52630615234375}}, {"key": "123", "attributes": {"color": "#3CF0C7", "label": "Obtaining confidence intervals for the risk ratio in cohort studies", "size": null, "x": 74.67649841308594, "y": -203.65281677246094}}, {"key": "124", "attributes": {"color": "#AB6850", "label": "On sample sizes to estimate the protective efficacy of a vaccine", "size": null, "x": 76.95032501220703, "y": -196.43931579589844}}, {"key": "125", "attributes": {"color": "#AB6850", "label": "Approximate is better than \"exact\" for interval estimation of binomial proportions", "size": null, "x": 75.38580322265625, "y": -197.36831665039062}}, {"key": "126", "attributes": {"color": "#AB6850", "label": "Confidence intervals for a binomial proportion", "size": null, "x": 76.58820343017578, "y": -195.98130798339844}}, {"key": "127", "attributes": {"color": "#AB6850", "label": "Bayesian estimation of vaccine efficacy", "size": null, "x": 75.54396057128906, "y": -196.17147827148438}}, {"key": "128", "attributes": {"color": "#AB6850", "label": "A bayesian framework for the ratio of two poisson rates in the context of vaccine efficacy trials", "size": null, "x": 77.1688003540039, "y": -196.5752410888672}}, {"key": "129", "attributes": {"color": "#AB6850", "label": "Reference posterior distributions for bayesian inference", "size": null, "x": 76.1336669921875, "y": -197.4116668701172}}, {"key": "130", "attributes": {"color": "#AB6850", "label": "Bayesian data analysis", "size": null, "x": 76.65496063232422, "y": -196.64349365234375}}, {"key": "131", "attributes": {"color": "#AB6850", "label": "Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints", "size": null, "x": 75.31946563720703, "y": -196.75160217285156}}, {"key": "132", "attributes": {"color": "#AB6850", "label": "Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization", "size": null, "x": 76.4036865234375, "y": -196.56349182128906}}, {"key": "133", "attributes": {"color": "#AB6850", "label": "Second interim analysis of clinical trial data", "size": null, "x": 76.63639068603516, "y": -197.62245178222656}}, {"key": "134", "attributes": {"color": "#AB6850", "label": "Array programming with NumPy", "size": null, "x": 75.76561737060547, "y": -197.57460021972656}}, {"key": "135", "attributes": {"color": "#AB6850", "label": "Matplotlib: A 2d graphics environment", "size": null, "x": 77.34231567382812, "y": -197.16854858398438}}, {"key": "136", "attributes": {"color": "#AB6850", "label": "Long-term persistence of zoster vaccine efficacy", "size": null, "x": 75.96207427978516, "y": -195.89553833007812}}, {"key": "137", "attributes": {"color": "#F8C71B", "label": "Pricing the COVID-19 Vaccine: A Mathematical Approach *", "size": null, "x": 36.64155578613281, "y": 154.87782287597656}}, {"key": "138", "attributes": {"color": "#F8C71B", "label": "ICU capacity management during the COVID-19 pandemic using a process simulation", "size": null, "x": 37.08577346801758, "y": 154.84837341308594}}, {"key": "139", "attributes": {"color": "#F8C71B", "label": "Asymmetric Bertrand-Edgeworth-Chamberlin Competition with Linear Demand: A Pediatric Vaccine Pricing Model", "size": null, "x": 37.32345199584961, "y": 154.3828125}}, {"key": "140", "attributes": {"color": "#F8C71B", "label": "Why experts say Moderna COVID-19 vaccine holds advantage over Pfizer's candidate", "size": null, "x": 37.77378463745117, "y": 154.66542053222656}}, {"key": "141", "attributes": {"color": "#F8C71B", "label": "Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2", "size": null, "x": 36.882328033447266, "y": 156.07296752929688}}, {"key": "142", "attributes": {"color": "#F8C71B", "label": "Trump Administration Acts to Ensure Coverage of Life-Saving COVID-19 Vaccines and Therapeutics", "size": null, "x": 36.752906799316406, "y": 153.78004455566406}}, {"key": "143", "attributes": {"color": "#F8C71B", "label": "Centers for Disease Control and Prevention as a Strategic Agent in the Pediatric Vaccine Market: An Analytical Approach\". In: Manufacturing and Service Operations Management Articles in Advance", "size": null, "x": 37.94879150390625, "y": 154.2307586669922}}, {"key": "144", "attributes": {"color": "#F8C71B", "label": "The NEOS Server 4.0 Administrative Guide", "size": null, "x": 37.05683135986328, "y": 154.6196746826172}}, {"key": "145", "attributes": {"color": "#F8C71B", "label": "WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: Supporting developing country production capacity through technology transfer", "size": null, "x": 36.11949157714844, "y": 155.0779571533203}}, {"key": "146", "attributes": {"color": "#F8C71B", "label": "Early Data Show Moderna's Coronavirus Vaccine Is 94.5% Effective", "size": null, "x": 35.64445114135742, "y": 155.88442993164062}}, {"key": "147", "attributes": {"color": "#F8C71B", "label": "Optimization Environments and the NEOS Server", "size": null, "x": 36.78300857543945, "y": 155.7759246826172}}, {"key": "148", "attributes": {"color": "#F8C71B", "label": "Predicting the impacts of epidemic outbreaks on global supply chains: A simulation-based analysis on the coronavirus outbreak (COVID-19/SARS-CoV-2) case", "size": null, "x": 36.526832580566406, "y": 154.8267364501953}}, {"key": "149", "attributes": {"color": "#F8C71B", "label": "Mathematical modeling of the spread of the coronavirus disease 2019 (COVID-19) taking into account the undetected infections. The case of China", "size": null, "x": 35.69443893432617, "y": 154.62448120117188}}, {"key": "150", "attributes": {"color": "#F8C71B", "label": "How Much Will A COVID-19 Vaccine Cost? Forbes", "size": null, "x": 37.25581741333008, "y": 153.7621307373047}}, {"key": "151", "attributes": {"color": "#F8C71B", "label": "A model of supply-chain decisions for resource sharing with an application to ventilator allocation to combat COVID-19", "size": null, "x": 37.69150924682617, "y": 154.2320556640625}}, {"key": "152", "attributes": {"color": "#F8C71B", "label": "Company History and Information: mRNA Science -Moderna", "size": null, "x": 35.081790924072266, "y": 154.22898864746094}}, {"key": "153", "attributes": {"color": "#F8C71B", "label": "Pfizer's COVID vaccine comes with a chilly complication", "size": null, "x": 37.43428039550781, "y": 156.2725830078125}}, {"key": "154", "attributes": {"color": "#F8C71B", "label": "A Multiclass, Multiproduct COVID-19 Convalescent Plasma Donor Equilibrium Model", "size": null, "x": 35.76851272583008, "y": 155.151611328125}}, {"key": "155", "attributes": {"color": "#45E73B", "label": "Coronavirus Vaccine Tracker", "size": null, "x": 36.254371643066406, "y": 153.67550659179688}}, {"key": "156", "attributes": {"color": "#F8C71B", "label": "How much could Pfizer make from a COVID-19 vaccine? Marketplace", "size": null, "x": 37.162776947021484, "y": 155.13470458984375}}, {"key": "157", "attributes": {"color": "#F8C71B", "label": "Immunizations in the United States: Success, structure, and stress", "size": null, "x": 35.360008239746094, "y": 155.07862854003906}}, {"key": "158", "attributes": {"color": "#F8C71B", "label": "mRNA vaccines-a new era in vaccinology", "size": null, "x": 37.71586608886719, "y": 155.54293823242188}}, {"key": "159", "attributes": {"color": "#F8C71B", "label": "Pfizer and BioNTech Conclude Phase 3 study of COVID-19 Vaccine Candidate, Meeting all Primary Efficacy Endpoints", "size": null, "x": 37.8305549621582, "y": 153.7574462890625}}, {"key": "160", "attributes": {"color": "#F8C71B", "label": "Pfizer Company Fact Sheet", "size": null, "x": 36.29744338989258, "y": 154.40052795410156}}, {"key": "161", "attributes": {"color": "#F8C71B", "label": "How Much Will You Pay for a COVID-19 Vaccine? Here's What We Know", "size": null, "x": 37.935997009277344, "y": 155.63546752929688}}, {"key": "162", "attributes": {"color": "#F8C71B", "label": "High-Quality Masks Can Reduce Infections and Deaths in the U.S", "size": null, "x": 37.28118896484375, "y": 155.49359130859375}}, {"key": "163", "attributes": {"color": "#F8C71B", "label": "Natural history of COVID-19 and current knowledge on treatment therapeutic options", "size": null, "x": 36.13860321044922, "y": 154.078369140625}}, {"key": "164", "attributes": {"color": "#F8C71B", "label": "Vaccine Coverage, Pricing, and Reimbursement in the U", "size": null, "x": 35.43091583251953, "y": 155.61373901367188}}, {"key": "165", "attributes": {"color": "#F8C71B", "label": "Why Does Pfizer's COVID-19 Vaccine Need To Be Kept Colder Than Antarctica? NPR", "size": null, "x": 36.579872131347656, "y": 153.26138305664062}}, {"key": "166", "attributes": {"color": "#F8C71B", "label": "Impact of COVID-19 on logistics systems and disruptions in food supply chain", "size": null, "x": 36.46689987182617, "y": 155.89048767089844}}, {"key": "167", "attributes": {"color": "#F8C71B", "label": "A polyhedral branch-and-cut approach to global optimization", "size": null, "x": 34.60822677612305, "y": 155.130126953125}}, {"key": "168", "attributes": {"color": "#F8C71B", "label": "New Pfizer Results: Coronavirus Vaccine Is Safe and 95% Effective", "size": null, "x": 35.4254150390625, "y": 153.82809448242188}}, {"key": "169", "attributes": {"color": "#F8C71B", "label": "COVID-19 Vaccination Program Interim Playbook for Jurisdiction Operations", "size": null, "x": 35.708316802978516, "y": 154.83425903320312}}, {"key": "170", "attributes": {"color": "#F8C71B", "label": "Historical Reference of Seasonal Influenza Vaccine Doses Distributed", "size": null, "x": 36.803165435791016, "y": 154.46551513671875}}, {"key": "171", "attributes": {"color": "#F8C71B", "label": "MRNA -Moderna Inc. Annual Income Statement -WSJ", "size": null, "x": 35.18091583251953, "y": 154.49937438964844}}, {"key": "172", "attributes": {"color": "#F8C71B", "label": "WHO Coronavirus Disease (COVID-19) Dashboard. https: //covid19.who.int/. Accessed", "size": null, "x": 37.56623458862305, "y": 155.16262817382812}}, {"key": "173", "attributes": {"color": "#C5F22E", "label": "Morbidity and Mortality Weekly Report The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine -United States, December 2020", "size": null, "x": 182.57992553710938, "y": 151.60423278808594}}, {"key": "174", "attributes": {"color": "#C5F22E", "label": "Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration", "size": null, "x": 182.02659606933594, "y": 151.1820526123047}}, {"key": "175", "attributes": {"color": "#C5F22E", "label": "The Advisory Committee on Immunization Practices' interim recommendation for allocating initial supplies of COVID-19 vaccine-United States", "size": null, "x": 183.17507934570312, "y": 151.4989013671875}}, {"key": "176", "attributes": {"color": "#C5F22E", "label": "US Department of Health and Human Services, CDC; 2020", "size": null, "x": 182.0664520263672, "y": 152.07437133789062}}, {"key": "177", "attributes": {"color": "#C5F22E", "label": "Advisory Committee on Immunization Practices (ACIP): GRADE (grading of recommendations, assessment, development and evaluation)", "size": null, "x": 182.657958984375, "y": 152.05006408691406}}, {"key": "178", "attributes": {"color": "#D2FDEF", "label": "Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients", "size": null, "x": -9.517855644226074, "y": -155.82107543945312}}, {"key": "179", "attributes": {"color": "#D2FDEF", "label": "Celgene: Honoraria, Research Funding, Speakers Bureau; Sierra Oncology: Honoraria; Promedior: Honoraria; Shire: Honoraria, Speakers Bureau; AOP Orphan Pharmaceuticals: Honoraria; Novartis: Honoraria, Research Funding", "size": null, "x": -10.480133056640625, "y": -156.6743621826172}}, {"key": "180", "attributes": {"color": "#D2FDEF", "label": "Roche Diagnostics: Honoraria", "size": null, "x": -10.633230209350586, "y": -155.10955810546875}}, {"key": "181", "attributes": {"color": "#D2FDEF", "label": "Blueprint Medicines: Honoraria; Novartis: Honoraria, Research Funding; SagerStrong Foundation: Other: Grant Support; DAVA Oncology: Honoraria; Samus Therapeutics: Research Funding; Cellectis: Research Funding", "size": null, "x": -10.560667037963867, "y": -155.75315856933594}}, {"key": "182", "attributes": {"color": "#D2FDEF", "label": "Research Funding; Celgene: Honoraria; AbbVie: Honoraria", "size": null, "x": -9.1690673828125, "y": -155.46682739257812}}, {"key": "183", "attributes": {"color": "#D2FDEF", "label": "MustangBio: Honoraria; LFB Biotechnologies: Honoraria; Pacylex Pharmaceuticals: Consultancy. Vannucchi: Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -9.85966968536377, "y": -156.9730682373047}}, {"key": "184", "attributes": {"color": "#D2FDEF", "label": "Gupta: Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sierra Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bristol MyersSquibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Honoraria", "size": null, "x": -8.820592880249023, "y": -155.85324096679688}}, {"key": "185", "attributes": {"color": "#D2FDEF", "label": "Research Funding; Otsuka Pharmaceutical: Research Funding; Celgene: Honoraria; Perseus Proteomics: Research Funding", "size": null, "x": -9.613007545471191, "y": -154.96815490722656}}, {"key": "186", "attributes": {"color": "#D2FDEF", "label": "Research Funding", "size": null, "x": -10.3751859664917, "y": -110.10980224609375}}, {"key": "187", "attributes": {"color": "#D2FDEF", "label": "Research Funding; Bristol-Myers Squibb: Honoraria", "size": null, "x": -8.913653373718262, "y": -154.9095458984375}}, {"key": "188", "attributes": {"color": "#D2FDEF", "label": "Takeda Pharmaceutical Company: Honoraria; Novartis: Honoraria, Research Funding; Shire plc: Honoraria", "size": null, "x": -10.358088493347168, "y": -157.2292022705078}}, {"key": "189", "attributes": {"color": "#D2FDEF", "label": "Kiladjian: AOP Orphan: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -8.422802925109863, "y": -155.53604125976562}}, {"key": "190", "attributes": {"color": "#D2FDEF", "label": "Patents & Royalties: PCT/JP2020/008434", "size": null, "x": -9.673173904418945, "y": -155.9755096435547}}, {"key": "191", "attributes": {"color": "#D2FDEF", "label": "Novartis Pharma KK", "size": null, "x": -9.073214530944824, "y": -156.5230255126953}}, {"key": "192", "attributes": {"color": "#D2FDEF", "label": "Novartis: Consultancy, Honoraria; Amgen: Consultancy", "size": null, "x": -10.304556846618652, "y": -156.01998901367188}}, {"key": "193", "attributes": {"color": "#D2FDEF", "label": "Amgen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -9.18600082397461, "y": -157.18040466308594}}, {"key": "194", "attributes": {"color": "#D2FDEF", "label": "AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -10.101825714111328, "y": -154.76596069335938}}, {"key": "195", "attributes": {"color": "#D2FDEF", "label": "Consultancy, Honoraria, Other: Travel, Accommodation, Expenses", "size": null, "x": -10.194849014282227, "y": -155.3163604736328}}, {"key": "196", "attributes": {"color": "#D2FDEF", "label": "Takeda: Consultancy, Honoraria, Other: Travel, Accommodation, Expenses, Research Funding; Pfizer: Consultancy, Honoraria, Other: Travel, Accommodation, Expenses, Research Funding. Mesa: Samus Therapeutics: Research Funding", "size": null, "x": -8.543323516845703, "y": -156.2811279296875}}, {"key": "197", "attributes": {"color": "#540392", "label": "Rapid Reduction of Anti-Sars-Cov-2 Antibodies in Convalescent Plasma Donors; Results of a Phase 2 Clinical Study", "size": null, "x": -105.92064666748047, "y": 148.55056762695312}}, {"key": "198", "attributes": {"color": "#540392", "label": "Research Funding; Celgene: Honoraria; Sanofi: Honoraria. Pappa: Genesis pharma SA: Research Funding. Dimopoulos: BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Personal fees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Personal fees, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Personal fees, Research Funding, Speakers Bureau; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Personal fees, Research Funding", "size": null, "x": -106.440185546875, "y": 148.672119140625}}, {"key": "199", "attributes": {"color": "#65E754", "label": "COVID-19 Impact on Lymphoma Patients' Clinical Outcomes -an Observational Cohort Study", "size": null, "x": -41.430721282958984, "y": -84.5953369140625}}, {"key": "200", "attributes": {"color": "#65E754", "label": "COVID-19 infection. Further investigations to determine infectivity of patients with prolonged SARS-CoV2 shedding are needed", "size": null, "x": -41.5448112487793, "y": -83.83622741699219}}, {"key": "201", "attributes": {"color": "#65E754", "label": "Research Funding; Loxo: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding; TG Therapeutics: Consultancy, Research Funding", "size": null, "x": -41.12509536743164, "y": -85.25537872314453}}, {"key": "202", "attributes": {"color": "#85D4B4", "label": "Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -29.659120559692383, "y": -78.1201171875}}, {"key": "203", "attributes": {"color": "#65E754", "label": "Membership on an entity's Board of Directors or advisory committees; KitePharma: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ADC therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bayer: Consultancy, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -42.92979049682617, "y": -85.24104309082031}}, {"key": "204", "attributes": {"color": "#65E754", "label": "Research Funding; Infinity: Research Funding; Karyopharm: Research Funding", "size": null, "x": -43.203514099121094, "y": -84.32801818847656}}, {"key": "205", "attributes": {"color": "#65E754", "label": "Research Funding; AbbVie: Research Funding; MD Anderson: Research Funding; Regional Cancer Care Associates/OMI: Current Employment; Infinity Verastem: Research Funding", "size": null, "x": -41.92161560058594, "y": -85.16883087158203}}, {"key": "206", "attributes": {"color": "#65E754", "label": "Research Funding; COTA: Consultancy, Current equity holder in publicly-traded company, Other: leadership role", "size": null, "x": -41.305511474609375, "y": -85.77566528320312}}, {"key": "207", "attributes": {"color": "#65E754", "label": "Gilead Company: Consultancy, Current equity holder in publicly-traded company, Honoraria, Other: leadership role, Research Funding; Janssen: Consultancy, Honoraria, Other: leadership role", "size": null, "x": -42.0166015625, "y": -84.39453125}}, {"key": "208", "attributes": {"color": "#65E754", "label": "AstraZeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: leadership role, Research Funding; Acerta: Consultancy, Honoraria, Other: leadership role", "size": null, "x": -42.295352935791016, "y": -84.75776672363281}}, {"key": "209", "attributes": {"color": "#65E754", "label": "Research Funding; Celgene: Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Portola: Research Funding", "size": null, "x": -42.158363342285156, "y": -85.715576171875}}, {"key": "210", "attributes": {"color": "#65E754", "label": "Other: Travel expenses, Research Funding, Speakers Bureau; Janssen: Speakers Bureau; AstraZeneca: Consultancy; Corvus: Research Funding; Rhizen: Research Funding; Pfizer: Research Funding; Kite: Honoraria, Other: Travel expenses", "size": null, "x": -42.00062561035156, "y": -83.6434555053711}}, {"key": "211", "attributes": {"color": "#65E754", "label": "Research Funding; Trillium: Research Funding; Bayer: Consultancy, Honoraria", "size": null, "x": -41.0141716003418, "y": -84.46561431884766}}, {"key": "212", "attributes": {"color": "#65E754", "label": "Amgen: Research Funding; Eisai: Research Funding", "size": null, "x": -42.738399505615234, "y": -84.51385498046875}}, {"key": "213", "attributes": {"color": "#ECE012", "label": "Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area", "size": null, "x": -221.6788330078125, "y": 56.67996597290039}}, {"key": "214", "attributes": {"color": "#ECE012", "label": "Race/ethnicity demographics are as follows: Hispanics (H)/ African Americans (AA) represented", "size": null, "x": -222.61050415039062, "y": 56.40283203125}}, {"key": "215", "attributes": {"color": "#ECE012", "label": "32%/42% of RUSH patients, and 36%/51% of UIC patients, respectively (Figure 1)", "size": null, "x": -221.85777282714844, "y": 57.319217681884766}}, {"key": "216", "attributes": {"color": "#ECE012", "label": "7% (70 VTE/PE", "size": null, "x": -221.41510009765625, "y": 57.242549896240234}}, {"key": "217", "attributes": {"color": "#ECE012", "label": "VTE/PE, 4 arterial and 0 with both venous/arterial). Patients that developed a thrombotic event were similar by age, sex, and BMI References -Tang et", "size": null, "x": -221.23887634277344, "y": 56.184146881103516}}, {"key": "218", "attributes": {"color": "#ECE012", "label": "COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection", "size": null, "x": -221.284423828125, "y": 56.82957458496094}}, {"key": "219", "attributes": {"color": "#ECE012", "label": "Stiff: Macrogenics: Research Funding; Delta-Fly: Research Funding; Unum: Research Funding", "size": null, "x": -221.10354614257812, "y": 55.55607223510742}}, {"key": "220", "attributes": {"color": "#ECE012", "label": "Research Funding; Amgen: Research Funding; Gamida Cell: Research Funding. Saraf: Novartis, Global Blood Therapeutics: Membership on an entity's Board of Directors or advisory committees; Global Blood Therapeutics: Membership on an entity's Board of Directors or advisory committees, Other: Advisory Boards", "size": null, "x": -222.21266174316406, "y": 56.3043327331543}}, {"key": "221", "attributes": {"color": "#ECE012", "label": "Global Blood Therapeutics, Novartis: Research Funding", "size": null, "x": -220.9562530517578, "y": 57.44485855102539}}, {"key": "222", "attributes": {"color": "#F3AFE9", "label": "Impact of Sars-CoV2 Infection on 491 Hematological Patients: The Ecovidehe Multicenter Study", "size": null, "x": -32.078269958496094, "y": -85.77486419677734}}, {"key": "223", "attributes": {"color": "#F3AFE9", "label": "Janssen: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -33.319881439208984, "y": -91.07758331298828}}, {"key": "224", "attributes": {"color": "#F3AFE9", "label": "Abbvie: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -31.617473602294922, "y": -86.27507781982422}}, {"key": "225", "attributes": {"color": "#F3AFE9", "label": "Rovi: Membership on an entity's Board of Directors or advisory committees. Ocio: MDS: Honoraria", "size": null, "x": -32.23777389526367, "y": -85.22814178466797}}, {"key": "226", "attributes": {"color": "#F3AFE9", "label": "CÃ³rdoba: Takeda FarmacÃ©utica EspaÃ±a S.A.: Speakers Bureau; Janssen: Honoraria, Other: travel and accommodation; Abbvie: Honoraria, Other: travel and accommodation; Roche: Honoraria, Other: travel and accommodation", "size": null, "x": -32.71794509887695, "y": -85.83338165283203}}, {"key": "227", "attributes": {"color": "#F3AFE9", "label": "Research Funding; Pharmacyclics: Honoraria; Novartis: Honoraria; Janssen: Honoraria, Research Funding; Incyte: Research Funding; Gilead: Honoraria, Research Funding; BMS: Honoraria", "size": null, "x": -32.08554458618164, "y": -86.59391021728516}}, {"key": "228", "attributes": {"color": "#981CDF", "label": "Sars Cov-2/COVID-19 in Multiple Myeloma Latin-American Patients COVID-Lamm Study on Behalf of Gelamm ( Grupo de Estudio Latino-Americano de Mieloma MÃºltiple )", "size": null, "x": -11.48460578918457, "y": -70.14224243164062}}, {"key": "229", "attributes": {"color": "#981CDF", "label": "BindingSite: Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sandoz: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -12.075743675231934, "y": -70.40394592285156}}, {"key": "230", "attributes": {"color": "#981CDF", "label": "Abbvie: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -11.204122543334961, "y": -67.5473403930664}}, {"key": "231", "attributes": {"color": "#981CDF", "label": "Research Funding; Takeda: Honoraria, Research Funding; Dr. Reddy's: Consultancy, Research Funding; Abbvie: Consultancy, Research Funding. Idrobo: Abbvie: Honoraria, Speakers Bureau; Tecnofarma: Honoraria", "size": null, "x": -10.900238037109375, "y": -70.3395004272461}}, {"key": "232", "attributes": {"color": "#981CDF", "label": "Rojas: Novartis: Consultancy; Roche: Honoraria; Sandoz: Honoraria; Abbvie: Honoraria. Remaggi: Takeda: Honoraria; Raffo Argentina: Honoraria", "size": null, "x": -11.663183212280273, "y": -69.75647735595703}}, {"key": "233", "attributes": {"color": "#981CDF", "label": "Alvarado: Celgene: Speakers Bureau; Alexion: Speakers Bureau", "size": null, "x": -11.093107223510742, "y": -69.434326171875}}, {"key": "234", "attributes": {"color": "#3CF0C7", "label": "Covid-19 Vaccine Efficacy: Accuracy, Uncertainty and Projection of Cases", "size": null, "x": 73.17147064208984, "y": -210.04762268066406}}, {"key": "235", "attributes": {"color": "#3CF0C7", "label": "Food and Drug Administration Emergency Use Authorization for Vaccines to Prevent COVID-19", "size": null, "x": 72.92903900146484, "y": -211.319091796875}}, {"key": "236", "attributes": {"color": "#3CF0C7", "label": "Food and Drug Administration Development and Licensure of Vaccines to Prevent", "size": null, "x": 72.47608184814453, "y": -210.2191619873047}}, {"key": "237", "attributes": {"color": "#3CF0C7", "label": "Guidance for Industry", "size": null, "x": 74.02063751220703, "y": -210.8309783935547}}, {"key": "238", "attributes": {"color": "#3CF0C7", "label": "Office of Workforce and Career Development (2006) Principles of Epidemiology in Public Health Practice -An Introduction to Epidemiology and Biostatistics", "size": null, "x": 73.5946273803711, "y": -211.52981567382812}}, {"key": "239", "attributes": {"color": "#3CF0C7", "label": "Pfizer and BioNTech Press Release on November 9", "size": null, "x": 73.03572082519531, "y": -210.81297302246094}}, {"key": "240", "attributes": {"color": "#3CF0C7", "label": "Moderna News Release on November", "size": null, "x": 73.08259582519531, "y": -209.54881286621094}}, {"key": "241", "attributes": {"color": "#3CF0C7", "label": "Moderna News Release on", "size": null, "x": 74.060302734375, "y": -211.34727478027344}}, {"key": "242", "attributes": {"color": "#3CF0C7", "label": "Regression Analysis, Theory, Methods and Applications", "size": null, "x": 72.82048034667969, "y": -210.1999053955078}}, {"key": "243", "attributes": {"color": "#3CF0C7", "label": "Recommendations for the use of Taylor series confidence intervals for estimates of vaccine efficacy", "size": null, "x": 73.58418273925781, "y": -209.9971923828125}}, {"key": "244", "attributes": {"color": "#3CF0C7", "label": "Review and evaluation of methods for computing confidence intervals for the ratio of two proportions and considerations for non-inferiority clinical trials", "size": null, "x": 73.50745391845703, "y": -210.65505981445312}}, {"key": "245", "attributes": {"color": "#3CF0C7", "label": "Moderna News Release on October", "size": null, "x": 72.26985931396484, "y": -210.82655334472656}}, {"key": "246", "attributes": {"color": "#F4F361", "label": "Treating Acute Leukemia during the COVID-19 Pandemic: A Multicenter Latin American Registry", "size": null, "x": 222.59947204589844, "y": -67.37835693359375}}, {"key": "247", "attributes": {"color": "#F4F361", "label": "1%) developed COVID-19 disease, the majority mild-moderate disease (54.2%), 27.7% severe disease and 18.1% critically ill; 27.7% required mechanical ventilation and 37.7% died from COVID-19 disease", "size": null, "x": 223.03900146484375, "y": -67.26627349853516}}, {"key": "248", "attributes": {"color": "#F4F361", "label": "We identify as risk factors for COVID-19 disease the presence of active leukemia (newly diagnosed or relapsed) (OR 3", "size": null, "x": 221.79286193847656, "y": -67.35497283935547}}, {"key": "249", "attributes": {"color": "#F4F361", "label": "Treatment modifications, appointment prolongations or the use of virtual consultation were not associated with a reduction in the risk of COVID-19", "size": null, "x": 222.50567626953125, "y": -68.03656768798828}}, {"key": "250", "attributes": {"color": "#F4F361", "label": "On the other hand, 16.7% of patients died during period analyzed due to leukemia (57.5%)", "size": null, "x": 222.4771728515625, "y": -66.65298461914062}}, {"key": "251", "attributes": {"color": "#F4F361", "label": "Independent factors associated with mortality were AML vs. ALL (OR 1.89 [95% CI: 1.12-3.18], p=0.016), relapsed-refractory disease", "size": null, "x": 223.37173461914062, "y": -66.70520782470703}}, {"key": "252", "attributes": {"color": "#F4F361", "label": "The COVID-19 pandemic led to significant modifications in the standard of care treatment of patients with acute leukemia. The incidence of COVID-19 disease in acute leukemia patients was considerable and more than a third of the patients with acute leukemia and COVID-19 disease died. Despite a short-follow up, 16.7% of the patients died and leukemia-related deaths were the most frequent. In low-and middleincome countries with fragile health systems, the collateral damage for patients with acute leukemia may be", "size": null, "x": 221.99826049804688, "y": -67.87506103515625}}, {"key": "253", "attributes": {"color": "#F4F361", "label": "Amgen: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": 223.13296508789062, "y": -67.35565948486328}}, {"key": "254", "attributes": {"color": "#F4F361", "label": "Board of Directors or advisory committees, Speakers Bureau; AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": 222.84938049316406, "y": -66.91957092285156}}, {"key": "255", "attributes": {"color": "#689070", "label": "Outcomes of Adult and Pediatric Patients with Hematologic Malignancies and COVID-19: A Systematic Review and Meta-Analysis of 1847 Patients", "size": null, "x": -60.316524505615234, "y": 232.3144989013672}}, {"key": "256", "attributes": {"color": "#689070", "label": "Research Funding; Celgene: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; IQVIA: Research Funding; Sanofi: Consultancy", "size": null, "x": -61.02333450317383, "y": 231.35511779785156}}, {"key": "257", "attributes": {"color": "#689070", "label": "Dova: Honoraria, Other: Advisory board", "size": null, "x": -60.089393615722656, "y": 232.2686767578125}}, {"key": "258", "attributes": {"color": "#689070", "label": "Other: Advisory board; Incyte: Research Funding; Quercegen: Research Funding", "size": null, "x": -59.883399963378906, "y": 231.6195068359375}}, {"key": "259", "attributes": {"color": "#689070", "label": "Parexel: Consultancy; Sanofi: Consultancy; CSL: Consultancy", "size": null, "x": -60.67227554321289, "y": 232.93853759765625}}, {"key": "260", "attributes": {"color": "#689070", "label": "Other: Advisory board. Scarfo: Gilead: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -59.72236633300781, "y": 232.7855987548828}}, {"key": "261", "attributes": {"color": "#689070", "label": "AstraZeneca: Honoraria; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Wood: Pfizer: Research Funding", "size": null, "x": -60.80583190917969, "y": 232.17901611328125}}, {"key": "262", "attributes": {"color": "#689070", "label": "Koneksa Health: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees; Elektra Labs: Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -60.498382568359375, "y": 231.60447692871094}}, {"key": "263", "attributes": {"color": "#8F00EA", "label": "Evaluation of the Prothrombin Fragment 1.2 in Patients with COVID-19", "size": null, "x": 94.91770935058594, "y": 207.4890594482422}}, {"key": "264", "attributes": {"color": "#8F00EA", "label": "analyses while the D-dimer was not. PF1.2 may be a useful assay, and potentially more discriminant than D-dimer, in identifying thrombotic manifestations in hospitalized patients with COVID-19", "size": null, "x": 94.92232513427734, "y": 206.7100372314453}}, {"key": "265", "attributes": {"color": "#8F00EA", "label": "Rigel: Consultancy; Agios: Consultancy, Research Funding; Argenx: Consultancy; Amgen: Research Funding; Dova: Consultancy, Research Funding", "size": null, "x": 95.79679870605469, "y": 208.32896423339844}}, {"key": "266", "attributes": {"color": "#8F00EA", "label": "Immunovant: Other: Travel Expenses, Research Funding; CRICO: Consultancy, Honoraria", "size": null, "x": 95.87696838378906, "y": 207.3879852294922}}, {"key": "267", "attributes": {"color": "#8F00EA", "label": "Patents & Royalties; Zafgen: Consultancy, Honoraria; Sanofi (Genzyme): Consultancy, Honoraria; Shionogi: Consultancy, Honoraria; Shire: Consultancy, Honoraria; Shionogi: Consultancy; Protalix Biotherapeutics: Consultancy; Principia: Consultancy, Research Funding", "size": null, "x": 94.45464324951172, "y": 207.87022399902344}}, {"key": "268", "attributes": {"color": "#8F00EA", "label": "Research Funding; Alnylam: Consultancy, Honoraria, Other: Travel Expenses, Research Funding; Agios: Consultancy, Honoraria, Other: Travel Expenses, Research Funding; Daiichi Sankyo: Consultancy, Honoraria; Actelion (Syntimmune): Consultancy, Honoraria, Other: Travel Expenses", "size": null, "x": 95.7018814086914, "y": 206.90188598632812}}, {"key": "269", "attributes": {"color": "#8F00EA", "label": "Research Funding; Argenx: Consultancy, Honoraria, Other: Travel Expenses, Research Funding", "size": null, "x": 95.33305358886719, "y": 207.6346893310547}}, {"key": "270", "attributes": {"color": "#8F00EA", "label": "Platelet Disorder Support Association: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Novartis: Consultancy, Honoraria", "size": null, "x": 94.34613800048828, "y": 207.04405212402344}}, {"key": "271", "attributes": {"color": "#8F00EA", "label": "Momenta: Consultancy, Honoraria; Merck Sharp Dohme: Consultancy, Honoraria; Rigel: Consultancy, Honoraria, Other", "size": null, "x": 94.14971923828125, "y": 207.31866455078125}}, {"key": "272", "attributes": {"color": "#8F00EA", "label": "Dova: Consultancy, Honoraria; Genzyme: Consultancy, Honoraria; Immunovant: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Kyowa-Kirin: Consultancy, Honoraria; Protalex: Consultancy, Honoraria, Other, Research Funding; Principia Biopharma: Consultancy, Honoraria, Other", "size": null, "x": 95.09561920166016, "y": 208.1529541015625}}, {"key": "273", "attributes": {"color": "#92EB8C", "label": "7 Population Health Sci-ences, Mays Cancer Center", "size": null, "x": -120.599853515625, "y": -144.3333740234375}}, {"key": "274", "attributes": {"color": "#92EB8C", "label": "Travel/Accommodation/Expenses, Shareholder/Stockholder/Stock options: Doximity", "size": null, "x": -121.09637451171875, "y": -146.29737854003906}}, {"key": "275", "attributes": {"color": "#92EB8C", "label": "Travel/Accommodation/Expenses: Syapse; Licensing/Royalties: Uptodate. S. Peters: Honoraria (self), Honoraria (institution), Advisory/Consultancy: AbbVie", "size": null, "x": -121.95419311523438, "y": -145.4006805419922}}, {"key": "276", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy, Research grant/Funding (self): Amgen; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses", "size": null, "x": -121.31510162353516, "y": -142.95664978027344}}, {"key": "277", "attributes": {"color": "#92EB8C", "label": "Honoraria (self), Honoraria (institution), Advisory/Consultancy: Bayer", "size": null, "x": -121.17520904541016, "y": -145.48973083496094}}, {"key": "278", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy: Biocartis; Honoraria (self), Honoraria (institution), Advisory/Consultancy: Bioinvent", "size": null, "x": -121.7513427734375, "y": -142.7401885986328}}, {"key": "279", "attributes": {"color": "#92EB8C", "label": "Advisory/ Consultancy: Blueprint Medicines", "size": null, "x": -121.56124877929688, "y": -143.6865234375}}, {"key": "280", "attributes": {"color": "#92EB8C", "label": "Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self): Boehringer-Ingelheim", "size": null, "x": -122.1724624633789, "y": -144.12417602539062}}, {"key": "281", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Bristol-Myers Squibb", "size": null, "x": -122.6622085571289, "y": -143.9207763671875}}, {"key": "282", "attributes": {"color": "#92EB8C", "label": "Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/ Funding (self): Clovis", "size": null, "x": -120.34838104248047, "y": -146.64117431640625}}, {"key": "283", "attributes": {"color": "#92EB8C", "label": "Honoraria (self), Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Daiichi Sankyo", "size": null, "x": -119.84521484375, "y": -143.7684326171875}}, {"key": "284", "attributes": {"color": "#92EB8C", "label": "Honoraria (self), Honoraria (institution), Advisory/Consultancy: Debiopharm", "size": null, "x": -118.87998962402344, "y": -144.0634002685547}}, {"key": "285", "attributes": {"color": "#92EB8C", "label": "Honoraria (self), Honoraria (institution), Advisory/Consultancy", "size": null, "x": -118.86822509765625, "y": -143.5552215576172}}, {"key": "286", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy, Research grant/Funding (self), Travel/ Accommodation/Expenses: F. Hoffmann-La Roche", "size": null, "x": -119.49109649658203, "y": -144.61593627929688}}, {"key": "287", "attributes": {"color": "#92EB8C", "label": "Honoraria (self), Honoraria (institution)", "size": null, "x": -120.79603576660156, "y": -145.86093139648438}}, {"key": "288", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Ilumina; Honoraria (self), Honoraria (institution)", "size": null, "x": -121.39850616455078, "y": -143.3141326904297}}, {"key": "289", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Merck Sharp and Dohme", "size": null, "x": -121.16065979003906, "y": -145.0890655517578}}, {"key": "290", "attributes": {"color": "#92EB8C", "label": "Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self)", "size": null, "x": -121.95328521728516, "y": -143.54217529296875}}, {"key": "291", "attributes": {"color": "#92EB8C", "label": "Honoraria (self), Honoraria (institution), Advisory/Consultancy: Merrimack", "size": null, "x": -118.91980743408203, "y": -145.09104919433594}}, {"key": "292", "attributes": {"color": "#92EB8C", "label": "Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self): Novartis", "size": null, "x": -120.93601989746094, "y": -142.35494995117188}}, {"key": "293", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy: PharmaMar; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self): Pfizer; Honoraria (self), Honoraria (institution), Advisory/Consultancy: Regeneron", "size": null, "x": -119.52433776855469, "y": -145.34573364257812}}, {"key": "294", "attributes": {"color": "#92EB8C", "label": "Honoraria (self), Honoraria (institution), Advisory/Consultancy: Sanofi", "size": null, "x": -120.63191986083984, "y": -143.89462280273438}}, {"key": "295", "attributes": {"color": "#92EB8C", "label": "Honoraria (self), Honoraria (institution), Advisory/Consultancy: Takeda", "size": null, "x": -122.00601959228516, "y": -144.69955444335938}}, {"key": "296", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy: Vaccibody", "size": null, "x": -120.54458618164062, "y": -145.02740478515625}}, {"key": "297", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy: Celldex", "size": null, "x": -120.4057846069336, "y": -141.89488220214844}}, {"key": "298", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy: Invitae", "size": null, "x": -119.66698455810547, "y": -142.46823120117188}}, {"key": "299", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy: Total Health", "size": null, "x": -118.59369659423828, "y": -144.33041381835938}}, {"key": "300", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy: Beyond Springs", "size": null, "x": -120.22872924804688, "y": -143.66822814941406}}, {"key": "301", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy: BAyer", "size": null, "x": -121.67362976074219, "y": -145.6889190673828}}, {"key": "302", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy: Spectrum Pharmaceuticals. S. Gulati: Advisory/Consultancy: Puma Biotechnology", "size": null, "x": -121.60778045654297, "y": -146.1152801513672}}, {"key": "303", "attributes": {"color": "#92EB8C", "label": "Research grant/Funding (self): AstraZeneca; Research grant/Funding (self): IsoRay. T.K. Choueiri: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self", "size": null, "x": -122.29578399658203, "y": -146.0109405517578}}, {"key": "304", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy, Research grant/Funding (self): Alexion; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self", "size": null, "x": -119.66138458251953, "y": -145.8521728515625}}, {"key": "305", "attributes": {"color": "#92EB8C", "label": "Advisory/ Consultancy, Research grant/Funding (self): BMS", "size": null, "x": -121.56159210205078, "y": -144.49575805664062}}, {"key": "306", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy, Research grant/Funding (self): Cerulean", "size": null, "x": -119.00873565673828, "y": -145.6388702392578}}, {"key": "307", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy, Research grant/Funding (self): Eisai", "size": null, "x": -122.81086730957031, "y": -144.66407775878906}}, {"key": "308", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy, Research grant/Funding (self): Foundation Medicine", "size": null, "x": -121.16182708740234, "y": -144.40162658691406}}, {"key": "309", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy, Research grant/Funding (self): Exelixis", "size": null, "x": -121.57269287109375, "y": -144.15591430664062}}, {"key": "310", "attributes": {"color": "#92EB8C", "label": "Research grant/Funding (self): Ipsen; Research grant/Funding (self): Tracon", "size": null, "x": -120.87715148925781, "y": -144.73397827148438}}, {"key": "311", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy, Research grant/Funding (self): Genentech", "size": null, "x": -121.66295623779297, "y": -143.05880737304688}}, {"key": "312", "attributes": {"color": "#92EB8C", "label": "Advisory/ Consultancy, Research grant/Funding (self): Roche", "size": null, "x": -121.06413269042969, "y": -143.7020263671875}}, {"key": "313", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy, Research grant/Funding (self): GSK", "size": null, "x": -122.51813507080078, "y": -143.99234008789062}}, {"key": "314", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy, Research grant/Funding (self", "size": null, "x": -121.28255462646484, "y": -144.69442749023438}}, {"key": "315", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy, Research grant/Funding (self): Merck", "size": null, "x": -120.16301727294922, "y": -143.3651885986328}}, {"key": "316", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy, Research grant/Funding (self): Novartis", "size": null, "x": -119.5633544921875, "y": -143.4286346435547}}, {"key": "317", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy, Research grant/Funding (self): Peloton", "size": null, "x": -120.09907531738281, "y": -145.06480407714844}}, {"key": "318", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy, Research grant/Funding (self): Promethius Labs", "size": null, "x": -120.66275024414062, "y": -145.7001190185547}}, {"key": "319", "attributes": {"color": "#92EB8C", "label": "Research grant/Funding (self): Corvus; Research grant/ Funding (self): Calithera", "size": null, "x": -121.44608306884766, "y": -145.2282257080078}}, {"key": "320", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy, Research grant/Funding (self)", "size": null, "x": -119.94520568847656, "y": -144.54478454589844}}, {"key": "321", "attributes": {"color": "#92EB8C", "label": "Research grant/Funding (self): Sanofi/Aventis; Research grant/ Funding (self): Takeda", "size": null, "x": -120.4233169555664, "y": -144.40562438964844}}, {"key": "322", "attributes": {"color": "#92EB8C", "label": "Honoraria (self)", "size": null, "x": -118.56713104248047, "y": -144.94326782226562}}, {"key": "323", "attributes": {"color": "#92EB8C", "label": "Honoraria (self): Navinata Healthcare; Honoraria (self), Advisory/Consultancy: NCCN", "size": null, "x": -119.25552368164062, "y": -144.76756286621094}}, {"key": "324", "attributes": {"color": "#92EB8C", "label": "MJH) Associates, Inc (Healthcare Communications Company with several brands such as OnClive", "size": null, "x": -122.20381164550781, "y": -143.4476776123047}}, {"key": "325", "attributes": {"color": "#92EB8C", "label": "Honoraria (self): Research to Practice", "size": null, "x": -120.11260986328125, "y": -144.138427734375}}, {"key": "326", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy: BM Watson Health", "size": null, "x": -120.76526641845703, "y": -142.97134399414062}}, {"key": "327", "attributes": {"color": "#92EB8C", "label": "Advisory/Consultancy: westat; Leadership role, Shareholder/Stockholder/ Stock options: HemOnc.org LLC", "size": null, "x": -120.10261535644531, "y": -145.6503143310547}}, {"key": "328", "attributes": {"color": "#17A75B", "label": "All other authors have declared no conflicts of interest", "size": null, "x": -131.74916076660156, "y": -134.6259002685547}}, {"key": "329", "attributes": {"color": "#92EB8C", "label": "LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19)", "size": null, "x": -120.41771697998047, "y": -146.15354919433594}}, {"key": "330", "attributes": {"color": "#92EB8C", "label": "Division of Cancer Control and Population Sciences", "size": null, "x": -119.15523529052734, "y": -143.06478881835938}}, {"key": "331", "attributes": {"color": "#92EB8C", "label": "The impact of clinicopathologic factors, cancer type, stage or therapies on outcomes of pts with COVID19 is not well defined. We systematically and comprehensively identified and assessed factors associated with high mortality (M) in the largest cohort of pts with cancer and COVID-19", "size": null, "x": -120.06007385253906, "y": -142.7885284423828}}, {"key": "332", "attributes": {"color": "#92EB8C", "label": "Analysis was limited to lab-confirmed COVID-19. Primary endpoint: all-cause 30-day M. Multivariable logistic regression was used to assess association between 30-day M and a priori identified demographic/clinicopathologic risk factors (age, sex, race, region, smoking, obesity, comorbidities, ECOG PS, cancer status, recent", "size": null, "x": -119.42804718017578, "y": -144.08787536621094}}, {"key": "333", "attributes": {"color": "#92EB8C", "label": "In 3830 pts with lab confirmed COVID19, 30-day M was 14% overall and 23% in hospitalized pts. Table shows adjusted [a]OR for overall and hospitalized pts. Age, male sex, smoking, >2 comorbidities, ECOG PS1, progressive cancer, hematologic or >1 cancer, and severe baseline COVID19 at presentation were associated with worse 30-day M", "size": null, "x": -119.69063568115234, "y": -146.19970703125}}, {"key": "334", "attributes": {"color": "#92EB8C", "label": "OVERall (N[3819) Hospitalized (N[2168)", "size": null, "x": -120.00083923339844, "y": -143.03399658203125}}, {"key": "335", "attributes": {"color": "#72B09D", "label": "Immunogenicity of one-and two-dose regimens of the Ad26.COV2.S COVID-19 vaccine candidate in adult and aged rhesus macaques", "size": null, "x": 57.13570022583008, "y": -30.836889266967773}}, {"key": "336", "attributes": {"color": "#72B09D", "label": "Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D", "size": null, "x": 56.97935104370117, "y": -30.069971084594727}}, {"key": "337", "attributes": {"color": "#72B09D", "label": "Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults", "size": null, "x": 58.118499755859375, "y": -31.99606704711914}}, {"key": "338", "attributes": {"color": "#72B09D", "label": "Firstin-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)", "size": null, "x": 58.45365524291992, "y": -31.952350616455078}}, {"key": "339", "attributes": {"color": "#72B09D", "label": "Ad26 vector-based COVID-19 vaccine encoding a prefusionstabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses", "size": null, "x": 58.6842155456543, "y": -32.12784957885742}}, {"key": "340", "attributes": {"color": "#72B09D", "label": "Coronavirus vaccine-associated lung immunopathology-what is the significance? Microbes and Infection", "size": null, "x": 58.0545654296875, "y": -33.11444854736328}}, {"key": "341", "attributes": {"color": "#72B09D", "label": "Activation-induce markers detect vaccine-specific CD4+ T cell responses not measured by assays conventionally used in clinical trials", "size": null, "x": 58.162811279296875, "y": -32.47092056274414}}, {"key": "342", "attributes": {"color": "#72B09D", "label": "A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates", "size": null, "x": 56.63753128051758, "y": -31.4440975189209}}, {"key": "343", "attributes": {"color": "#72B09D", "label": "Coronavirus Disease 2019 (COVID-19)", "size": null, "x": 56.37550354003906, "y": -30.69664764404297}}, {"key": "344", "attributes": {"color": "#72B09D", "label": "Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding Region", "size": null, "x": 58.466041564941406, "y": -29.815710067749023}}, {"key": "345", "attributes": {"color": "#72B09D", "label": "How long do vaccines last? The surprising answers may help protect people longer", "size": null, "x": 58.76636505126953, "y": -30.56756591796875}}, {"key": "346", "attributes": {"color": "#72B09D", "label": "Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates", "size": null, "x": 46.123714447021484, "y": -27.29709815979004}}, {"key": "347", "attributes": {"color": "#72B09D", "label": "Immunosenescence and human vaccine immune responses", "size": null, "x": 59.193626403808594, "y": -31.499771118164062}}, {"key": "348", "attributes": {"color": "#72B09D", "label": "WHO Declares COVID-19 a Pandemic", "size": null, "x": 58.722171783447266, "y": -30.180679321289062}}, {"key": "349", "attributes": {"color": "#72B09D", "label": "Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge", "size": null, "x": 57.6817741394043, "y": -29.91485595703125}}, {"key": "350", "attributes": {"color": "#72B09D", "label": "Influence of immune aging on vaccine responses", "size": null, "x": 88.96613311767578, "y": -37.837921142578125}}, {"key": "351", "attributes": {"color": "#72B09D", "label": "Prospects for a safe COVID-19 vaccine", "size": null, "x": 59.5948486328125, "y": -31.473600387573242}}, {"key": "352", "attributes": {"color": "#72B09D", "label": "Prime-boost interval matters: A randomized phase 1 study to identify the minimum interval necessary to observe the h5 dna influenza vaccine priming effect", "size": null, "x": 57.67454147338867, "y": -29.186264038085938}}, {"key": "353", "attributes": {"color": "#72B09D", "label": "Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies", "size": null, "x": 47.22816848754883, "y": -27.33559799194336}}, {"key": "354", "attributes": {"color": "#72B09D", "label": "The coronavirus is most deadly if you are older and male -new data reveal the risks", "size": null, "x": 56.2746696472168, "y": -31.606000900268555}}, {"key": "355", "attributes": {"color": "#3005C7", "label": "Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques", "size": null, "x": 46.192771911621094, "y": -27.761966705322266}}, {"key": "356", "attributes": {"color": "#72B09D", "label": "Immunological mechanisms of vaccination", "size": null, "x": 46.61958694458008, "y": -27.908292770385742}}, {"key": "357", "attributes": {"color": "#72B09D", "label": "Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized", "size": null, "x": 57.446510314941406, "y": -30.976770401000977}}, {"key": "358", "attributes": {"color": "#72B09D", "label": "Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations", "size": null, "x": 57.97703552246094, "y": -30.902956008911133}}, {"key": "359", "attributes": {"color": "#72B09D", "label": "From Vaccines to Memory and Back", "size": null, "x": 57.695098876953125, "y": -31.660852432250977}}, {"key": "360", "attributes": {"color": "#72B09D", "label": "C6Â® cells as a serum-free suspension cell platform for the production of high titer poliovirus: A potential low cost of goods option for world supply of inactivated poliovirus vaccine", "size": null, "x": 58.359375, "y": -31.381031036376953}}, {"key": "361", "attributes": {"color": "#72B09D", "label": "Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques", "size": null, "x": 59.18289566040039, "y": -30.302093505859375}}, {"key": "362", "attributes": {"color": "#72B09D", "label": "Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters", "size": null, "x": 58.65391159057617, "y": -29.445741653442383}}, {"key": "363", "attributes": {"color": "#72B09D", "label": "ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques", "size": null, "x": 57.20669174194336, "y": -32.414344787597656}}, {"key": "364", "attributes": {"color": "#72B09D", "label": "A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates", "size": null, "x": 58.56745529174805, "y": -30.85929298400879}}, {"key": "365", "attributes": {"color": "#72B09D", "label": "Age-related differences in humoral and cellular immune responses after primary immunisation: Indications for stratified vaccination schedules", "size": null, "x": 59.28926086425781, "y": -30.799633026123047}}, {"key": "366", "attributes": {"color": "#72B09D", "label": "Vaccines for the elderly: Current use and future challenges", "size": null, "x": 58.06136703491211, "y": -29.724027633666992}}, {"key": "367", "attributes": {"color": "#72B09D", "label": "Weekly update on COVID-19 -23", "size": null, "x": 58.96113586425781, "y": -32.2067985534668}}, {"key": "368", "attributes": {"color": "#72B09D", "label": "A new coronavirus associated with human respiratory disease in China", "size": null, "x": 28.591100692749023, "y": -5.205857276916504}}, {"key": "369", "attributes": {"color": "#72B09D", "label": "Potent And Short Promoter For Expression Of Heterologous Genes (Patent No", "size": null, "x": 59.018943786621094, "y": -29.870267868041992}}, {"key": "370", "attributes": {"color": "#72B09D", "label": "DNA vaccine protection against SARS-CoV-2 in rhesus macaques", "size": null, "x": 46.52155685424805, "y": -27.109619140625}}, {"key": "371", "attributes": {"color": "#72B09D", "label": "Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species", "size": null, "x": 57.27046585083008, "y": -31.068490982055664}}, {"key": "372", "attributes": {"color": "#72B09D", "label": "A novel coronavirus from patients with pneumonia in China", "size": null, "x": 58.16128158569336, "y": -30.77301597595215}}, {"key": "373", "attributes": {"color": "#72B09D", "label": "Factors That Influence the Immune Response to Vaccination", "size": null, "x": 59.66559982299805, "y": -30.522642135620117}}, {"key": "374", "attributes": {"color": "#69D6D4", "label": "COVID-19 in Patients with Hematological Malignancies: High False Negative Rate with High Mortality", "size": null, "x": -132.57406616210938, "y": -235.77268981933594}}, {"key": "375", "attributes": {"color": "#69D6D4", "label": "Amgen: Honoraria; Verastem: Honoraria", "size": null, "x": -131.94598388671875, "y": -235.53939819335938}}, {"key": "376", "attributes": {"color": "#69D6D4", "label": "Saba: Kite: Other: Advisory Board; Pharmacyclics: Other: Advisory Board, Speakers Bureau; AbbVie: Consultancy, Other: Advisory Board, Speakers Bureau; Janssen: Other: Advisory Board, Speakers Bureau; Kyowa Kirin: Other: Advisory Board", "size": null, "x": -133.00070190429688, "y": -236.02255249023438}}, {"key": "377", "attributes": {"color": "#E2AD82", "label": "mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach", "size": null, "x": -67.84127044677734, "y": -152.60507202148438}}, {"key": "378", "attributes": {"color": "#E2AD82", "label": "Coronavirus by the numbers: coronavirus is surging: how severe is your state's outbreak? National Public Radio", "size": null, "x": -69.6808090209961, "y": -152.94871520996094}}, {"key": "379", "attributes": {"color": "#E2AD82", "label": "Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine -United States", "size": null, "x": -66.79114532470703, "y": -153.29713439941406}}, {"key": "380", "attributes": {"color": "#E2AD82", "label": "Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States-Appendix B", "size": null, "x": -67.88292694091797, "y": -152.04705810546875}}, {"key": "381", "attributes": {"color": "#E2AD82", "label": "Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine", "size": null, "x": -67.71247100830078, "y": -152.9640655517578}}, {"key": "382", "attributes": {"color": "#E2AD82", "label": "Food and Drug Administration. Moderna COVID-19 vaccine", "size": null, "x": -66.7570571899414, "y": -152.10740661621094}}, {"key": "383", "attributes": {"color": "#E2AD82", "label": "Food and Drug Administration, Vaccines and Related Biological Products Advisory Committee", "size": null, "x": -66.20802307128906, "y": -152.6055908203125}}, {"key": "384", "attributes": {"color": "#E2AD82", "label": "Pfizer-BioNTech COVID-19 vaccine (BNT162, PF-07302048)", "size": null, "x": -68.9349594116211, "y": -151.25245666503906}}, {"key": "385", "attributes": {"color": "#E2AD82", "label": "Risk of anaphylaxis after vaccination in children and adults", "size": null, "x": -68.57910919189453, "y": -150.65098571777344}}, {"key": "386", "attributes": {"color": "#E2AD82", "label": "Immune-mediated adverse reactions to vaccines", "size": null, "x": -68.59977722167969, "y": -152.69248962402344}}, {"key": "387", "attributes": {"color": "#E2AD82", "label": "Change in gelatin content of vaccines associated with reduction in reports of allergic reactions", "size": null, "x": -67.94371032714844, "y": -153.68600463867188}}, {"key": "388", "attributes": {"color": "#E2AD82", "label": "MMR vaccination of children with egg allergy is safe", "size": null, "x": -66.27941131591797, "y": -153.74110412597656}}, {"key": "389", "attributes": {"color": "#E2AD82", "label": "Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized", "size": null, "x": -67.37992095947266, "y": -151.36395263671875}}, {"key": "390", "attributes": {"color": "#E2AD82", "label": "Excipients in vaccines per 0.5 mL dose", "size": null, "x": -67.93000793457031, "y": -151.4766082763672}}, {"key": "391", "attributes": {"color": "#E2AD82", "label": "Anaphylaxis to PEGylated liposomal echocardiogram contrast in a patient with IgE-mediated macrogol allergy", "size": null, "x": -68.61908721923828, "y": -152.11903381347656}}, {"key": "392", "attributes": {"color": "#E2AD82", "label": "Anti-PEG immunity: emergence, characteristics, and unaddressed questions", "size": null, "x": -66.49707794189453, "y": -153.4911346435547}}, {"key": "393", "attributes": {"color": "#E2AD82", "label": "Anti-PEG IgE in anaphylaxis associated with polyethylene glycol", "size": null, "x": -67.33836364746094, "y": -153.6141815185547}}, {"key": "394", "attributes": {"color": "#E2AD82", "label": "Immediate-type hypersensitivity to polyethylene glycols: a review", "size": null, "x": -67.87718200683594, "y": -154.17568969726562}}, {"key": "395", "attributes": {"color": "#E2AD82", "label": "Polyethylene glycol-induced systemic allergic reactions (anaphylaxis)", "size": null, "x": -68.14286041259766, "y": -153.20526123046875}}, {"key": "396", "attributes": {"color": "#E2AD82", "label": "Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly", "size": null, "x": -66.43836975097656, "y": -151.5037078857422}}, {"key": "397", "attributes": {"color": "#E2AD82", "label": "Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review", "size": null, "x": -68.50855255126953, "y": -153.84405517578125}}, {"key": "398", "attributes": {"color": "#E2AD82", "label": "Anaphylaxis to polyethylene glycol (ColyteÃ) in a patient with diverticulitis", "size": null, "x": -65.86497497558594, "y": -151.7944793701172}}, {"key": "399", "attributes": {"color": "#E2AD82", "label": "Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions", "size": null, "x": -65.92909240722656, "y": -152.88389587402344}}, {"key": "400", "attributes": {"color": "#E2AD82", "label": "Fluorescent molecular rotors as dyes to characterize polysorbate-containing IgG formulations", "size": null, "x": -67.49261474609375, "y": -152.4109344482422}}, {"key": "401", "attributes": {"color": "#E2AD82", "label": "Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy", "size": null, "x": -68.96736907958984, "y": -153.1885528564453}}, {"key": "402", "attributes": {"color": "#E2AD82", "label": "Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80", "size": null, "x": -66.89948272705078, "y": -152.56382751464844}}, {"key": "403", "attributes": {"color": "#E2AD82", "label": "Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin", "size": null, "x": -69.08622741699219, "y": -154.120361328125}}, {"key": "404", "attributes": {"color": "#E2AD82", "label": "An allergic reaction to erythropoietin secondary to polysorbate hypersensitivity", "size": null, "x": -67.78414916992188, "y": -154.60916137695312}}, {"key": "405", "attributes": {"color": "#E2AD82", "label": "Potential cross-reactivity of polysorbate 80 and cremophor: a case report", "size": null, "x": -66.56431579589844, "y": -152.64198303222656}}, {"key": "406", "attributes": {"color": "#E2AD82", "label": "Anaphylaxis due to the excipient polysorbate 80", "size": null, "x": -69.16390228271484, "y": -152.13796997070312}}, {"key": "407", "attributes": {"color": "#E2AD82", "label": "Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol?", "size": null, "x": -67.26014709472656, "y": -153.0120849609375}}, {"key": "408", "attributes": {"color": "#E2AD82", "label": "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK", "size": null, "x": -69.38739776611328, "y": -152.6270294189453}}, {"key": "409", "attributes": {"color": "#E2AD82", "label": "Acute anaphylaxis associated with serum complement depletion", "size": null, "x": -67.00050354003906, "y": -153.6787872314453}}, {"key": "410", "attributes": {"color": "#E2AD82", "label": "Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes: role of complement and inhibition by soluble CR1 and anti-C5a antibody", "size": null, "x": -68.23511505126953, "y": -151.8409881591797}}, {"key": "411", "attributes": {"color": "#E2AD82", "label": "Suspicions grow that nanoparticles in Pfizer's COVID-19 vaccine trigger rare allergic reactions. Science Magazine", "size": null, "x": -67.37242889404297, "y": -151.66688537597656}}, {"key": "412", "attributes": {"color": "#E2AD82", "label": "Understanding the role of anti-PEG antibodies in the complement activation by doxil in vitro", "size": null, "x": -67.29158782958984, "y": -154.1822509765625}}, {"key": "413", "attributes": {"color": "#E2AD82", "label": "Prevaccination checklist for COVID-19 vaccines", "size": null, "x": -68.5961685180664, "y": -153.16497802734375}}, {"key": "414", "attributes": {"color": "#E2AD82", "label": "Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs", "size": null, "x": -68.0287094116211, "y": -151.2334747314453}}, {"key": "415", "attributes": {"color": "#E2AD82", "label": "Adverse reactions to vaccines practice parameter 2012 update", "size": null, "x": -68.81285095214844, "y": -151.4675750732422}}, {"key": "416", "attributes": {"color": "#E2AD82", "label": "Food and Drug Administration, U.S. Department of Health and Human Services", "size": null, "x": -68.11774444580078, "y": -152.5734100341797}}, {"key": "417", "attributes": {"color": "#E2AD82", "label": "V-safe after vaccination health checker", "size": null, "x": -69.48143768310547, "y": -153.4769287109375}}, {"key": "418", "attributes": {"color": "#E2AD82", "label": "Interim considerations: preparing for the potential management of anaphylaxis after COVID-19 vaccination", "size": null, "x": -66.9980697631836, "y": -151.58108520507812}}, {"key": "419", "attributes": {"color": "#E2AD82", "label": "Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis", "size": null, "x": -69.27023315429688, "y": -151.408935546875}}, {"key": "420", "attributes": {"color": "#E2AD82", "label": "Winnipeg Regional Health Authority", "size": null, "x": -69.35291290283203, "y": -154.3241729736328}}, {"key": "421", "attributes": {"color": "#E2AD82", "label": "Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis", "size": null, "x": -69.62818145751953, "y": -152.09214782714844}}, {"key": "422", "attributes": {"color": "#3E8A9B", "label": "CASE REPORT De Novo Immunoglobulin A Vasculitis Following Exposure to SARS-CoV-2 Immunization", "size": null, "x": 1.094779372215271, "y": -207.98902893066406}}, {"key": "423", "attributes": {"color": "#3E8A9B", "label": "Current understanding of clinical manifestations of COVID-19 in glomerular disease", "size": null, "x": 0.913066565990448, "y": -207.16983032226562}}, {"key": "424", "attributes": {"color": "#3E8A9B", "label": "AKI and collapsing glomerulopathy associated with COVID-19 and APOL1 high-risk genotype", "size": null, "x": 0.8163812756538391, "y": -209.5037384033203}}, {"key": "425", "attributes": {"color": "#3E8A9B", "label": "De novo and relapsing glomerular diseases after COVID-19 vaccination: what do we know so far?", "size": null, "x": 0.48014527559280396, "y": -207.18753051757812}}, {"key": "426", "attributes": {"color": "#3E8A9B", "label": "Anti-GBM nephritis with mesangial IgA deposits after SARS-CoV-2 mRNA vaccination", "size": null, "x": 1.0283606052398682, "y": -208.70362854003906}}, {"key": "427", "attributes": {"color": "#3E8A9B", "label": "Minimal change disease following influenza vaccination and acute renal failure: just a coincidence?", "size": null, "x": 1.437825083732605, "y": -207.9320068359375}}, {"key": "428", "attributes": {"color": "#3E8A9B", "label": "Minimal change nephrotic syndrome, lymphadenopathy and hyperimmunoglobulinemia after immunization with a pneumococcal vaccine", "size": null, "x": -0.4024301767349243, "y": -208.70443725585938}}, {"key": "429", "attributes": {"color": "#3E8A9B", "label": "Membranous nephropathy and severe acute kidney injury following influenza vaccination", "size": null, "x": 2.3046488761901855, "y": -208.32192993164062}}, {"key": "430", "attributes": {"color": "#3E8A9B", "label": "A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination", "size": null, "x": -0.5793416500091553, "y": -208.0474395751953}}, {"key": "431", "attributes": {"color": "#3E8A9B", "label": "Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy", "size": null, "x": 2.4191229343414307, "y": -207.6304931640625}}, {"key": "432", "attributes": {"color": "#3E8A9B", "label": "Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy", "size": null, "x": 0.33419209718704224, "y": -206.65863037109375}}, {"key": "433", "attributes": {"color": "#3E8A9B", "label": "IgA nephropathy flare-up following SARS-CoV-2 vaccination", "size": null, "x": 1.8656628131866455, "y": -206.8782196044922}}, {"key": "434", "attributes": {"color": "#3E8A9B", "label": "Regulatory T cell frequencies and phenotypes following anti-viral vaccination", "size": null, "x": 1.5632688999176025, "y": -208.5040740966797}}, {"key": "435", "attributes": {"color": "#3E8A9B", "label": "Pathogenesis of lipoid nephrosis: a disorder of T-cell function", "size": null, "x": 2.661695718765259, "y": -208.4417266845703}}, {"key": "436", "attributes": {"color": "#3E8A9B", "label": "Minimal change nephrotic syndrome in a 65-year-old patient following influenza vaccination", "size": null, "x": 1.4397577047348022, "y": -207.51156616210938}}, {"key": "437", "attributes": {"color": "#3E8A9B", "label": "Minimal change disease following the Pfizer-BioNTech COVID-19 vaccine", "size": null, "x": 0.934270441532135, "y": -209.0011444091797}}, {"key": "438", "attributes": {"color": "#3E8A9B", "label": "Minimal change nephrotic syndrome in an 82 year old patient following a tetanus-diphteria-poliomyelitis-vaccination", "size": null, "x": 0.6193799376487732, "y": -207.96636962890625}}, {"key": "439", "attributes": {"color": "#3E8A9B", "label": "Minimal-change nephrotic syndrome in a hematopoietic stem-cell transplant recipient", "size": null, "x": 1.183942437171936, "y": -209.33140563964844}}, {"key": "440", "attributes": {"color": "#3E8A9B", "label": "Nephrotic syndrome following hepatitis B vaccination", "size": null, "x": 3.0456936359405518, "y": -207.70663452148438}}, {"key": "441", "attributes": {"color": "#3E8A9B", "label": "Nephrotic syndrome associated with recombinant hepatitis B vaccination: a causal relationship or just a mere association?", "size": null, "x": 0.4319634437561035, "y": -208.72764587402344}}, {"key": "442", "attributes": {"color": "#3E8A9B", "label": "IgA nephropathy after SARS-CoV-2 vaccination", "size": null, "x": 1.8569003343582153, "y": -208.840087890625}}, {"key": "443", "attributes": {"color": "#3E8A9B", "label": "De novo vasculitis after mRNA-1273 (Moderna) vaccination", "size": null, "x": 0.10257407277822495, "y": -209.18675231933594}}, {"key": "444", "attributes": {"color": "#3E8A9B", "label": "A method for estimating the probability of adverse drug reactions", "size": null, "x": 1.0159831047058105, "y": -206.5447235107422}}, {"key": "445", "attributes": {"color": "#3E8A9B", "label": "Italian Multicenter Study Group for Drug and Vaccine Safety in Children. Henoch-SchÃ¶nlein purpura and drug and vaccine use in childhood: a case-control study", "size": null, "x": 0.4023325741291046, "y": -207.38072204589844}}, {"key": "446", "attributes": {"color": "#3E8A9B", "label": "Brighton Collaboration Vasculitis Working Group. Vasculitis as an adverse event following immunization -systematic literature review", "size": null, "x": 1.6541991233825684, "y": -207.49496459960938}}, {"key": "447", "attributes": {"color": "#3E8A9B", "label": "Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases", "size": null, "x": 2.4114134311676025, "y": -206.91261291503906}}, {"key": "448", "attributes": {"color": "#3E8A9B", "label": "Henoch-SchÃ¶nlein purpura presenting post COVID-19 vaccination", "size": null, "x": 2.020512342453003, "y": -208.1196746826172}}, {"key": "449", "attributes": {"color": "#3E8A9B", "label": "Granulomatous vasculitis after the AstraZeneca anti-SARS-CoV-2 vaccine", "size": null, "x": -0.06727104634046555, "y": -207.39784240722656}}, {"key": "450", "attributes": {"color": "#3E8A9B", "label": "Leukocytoclastic vasculitis in children: clinical characteristics, subtypes, causes and direct immunofluorescence findings of 56 biopsy-confirmed cases", "size": null, "x": 0.022121118381619453, "y": -208.12351989746094}}, {"key": "451", "attributes": {"color": "#5CE4D5", "label": "Outcomes in Patients with Hematologic Malignancies Infected with Sars-Cov-2: The Northwestern University Experience Background", "size": null, "x": 87.59131622314453, "y": 142.95797729492188}}, {"key": "452", "attributes": {"color": "#5CE4D5", "label": "Larger studies are needed to confirm our findings and help guide management of pts with hematologic malignancies during the SARS-CoV-2 pandemic", "size": null, "x": 88.62250518798828, "y": 142.81735229492188}}, {"key": "453", "attributes": {"color": "#5CE4D5", "label": "Janssen: Consultancy; Immune Pharmaceuticals: Consultancy; Syros: Consultancy; Genentech: Research Funding; Novartis: Consultancy; Amphivena: Research Funding; Amgen: Research Funding; Aprea: Research Funding; ImmunoGen: Research Funding; Celgene: Research Funding; Boehringer Ingelheim: Research Funding; Fujifilm: Research Funding; Kartos: Research Funding; AbbVie: Other: advisory board, Research Funding; Kura Oncology: Other: Scientific Advisory Board -no payment accepted", "size": null, "x": 87.50747680664062, "y": 143.5528564453125}}, {"key": "454", "attributes": {"color": "#5CE4D5", "label": "Other: Advisory Board -no payment but was reimbursed for travel; Agios: Other: advisory board, Research Funding; Glycomimetics: Other: Data safety and monitoring committee", "size": null, "x": 86.87577819824219, "y": 142.6474151611328}}, {"key": "455", "attributes": {"color": "#5CE4D5", "label": "Research Funding; Theradex: Other: Advisory Board", "size": null, "x": 87.81389617919922, "y": 142.03648376464844}}, {"key": "456", "attributes": {"color": "#5CE4D5", "label": "France Foundation: Consultancy; PeerView: Consultancy; PrIME Oncology: Consultancy. Winter: Delta Fly Pharma: Consultancy", "size": null, "x": 87.99994659423828, "y": 142.80328369140625}}, {"key": "457", "attributes": {"color": "#5CE4D5", "label": "Funding; Novartis: Research Funding; Kite: Consultancy, Honoraria; Pharmacyclics, LLC, an AbbVie Company: Consultancy, Honoraria, Research Funding", "size": null, "x": 88.35360717773438, "y": 142.15335083007812}}, {"key": "458", "attributes": {"color": "#5CE4D5", "label": "BMS/Celgene/Juno: Honoraria, Other, Research Funding", "size": null, "x": 88.20967864990234, "y": 143.41677856445312}}, {"key": "459", "attributes": {"color": "#17A75B", "label": "711P SARS-CoV-2 infection in prostate cancer patients: Data from a high- incidence area in Italy 1712P Risk of SARS-CoV-2 infection and outcome after infection: Experience from the day-care unit at CHU LiÃ¨ge in Belgium", "size": null, "x": -143.016845703125, "y": -124.78741455078125}}, {"key": "460", "attributes": {"color": "#17A75B", "label": "Advisory/Consultancy: Clovis; Sanofi", "size": null, "x": -145.15940856933594, "y": -123.60504150390625}}, {"key": "461", "attributes": {"color": "#17A75B", "label": "Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Amgen; Pfizer; Advisory/ Consultancy: Servier; Bayer; Merck; Lilly; Sanofi; Sirtex; Celgene; Ipsen; Novartis. P. Freres: Advisory/ Consultancy: Ipsen; Merck; BMS. C. Gennigens: Advisory/Consultancy", "size": null, "x": -143.67837524414062, "y": -124.21082305908203}}, {"key": "462", "attributes": {"color": "#17A75B", "label": "Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Novartis; Roche", "size": null, "x": -145.01182556152344, "y": -124.31970977783203}}, {"key": "463", "attributes": {"color": "#17A75B", "label": "Travel/Accommodation/Expenses: Lilly; Advisory/Consultancy", "size": null, "x": -143.24884033203125, "y": -123.74402618408203}}, {"key": "464", "attributes": {"color": "#17A75B", "label": "1713P Active smoking and severity of COVID-19 infection in cancer patients", "size": null, "x": -145.0003662109375, "y": -124.8531265258789}}, {"key": "465", "attributes": {"color": "#17A75B", "label": "Hospital Clinic y Provincial de Barcelona", "size": null, "x": -144.6162872314453, "y": -123.76406860351562}}, {"key": "466", "attributes": {"color": "#17A75B", "label": "HÃ´pital EuropÃ©en George Pompidou", "size": null, "x": -142.8582763671875, "y": -124.25601959228516}}, {"key": "467", "attributes": {"color": "#17A75B", "label": "Hospital del Mar", "size": null, "x": -144.4072265625, "y": -124.7026596069336}}, {"key": "468", "attributes": {"color": "#17A75B", "label": "Thoracic tumors were the most common (52%), 72% had advanced disease and 56% were under systemic therapy. 92% of active smokers required hospitalization, 68% developed pneumonia and 58% required oxygen. Only 4% were escalated to the intensive care unit. Active smokers received treatment with hydroxychloroquine (91%), azithromycin (61%), antiviral therapy (33%) and steroids (29%). Only 4% received immunomodulatory drugs. SARF was the most common complication (25%) and no thromboembolic events were observed. A pro-inflammatory status was observed at COVID-19 diagnosis in active smokers", "size": null, "x": -142.7203826904297, "y": -123.49153137207031}}, {"key": "469", "attributes": {"color": "#17A75B", "label": "Conclusions: Active smoking might be associated with severe COVID-19 infection and early death in cancer patients. Smoking induced-inflammation should be further explored", "size": null, "x": -143.64657592773438, "y": -124.84965515136719}}, {"key": "470", "attributes": {"color": "#F4F361", "label": "Outpatient Transplantation during the COVID19 Pandemic: Stretching the Limits for Continuing Care", "size": null, "x": 223.52532958984375, "y": -65.6339340209961}}, {"key": "471", "attributes": {"color": "#F4F361", "label": "Conclusion: Outpatient transplantation is a feasible alternative for performing HSCT during the COVID-19 pandemic minimizing the risk of infection and providing a safe environment for patients, donors", "size": null, "x": 224.03250122070312, "y": -65.20390319824219}}, {"key": "472", "attributes": {"color": "#F4F361", "label": "Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": 223.96646118164062, "y": -66.02100372314453}}, {"key": "473", "attributes": {"color": "#6270E4", "label": "Addressing COVID-19 Drug Development with Artificial Intelligence", "size": null, "x": 135.48004150390625, "y": -136.2115020751953}}, {"key": "474", "attributes": {"color": "#6270E4", "label": "Ministry of Education (MOE) Tier 1 FRC grant, and Singapore Ministry of Health's National Medical Research Council under its Open Fund-Large Collaborative Grant", "size": null, "x": 134.8508758544922, "y": -136.0169219970703}}, {"key": "475", "attributes": {"color": "#6270E4", "label": "Proc. Natl. Acad. Sci", "size": null, "x": 135.55348205566406, "y": -136.3087615966797}}, {"key": "476", "attributes": {"color": "#6270E4", "label": "10, eaan0941; b)", "size": null, "x": 135.70033264160156, "y": -135.68344116210938}}, {"key": "477", "attributes": {"color": "#69FAED", "label": "Evidence of Microangiopathy in Children with Sars-Cov-2 Regardless of Clinical Presentation", "size": null, "x": 151.4971923828125, "y": -192.33013916015625}}, {"key": "478", "attributes": {"color": "#69FAED", "label": "Children's Hospital of Philadelphia: Research Funding", "size": null, "x": 151.8257598876953, "y": -191.72930908203125}}, {"key": "479", "attributes": {"color": "#69FAED", "label": "Research Funding; Educational Concepts in Medicine: Consultancy; Shionogi: Consultancy; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": 151.31033325195312, "y": -193.08840942382812}}, {"key": "480", "attributes": {"color": "#69FAED", "label": "Membership on an entity's Board of Directors or advisory committees; Principia: Consultancy, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": 152.33847045898438, "y": -192.3025360107422}}, {"key": "481", "attributes": {"color": "#69FAED", "label": "PDSA): Consultancy; AstraZeneca: Research Funding", "size": null, "x": 151.29629516601562, "y": -192.05104064941406}}, {"key": "482", "attributes": {"color": "#69FAED", "label": "Research Funding; NIAID: Research Funding. Bassiri: CSL Behring: Other: Spouse receives stocks . Behrens: NIH/NIAID: Research Funding. Teachey: Janssen: Consultancy", "size": null, "x": 152.01087951660156, "y": -192.76235961914062}}, {"key": "483", "attributes": {"color": "#69FAED", "label": "Consultancy; Sobi: Consultancy", "size": null, "x": 150.727783203125, "y": -192.29701232910156}}, {"key": "484", "attributes": {"color": "#72F712", "label": "Prospective Multicentric Observational Study of COVID19 in Oncohematological Patients in the Catalonia Region: The Opposite Effect of Steroids on Survival", "size": null, "x": 183.16700744628906, "y": -146.61538696289062}}, {"key": "485", "attributes": {"color": "#72F712", "label": "Sureda Balari: Gilead/Kite: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; BMS: Speakers Bureau; Roche: Honoraria; Sanofi: Consultancy, Honoraria", "size": null, "x": 182.95689392089844, "y": -145.98724365234375}}, {"key": "486", "attributes": {"color": "#72F712", "label": "Janssen: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Celgene/Bristol-Myers Squibb: Consultancy, Honoraria; Takeda: Consultancy, Honoraria", "size": null, "x": 183.41075134277344, "y": -147.11705017089844}}, {"key": "487", "attributes": {"color": "#7EC1D0", "label": "Thrombosis and Risk Management in Paediatric Inflammatory Multisystem Syndrome - Temporally Associated with Sars-CoV2 (PIMS-TS)", "size": null, "x": -82.49323272705078, "y": -260.2895202636719}}, {"key": "488", "attributes": {"color": "#7EC1D0", "label": "Other: Steering committee participation, Research Funding, Speakers Bureau; Bluebird bio: Research Funding; Novartis: Honoraria, Other: Steering committee participation, Research Funding, Speakers Bureau; Global Blood Therapeutics: Honoraria, Other: Steering committee participation", "size": null, "x": -82.12739562988281, "y": -260.6800537109375}}, {"key": "489", "attributes": {"color": "#3005C7", "label": "COVID-19 Vaccines: The Status and Perspectives in Delivery Points of View", "size": null, "x": 35.437950134277344, "y": -24.31073570251465}}, {"key": "490", "attributes": {"color": "#3005C7", "label": "Cultivation of a Novel Type of Common-Cold Virus in Organ Cultures", "size": null, "x": 33.6245231628418, "y": -21.942245483398438}}, {"key": "491", "attributes": {"color": "#3005C7", "label": "Origin and evolution of pathogenic coronaviruses", "size": null, "x": 17.788618087768555, "y": -1.0418342351913452}}, {"key": "492", "attributes": {"color": "#3005C7", "label": "Human Coronavirus-229E,-OC43,-NL63, and-HKU1, Reference Module in Life Sciences", "size": null, "x": 37.16476821899414, "y": -23.283056259155273}}, {"key": "493", "attributes": {"color": "#3005C7", "label": "Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections", "size": null, "x": 36.61410140991211, "y": -25.4508056640625}}, {"key": "494", "attributes": {"color": "#3005C7", "label": "Aerosol emission of child voices during speaking, singing and shouting", "size": null, "x": 36.19707489013672, "y": -21.415035247802734}}, {"key": "495", "attributes": {"color": "#3005C7", "label": "Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy", "size": null, "x": 34.03494644165039, "y": -24.523984909057617}}, {"key": "496", "attributes": {"color": "#3005C7", "label": "Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1", "size": null, "x": 33.23856735229492, "y": -24.96415901184082}}, {"key": "497", "attributes": {"color": "#3005C7", "label": "High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice", "size": null, "x": 37.499027252197266, "y": -27.12148666381836}}, {"key": "498", "attributes": {"color": "#3005C7", "label": "It is time to address airborne transmission of COVID-19", "size": null, "x": 37.11454391479492, "y": -21.57457160949707}}, {"key": "499", "attributes": {"color": "#3005C7", "label": "Aerosol transmission of SARS-CoV-2? Evidence, prevention and control", "size": null, "x": 33.20730209350586, "y": -21.360750198364258}}, {"key": "500", "attributes": {"color": "#3005C7", "label": "Probable Evidence of Fecal Aerosol Transmission of SARS-CoV-2 in a High-Rise Building", "size": null, "x": 34.49482345581055, "y": -24.899810791015625}}, {"key": "501", "attributes": {"color": "#3005C7", "label": "Evidence of airborne transmission of the severe acute respiratory syndrome virus", "size": null, "x": 35.550872802734375, "y": -20.786121368408203}}, {"key": "502", "attributes": {"color": "#3005C7", "label": "Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review", "size": null, "x": 37.931243896484375, "y": -24.164316177368164}}, {"key": "503", "attributes": {"color": "#3005C7", "label": "A pneumonia outbreak associated with a new coronavirus of probable bat origin", "size": null, "x": 36.40449523925781, "y": -20.740978240966797}}, {"key": "504", "attributes": {"color": "#3005C7", "label": "Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics", "size": null, "x": 33.28288269042969, "y": -23.053482055664062}}, {"key": "505", "attributes": {"color": "#54A214", "label": "The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application", "size": null, "x": 55.04263687133789, "y": -78.70852661132812}}, {"key": "506", "attributes": {"color": "#3005C7", "label": "Immune-mediated approaches against COVID-19", "size": null, "x": 32.74559783935547, "y": -21.713876724243164}}, {"key": "507", "attributes": {"color": "#3005C7", "label": "The trinity of COVID-19: immunity, inflammation and intervention", "size": null, "x": 35.52852249145508, "y": -26.931461334228516}}, {"key": "508", "attributes": {"color": "#3005C7", "label": "Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19)", "size": null, "x": 37.914512634277344, "y": -27.35746955871582}}, {"key": "509", "attributes": {"color": "#3005C7", "label": "The contribution of vaccination to global health: past, present and future", "size": null, "x": 36.731468200683594, "y": -25.97745132446289}}, {"key": "510", "attributes": {"color": "#3005C7", "label": "CDC 2020-2021 Flu Vaccine Campaign Kickoff", "size": null, "x": 34.76664352416992, "y": -25.810274124145508}}, {"key": "511", "attributes": {"color": "#3005C7", "label": "The Social Value Of Vaccination Programs: Beyond Cost-Effectiveness", "size": null, "x": 33.285404205322266, "y": -25.494966506958008}}, {"key": "512", "attributes": {"color": "#3005C7", "label": "Next-generation vaccine platforms for COVID-19", "size": null, "x": 34.67914962768555, "y": -20.4140682220459}}, {"key": "513", "attributes": {"color": "#3005C7", "label": "A materials-science perspective on tackling COVID-19", "size": null, "x": 35.26236343383789, "y": -27.232288360595703}}, {"key": "514", "attributes": {"color": "#3005C7", "label": "Insights from nanotechnology in COVID-19 treatment", "size": null, "x": 36.962120056152344, "y": -22.03441047668457}}, {"key": "515", "attributes": {"color": "#9163E2", "label": "COVID-19 Vaccine Frontrunners and Their Nanotechnology Design", "size": null, "x": -52.5295524597168, "y": -20.488040924072266}}, {"key": "516", "attributes": {"color": "#3005C7", "label": "Why Go NANO on COVID-19 Pandemic?", "size": null, "x": 34.31917190551758, "y": -20.596101760864258}}, {"key": "517", "attributes": {"color": "#3005C7", "label": "Nanomedicine and the COVID-19 vaccines", "size": null, "x": 32.34629440307617, "y": -23.6773681640625}}, {"key": "518", "attributes": {"color": "#45E73B", "label": "Developing Covid-19 vaccines at pandemic speed", "size": null, "x": 93.83203887939453, "y": 3.39302134513855}}, {"key": "519", "attributes": {"color": "#3005C7", "label": "Whither COVID-19 vaccines?", "size": null, "x": 38.01367950439453, "y": -22.90909194946289}}, {"key": "520", "attributes": {"color": "#3005C7", "label": "The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity, bioRxiv", "size": null, "x": 37.626155853271484, "y": -25.109214782714844}}, {"key": "521", "attributes": {"color": "#3005C7", "label": "Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus", "size": null, "x": 32.73239517211914, "y": -25.202951431274414}}, {"key": "522", "attributes": {"color": "#3005C7", "label": "Structure, function, and evolution of coronavirus spike proteins", "size": null, "x": 38.98426818847656, "y": -25.57271385192871}}, {"key": "523", "attributes": {"color": "#3005C7", "label": "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response", "size": null, "x": 35.99021911621094, "y": -20.320072174072266}}, {"key": "524", "attributes": {"color": "#3005C7", "label": "Coronavirus envelope protein: current knowledge", "size": null, "x": 17.4376220703125, "y": -2.3258631229400635}}, {"key": "525", "attributes": {"color": "#3005C7", "label": "Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein", "size": null, "x": 32.2836799621582, "y": -25.732807159423828}}, {"key": "526", "attributes": {"color": "#DA049E", "label": "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor", "size": null, "x": -25.41863250732422, "y": 110.04898834228516}}, {"key": "527", "attributes": {"color": "#3005C7", "label": "Cell entry mechanisms of SARS-CoV-2", "size": null, "x": 36.236942291259766, "y": -25.11863899230957}}, {"key": "528", "attributes": {"color": "#3005C7", "label": "SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues", "size": null, "x": 36.312252044677734, "y": -23.735715866088867}}, {"key": "529", "attributes": {"color": "#3005C7", "label": "Single-cell RNA expression profiling shows that ACE2, the putative receptor of Wuhan 2019-nCoV, has significant expression in the nasal, mouth, lung and colon tissues, and tends to be co-expressed with HLA-DRB1 in the four tissues", "size": null, "x": 33.75738525390625, "y": -22.843332290649414}}, {"key": "530", "attributes": {"color": "#3005C7", "label": "SARS-CoV-2 invades host cells via a novel route: CD147-spike protein", "size": null, "x": 37.78290939331055, "y": -26.12312889099121}}, {"key": "531", "attributes": {"color": "#3005C7", "label": "Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4", "size": null, "x": 34.712554931640625, "y": -26.69869041442871}}, {"key": "532", "attributes": {"color": "#3005C7", "label": "Middle East respiratory syndrome-coronavirus infection into established hDDP4-transgenic mice accelerates lung damage via activation of the pro-inflammatory response and pulmonary fibrosis", "size": null, "x": 38.3026123046875, "y": -24.142242431640625}}, {"key": "533", "attributes": {"color": "#3005C7", "label": "Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26", "size": null, "x": 34.33470916748047, "y": -24.30670738220215}}, {"key": "534", "attributes": {"color": "#3005C7", "label": "Molecular structure analyses suggest strategies to therapeutically target SARS-CoV-2", "size": null, "x": 34.08571243286133, "y": -23.721660614013672}}, {"key": "535", "attributes": {"color": "#3005C7", "label": "Nanotechnology for COVID-19: therapeutics and vaccine research", "size": null, "x": 36.59458541870117, "y": -23.471364974975586}}, {"key": "536", "attributes": {"color": "#3005C7", "label": "Coronaviruses pandemics: Can neutralizing antibodies help?", "size": null, "x": 37.57865524291992, "y": -23.019634246826172}}, {"key": "537", "attributes": {"color": "#3005C7", "label": "A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection", "size": null, "x": 37.460365295410156, "y": -27.918075561523438}}, {"key": "538", "attributes": {"color": "#3005C7", "label": "Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid", "size": null, "x": 35.581668853759766, "y": -25.138673782348633}}, {"key": "539", "attributes": {"color": "#3005C7", "label": "Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus", "size": null, "x": 36.437015533447266, "y": -21.7369384765625}}, {"key": "540", "attributes": {"color": "#3005C7", "label": "Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity", "size": null, "x": 34.37143325805664, "y": -24.65519142150879}}, {"key": "541", "attributes": {"color": "#3005C7", "label": "Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine", "size": null, "x": 34.957332611083984, "y": -26.80124855041504}}, {"key": "542", "attributes": {"color": "#3005C7", "label": "The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes", "size": null, "x": 35.45766067504883, "y": -23.416372299194336}}, {"key": "543", "attributes": {"color": "#3005C7", "label": "SARS-CoV-2 Vaccines: Status Report", "size": null, "x": 36.63014602661133, "y": -26.911731719970703}}, {"key": "544", "attributes": {"color": "#3005C7", "label": "Innate Immunity of the Lung: From Basic Mechanisms to Translational Medicine", "size": null, "x": 33.669647216796875, "y": -26.29229164123535}}, {"key": "545", "attributes": {"color": "#3005C7", "label": "The innate immune function of airway epithelial cells in inflammatory lung disease", "size": null, "x": 34.91093063354492, "y": -23.912038803100586}}, {"key": "546", "attributes": {"color": "#3005C7", "label": "Cellular immune reactions in the lung", "size": null, "x": 33.869850158691406, "y": -24.724628448486328}}, {"key": "547", "attributes": {"color": "#3005C7", "label": "Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic", "size": null, "x": 18.00657081604004, "y": -2.480957508087158}}, {"key": "548", "attributes": {"color": "#3005C7", "label": "SARS-CoV-2 infection-induced immune responses: Friends or foes?", "size": null, "x": 36.21324920654297, "y": -24.57808494567871}}, {"key": "549", "attributes": {"color": "#3005C7", "label": "Alveolar macrophages: plasticity in a tissue-specific context", "size": null, "x": 38.135318756103516, "y": -25.09084129333496}}, {"key": "550", "attributes": {"color": "#3005C7", "label": "Differential roles of lung dendritic cell subsets against respiratory virus infection", "size": null, "x": 32.26497268676758, "y": -24.566425323486328}}, {"key": "551", "attributes": {"color": "#3005C7", "label": "Tissue-resident dendritic cells and diseases involving dendritic cell malfunction", "size": null, "x": 35.8101692199707, "y": -27.210004806518555}}, {"key": "552", "attributes": {"color": "#3005C7", "label": "Influenza virusspecific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination", "size": null, "x": 38.89750671386719, "y": -24.213682174682617}}, {"key": "553", "attributes": {"color": "#3005C7", "label": "T Follicular Helper Cell Biology: A Decade of Discovery and Diseases", "size": null, "x": 35.57551193237305, "y": -22.995779037475586}}, {"key": "554", "attributes": {"color": "#3005C7", "label": "Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8(+) T cell responses to influenza", "size": null, "x": 36.69426727294922, "y": -24.19879722595215}}, {"key": "555", "attributes": {"color": "#3005C7", "label": "Host Immune Response to Influenza A Virus Infection", "size": null, "x": 39.21502685546875, "y": -25.48727035522461}}, {"key": "556", "attributes": {"color": "#3005C7", "label": "Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+ CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus, bioRxiv", "size": null, "x": 34.0013427734375, "y": -25.184682846069336}}, {"key": "557", "attributes": {"color": "#3005C7", "label": "SARS-CoV-2 infection: The role of cytokines in COVID-19 disease", "size": null, "x": 33.38626480102539, "y": -22.587955474853516}}, {"key": "558", "attributes": {"color": "#3005C7", "label": "COVID-19: immunopathogenesis and Immunotherapeutics", "size": null, "x": 33.34139633178711, "y": -23.448740005493164}}, {"key": "559", "attributes": {"color": "#3005C7", "label": "SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes", "size": null, "x": 36.64417266845703, "y": -26.66194725036621}}, {"key": "560", "attributes": {"color": "#3005C7", "label": "Human coronaviruses: a review of virus-host interactions", "size": null, "x": 33.02963638305664, "y": -23.783824920654297}}, {"key": "561", "attributes": {"color": "#3005C7", "label": "Interferon-stimulated genes: a complex web of host defenses", "size": null, "x": 33.57211685180664, "y": -23.940820693969727}}, {"key": "562", "attributes": {"color": "#3005C7", "label": "Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis", "size": null, "x": 37.3723030090332, "y": -24.141029357910156}}, {"key": "563", "attributes": {"color": "#3005C7", "label": "Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response", "size": null, "x": 37.5888557434082, "y": -22.773326873779297}}, {"key": "564", "attributes": {"color": "#3005C7", "label": "SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum", "size": null, "x": 34.37382888793945, "y": -25.74510955810547}}, {"key": "565", "attributes": {"color": "#3005C7", "label": "Expression and Cleavage of Middle East Respiratory Syndrome Coronavirus", "size": null, "x": 35.09914016723633, "y": -20.35271453857422}}, {"key": "566", "attributes": {"color": "#3005C7", "label": "Polyprotein Induce the Formation of Double-Membrane Vesicles That Mimic Those Associated with Coronaviral RNA Replication, mBio", "size": null, "x": 37.676212310791016, "y": -25.903425216674805}}, {"key": "567", "attributes": {"color": "#3005C7", "label": "Middle East respiratory syndrome coronavirus M protein suppresses type I interferon expression through the inhibition of TBK1-dependent phosphorylation of IRF3", "size": null, "x": 36.55713653564453, "y": -22.95481300354004}}, {"key": "568", "attributes": {"color": "#3005C7", "label": "Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist", "size": null, "x": 35.335350036621094, "y": -22.85758399963379}}, {"key": "569", "attributes": {"color": "#3005C7", "label": "Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling", "size": null, "x": 34.937686920166016, "y": -27.313907623291016}}, {"key": "570", "attributes": {"color": "#3005C7", "label": "Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease", "size": null, "x": 36.1756477355957, "y": -24.131576538085938}}, {"key": "571", "attributes": {"color": "#3005C7", "label": "SARS Coronavirus Papain-Like Protease Inhibits the TLR7 Signaling Pathway through Removing Lys63-Linked Polyubiquitination of TRAF3 and TRAF6", "size": null, "x": 37.81102752685547, "y": -26.627582550048828}}, {"key": "572", "attributes": {"color": "#3005C7", "label": "Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain", "size": null, "x": 34.15015411376953, "y": -23.052114486694336}}, {"key": "573", "attributes": {"color": "#3005C7", "label": "Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists", "size": null, "x": 35.7947998046875, "y": -26.90682601928711}}, {"key": "574", "attributes": {"color": "#3005C7", "label": "Hidden immune weakness found in 14% of gravely ill COVID-19 patients", "size": null, "x": 34.21269226074219, "y": -25.96472930908203}}, {"key": "575", "attributes": {"color": "#3005C7", "label": "Pathogenesis of COVID-19 from a cell biology perspective", "size": null, "x": 35.77840042114258, "y": -23.245532989501953}}, {"key": "576", "attributes": {"color": "#3005C7", "label": "SARS-CoV-2 viral load predicts COVID-19 mortality", "size": null, "x": 39.20649719238281, "y": -24.740724563598633}}, {"key": "577", "attributes": {"color": "#54A214", "label": "Virological assessment of hospitalized patients with COVID-2019", "size": null, "x": 55.521236419677734, "y": -78.51189422607422}}, {"key": "578", "attributes": {"color": "#3005C7", "label": "Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention", "size": null, "x": 35.30601119995117, "y": -25.36089324951172}}, {"key": "579", "attributes": {"color": "#3005C7", "label": "Impaired Cytotoxic CD8(+) T Cell Response in Elderly COVID-19 Patients", "size": null, "x": 34.7706184387207, "y": -21.38251495361328}}, {"key": "580", "attributes": {"color": "#3005C7", "label": "Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages", "size": null, "x": 34.06421661376953, "y": -22.663875579833984}}, {"key": "581", "attributes": {"color": "#3005C7", "label": "Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage", "size": null, "x": 38.63621520996094, "y": -26.62721824645996}}, {"key": "582", "attributes": {"color": "#3005C7", "label": "MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile", "size": null, "x": 38.060707092285156, "y": -25.979917526245117}}, {"key": "583", "attributes": {"color": "#3005C7", "label": "Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome", "size": null, "x": 33.56346893310547, "y": -23.517311096191406}}, {"key": "584", "attributes": {"color": "#3005C7", "label": "Cytokine storm syndrome in coronavirus disease 2019: A narrative review", "size": null, "x": 37.44077682495117, "y": -25.467164993286133}}, {"key": "585", "attributes": {"color": "#3005C7", "label": "The pathogenesis and treatment of the `Cytokine Storm' in COVID-19", "size": null, "x": 34.942630767822266, "y": -25.615110397338867}}, {"key": "586", "attributes": {"color": "#3005C7", "label": "Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications", "size": null, "x": 35.04645919799805, "y": -27.045162200927734}}, {"key": "587", "attributes": {"color": "#3005C7", "label": "Dysregulation of Immune Response in Patients With Coronavirus", "size": null, "x": 32.79466247558594, "y": -22.511831283569336}}, {"key": "588", "attributes": {"color": "#3005C7", "label": "Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19", "size": null, "x": 35.12841033935547, "y": -21.79375648498535}}, {"key": "589", "attributes": {"color": "#3005C7", "label": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, The Lancet", "size": null, "x": 35.75056076049805, "y": -22.31809425354004}}, {"key": "590", "attributes": {"color": "#3005C7", "label": "CT Manifestations of Two Cases of 2019 Novel Coronavirus (2019-nCoV) Pneumonia", "size": null, "x": 36.26374435424805, "y": -25.646135330200195}}, {"key": "591", "attributes": {"color": "#3005C7", "label": "Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)", "size": null, "x": 34.336036682128906, "y": -23.06983184814453}}, {"key": "592", "attributes": {"color": "#3005C7", "label": "The emerging role of resident memory T cells in protective immunity and inflammatory disease", "size": null, "x": 32.59291458129883, "y": -23.73883056640625}}, {"key": "593", "attributes": {"color": "#3005C7", "label": "Skin infection generates non-migratory memory CD8+ T RM cells providing global skin immunity", "size": null, "x": 37.99944305419922, "y": -21.606201171875}}, {"key": "594", "attributes": {"color": "#3005C7", "label": "Mucosal resident memory CD4 T cells in protection and immunopathology", "size": null, "x": 37.412654876708984, "y": -21.296937942504883}}, {"key": "595", "attributes": {"color": "#3005C7", "label": "Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike", "size": null, "x": 38.79175567626953, "y": -24.883384704589844}}, {"key": "596", "attributes": {"color": "#3005C7", "label": "Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses", "size": null, "x": 36.84702682495117, "y": -20.941513061523438}}, {"key": "597", "attributes": {"color": "#3005C7", "label": "Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019", "size": null, "x": 36.04038619995117, "y": -23.69438934326172}}, {"key": "598", "attributes": {"color": "#3005C7", "label": "Antibody responses against SARS-CoV-2 in COVID-19 patients", "size": null, "x": 38.663150787353516, "y": -24.44827651977539}}, {"key": "599", "attributes": {"color": "#3005C7", "label": "Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19", "size": null, "x": 33.76096725463867, "y": -26.780988693237305}}, {"key": "600", "attributes": {"color": "#3005C7", "label": "Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients", "size": null, "x": 34.49686813354492, "y": -23.492414474487305}}, {"key": "601", "attributes": {"color": "#3005C7", "label": "IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study", "size": null, "x": 32.99855041503906, "y": -26.182315826416016}}, {"key": "602", "attributes": {"color": "#3005C7", "label": "A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease", "size": null, "x": 33.83570098876953, "y": -24.00902557373047}}, {"key": "603", "attributes": {"color": "#3005C7", "label": "Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)", "size": null, "x": 38.45541000366211, "y": -22.578903198242188}}, {"key": "604", "attributes": {"color": "#3005C7", "label": "Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection", "size": null, "x": 34.439022064208984, "y": -22.414575576782227}}, {"key": "605", "attributes": {"color": "#3005C7", "label": "Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections", "size": null, "x": 37.281681060791016, "y": -26.056062698364258}}, {"key": "606", "attributes": {"color": "#3005C7", "label": "Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome", "size": null, "x": 36.76432418823242, "y": -24.583637237548828}}, {"key": "607", "attributes": {"color": "#3005C7", "label": "Middle East Respiratory Syndrome Coronavirus Infection Dynamics and Antibody Responses among Clinically Diverse Patients, Saudi Arabia", "size": null, "x": 35.35070037841797, "y": -21.61837387084961}}, {"key": "608", "attributes": {"color": "#3005C7", "label": "SARS-CoV-2 neutralizing antibody development strategies", "size": null, "x": 33.80623245239258, "y": -25.48868179321289}}, {"key": "609", "attributes": {"color": "#3005C7", "label": "From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses", "size": null, "x": 38.31945037841797, "y": -27.142120361328125}}, {"key": "610", "attributes": {"color": "#3005C7", "label": "Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19", "size": null, "x": 35.59760665893555, "y": -26.424386978149414}}, {"key": "611", "attributes": {"color": "#3005C7", "label": "Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19", "size": null, "x": 36.170928955078125, "y": -21.736717224121094}}, {"key": "612", "attributes": {"color": "#3005C7", "label": "Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review", "size": null, "x": 35.13798141479492, "y": -21.07175064086914}}, {"key": "613", "attributes": {"color": "#3005C7", "label": "Drug Administration, Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment", "size": null, "x": 36.09113693237305, "y": -27.051544189453125}}, {"key": "614", "attributes": {"color": "#3005C7", "label": "Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection", "size": null, "x": 35.83650207519531, "y": -24.433752059936523}}, {"key": "615", "attributes": {"color": "#3005C7", "label": "Rapid review for the anti-coronavirus effect of remdesivir", "size": null, "x": 37.76370620727539, "y": -24.941513061523438}}, {"key": "616", "attributes": {"color": "#45E73B", "label": "Development of an inactivated vaccine candidate for SARS-CoV-2", "size": null, "x": 93.69975280761719, "y": 4.036618709564209}}, {"key": "617", "attributes": {"color": "#3005C7", "label": "Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase", "size": null, "x": 17.93692398071289, "y": -1.745651125907898}}, {"key": "618", "attributes": {"color": "#3005C7", "label": "An Update on Current Therapeutic Drugs Treating COVID-19", "size": null, "x": 36.25458526611328, "y": -24.01151466369629}}, {"key": "619", "attributes": {"color": "#3005C7", "label": "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in", "size": null, "x": 38.17400360107422, "y": -22.58141326904297}}, {"key": "620", "attributes": {"color": "#3005C7", "label": "Clinical trials on drug repositioning for COVID-19 treatment", "size": null, "x": 35.53152084350586, "y": -22.086877822875977}}, {"key": "621", "attributes": {"color": "#3005C7", "label": "Treatment With Lopinavir/Ritonavir or Interferon-beta1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset", "size": null, "x": 39.35926818847656, "y": -25.060144424438477}}, {"key": "622", "attributes": {"color": "#3005C7", "label": "Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial", "size": null, "x": 34.52688980102539, "y": -24.126327514648438}}, {"key": "623", "attributes": {"color": "#3005C7", "label": "Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review", "size": null, "x": 33.3546028137207, "y": -24.213712692260742}}, {"key": "624", "attributes": {"color": "#3005C7", "label": "An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors", "size": null, "x": 36.1269416809082, "y": -23.868728637695312}}, {"key": "625", "attributes": {"color": "#3005C7", "label": "Prosper, Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2", "size": null, "x": 36.02485275268555, "y": -23.825878143310547}}, {"key": "626", "attributes": {"color": "#3005C7", "label": "The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro", "size": null, "x": 18.380403518676758, "y": -1.9682464599609375}}, {"key": "627", "attributes": {"color": "#3005C7", "label": "Antiviral and antiinflammatory activity of arbidol hydrochloride in influenza A (H1N1) virus infection", "size": null, "x": 37.74751663208008, "y": -25.488048553466797}}, {"key": "628", "attributes": {"color": "#3005C7", "label": "Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases", "size": null, "x": 35.0931396484375, "y": -24.649124145507812}}, {"key": "629", "attributes": {"color": "#3005C7", "label": "Chloroquine is a potent inhibitor of SARS coronavirus infection and spread", "size": null, "x": 17.19415855407715, "y": -1.7372444868087769}}, {"key": "630", "attributes": {"color": "#3005C7", "label": "Hydroxychloroquine: An old drug with new relevance", "size": null, "x": 33.87317657470703, "y": -27.247215270996094}}, {"key": "631", "attributes": {"color": "#3005C7", "label": "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial", "size": null, "x": 33.80014419555664, "y": -22.60529327392578}}, {"key": "632", "attributes": {"color": "#3005C7", "label": "Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial", "size": null, "x": 33.95475387573242, "y": -23.573715209960938}}, {"key": "633", "attributes": {"color": "#3005C7", "label": "Drug Administration, Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine", "size": null, "x": 35.7165412902832, "y": -21.171340942382812}}, {"key": "634", "attributes": {"color": "#3005C7", "label": "Positive RT-PCR Test Results in Patients Recovered From COVID-19", "size": null, "x": 34.544803619384766, "y": -26.476238250732422}}, {"key": "635", "attributes": {"color": "#3005C7", "label": "Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19", "size": null, "x": 36.04262161254883, "y": -25.854501724243164}}, {"key": "636", "attributes": {"color": "#3005C7", "label": "Immunomodulation in COVID-19", "size": null, "x": 32.92588424682617, "y": -25.80712127685547}}, {"key": "637", "attributes": {"color": "#3005C7", "label": "Interleukin-6 in COVID-19: a systematic review and metaanalysis", "size": null, "x": 33.12404251098633, "y": -22.518295288085938}}, {"key": "638", "attributes": {"color": "#3005C7", "label": "Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial", "size": null, "x": 37.81959915161133, "y": -23.34859275817871}}, {"key": "639", "attributes": {"color": "#3005C7", "label": "FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome", "size": null, "x": 34.56647872924805, "y": -25.93590545654297}}, {"key": "640", "attributes": {"color": "#3005C7", "label": "Effective treatment of severe COVID-19 patients with tocilizumab", "size": null, "x": 35.64464569091797, "y": -25.369810104370117}}, {"key": "641", "attributes": {"color": "#3005C7", "label": "Impact of sarilumab on mechanical ventilation in patients with COVID-19. Response to: 'Correspondence on: 'Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study' by Della-Torre et al' by Cheng and Zhang", "size": null, "x": 36.93031311035156, "y": -22.844512939453125}}, {"key": "642", "attributes": {"color": "#3005C7", "label": "JAK inhibition as a therapeutic strategy for immune and inflammatory diseases", "size": null, "x": 38.338802337646484, "y": -23.418182373046875}}, {"key": "643", "attributes": {"color": "#3005C7", "label": "Baricitinib as potential treatment for 2019-nCoV acute respiratory disease", "size": null, "x": 35.87038803100586, "y": -26.377212524414062}}, {"key": "644", "attributes": {"color": "#3005C7", "label": "The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19", "size": null, "x": 33.325130462646484, "y": -21.93990135192871}}, {"key": "645", "attributes": {"color": "#3005C7", "label": "Association between Administration of Systemic Corticosteroids and Mortality among critically ill patients with COVID-19: a meta-analysis", "size": null, "x": 34.084110260009766, "y": -21.712865829467773}}, {"key": "646", "attributes": {"color": "#3005C7", "label": "Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic", "size": null, "x": 33.966156005859375, "y": -26.3220157623291}}, {"key": "647", "attributes": {"color": "#3005C7", "label": "Use of corticosteroids in influenza-associated acute respiratory distress syndrome and severe pneumonia: a systemic review and meta-analysis", "size": null, "x": 36.86269760131836, "y": -23.471445083618164}}, {"key": "648", "attributes": {"color": "#3005C7", "label": "Blood Institute Acute Respiratory Distress Syndrome Clinical Trials, Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome", "size": null, "x": 32.602210998535156, "y": -24.544193267822266}}, {"key": "649", "attributes": {"color": "#3005C7", "label": "Dexamethasone in Hospitalized Patients with Covid-19-Preliminary Report", "size": null, "x": 36.851810455322266, "y": -24.939504623413086}}, {"key": "650", "attributes": {"color": "#3005C7", "label": "Dexamethasone nanomedicines for COVID-19", "size": null, "x": 34.098140716552734, "y": -23.347997665405273}}, {"key": "651", "attributes": {"color": "#3005C7", "label": "Roles of natural killer cells in antiviral immunity", "size": null, "x": 36.605648040771484, "y": -25.702123641967773}}, {"key": "652", "attributes": {"color": "#3005C7", "label": "Cellular immune responses to severe acute respiratory syndrome coronavirus", "size": null, "x": 34.950557708740234, "y": -25.021564483642578}}, {"key": "653", "attributes": {"color": "#3005C7", "label": "Natural killer cell immunotypes related to COVID-19 disease severity", "size": null, "x": 36.30328369140625, "y": -25.307754516601562}}, {"key": "654", "attributes": {"color": "#3005C7", "label": "Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19", "size": null, "x": 34.214176177978516, "y": -24.40203094482422}}, {"key": "655", "attributes": {"color": "#3005C7", "label": "Mesenchymal stem cell perspective: cell biology to clinical progress", "size": null, "x": 31.68166160583496, "y": -24.804353713989258}}, {"key": "656", "attributes": {"color": "#3005C7", "label": "Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment", "size": null, "x": 37.1494140625, "y": -23.904388427734375}}, {"key": "657", "attributes": {"color": "#3005C7", "label": "Systematic identification of factors for provirus silencing in embryonic stem cells", "size": null, "x": 34.769718170166016, "y": -23.08428955078125}}, {"key": "658", "attributes": {"color": "#3005C7", "label": "Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome", "size": null, "x": 36.62615203857422, "y": -25.050600051879883}}, {"key": "659", "attributes": {"color": "#3005C7", "label": "Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study", "size": null, "x": 36.50981140136719, "y": -27.110010147094727}}, {"key": "660", "attributes": {"color": "#3005C7", "label": "Convalescent plasma in Covid-19: Possible mechanisms of action", "size": null, "x": 35.834556579589844, "y": -23.395246505737305}}, {"key": "661", "attributes": {"color": "#3005C7", "label": "Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19", "size": null, "x": 32.995849609375, "y": -23.39177131652832}}, {"key": "662", "attributes": {"color": "#3005C7", "label": "US Food and Drug Administration, Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19", "size": null, "x": 36.88956069946289, "y": -25.82589340209961}}, {"key": "663", "attributes": {"color": "#3005C7", "label": "Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association", "size": null, "x": 35.22970962524414, "y": -21.158063888549805}}, {"key": "664", "attributes": {"color": "#3005C7", "label": "Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus", "size": null, "x": 36.157718658447266, "y": -23.795948028564453}}, {"key": "665", "attributes": {"color": "#3005C7", "label": "Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants", "size": null, "x": 37.26313781738281, "y": -21.77627182006836}}, {"key": "666", "attributes": {"color": "#3005C7", "label": "Potent crossreactive neutralization of SARS coronavirus isolates by human monoclonal antibodies", "size": null, "x": 35.705379486083984, "y": -27.67323112487793}}, {"key": "667", "attributes": {"color": "#3005C7", "label": "Monoclonal Antibody as a Potential Anti-COVID-19", "size": null, "x": 35.258575439453125, "y": -23.710529327392578}}, {"key": "668", "attributes": {"color": "#3005C7", "label": "A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2", "size": null, "x": 35.29099655151367, "y": -23.921728134155273}}, {"key": "669", "attributes": {"color": "#3005C7", "label": "Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody", "size": null, "x": 33.07572937011719, "y": -24.03228187561035}}, {"key": "670", "attributes": {"color": "#3005C7", "label": "Effectiveness of convalescent plasma therapy in severe COVID-19 patients", "size": null, "x": 33.58623504638672, "y": -22.078628540039062}}, {"key": "671", "attributes": {"color": "#3005C7", "label": "Convalescent Plasma to Treat COVID-19: Possibilities and Challenges", "size": null, "x": 37.153038024902344, "y": -26.531858444213867}}, {"key": "672", "attributes": {"color": "#3005C7", "label": "Potential neurological effects of severe COVID-19 infection", "size": null, "x": 35.61330032348633, "y": -23.521074295043945}}, {"key": "673", "attributes": {"color": "#3005C7", "label": "COVID-19 herd immunity: where are we?", "size": null, "x": 37.51076126098633, "y": -23.5319881439209}}, {"key": "674", "attributes": {"color": "#3005C7", "label": "Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature", "size": null, "x": 34.07979965209961, "y": -23.942962646484375}}, {"key": "675", "attributes": {"color": "#3005C7", "label": "Agedependent effects in the transmission and control of COVID-19 epidemics", "size": null, "x": 35.620574951171875, "y": -23.725553512573242}}, {"key": "676", "attributes": {"color": "#3005C7", "label": "Genomic evidence for reinfection with SARS-CoV-2: a case study", "size": null, "x": 17.574756622314453, "y": -1.3968209028244019}}, {"key": "677", "attributes": {"color": "#3005C7", "label": "Selecting Viruses for the Seasonal Influenza Vaccine", "size": null, "x": 38.023929595947266, "y": -23.54606056213379}}, {"key": "678", "attributes": {"color": "#3005C7", "label": "Peptide Vaccine: Progress and Challenges, Vaccines (Basel)", "size": null, "x": 37.76987838745117, "y": -25.639131546020508}}, {"key": "679", "attributes": {"color": "#3005C7", "label": "Present Yourself! By MHC Class I and MHC Class II Molecules", "size": null, "x": 33.78186798095703, "y": -24.78506851196289}}, {"key": "680", "attributes": {"color": "#3005C7", "label": "CD4 CTL, a cytotoxic subset of CD4+ T cells, their differentiation and function", "size": null, "x": 36.64965057373047, "y": -23.988380432128906}}, {"key": "681", "attributes": {"color": "#3005C7", "label": "T cell responses in patients with COVID-19", "size": null, "x": 35.07634735107422, "y": -28.01890754699707}}, {"key": "682", "attributes": {"color": "#3005C7", "label": "Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals", "size": null, "x": 35.26665496826172, "y": -22.730243682861328}}, {"key": "683", "attributes": {"color": "#3005C7", "label": "Oxford Immunology Network Covid-19 Response, I.C. Investigators", "size": null, "x": 37.60200500488281, "y": -24.874380111694336}}, {"key": "684", "attributes": {"color": "#3005C7", "label": "A mouse-adapted SARScoronavirus causes disease and mortality in BALB/c mice", "size": null, "x": 36.68466567993164, "y": -22.250497817993164}}, {"key": "685", "attributes": {"color": "#3005C7", "label": "Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV", "size": null, "x": 37.77696990966797, "y": -24.23572540283203}}, {"key": "686", "attributes": {"color": "#3005C7", "label": "A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge", "size": null, "x": 36.36900329589844, "y": -22.720643997192383}}, {"key": "687", "attributes": {"color": "#3005C7", "label": "Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2", "size": null, "x": 37.06326675415039, "y": -23.122299194335938}}, {"key": "688", "attributes": {"color": "#3005C7", "label": "A perspective on potential antibody-dependent enhancement of SARS-CoV-2", "size": null, "x": 37.045352935791016, "y": -22.85391616821289}}, {"key": "689", "attributes": {"color": "#3005C7", "label": "Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets", "size": null, "x": 34.63821029663086, "y": -24.564247131347656}}, {"key": "690", "attributes": {"color": "#3005C7", "label": "Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection", "size": null, "x": 32.80591583251953, "y": -22.193157196044922}}, {"key": "691", "attributes": {"color": "#3005C7", "label": "Human leukocyte antigen susceptibility map for SARS-CoV-2", "size": null, "x": 37.281375885009766, "y": -26.901105880737305}}, {"key": "692", "attributes": {"color": "#3005C7", "label": "Progress and prospects on vaccine development against SARS-CoV-2, Vaccines", "size": null, "x": 37.571495056152344, "y": -27.355735778808594}}, {"key": "693", "attributes": {"color": "#3005C7", "label": "Mutations in the Coronavirus Spike Protein", "size": null, "x": 38.471351623535156, "y": -23.904829025268555}}, {"key": "694", "attributes": {"color": "#3005C7", "label": "Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease", "size": null, "x": 37.97382736206055, "y": -26.494966506958008}}, {"key": "695", "attributes": {"color": "#3005C7", "label": "Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies", "size": null, "x": 38.669002532958984, "y": -23.209489822387695}}, {"key": "696", "attributes": {"color": "#3005C7", "label": "Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model", "size": null, "x": 35.39360809326172, "y": -24.754444122314453}}, {"key": "697", "attributes": {"color": "#3005C7", "label": "D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization", "size": null, "x": 34.43712615966797, "y": -21.931428909301758}}, {"key": "698", "attributes": {"color": "#3005C7", "label": "SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate", "size": null, "x": 33.71455001831055, "y": -25.270965576171875}}, {"key": "699", "attributes": {"color": "#3005C7", "label": "Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits", "size": null, "x": 32.82585906982422, "y": -24.837188720703125}}, {"key": "700", "attributes": {"color": "#3005C7", "label": "The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement", "size": null, "x": 36.88175582885742, "y": -25.4687442779541}}, {"key": "701", "attributes": {"color": "#3005C7", "label": "Expression of SARS-coronavirus nucleocapsid protein in Escherichia coli and Lactococcus lactis for serodiagnosis and mucosal vaccination", "size": null, "x": 33.006221771240234, "y": -25.28956413269043}}, {"key": "702", "attributes": {"color": "#3005C7", "label": "Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates", "size": null, "x": 34.978824615478516, "y": -22.756465911865234}}, {"key": "703", "attributes": {"color": "#3005C7", "label": "Host Immune Response and Immunobiology of Human SARS-CoV-2 Infection", "size": null, "x": 36.16584777832031, "y": -23.356733322143555}}, {"key": "704", "attributes": {"color": "#3005C7", "label": "Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex", "size": null, "x": 36.01274108886719, "y": -25.04648780822754}}, {"key": "705", "attributes": {"color": "#3005C7", "label": "MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape", "size": null, "x": 33.91025161743164, "y": -21.492277145385742}}, {"key": "706", "attributes": {"color": "#3005C7", "label": "Cutting edge: control of Mycobacterium tuberculosis infection by a subset of lung parenchyma-homing CD4 T cells", "size": null, "x": 35.0793342590332, "y": -23.362966537475586}}, {"key": "707", "attributes": {"color": "#3005C7", "label": "Activated antigen-specific CD8+ T cells persist in the lungs following recovery from respiratory virus infections", "size": null, "x": 38.324798583984375, "y": -26.43158721923828}}, {"key": "708", "attributes": {"color": "#3005C7", "label": "Lung niches for the generation and maintenance of tissue-resident memory T cells", "size": null, "x": 38.548885345458984, "y": -24.59746551513672}}, {"key": "709", "attributes": {"color": "#3005C7", "label": "Cutting edge: Tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection", "size": null, "x": 34.99814224243164, "y": -25.945016860961914}}, {"key": "710", "attributes": {"color": "#3005C7", "label": "Airway-Resident Memory CD8 T Cells Provide Antigen-Specific Protection against Respiratory Virus Challenge through Rapid IFN-gamma Production", "size": null, "x": 35.31179428100586, "y": -22.584630966186523}}, {"key": "711", "attributes": {"color": "#3005C7", "label": "Airway T cells protect against RSV infection in the absence of antibody", "size": null, "x": 32.589378356933594, "y": -24.033008575439453}}, {"key": "712", "attributes": {"color": "#3005C7", "label": "Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung", "size": null, "x": 36.30682373046875, "y": -27.219589233398438}}, {"key": "713", "attributes": {"color": "#2406AE", "label": "Immunological considerations for COVID-19 vaccine strategies", "size": null, "x": 31.7121524810791, "y": -65.29732513427734}}, {"key": "714", "attributes": {"color": "#3005C7", "label": "Heuze-Vourc'h, Inhalation of Immuno-Therapeutics/-Prophylactics to Fight Respiratory Tract Infections: An Appropriate Drug at the Right Place!", "size": null, "x": 37.56461715698242, "y": -24.55706787109375}}, {"key": "715", "attributes": {"color": "#3005C7", "label": "Safety and Immunogenicity of NasoVAX, a Novel Intranasal Influenza Vaccine: 2554, Open Forum Infectious Diseases", "size": null, "x": 32.313209533691406, "y": -25.475513458251953}}, {"key": "716", "attributes": {"color": "#3005C7", "label": "Cold chain transportation decision in the vaccine supply chain", "size": null, "x": 33.36369705200195, "y": -24.930721282958984}}, {"key": "717", "attributes": {"color": "#3005C7", "label": "Preclinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection, bioRxiv", "size": null, "x": 36.306392669677734, "y": -26.81153106689453}}, {"key": "718", "attributes": {"color": "#3005C7", "label": "A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS", "size": null, "x": 34.886966705322266, "y": -21.38668441772461}}, {"key": "719", "attributes": {"color": "#3005C7", "label": "Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding", "size": null, "x": 17.969905853271484, "y": -2.205160617828369}}, {"key": "720", "attributes": {"color": "#3005C7", "label": "Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health", "size": null, "x": 35.01070022583008, "y": -23.538185119628906}}, {"key": "721", "attributes": {"color": "#3005C7", "label": "Nanoparticle formulated vaccines: opportunities and challenges", "size": null, "x": 33.608612060546875, "y": -27.54057502746582}}, {"key": "722", "attributes": {"color": "#3005C7", "label": "Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies", "size": null, "x": 35.43439483642578, "y": -24.322589874267578}}, {"key": "723", "attributes": {"color": "#3005C7", "label": "The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines", "size": null, "x": 37.41885757446289, "y": -24.805335998535156}}, {"key": "724", "attributes": {"color": "#3005C7", "label": "Correction: Immunodominant SARS Coronavirus Epitopes in Humans Elicited Both Enhancing and Neutralizing Effects on Infection in Nonhuman Primates", "size": null, "x": 36.04358673095703, "y": -27.604537963867188}}, {"key": "725", "attributes": {"color": "#3005C7", "label": "SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines", "size": null, "x": 32.44073486328125, "y": -22.826383590698242}}, {"key": "726", "attributes": {"color": "#3005C7", "label": "The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development", "size": null, "x": 33.413970947265625, "y": -24.461517333984375}}, {"key": "727", "attributes": {"color": "#3005C7", "label": "World Health Organization, DRAFT landscape of COVID-19 candidate vaccines", "size": null, "x": 35.79097366333008, "y": -24.721385955810547}}, {"key": "728", "attributes": {"color": "#3005C7", "label": "Author Correction: Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo", "size": null, "x": 33.75767135620117, "y": -24.139951705932617}}, {"key": "729", "attributes": {"color": "#3005C7", "label": "Artificial molecular clamp: a novel device for synthetic polymerases", "size": null, "x": 35.28459930419922, "y": -24.540700912475586}}, {"key": "730", "attributes": {"color": "#3005C7", "label": "Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development", "size": null, "x": 33.14483642578125, "y": -24.3281307220459}}, {"key": "731", "attributes": {"color": "#3005C7", "label": "Cancer DNA vaccines: current preclinical and clinical developments and future perspectives", "size": null, "x": 37.200592041015625, "y": -25.10877799987793}}, {"key": "732", "attributes": {"color": "#3005C7", "label": "Advances in mRNA vaccines for infectious diseases", "size": null, "x": 32.96412658691406, "y": -26.015653610229492}}, {"key": "733", "attributes": {"color": "#3005C7", "label": "The past, current and future trends in DNA vaccine immunisations", "size": null, "x": 33.32994079589844, "y": -25.26460838317871}}, {"key": "734", "attributes": {"color": "#292F8F", "label": "mRNA vaccines -a new era in vaccinology", "size": null, "x": 123.19254302978516, "y": -46.08018112182617}}, {"key": "735", "attributes": {"color": "#3005C7", "label": "DNA vaccines: a key for inducing long-term cellular immunity", "size": null, "x": 32.62808609008789, "y": -25.65120506286621}}, {"key": "736", "attributes": {"color": "#3005C7", "label": "DNA vaccines: ready for prime time?", "size": null, "x": 33.539527893066406, "y": -26.497365951538086}}, {"key": "737", "attributes": {"color": "#3005C7", "label": "A comparison of plasmid DNA and mrna as vaccine technologies, Vaccines", "size": null, "x": 32.200199127197266, "y": -24.23036766052246}}, {"key": "738", "attributes": {"color": "#3005C7", "label": "DNA Vaccines-How Far From Clinical Use?", "size": null, "x": 35.075618743896484, "y": -22.15719985961914}}, {"key": "739", "attributes": {"color": "#3005C7", "label": "Immunogenicity of a DNA vaccine candidate for COVID-19", "size": null, "x": 34.82354736328125, "y": -20.71680450439453}}, {"key": "740", "attributes": {"color": "#3005C7", "label": "m, An mRNA Vaccine against SARS-CoV-2 -Preliminary Report", "size": null, "x": 35.52748107910156, "y": -24.938398361206055}}, {"key": "741", "attributes": {"color": "#3005C7", "label": "Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability", "size": null, "x": 36.60750198364258, "y": -26.25521469116211}}, {"key": "742", "attributes": {"color": "#3005C7", "label": "Materials for non-viral intracellular delivery of messenger RNA therapeutics", "size": null, "x": 35.932926177978516, "y": -24.59598159790039}}, {"key": "743", "attributes": {"color": "#3005C7", "label": "Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems", "size": null, "x": 36.393798828125, "y": -26.55670166015625}}, {"key": "744", "attributes": {"color": "#3005C7", "label": "Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity", "size": null, "x": 36.287960052490234, "y": -24.765565872192383}}, {"key": "745", "attributes": {"color": "#3005C7", "label": "Intradermal electroporation of naked replicon RNA elicits strong immune responses", "size": null, "x": 35.891788482666016, "y": -25.560386657714844}}, {"key": "746", "attributes": {"color": "#3005C7", "label": "Electroporation-enhanced gene delivery in mammary tumors", "size": null, "x": 35.08485794067383, "y": -24.89263153076172}}, {"key": "747", "attributes": {"color": "#3005C7", "label": "Leveraging mRNA Sequences and Nanoparticles to Deliver SARS-CoV-2 Antigens In Vivo", "size": null, "x": 36.187984466552734, "y": -21.15615463256836}}, {"key": "748", "attributes": {"color": "#3005C7", "label": "Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency", "size": null, "x": 34.23324966430664, "y": -26.086755752563477}}, {"key": "749", "attributes": {"color": "#3005C7", "label": "Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection", "size": null, "x": 34.33214569091797, "y": -25.026203155517578}}, {"key": "750", "attributes": {"color": "#3005C7", "label": "COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses", "size": null, "x": 35.72075271606445, "y": -24.3100528717041}}, {"key": "751", "attributes": {"color": "#3005C7", "label": "A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates, bioRxiv", "size": null, "x": 34.22368621826172, "y": -20.932785034179688}}, {"key": "752", "attributes": {"color": "#3005C7", "label": "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine", "size": null, "x": 35.46428298950195, "y": -22.410083770751953}}, {"key": "753", "attributes": {"color": "#3005C7", "label": "s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study", "size": null, "x": 35.64594650268555, "y": -25.941585540771484}}, {"key": "754", "attributes": {"color": "#3005C7", "label": "Pfizer and BioNTech achieve first authorization in the world for a vaccine to combat covid-19", "size": null, "x": 38.222129821777344, "y": -25.38315200805664}}, {"key": "755", "attributes": {"color": "#3005C7", "label": "Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection", "size": null, "x": 37.27350616455078, "y": -23.61722755432129}}, {"key": "756", "attributes": {"color": "#3005C7", "label": "Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination", "size": null, "x": 36.99913787841797, "y": -24.287813186645508}}, {"key": "757", "attributes": {"color": "#3005C7", "label": "History of vaccination", "size": null, "x": 34.787235260009766, "y": -24.300485610961914}}, {"key": "758", "attributes": {"color": "#3005C7", "label": "Identification of the mechanisms causing reversion to virulence in an attenuated SARS-CoV for the design of a genetically stable vaccine", "size": null, "x": 36.434207916259766, "y": -23.177255630493164}}, {"key": "759", "attributes": {"color": "#3005C7", "label": "Evolutionary reversion of live viral vaccines: Can genetic engineering subdue it?", "size": null, "x": 36.85232925415039, "y": -27.531341552734375}}, {"key": "760", "attributes": {"color": "#3005C7", "label": "Deletion of both the tyrosine-based endocytosis signal and the endoplasmic reticulum retrieval signal in the cytoplasmic tail of spike protein attenuates porcine epidemic diarrhea virus in pigs", "size": null, "x": 37.433982849121094, "y": -22.435802459716797}}, {"key": "761", "attributes": {"color": "#3005C7", "label": "Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein", "size": null, "x": 33.222774505615234, "y": -26.98039436340332}}, {"key": "762", "attributes": {"color": "#3005C7", "label": "Generation of influenza A viruses as live but replication-incompetent virus vaccines", "size": null, "x": 37.31142044067383, "y": -26.168338775634766}}, {"key": "763", "attributes": {"color": "#3005C7", "label": "Synthesis at the interface of virology and genetic code expansion", "size": null, "x": 32.548789978027344, "y": -22.590211868286133}}, {"key": "764", "attributes": {"color": "#3005C7", "label": "Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform, bioRxiv", "size": null, "x": 31.924541473388672, "y": -23.521900177001953}}, {"key": "765", "attributes": {"color": "#3005C7", "label": "An infectious cDNA clone of SARS-CoV-2", "size": null, "x": 36.51820373535156, "y": -24.967647552490234}}, {"key": "766", "attributes": {"color": "#3005C7", "label": "A recombinant respiratory syncytial virus vaccine candidate attenuated by a low-fusion F protein is immunogenic and protective against challenge in cotton rats", "size": null, "x": 37.90924072265625, "y": -24.538482666015625}}, {"key": "767", "attributes": {"color": "#3005C7", "label": "Vaccine analysis: strategies, principles, and control", "size": null, "x": 33.59330749511719, "y": -23.569835662841797}}, {"key": "768", "attributes": {"color": "#3005C7", "label": "Site-specific glycan analysis of the SARS-CoV-2 spike", "size": null, "x": 37.05039596557617, "y": -23.388397216796875}}, {"key": "769", "attributes": {"color": "#3005C7", "label": "Rationalizing the development of live attenuated virus vaccines", "size": null, "x": 34.6857795715332, "y": -21.965452194213867}}, {"key": "770", "attributes": {"color": "#45E73B", "label": "Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2", "size": null, "x": 93.13409423828125, "y": 3.6339261531829834}}, {"key": "771", "attributes": {"color": "#3005C7", "label": "Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine", "size": null, "x": 38.88795852661133, "y": -23.480735778808594}}, {"key": "772", "attributes": {"color": "#3005C7", "label": "Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus", "size": null, "x": 37.384544372558594, "y": -26.573511123657227}}, {"key": "773", "attributes": {"color": "#3005C7", "label": "Viral vectors for vaccine applications", "size": null, "x": 33.52766418457031, "y": -26.813941955566406}}, {"key": "774", "attributes": {"color": "#3005C7", "label": "Developments in Viral Vector-Based Vaccines, Vaccines (Basel)", "size": null, "x": 33.188385009765625, "y": -21.734294891357422}}, {"key": "775", "attributes": {"color": "#3005C7", "label": "Engineering targeted viral vectors for gene therapy", "size": null, "x": 34.52632141113281, "y": -22.978687286376953}}, {"key": "776", "attributes": {"color": "#3005C7", "label": "Novel viral vectors in infectious diseases", "size": null, "x": 36.83562088012695, "y": -26.774145126342773}}, {"key": "777", "attributes": {"color": "#3005C7", "label": "Immune Responses to Viral Gene Therapy Vectors", "size": null, "x": 34.15087127685547, "y": -22.372220993041992}}, {"key": "778", "attributes": {"color": "#3005C7", "label": "Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind", "size": null, "x": 35.22425842285156, "y": -25.488550186157227}}, {"key": "779", "attributes": {"color": "#3005C7", "label": "Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model, npj Vaccines", "size": null, "x": 37.46577835083008, "y": -22.13917350769043}}, {"key": "780", "attributes": {"color": "#3005C7", "label": "Development of novel vaccine vectors: Chimpanzee adenoviral vectors", "size": null, "x": 32.64289855957031, "y": -26.303232192993164}}, {"key": "781", "attributes": {"color": "#3005C7", "label": "Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial", "size": null, "x": 36.38562774658203, "y": -22.014060974121094}}, {"key": "782", "attributes": {"color": "#3005C7", "label": "A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults", "size": null, "x": 35.84410858154297, "y": -22.491744995117188}}, {"key": "783", "attributes": {"color": "#3005C7", "label": "An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques", "size": null, "x": 36.08552551269531, "y": -26.425708770751953}}, {"key": "784", "attributes": {"color": "#3005C7", "label": "Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26. ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania", "size": null, "x": 35.35390853881836, "y": -22.30770492553711}}, {"key": "785", "attributes": {"color": "#3005C7", "label": "Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys", "size": null, "x": 31.481781005859375, "y": -24.23914337158203}}, {"key": "786", "attributes": {"color": "#3005C7", "label": "Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, nonrandomised, uncontrolled, phase 1 trial, The Lancet Infectious Diseases", "size": null, "x": 33.693050384521484, "y": -25.03228759765625}}, {"key": "787", "attributes": {"color": "#3005C7", "label": "A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime-MVA85A boost in healthy UK adults", "size": null, "x": 38.12781524658203, "y": -23.740917205810547}}, {"key": "788", "attributes": {"color": "#3005C7", "label": "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind", "size": null, "x": 32.80277633666992, "y": -26.8820858001709}}, {"key": "789", "attributes": {"color": "#3005C7", "label": "Virus-like particles for the prevention of human papillomavirusassociated malignancies", "size": null, "x": 37.10343551635742, "y": -25.772768020629883}}, {"key": "790", "attributes": {"color": "#3005C7", "label": "A virus-like particle of the hepatitis B virus preS antigen elicits robust neutralizing antibodies and T cell responses in mice", "size": null, "x": 34.4640007019043, "y": -25.55388069152832}}, {"key": "791", "attributes": {"color": "#3005C7", "label": "Virus-like particle vaccines: immunology and formulation for clinical translation", "size": null, "x": 36.69413757324219, "y": -21.57980728149414}}, {"key": "792", "attributes": {"color": "#3005C7", "label": "Advances and challenges in enveloped virus-like particle (VLP)-based vaccines", "size": null, "x": 34.06431198120117, "y": -21.246782302856445}}, {"key": "793", "attributes": {"color": "#3005C7", "label": "Synergistic antiviral effects against SARS-CoV-2 by plant-based molecules", "size": null, "x": 36.700130462646484, "y": -26.62846565246582}}, {"key": "794", "attributes": {"color": "#3005C7", "label": "Dendritic cell-based immunotherapy", "size": null, "x": 32.784080505371094, "y": -24.297571182250977}}, {"key": "795", "attributes": {"color": "#3005C7", "label": "Engineering dendritic cell vaccines to improve cancer immunotherapy", "size": null, "x": 37.80910873413086, "y": -24.71090316772461}}, {"key": "796", "attributes": {"color": "#3005C7", "label": "Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing", "size": null, "x": 33.866092681884766, "y": -25.817060470581055}}, {"key": "797", "attributes": {"color": "#3005C7", "label": "SARS-CoV-2 does not replicate in embryonated hen\"s eggs or in MDCK cell lines", "size": null, "x": 33.14678192138672, "y": -25.1066837310791}}, {"key": "798", "attributes": {"color": "#3005C7", "label": "Vaccine Adjuvants: from 1920 to 2015 and Beyond, Vaccines (Basel)", "size": null, "x": 35.26747512817383, "y": -26.057632446289062}}, {"key": "799", "attributes": {"color": "#3005C7", "label": "Challenges in the development of an HIV-1 vaccine", "size": null, "x": 34.40900421142578, "y": -22.438703536987305}}, {"key": "800", "attributes": {"color": "#3005C7", "label": "Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus", "size": null, "x": 34.88249588012695, "y": -26.379499435424805}}, {"key": "801", "attributes": {"color": "#3005C7", "label": "How advances in immunology provide insight into improving vaccine efficacy", "size": null, "x": 35.028011322021484, "y": -22.45978546142578}}, {"key": "802", "attributes": {"color": "#3005C7", "label": "Novel antigen delivery systems", "size": null, "x": 37.0736198425293, "y": -27.305850982666016}}, {"key": "803", "attributes": {"color": "#3005C7", "label": "Reverse genetic systems: Rational design of coronavirus live attenuated vaccines with immune sequelae", "size": null, "x": 35.77178955078125, "y": -20.865276336669922}}, {"key": "804", "attributes": {"color": "#3005C7", "label": "Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform", "size": null, "x": 33.180294036865234, "y": -24.72185516357422}}, {"key": "805", "attributes": {"color": "#3005C7", "label": "Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives", "size": null, "x": 36.00534439086914, "y": -21.85016441345215}}, {"key": "806", "attributes": {"color": "#3005C7", "label": "Live attenuated versus inactivated influenza vaccine in infants and young children", "size": null, "x": 36.39085006713867, "y": -26.07249641418457}}, {"key": "807", "attributes": {"color": "#3005C7", "label": "Engineering adeno-associated virus vectors for gene therapy", "size": null, "x": 34.45383071899414, "y": -23.771137237548828}}, {"key": "808", "attributes": {"color": "#3005C7", "label": "Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines", "size": null, "x": 36.54304504394531, "y": -21.219757080078125}}, {"key": "809", "attributes": {"color": "#3005C7", "label": "Correction: Review: a comprehensive summary of a decade development of the recombinase polymerase amplification", "size": null, "x": 35.75861740112305, "y": -22.869577407836914}}, {"key": "810", "attributes": {"color": "#3005C7", "label": "Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines?", "size": null, "x": 32.329139709472656, "y": -25.100658416748047}}, {"key": "811", "attributes": {"color": "#3005C7", "label": "Nanoparticle Vaccines Against Infectious Diseases, Front Immunol", "size": null, "x": 35.83863830566406, "y": -24.11954689025879}}, {"key": "812", "attributes": {"color": "#3005C7", "label": "Nanoparticle-based vaccines: opportunities and limitations, Nanopharmaceuticals, Elsevier2020", "size": null, "x": 34.00269317626953, "y": -23.54791831970215}}, {"key": "813", "attributes": {"color": "#3005C7", "label": "Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes", "size": null, "x": 33.71868896484375, "y": -24.41097068786621}}, {"key": "814", "attributes": {"color": "#3005C7", "label": "Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis", "size": null, "x": 35.115806579589844, "y": -24.120424270629883}}, {"key": "815", "attributes": {"color": "#3005C7", "label": "Design and evaluation of the immunogenicity and efficacy of a biomimetic particulate formulation of viral antigens", "size": null, "x": 34.70173645019531, "y": -27.284847259521484}}, {"key": "816", "attributes": {"color": "#3005C7", "label": "Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses", "size": null, "x": 35.128387451171875, "y": -26.647520065307617}}, {"key": "817", "attributes": {"color": "#3005C7", "label": "Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice", "size": null, "x": 38.173213958740234, "y": -25.76383399963379}}, {"key": "818", "attributes": {"color": "#3005C7", "label": "Adjuvants for Coronavirus Vaccines", "size": null, "x": 33.120582580566406, "y": -27.37660789489746}}, {"key": "819", "attributes": {"color": "#3005C7", "label": "Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches", "size": null, "x": 33.015323638916016, "y": -24.919008255004883}}, {"key": "820", "attributes": {"color": "#3005C7", "label": "Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen", "size": null, "x": 38.93748474121094, "y": -24.969358444213867}}, {"key": "821", "attributes": {"color": "#3005C7", "label": "Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine", "size": null, "x": 38.75829315185547, "y": -25.683300018310547}}, {"key": "822", "attributes": {"color": "#3005C7", "label": "Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus", "size": null, "x": 35.17334747314453, "y": -23.021728515625}}, {"key": "823", "attributes": {"color": "#3005C7", "label": "Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus", "size": null, "x": 33.486846923828125, "y": -22.243820190429688}}, {"key": "824", "attributes": {"color": "#3005C7", "label": "Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus", "size": null, "x": 33.71771240234375, "y": -23.04769515991211}}, {"key": "825", "attributes": {"color": "#3005C7", "label": "Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen", "size": null, "x": 34.33034133911133, "y": -22.77076530456543}}, {"key": "826", "attributes": {"color": "#3005C7", "label": "Effects of different immunization protocols and adjuvant on antibody responses to inactivated SARS-CoV vaccine", "size": null, "x": 37.14390182495117, "y": -24.5134220123291}}, {"key": "827", "attributes": {"color": "#3005C7", "label": "The immune responses of HLA-A*0201 restricted SARS-CoV S peptide-specific CD8+ T cells are augmented in varying degrees by CpG ODN, PolyI:C and R848", "size": null, "x": 34.322654724121094, "y": -26.772676467895508}}, {"key": "828", "attributes": {"color": "#3005C7", "label": "Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection", "size": null, "x": 31.909137725830078, "y": -25.0571231842041}}, {"key": "829", "attributes": {"color": "#3005C7", "label": "Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study", "size": null, "x": 37.84687423706055, "y": -22.40912628173828}}, {"key": "830", "attributes": {"color": "#3005C7", "label": "Dendritic cells based immunotherapy", "size": null, "x": 33.56673049926758, "y": -25.799875259399414}}, {"key": "831", "attributes": {"color": "#3005C7", "label": "The ins and outs of MHC class II-mediated antigen processing and presentation", "size": null, "x": 36.01206588745117, "y": -22.312606811523438}}, {"key": "832", "attributes": {"color": "#3005C7", "label": "Dendritic cell migration in health and disease", "size": null, "x": 34.811038970947266, "y": -22.417251586914062}}, {"key": "833", "attributes": {"color": "#3005C7", "label": "Dendritic cell-based vaccines: barriers and opportunities", "size": null, "x": 37.98964309692383, "y": -26.831172943115234}}, {"key": "834", "attributes": {"color": "#3005C7", "label": "Overview of the immune response", "size": null, "x": 38.27126693725586, "y": -24.619935989379883}}, {"key": "835", "attributes": {"color": "#3005C7", "label": "Therapeutic siRNA silencing in inflammatory monocytes in mice", "size": null, "x": 35.62495040893555, "y": -25.74072265625}}, {"key": "836", "attributes": {"color": "#3005C7", "label": "Nanomedicine for immunosuppressive therapy: achievements in pre-clinical and clinical research", "size": null, "x": 34.638206481933594, "y": -23.90959930419922}}, {"key": "837", "attributes": {"color": "#3005C7", "label": "A novel anti-IL4Ralpha nanoparticle efficiently controls lung inflammation during asthma", "size": null, "x": 35.607093811035156, "y": -24.401630401611328}}, {"key": "838", "attributes": {"color": "#3005C7", "label": "The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes", "size": null, "x": 38.96878433227539, "y": -23.12865447998047}}, {"key": "839", "attributes": {"color": "#3005C7", "label": "Calming the Cytokine Storm in Pneumonia by Biomimetic Nanoparticles", "size": null, "x": 37.755577087402344, "y": -21.74416732788086}}, {"key": "840", "attributes": {"color": "#3005C7", "label": "Cellular nanosponges inhibit SARS-CoV-2 infectivity", "size": null, "x": 32.782020568847656, "y": -27.568510055541992}}, {"key": "841", "attributes": {"color": "#3005C7", "label": "Treatments in the COVID-19 pandemic: an update on clinical trials", "size": null, "x": 37.23786163330078, "y": -23.693525314331055}}, {"key": "842", "attributes": {"color": "#3005C7", "label": "Warp Speed\" operations in the COVID-19 pandemic: moving too quickly?", "size": null, "x": 34.286842346191406, "y": -21.21412467956543}}, {"key": "843", "attributes": {"color": "#3005C7", "label": "Potential shortages of hydroxychloroquine for patients with lupus during the coronavirus disease 2019 pandemic", "size": null, "x": 32.99029541015625, "y": -23.32111167907715}}, {"key": "844", "attributes": {"color": "#3005C7", "label": "SARS-CoV-2 Vaccine Development: Current Status", "size": null, "x": 32.02480697631836, "y": -23.94987678527832}}, {"key": "845", "attributes": {"color": "#3005C7", "label": "Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine", "size": null, "x": 36.10352325439453, "y": -23.037059783935547}}, {"key": "846", "attributes": {"color": "#54A214", "label": "Vaccines that prevent SARS-CoV-2 transmission may prevent or dampen a spring wave of COVID-19 cases and deaths in 2021", "size": null, "x": 75.15204620361328, "y": -133.0067596435547}}, {"key": "847", "attributes": {"color": "#54A214", "label": "Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials", "size": null, "x": 73.30543518066406, "y": -133.0874481201172}}, {"key": "848", "attributes": {"color": "#54A214", "label": "Understanding COVID-19 vaccine efficacy", "size": null, "x": 74.3179702758789, "y": -134.04689025878906}}, {"key": "849", "attributes": {"color": "#54A214", "label": "Optimizing Vaccine Allocation to Combat the COVID-19 Pandemic. medRxiv", "size": null, "x": 74.70320892333984, "y": -134.92990112304688}}, {"key": "850", "attributes": {"color": "#54A214", "label": "Dynamic Prioritization of COVID-19", "size": null, "x": 73.37553405761719, "y": -133.84759521484375}}, {"key": "851", "attributes": {"color": "#54A214", "label": "Vaccines When Social Distancing is Limited for Essential Workers. medRxiv", "size": null, "x": 76.65127563476562, "y": -133.3113250732422}}, {"key": "852", "attributes": {"color": "#54A214", "label": "Vaccine optimization for COVID-19: who to vaccinate first? medRxiv", "size": null, "x": 75.89276885986328, "y": -134.6876983642578}}, {"key": "853", "attributes": {"color": "#54A214", "label": "Direct and indirect effects in vaccine efficacy and effectiveness", "size": null, "x": 74.55848693847656, "y": -132.9453582763672}}, {"key": "854", "attributes": {"color": "#54A214", "label": "Systematic Review and Meta-analysis of Indirect Protection Afforded by 635 Vaccinating Children Against Seasonal Influenza: Implications for Policy", "size": null, "x": 74.36688232421875, "y": -132.72608947753906}}, {"key": "855", "attributes": {"color": "#54A214", "label": "Pathogen transmission from vaccinated hosts can cause dosedependent reduction in virulence", "size": null, "x": 74.137939453125, "y": -132.48919677734375}}, {"key": "856", "attributes": {"color": "#54A214", "label": "Clinical Outcomes Of A 640 COVID-19 Vaccine: Implementation Over Efficacy", "size": null, "x": 74.84464263916016, "y": -134.3173065185547}}, {"key": "857", "attributes": {"color": "#54A214", "label": "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 645 14", "size": null, "x": 75.4257583618164, "y": -134.47265625}}, {"key": "858", "attributes": {"color": "#54A214", "label": "Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing", "size": null, "x": 73.67279052734375, "y": -132.38148498535156}}, {"key": "859", "attributes": {"color": "#54A214", "label": "Temporal dynamics in viral shedding and transmissibility of COVID-19", "size": null, "x": 76.11679077148438, "y": -133.5009002685547}}, {"key": "860", "attributes": {"color": "#54A214", "label": "Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate. medRxiv", "size": null, "x": 74.62080383300781, "y": -133.6898956298828}}, {"key": "861", "attributes": {"color": "#54A214", "label": "Simulations for designing and interpreting intervention trials in infectious diseases", "size": null, "x": 73.1674575805664, "y": -132.52957153320312}}, {"key": "862", "attributes": {"color": "#54A214", "label": "Viral Load Kinetics of SARS-CoV-2 Infection in First Two Patients in Korea", "size": null, "x": 75.54204559326172, "y": -133.0620880126953}}, {"key": "863", "attributes": {"color": "#54A214", "label": "Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response", "size": null, "x": 76.39861297607422, "y": -132.443603515625}}, {"key": "864", "attributes": {"color": "#54A214", "label": "SARS-CoV-2 viral load is associated with increased disease severity 665 and mortality", "size": null, "x": 75.22589874267578, "y": -134.76809692382812}}, {"key": "865", "attributes": {"color": "#54A214", "label": "COVID-19 human challenge studies in the UK. The Lancet Respiratory Medicine", "size": null, "x": 74.83028411865234, "y": -133.0096435546875}}, {"key": "866", "attributes": {"color": "#54A214", "label": "Widespread testing, case isolation and contact tracing may allow safe school reopening with continued moderate physical distancing: A modeling analysis of 670 King County, WA data", "size": null, "x": 73.86671447753906, "y": -133.24014282226562}}, {"key": "867", "attributes": {"color": "#54A214", "label": "Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2 shedding and intensity of inflammatory response. medRxiv", "size": null, "x": 74.76478576660156, "y": -134.02926635742188}}, {"key": "868", "attributes": {"color": "#54A214", "label": "Slight 675 reduction in SARS-CoV-2 exposure viral load due to masking results in a significant reduction in transmission with widespread implementation. medRxiv", "size": null, "x": 75.64424133300781, "y": -132.64569091796875}}, {"key": "869", "attributes": {"color": "#54A214", "label": "Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period", "size": null, "x": 76.89695739746094, "y": -132.7626495361328}}, {"key": "870", "attributes": {"color": "#54A214", "label": "Estimating the Risk of Human Herpesvirus 6 and Cytomegalovirus Transmission to Ugandan Infants from Viral Shedding in Saliva by Household Contacts", "size": null, "x": 75.15316009521484, "y": -134.2572479248047}}, {"key": "871", "attributes": {"color": "#54A214", "label": "Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding", "size": null, "x": 75.92796325683594, "y": -131.4586639404297}}, {"key": "872", "attributes": {"color": "#54A214", "label": "690 Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China", "size": null, "x": 75.5398941040039, "y": -131.98114013671875}}, {"key": "873", "attributes": {"color": "#54A214", "label": "Estimating the generation interval for coronavirus disease (COVID-19) based on symptom onset data", "size": null, "x": 75.00070190429688, "y": -132.09152221679688}}, {"key": "874", "attributes": {"color": "#54A214", "label": "Rapid localized spread and immunologic containment define Herpes 695 simplex virus-2 reactivation in the human genital tract", "size": null, "x": 75.0022201538086, "y": -135.04315185546875}}, {"key": "875", "attributes": {"color": "#54A214", "label": "Development of a doseresponse model for SARS coronavirus", "size": null, "x": 76.30632019042969, "y": -133.8766326904297}}, {"key": "876", "attributes": {"color": "#54A214", "label": "Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications 700 for Disease Pathogenesis and Transmissibility", "size": null, "x": 75.43429565429688, "y": -133.60467529296875}}, {"key": "877", "attributes": {"color": "#54A214", "label": "Pathogenesis and transmission of SARS-CoV-2 in golden hamsters", "size": null, "x": 75.17859649658203, "y": -132.25045776367188}}, {"key": "878", "attributes": {"color": "#54A214", "label": "Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19", "size": null, "x": 75.03903198242188, "y": -132.56410217285156}}, {"key": "879", "attributes": {"color": "#54A214", "label": "Maximum likelihood estimation of influenza vaccine effectiveness against transmission from the household and from the community", "size": null, "x": 74.17691040039062, "y": -131.69424438476562}}, {"key": "880", "attributes": {"color": "#54A214", "label": "Contagiousness of Varicella in Vaccinated CasesA Household Contact Study", "size": null, "x": 75.31451416015625, "y": -131.4507598876953}}, {"key": "881", "attributes": {"color": "#54A214", "label": "Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants. medRxiv", "size": null, "x": 76.82181549072266, "y": -132.39212036132812}}, {"key": "882", "attributes": {"color": "#54A214", "label": "Widespread testing, case isolation and contact tracing may allow safe 715 school reopening with continued moderate physical distancing: a modeling analysis of King County, WA data. medRxiv", "size": null, "x": 74.17749786376953, "y": -132.2861328125}}, {"key": "883", "attributes": {"color": "#54A214", "label": "Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis", "size": null, "x": 74.62319946289062, "y": -132.42279052734375}}, {"key": "884", "attributes": {"color": "#54A214", "label": "Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand", "size": null, "x": 73.97100067138672, "y": -133.62771606445312}}, {"key": "885", "attributes": {"color": "#54A214", "label": "SARS-CoV-2 viral dynamics in acute infections. medRxiv", "size": null, "x": 75.22498321533203, "y": -133.24716186523438}}, {"key": "886", "attributes": {"color": "#54A214", "label": "Widespread testing, case isolation and contact tracing may allow safe school reopening with continued moderate physical distancing: A modeling analysis of King County, WA data", "size": null, "x": 74.1673355102539, "y": -134.3826446533203}}, {"key": "887", "attributes": {"color": "#54A214", "label": "Potency and timing of antiviral therapy as 935 determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response", "size": null, "x": 75.17447662353516, "y": -133.97752380371094}}, {"key": "888", "attributes": {"color": "#54A214", "label": "Wrong person, place and time: viral load and contact network structure predict SARS-CoV-2 transmission and super-spreading events. medRxiv", "size": null, "x": 76.08649444580078, "y": -132.09466552734375}}, {"key": "889", "attributes": {"color": "#54A214", "label": "Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study", "size": null, "x": 76.01504516601562, "y": -134.0842742919922}}, {"key": "890", "attributes": {"color": "#54A214", "label": "Evaluating Transmission Heterogeneity and Super-Spreading Event of COVID-19 in a Metropolis of China", "size": null, "x": 75.78699493408203, "y": -132.1230010986328}}, {"key": "891", "attributes": {"color": "#54A214", "label": "Clustering and superspreading potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Hong Kong. PREPRINT (Version 1) available at Research Square", "size": null, "x": 75.06128692626953, "y": -131.42233276367188}}, {"key": "892", "attributes": {"color": "#54A214", "label": "Centre for the Mathematical Modelling of Infectious Diseases", "size": null, "x": 76.1693344116211, "y": -133.0673828125}}, {"key": "893", "attributes": {"color": "#54A214", "label": "Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China", "size": null, "x": 74.10832214355469, "y": -133.2425079345703}}, {"key": "894", "attributes": {"color": "#54A214", "label": "Serial Interval of COVID-19 among Publicly Reported Confirmed Cases", "size": null, "x": 75.4307632446289, "y": -133.9001007080078}}, {"key": "895", "attributes": {"color": "#3005C7", "label": "Journal Pre-proof One Year Update on the COVID-19 Pandemic: Where Are We Now?", "size": null, "x": -0.08202214539051056, "y": 20.149354934692383}}, {"key": "896", "attributes": {"color": "#3005C7", "label": "Arbidol as a broad-spectrum antiviral: an update", "size": null, "x": 1.369486689567566, "y": 18.816434860229492}}, {"key": "897", "attributes": {"color": "#3005C7", "label": "Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic", "size": null, "x": -1.6062067747116089, "y": 19.618328094482422}}, {"key": "898", "attributes": {"color": "#3005C7", "label": "Arbidol: a broad-spectrum antiviral compound that blocks viral fusion", "size": null, "x": -0.4741083085536957, "y": 22.29584503173828}}, {"key": "899", "attributes": {"color": "#3005C7", "label": "Immunity to viruses", "size": null, "x": -0.29593589901924133, "y": 19.11992645263672}}, {"key": "900", "attributes": {"color": "#3005C7", "label": "Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review)", "size": null, "x": -0.3319351077079773, "y": 20.894193649291992}}, {"key": "901", "attributes": {"color": "#3005C7", "label": "COVID vaccine excitement builds as Moderna reports third positive result", "size": null, "x": 1.4796479940414429, "y": 22.32754898071289}}, {"key": "902", "attributes": {"color": "#3005C7", "label": "Making sense of coronavirus mutations", "size": null, "x": -2.4252829551696777, "y": 21.7520809173584}}, {"key": "903", "attributes": {"color": "#3005C7", "label": "Russia announces positive COVID-vaccine results from controversial trial", "size": null, "x": -0.9186844825744629, "y": 19.846601486206055}}, {"key": "904", "attributes": {"color": "#3005C7", "label": "What Pfizer's landmark COVID vaccine results mean for the pandemic", "size": null, "x": -3.22694730758667, "y": 19.556169509887695}}, {"key": "905", "attributes": {"color": "#3005C7", "label": "The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro", "size": null, "x": 2.604686737060547, "y": 20.84910774230957}}, {"key": "906", "attributes": {"color": "#3005C7", "label": "Nuclear trafficking of proteins from RNA viruses: potential target for antivirals?", "size": null, "x": 0.4210312068462372, "y": 19.524019241333008}}, {"key": "907", "attributes": {"color": "#3005C7", "label": "Antiviral monotherapy for hospitalised patients with COVID-19 is not enough", "size": null, "x": -0.20563377439975739, "y": 21.29345703125}}, {"key": "908", "attributes": {"color": "#3005C7", "label": "A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19", "size": null, "x": 0.3282114267349243, "y": 20.357206344604492}}, {"key": "909", "attributes": {"color": "#3005C7", "label": "Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv", "size": null, "x": 1.2668118476867676, "y": 18.386398315429688}}, {"key": "910", "attributes": {"color": "#A36913", "label": "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study", "size": null, "x": -35.019935607910156, "y": 160.9991912841797}}, {"key": "911", "attributes": {"color": "#3005C7", "label": "Hosts and Sources of Endemic Human Coronaviruses", "size": null, "x": -0.8723625540733337, "y": 21.831235885620117}}, {"key": "912", "attributes": {"color": "#3005C7", "label": "Antivirals and antiviral strategies", "size": null, "x": 0.20702819526195526, "y": 20.08490753173828}}, {"key": "913", "attributes": {"color": "#3005C7", "label": "Host Factors in Coronavirus Replication", "size": null, "x": -0.8060465455055237, "y": 18.71307373046875}}, {"key": "914", "attributes": {"color": "#DA049E", "label": "SARS and MERS: recent insights into emerging coronaviruses", "size": null, "x": -11.732552528381348, "y": 66.08687591552734}}, {"key": "915", "attributes": {"color": "#3005C7", "label": "Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents", "size": null, "x": -0.22819599509239197, "y": 17.983591079711914}}, {"key": "916", "attributes": {"color": "#3005C7", "label": "Discovering drugs to treat coronavirus disease 2019 (COVID-19)", "size": null, "x": 41.90843200683594, "y": 53.62654113769531}}, {"key": "917", "attributes": {"color": "#3005C7", "label": "Identification of a novel coronavirus in patients with severe acute respiratory syndrome", "size": null, "x": 1.5769529342651367, "y": 20.539670944213867}}, {"key": "918", "attributes": {"color": "#3005C7", "label": "Membrane binding proteins of coronaviruses", "size": null, "x": 1.5882147550582886, "y": 21.313936233520508}}, {"key": "919", "attributes": {"color": "#3005C7", "label": "Data, disease and diplomacy: GISAID's innovative contribution to global health", "size": null, "x": 0.016516784206032753, "y": 19.09390640258789}}, {"key": "920", "attributes": {"color": "#3005C7", "label": "Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin", "size": null, "x": -0.037205301225185394, "y": 21.58125877380371}}, {"key": "921", "attributes": {"color": "#3005C7", "label": "Furin cleavage of the SARS coronavirus spike glycoprotein enhances cell-cell fusion but does not affect virion entry", "size": null, "x": -0.13557474315166473, "y": 19.590539932250977}}, {"key": "922", "attributes": {"color": "#3005C7", "label": "Molecular Evolution of Human Coronavirus Genomes", "size": null, "x": -2.5259549617767334, "y": 21.212331771850586}}, {"key": "923", "attributes": {"color": "#3005C7", "label": "Aetiology: Koch's postulates fulfilled for SARS virus", "size": null, "x": -0.5423198342323303, "y": 19.853591918945312}}, {"key": "924", "attributes": {"color": "#3005C7", "label": "Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients", "size": null, "x": -0.5753461718559265, "y": 19.560129165649414}}, {"key": "925", "attributes": {"color": "#3005C7", "label": "Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response", "size": null, "x": 2.0410268306732178, "y": 19.9421329498291}}, {"key": "926", "attributes": {"color": "#DA049E", "label": "Clinical characteristics of coronavirus disease 2019 in China", "size": null, "x": -12.397653579711914, "y": 66.39662170410156}}, {"key": "927", "attributes": {"color": "#3005C7", "label": "The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status", "size": null, "x": 0.5558293461799622, "y": 21.00774383544922}}, {"key": "928", "attributes": {"color": "#DA049E", "label": "Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics", "size": null, "x": -12.13164234161377, "y": 65.58177185058594}}, {"key": "929", "attributes": {"color": "#3005C7", "label": "Rapid repurposing of drugs for COVID-19", "size": null, "x": -0.6083841323852539, "y": 21.896236419677734}}, {"key": "930", "attributes": {"color": "#DA049E", "label": "Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis", "size": null, "x": -12.808712005615234, "y": 65.59455108642578}}, {"key": "931", "attributes": {"color": "#45E73B", "label": "Clinical vaccine development", "size": null, "x": -1.2946480512619019, "y": 19.76021385192871}}, {"key": "932", "attributes": {"color": "#3005C7", "label": "Evidence of the recombinant origin of a bat severe acute respiratory syndrome (SARS)-like coronavirus and its implications on the direct ancestor of SARS coronavirus", "size": null, "x": 1.0321779251098633, "y": 20.849637985229492}}, {"key": "933", "attributes": {"color": "#3005C7", "label": "No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19", "size": null, "x": 2.1262400150299072, "y": 19.502765655517578}}, {"key": "934", "attributes": {"color": "#3005C7", "label": "Identification of novel subgenomic RNAs and noncanonical transcription initiation signals of severe acute respiratory syndrome coronavirus", "size": null, "x": 0.8261299133300781, "y": 20.75847816467285}}, {"key": "935", "attributes": {"color": "#3005C7", "label": "Evidence supporting a zoonotic origin of human coronavirus strain NL63", "size": null, "x": -0.664365291595459, "y": 21.42978858947754}}, {"key": "936", "attributes": {"color": "#3005C7", "label": "Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted", "size": null, "x": 1.9535140991210938, "y": 21.899721145629883}}, {"key": "937", "attributes": {"color": "#3005C7", "label": "ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia", "size": null, "x": -1.6886569261550903, "y": 21.765731811523438}}, {"key": "938", "attributes": {"color": "#3005C7", "label": "A rapid advice guideline for the diagnosis and treatment of", "size": null, "x": 2.6641786098480225, "y": 19.73038101196289}}, {"key": "939", "attributes": {"color": "#3005C7", "label": "Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol", "size": null, "x": -0.22000037133693695, "y": 21.96025276184082}}, {"key": "940", "attributes": {"color": "#3005C7", "label": "Immunopotentiating compounds from Tinospora cordifolia", "size": null, "x": 0.5943579077720642, "y": 19.909305572509766}}, {"key": "941", "attributes": {"color": "#3005C7", "label": "Innate Immune Evasion by Human Respiratory RNA Viruses", "size": null, "x": -1.202407717704773, "y": 18.530651092529297}}, {"key": "942", "attributes": {"color": "#3005C7", "label": "Ribavirin in the treatment of SARS: A new trick for an old drug?", "size": null, "x": 1.051794409751892, "y": 19.862184524536133}}, {"key": "943", "attributes": {"color": "#3005C7", "label": "Messenger RNA-based vaccines: progress, challenges, applications", "size": null, "x": -1.5096012353897095, "y": 20.79828643798828}}, {"key": "944", "attributes": {"color": "#3005C7", "label": "Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (M(pro)) of SARS-CoV-2 and inhibit its activity", "size": null, "x": -0.898195207118988, "y": 18.852449417114258}}, {"key": "945", "attributes": {"color": "#3005C7", "label": "Updated approaches against SARS-CoV-2", "size": null, "x": 1.0599982738494873, "y": 20.733976364135742}}, {"key": "946", "attributes": {"color": "#3005C7", "label": "2020b. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia", "size": null, "x": -1.791625738143921, "y": 18.961475372314453}}, {"key": "947", "attributes": {"color": "#3005C7", "label": "Angiotensinconverting enzyme 2 is a functional receptor for the SARS coronavirus", "size": null, "x": -1.8618887662887573, "y": 18.524816513061523}}, {"key": "948", "attributes": {"color": "#3005C7", "label": "Bats are natural reservoirs of SARS-like coronaviruses", "size": null, "x": 0.576540470123291, "y": 22.04566764831543}}, {"key": "949", "attributes": {"color": "#3005C7", "label": "Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2", "size": null, "x": 1.1666773557662964, "y": 19.619842529296875}}, {"key": "950", "attributes": {"color": "#3005C7", "label": "Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR", "size": null, "x": -1.2498998641967773, "y": 19.07293701171875}}, {"key": "951", "attributes": {"color": "#3005C7", "label": "How COVID-19 can damage the brain", "size": null, "x": -1.95824134349823, "y": 21.922109603881836}}, {"key": "952", "attributes": {"color": "#3005C7", "label": "Fields virology", "size": null, "x": -0.5951349139213562, "y": 22.377832412719727}}, {"key": "953", "attributes": {"color": "#3005C7", "label": "A randomized, controlled trial of Ebola virus disease therapeutics", "size": null, "x": -1.8159548044204712, "y": 20.125606536865234}}, {"key": "954", "attributes": {"color": "#3005C7", "label": "New insights into the mechanisms of RNA recombination", "size": null, "x": -1.2578800916671753, "y": 21.300081253051758}}, {"key": "955", "attributes": {"color": "#3005C7", "label": "Mechanism of macrophage activation by (1,4)-alpha-D-glucan isolated from Tinospora cordifolia", "size": null, "x": -0.1354605108499527, "y": 20.4370059967041}}, {"key": "956", "attributes": {"color": "#3005C7", "label": "Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach", "size": null, "x": -1.2350857257843018, "y": 18.086400985717773}}, {"key": "957", "attributes": {"color": "#3005C7", "label": "How Does Arbidol Inhibit the Novel Coronavirus SARS-CoV-2? Atomistic Insights from Molecular Dynamics Simulations", "size": null, "x": 0.15768171846866608, "y": 20.911205291748047}}, {"key": "958", "attributes": {"color": "#3005C7", "label": "High Throughput Designing and Mutational Mapping of RBD-ACE2 Interface Guide Non-Conventional Therapeutic Strategies for COVID-19", "size": null, "x": 0.6494903564453125, "y": 18.61029815673828}}, {"key": "959", "attributes": {"color": "#3005C7", "label": "Rational Design of the Remdesivir Binding Site in the RNA-dependent RNA Polymerase of SARS-CoV-2: Implications for Potential Resistance", "size": null, "x": -0.5124532580375671, "y": 21.058212280273438}}, {"key": "960", "attributes": {"color": "#3005C7", "label": "Can SARS-CoV-2 Accumulate Mutations in the S-Protein to Increase Pathogenicity?", "size": null, "x": 0.7832304239273071, "y": 21.21672248840332}}, {"key": "961", "attributes": {"color": "#3005C7", "label": "Pandemic publishing poses a new COVID-19 challenge", "size": null, "x": -1.3835644721984863, "y": 19.388343811035156}}, {"key": "962", "attributes": {"color": "#3005C7", "label": "Repurposed antiviral drugs for COVID-19 -interim WHO SOLIDARITY trial results. medRxiv", "size": null, "x": -0.08105207979679108, "y": 19.351282119750977}}, {"key": "963", "attributes": {"color": "#3005C7", "label": "The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings", "size": null, "x": 0.8911210894584656, "y": 21.744075775146484}}, {"key": "964", "attributes": {"color": "#3005C7", "label": "Antiviral agents, An Introduction to Medicinal Chemistry 4ed", "size": null, "x": -1.3843907117843628, "y": 20.262605667114258}}, {"key": "965", "attributes": {"color": "#3005C7", "label": "Insider information: what viruses tell us about endocytosis", "size": null, "x": 0.1828530877828598, "y": 21.624303817749023}}, {"key": "966", "attributes": {"color": "#3005C7", "label": "The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal", "size": null, "x": -0.9216116666793823, "y": 17.672861099243164}}, {"key": "967", "attributes": {"color": "#3005C7", "label": "Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy", "size": null, "x": -1.6062995195388794, "y": 22.52509880065918}}, {"key": "968", "attributes": {"color": "#3005C7", "label": "The COVID-19 Cytokine Storm; What We Know So Far", "size": null, "x": -0.6607488393783569, "y": 18.16240882873535}}, {"key": "969", "attributes": {"color": "#3005C7", "label": "Essential functional molecules associated with SARS-CoV-2 infection: Potential therapeutic targets for COVID-19", "size": null, "x": 0.8598262071609497, "y": 18.241554260253906}}, {"key": "970", "attributes": {"color": "#3005C7", "label": "Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease", "size": null, "x": -0.5965061783790588, "y": 20.39715003967285}}, {"key": "971", "attributes": {"color": "#3005C7", "label": "SARS vaccines: where are we?", "size": null, "x": 0.33307233452796936, "y": 18.62495231628418}}, {"key": "972", "attributes": {"color": "#3005C7", "label": "Generation of coronavirus spike deletion variants by high-frequency recombination at regions of predicted RNA secondary structure", "size": null, "x": -1.2490503787994385, "y": 20.06841278076172}}, {"key": "973", "attributes": {"color": "#3005C7", "label": "Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)", "size": null, "x": -2.27540922164917, "y": 19.747135162353516}}, {"key": "974", "attributes": {"color": "#3005C7", "label": "Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More", "size": null, "x": -1.9272254705429077, "y": 20.930585861206055}}, {"key": "975", "attributes": {"color": "#3005C7", "label": "COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?", "size": null, "x": -1.6608818769454956, "y": 20.122011184692383}}, {"key": "976", "attributes": {"color": "#3005C7", "label": "Effects of chloroquine on viral infections: an old drug against today's diseases. The Lancet infectious diseases", "size": null, "x": -0.520311176776886, "y": 17.498493194580078}}, {"key": "977", "attributes": {"color": "#3005C7", "label": "Coronavirus transcription: a perspective", "size": null, "x": 0.6153340935707092, "y": 22.584712982177734}}, {"key": "978", "attributes": {"color": "#3005C7", "label": "Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology", "size": null, "x": 1.7591395378112793, "y": 20.843753814697266}}, {"key": "979", "attributes": {"color": "#3005C7", "label": "Immunomodulatory active compounds from Tinospora cordifolia", "size": null, "x": 2.095926523208618, "y": 20.513734817504883}}, {"key": "980", "attributes": {"color": "#3005C7", "label": "An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice", "size": null, "x": -1.5049645900726318, "y": 21.493572235107422}}, {"key": "981", "attributes": {"color": "#3005C7", "label": "COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses", "size": null, "x": -0.7149542570114136, "y": 19.204133987426758}}, {"key": "982", "attributes": {"color": "#3005C7", "label": "A review of studies on animal reservoirs of the SARS coronavirus", "size": null, "x": -2.050443649291992, "y": 19.218889236450195}}, {"key": "983", "attributes": {"color": "#3005C7", "label": "Clinical Features of Cytokine Storm Syndrome", "size": null, "x": -1.8987690210342407, "y": 19.332895278930664}}, {"key": "984", "attributes": {"color": "#3005C7", "label": "Dissecting virus entry via endocytosis", "size": null, "x": -0.7714719176292419, "y": 20.818464279174805}}, {"key": "985", "attributes": {"color": "#3005C7", "label": "CoV-GLUE: A Web Application for Tracking SARS-CoV-2 Genomic Variation", "size": null, "x": 1.3521512746810913, "y": 21.68358039855957}}, {"key": "986", "attributes": {"color": "#3005C7", "label": "A review of coronavirus disease-2019 (COVID-19)", "size": null, "x": -0.91069495677948, "y": 21.128368377685547}}, {"key": "987", "attributes": {"color": "#3005C7", "label": "Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses", "size": null, "x": 1.115102767944336, "y": 22.03459358215332}}, {"key": "988", "attributes": {"color": "#45E73B", "label": "The COVID-19 vaccine development landscape", "size": null, "x": -2.5253939628601074, "y": 20.662342071533203}}, {"key": "989", "attributes": {"color": "#3005C7", "label": "Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Metaanalysis", "size": null, "x": -2.201878309249878, "y": 21.46146583557129}}, {"key": "990", "attributes": {"color": "#3005C7", "label": "Pfizer Says New Results Show Vaccine Is Safe and 95% Effective, The New York Times", "size": null, "x": 2.144660472869873, "y": 21.175724029541016}}, {"key": "991", "attributes": {"color": "#3005C7", "label": "Pattern recognition receptors and the innate immune response to viral infection", "size": null, "x": 0.8442369103431702, "y": 19.200468063354492}}, {"key": "992", "attributes": {"color": "#3005C7", "label": "COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing", "size": null, "x": 0.08874884992837906, "y": 19.50349998474121}}, {"key": "993", "attributes": {"color": "#3005C7", "label": "Structural insights into coronavirus entry", "size": null, "x": -1.7643158435821533, "y": 17.941652297973633}}, {"key": "994", "attributes": {"color": "#3005C7", "label": "ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis", "size": null, "x": 0.05503406748175621, "y": 17.60258674621582}}, {"key": "995", "attributes": {"color": "#3005C7", "label": "A Review of SARS-CoV-2 and the Ongoing Clinical Trials", "size": null, "x": 0.7718949913978577, "y": 18.8341007232666}}, {"key": "996", "attributes": {"color": "#3005C7", "label": "Neurological and neuropsychiatric complications of COVID-19", "size": null, "x": 0.4573300778865814, "y": 19.171043395996094}}, {"key": "997", "attributes": {"color": "#3005C7", "label": "The COVID-19 epidemic", "size": null, "x": 0.8823496699333191, "y": 20.385726928710938}}, {"key": "998", "attributes": {"color": "#3005C7", "label": "Ivermectin is a specific inhibitor of importin Î±/Î²-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus", "size": null, "x": 0.23978938162326813, "y": 20.557464599609375}}, {"key": "999", "attributes": {"color": "#3005C7", "label": "Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein", "size": null, "x": -0.17630697786808014, "y": 18.7479190826416}}, {"key": "1000", "attributes": {"color": "#3005C7", "label": "Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus", "size": null, "x": -0.5798075199127197, "y": 18.51166534423828}}, {"key": "1001", "attributes": {"color": "#3005C7", "label": "SARS coronavirus entry into host cells through a novel clathrin-and caveolae-independent endocytic pathway", "size": null, "x": 0.9660105109214783, "y": 17.774627685546875}}, {"key": "1002", "attributes": {"color": "#3005C7", "label": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro", "size": null, "x": -2.206418037414551, "y": 20.34684181213379}}, {"key": "1003", "attributes": {"color": "#3005C7", "label": "Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4", "size": null, "x": 0.2461681067943573, "y": 21.950271606445312}}, {"key": "1004", "attributes": {"color": "#3005C7", "label": "Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2", "size": null, "x": -0.8742685317993164, "y": 19.519832611083984}}, {"key": "1005", "attributes": {"color": "#3005C7", "label": "Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment", "size": null, "x": -1.3459715843200684, "y": 21.733558654785156}}, {"key": "1006", "attributes": {"color": "#3005C7", "label": "Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus", "size": null, "x": -1.0080729722976685, "y": 21.40338706970215}}, {"key": "1007", "attributes": {"color": "#45E73B", "label": "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation", "size": null, "x": -11.702496528625488, "y": 65.61263275146484}}, {"key": "1008", "attributes": {"color": "#3005C7", "label": "Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China", "size": null, "x": -1.298336148262024, "y": 19.0581111907959}}, {"key": "1009", "attributes": {"color": "#3005C7", "label": "TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib", "size": null, "x": -0.14788085222244263, "y": 22.402179718017578}}, {"key": "1010", "attributes": {"color": "#3005C7", "label": "Mechanisms of host receptor adaptation by severe acute respiratory syndrome coronavirus", "size": null, "x": -1.0661888122558594, "y": 20.357969284057617}}, {"key": "1011", "attributes": {"color": "#3005C7", "label": "ORF8-Related Genetic Evidence for Chinese Horseshoe Bats as the Source of Human Severe Acute Respiratory Syndrome Coronavirus", "size": null, "x": 1.6846081018447876, "y": 19.370840072631836}}, {"key": "1012", "attributes": {"color": "#3005C7", "label": "Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein", "size": null, "x": -1.7741386890411377, "y": 20.62247085571289}}, {"key": "1013", "attributes": {"color": "#3005C7", "label": "Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19", "size": null, "x": 1.465593695640564, "y": 20.140705108642578}}, {"key": "1014", "attributes": {"color": "#45E73B", "label": "Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan", "size": null, "x": -2.591989040374756, "y": 19.224170684814453}}, {"key": "1015", "attributes": {"color": "#3005C7", "label": "Biomedical Science to Tackle the COVID-19 Pandemic: Current Status and Future Perspectives", "size": null, "x": 0.7661575675010681, "y": 21.4287109375}}, {"key": "1016", "attributes": {"color": "#3005C7", "label": "Corona virus versus existence of human on the earth: A computational and biophysical approach", "size": null, "x": 0.4162801504135132, "y": 19.801673889160156}}, {"key": "1017", "attributes": {"color": "#3005C7", "label": "Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes", "size": null, "x": -0.7981069684028625, "y": 20.441852569580078}}, {"key": "1018", "attributes": {"color": "#3005C7", "label": "SARSrelated virus predating SARS outbreak", "size": null, "x": -2.827357530593872, "y": 19.7133731842041}}, {"key": "1019", "attributes": {"color": "#3005C7", "label": "Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China", "size": null, "x": 1.444366455078125, "y": 19.68446159362793}}, {"key": "1020", "attributes": {"color": "#3005C7", "label": "Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19", "size": null, "x": 0.4362381398677826, "y": 17.8745174407959}}, {"key": "1021", "attributes": {"color": "#3005C7", "label": "Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus", "size": null, "x": 83.17231750488281, "y": 86.12104797363281}}, {"key": "1022", "attributes": {"color": "#DA049E", "label": "Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors", "size": null, "x": -23.95236587524414, "y": 113.23285675048828}}, {"key": "1023", "attributes": {"color": "#DA049E", "label": "Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?", "size": null, "x": -26.325746536254883, "y": 113.2762451171875}}, {"key": "1024", "attributes": {"color": "#A36913", "label": "Collider bias undermines our understanding of COVID-19 disease risk and severity", "size": null, "x": -34.430057525634766, "y": 159.0709686279297}}, {"key": "1025", "attributes": {"color": "#3B61DE", "label": "Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)", "size": null, "x": -160.04913330078125, "y": 27.690608978271484}}, {"key": "1026", "attributes": {"color": "#3B61DE", "label": "Griffiths: Celgene/BMS: Honoraria, Research Funding", "size": null, "x": -160.0903778076172, "y": 29.202558517456055}}, {"key": "1027", "attributes": {"color": "#3B61DE", "label": "AbbVie Inc: Honoraria; Persimmune: Research Funding; Novartis: Honoraria, Research Funding; Alexion Pharmaceuticals: Honoraria", "size": null, "x": -159.64498901367188, "y": 26.40488052368164}}, {"key": "1028", "attributes": {"color": "#3B61DE", "label": "Consultancy, Honoraria; Cardinal Health: Consultancy, Honoraria; Epizyme: Consultancy, Honoraria; Leukemia and Lymphoma Society: Other; Jazz: Consultancy, Honoraria; Trovagene: Consultancy, Honoraria, Research Funding; Ionis: Consultancy, Honoraria; Takeda: Consultancy, Honoraria", "size": null, "x": -160.47793579101562, "y": 27.847986221313477}}, {"key": "1029", "attributes": {"color": "#3B61DE", "label": "Research Funding; Otsuka: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Research Funding; Acceleron: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding", "size": null, "x": -161.14637756347656, "y": 26.560949325561523}}, {"key": "1030", "attributes": {"color": "#3B61DE", "label": "Research Funding; Aprea: Research Funding", "size": null, "x": -158.43446350097656, "y": 27.500120162963867}}, {"key": "1031", "attributes": {"color": "#3B61DE", "label": "Research Funding; Cardiff Oncology: Consultancy, Honoraria, Other; Incyte: Consultancy, Honoraria, Research Funding", "size": null, "x": -160.3522186279297, "y": 27.631608963012695}}, {"key": "1032", "attributes": {"color": "#3B61DE", "label": "France Foundation: Honoraria; Celgene: Consultancy, Speakers Bureau", "size": null, "x": -159.43060302734375, "y": 28.116546630859375}}, {"key": "1033", "attributes": {"color": "#3B61DE", "label": "Keating: Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -160.8797149658203, "y": 29.080129623413086}}, {"key": "1034", "attributes": {"color": "#3B61DE", "label": "Funding; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -159.03289794921875, "y": 27.85480499267578}}, {"key": "1035", "attributes": {"color": "#3B61DE", "label": "Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -160.12120056152344, "y": 26.551233291625977}}, {"key": "1036", "attributes": {"color": "#3B61DE", "label": "Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Consultancy; Servier: Membership on an entity's Board of Directors or advisory committees; Shire: Membership on an entity's Board of Directors or advisory committees; Taiho: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -160.2259063720703, "y": 26.092350006103516}}, {"key": "1037", "attributes": {"color": "#3B61DE", "label": "Consultancy, Speakers Bureau; Incyte Corporation: Consultancy, Honoraria", "size": null, "x": -159.0807342529297, "y": 27.150222778320312}}, {"key": "1038", "attributes": {"color": "#3B61DE", "label": "Novartis: Consultancy, Speakers Bureau; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -158.52639770507812, "y": 26.955175399780273}}, {"key": "1039", "attributes": {"color": "#3B61DE", "label": "Research Funding; Impact Biomedicines: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -160.0351104736328, "y": 28.477825164794922}}, {"key": "1040", "attributes": {"color": "#3B61DE", "label": "BioAscend: Honoraria; Delta Fly: Honoraria; Ascentage: Research Funding", "size": null, "x": -160.54420471191406, "y": 26.946434020996094}}, {"key": "1041", "attributes": {"color": "#3B61DE", "label": "Research Funding; Pfizer: Honoraria, Research Funding; Sanofi: Research Funding", "size": null, "x": -160.80572509765625, "y": 28.476224899291992}}, {"key": "1042", "attributes": {"color": "#3B61DE", "label": "Actinium: Honoraria, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -159.72940063476562, "y": 28.661502838134766}}, {"key": "1043", "attributes": {"color": "#3B61DE", "label": "Research Funding; Jazz: Research Funding; Oxford Biomedical: Honoraria; Amgen: Honoraria, Research Funding; Adaptive biotechnologies: Honoraria. DeZern: MEI: Consultancy; Celgene: Consultancy, Honoraria; Astex: Research Funding", "size": null, "x": -159.70338439941406, "y": 27.31935691833496}}, {"key": "1044", "attributes": {"color": "#3B61DE", "label": "Pfizer: Consultancy; Abbvie: Consultancy; Array BioPharma: Consultancy", "size": null, "x": -159.75828552246094, "y": 27.721637725830078}}, {"key": "1045", "attributes": {"color": "#3B61DE", "label": "Celltrion: Consultancy; Eisai: Consultancy; Jazz: Consultancy", "size": null, "x": -159.23910522460938, "y": 26.841459274291992}}, {"key": "1046", "attributes": {"color": "#3B61DE", "label": "Sandoz: Consultancy; Actinium: Consultancy; Argenx: Consultancy; Astellas: Consultancy", "size": null, "x": -160.48240661621094, "y": 26.683242797851562}}, {"key": "1047", "attributes": {"color": "#3B61DE", "label": "Daiichi Sankyo: Consultancy; AstraZeneca: Consultancy; Orsenix: Consultancy; Otsuka: Consultancy; Takeda: Consultancy; Trovagene: Consultancy; Cellectis: Research Funding", "size": null, "x": -160.67050170898438, "y": 26.009422302246094}}, {"key": "1048", "attributes": {"color": "#3B61DE", "label": "Epizyme: Consultancy; Helsinn: Consultancy; MEI Pharma: Consultancy. Busque: Pfizer: Honoraria", "size": null, "x": -159.2030792236328, "y": 29.01105499267578}}, {"key": "1049", "attributes": {"color": "#3B61DE", "label": "Research Funding; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -160.09622192382812, "y": 26.975360870361328}}, {"key": "1050", "attributes": {"color": "#3B61DE", "label": "Otsuka Pharmaceutical: Honoraria, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -158.64219665527344, "y": 28.321264266967773}}, {"key": "1051", "attributes": {"color": "#3B61DE", "label": "Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Treadwell: Honoraria, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -160.89686584472656, "y": 27.58133888244629}}, {"key": "1052", "attributes": {"color": "#3B61DE", "label": "Alexion: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -160.50967407226562, "y": 28.813018798828125}}, {"key": "1053", "attributes": {"color": "#3B61DE", "label": "Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -161.11538696289062, "y": 28.198793411254883}}, {"key": "1054", "attributes": {"color": "#3B61DE", "label": "Current Employment. Garcia-Manero: Acceleron Pharmaceuticals: Consultancy, Honoraria; AbbVie: Honoraria, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; H3 Biomedicine: Research Funding; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -161.33212280273438, "y": 27.828187942504883}}, {"key": "1055", "attributes": {"color": "#3B61DE", "label": "Research Funding; Merck: Research Funding; Jazz Pharmaceuticals: Consultancy; Celgene: Consultancy, Honoraria", "size": null, "x": -158.83432006835938, "y": 26.451608657836914}}, {"key": "1056", "attributes": {"color": "#F3AFE9", "label": "Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub", "size": null, "x": -34.51332473754883, "y": -96.65290832519531}}, {"key": "1057", "attributes": {"color": "#F3AFE9", "label": "Funding; Cellerant: Research Funding; Orsenix: Research Funding; ADC Therapeutics: Research Funding; Roche: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Jazz Pharma: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -35.15343475341797, "y": -97.89570617675781}}, {"key": "1058", "attributes": {"color": "#F3AFE9", "label": "Karyopharm: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Kite: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Apobiologix: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Acerta: Consultancy, Honoraria; TG therapeutics: Consultancy, Honoraria", "size": null, "x": -34.55269241333008, "y": -97.42574310302734}}, {"key": "1059", "attributes": {"color": "#F3AFE9", "label": "Seattle Genetics: Consultancy, Honoraria; F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Research Funding; MorphoSys: Consultancy, Honoraria", "size": null, "x": -35.400840759277344, "y": -97.01316833496094}}, {"key": "1060", "attributes": {"color": "#F3AFE9", "label": "Membership on an entity's Board of Directors or advisory committees; Oncopep and C4 Therapeutics.: Other: Scientific Founder of Oncopep and C4 Therapeutics.; Gilead: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -33.82744216918945, "y": -96.66357421875}}, {"key": "1061", "attributes": {"color": "#F3AFE9", "label": "Membership on an entity's Board of Directors or advisory committees. Goldberg: Dava Oncology: Honoraria; ADC Therapeutics: Research Funding", "size": null, "x": -34.7214241027832, "y": -96.85249328613281}}, {"key": "1062", "attributes": {"color": "#F3AFE9", "label": "Daiichi Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -34.0244255065918, "y": -97.19143676757812}}, {"key": "1063", "attributes": {"color": "#F3AFE9", "label": "Research Funding; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -34.45318603515625, "y": -97.67689514160156}}, {"key": "1064", "attributes": {"color": "#F3AFE9", "label": "Consultancy; Merck: Consultancy; Inivata: Consultancy; G1 Therapeutics: Consultancy. Niemeyer: Celgene: Consultancy; Novartis: Consultancy. Hicks: Gilead Sciences: Research Funding", "size": null, "x": -34.727176666259766, "y": -97.26912689208984}}, {"key": "1065", "attributes": {"color": "#713163", "label": "Journal Pre-proof Global and Country Level Time Series Analyses of the Effect of the COVID-19 Pandemic on Spontaneous Reporting Title: Global and Country Level Time Series Analyses of the Effect of the COVID-19 Pandemic on Spontaneous Reporting. Running heading: Time series analysis of the effect of the COVID-19 pandemic on spontaneous reporting Title: Global and Country Level Time Series Analyses of the Effect of the COVID-19 Pandemic on Spontaneous Reporting of Adverse Drug Events", "size": null, "x": 31.231937408447266, "y": 89.67179107666016}}, {"key": "1066", "attributes": {"color": "#713163", "label": "Virus Outbreak Pushes Italy's Health-Care System to the Brink. The Wall Street Journal", "size": null, "x": 32.26326370239258, "y": 89.39714813232422}}, {"key": "1067", "attributes": {"color": "#713163", "label": "Effects of COVID-19 on Global Healthcare Systems", "size": null, "x": 32.74119567871094, "y": 90.3285140991211}}, {"key": "1068", "attributes": {"color": "#713163", "label": "Statistical methodology: V. Time series analysis using autoregressive integrated moving average (ARIMA) models", "size": null, "x": 31.032333374023438, "y": 91.09567260742188}}, {"key": "1069", "attributes": {"color": "#713163", "label": "WHO. Rolling updates on coronavirus disease", "size": null, "x": 32.288543701171875, "y": 89.79943084716797}}, {"key": "1070", "attributes": {"color": "#713163", "label": "Understanding and using time series analyses in addiction research", "size": null, "x": 30.582435607910156, "y": 88.92657470703125}}, {"key": "1071", "attributes": {"color": "#713163", "label": "Very long and very short time series. Forecasting: Principles and Practice", "size": null, "x": 30.254234313964844, "y": 89.32772827148438}}, {"key": "1072", "attributes": {"color": "#713163", "label": "COVID-19 Dashboard by the Center for Systems Science and Engineering", "size": null, "x": 31.336755752563477, "y": 89.03431701660156}}, {"key": "1073", "attributes": {"color": "#713163", "label": "Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing", "size": null, "x": 30.528278350830078, "y": 90.6097412109375}}, {"key": "1074", "attributes": {"color": "#713163", "label": "Bias in spontaneous reporting of adverse drug reactions in Japan", "size": null, "x": 31.80253028869629, "y": 90.01384735107422}}, {"key": "1075", "attributes": {"color": "#713163", "label": "Time-Series Modeling for Statistical Process Control", "size": null, "x": 30.284774780273438, "y": 90.1146240234375}}, {"key": "1076", "attributes": {"color": "#713163", "label": "Modelling of Infectious Diseases for Providing Signal of Epidemics: A Measles Case Study in Bangladesh", "size": null, "x": 31.694931030273438, "y": 89.65861511230469}}, {"key": "1077", "attributes": {"color": "#713163", "label": "Detecting the start of an influenza outbreak using exponentially weighted moving average charts. BMC medical informatics and decision making", "size": null, "x": 29.75863265991211, "y": 89.74040985107422}}, {"key": "1078", "attributes": {"color": "#713163", "label": "Time Series Disturbance Detection for Hypothesis-Free Signal Detection in Longitudinal Observational Databases", "size": null, "x": 29.976831436157227, "y": 90.34127807617188}}, {"key": "1079", "attributes": {"color": "#713163", "label": "Prediction of the COVID-19 Pandemic for the Top 15 Affected Countries: Advanced Autoregressive Integrated Moving Average (ARIMA) Model", "size": null, "x": 31.18672752380371, "y": 88.59146118164062}}, {"key": "1080", "attributes": {"color": "#713163", "label": "Exponentially Weighted Moving Average (EWMA) Control Charts for Monitoring an Analytical Process. Industrial & Engineering Chemistry Research", "size": null, "x": 31.046754837036133, "y": 90.0811767578125}}, {"key": "1081", "attributes": {"color": "#713163", "label": "The consecutive disparity index, D: a measure of temporal variability in ecological studies", "size": null, "x": 30.887449264526367, "y": 89.64680480957031}}, {"key": "1082", "attributes": {"color": "#713163", "label": "WHO says 'delayed epidemic' takes hold in Eastern Europe as coronavirus cases in Russia rise", "size": null, "x": 31.745410919189453, "y": 89.08260345458984}}, {"key": "1083", "attributes": {"color": "#713163", "label": "Bridging the gap between theory and practice in basic statistical process monitoring. Quality Engineering", "size": null, "x": 31.657432556152344, "y": 90.75469970703125}}, {"key": "1084", "attributes": {"color": "#713163", "label": "Controversies and Contradictions in Statistical Process Control", "size": null, "x": 32.364990234375, "y": 90.2337875366211}}, {"key": "1085", "attributes": {"color": "#713163", "label": "MHRA. Coronavirus: new website for reporting medicines side effects and equipment incidents", "size": null, "x": 30.782217025756836, "y": 90.3020248413086}}, {"key": "1086", "attributes": {"color": "#73E080", "label": "Frequency, Clinical Characteristics and Outcome of Adult Patients with Acute Lymphoblastic Leukemia (ALL) and COVID-19 in Spain: Results of a Survey from Pethema and Geth Groups", "size": null, "x": 4.402127265930176, "y": 223.6747283935547}}, {"key": "1087", "attributes": {"color": "#73E080", "label": "Median age was 46 (range 20-78) yrs. and 19 were aged over 40 yrs. Fifteen pts were male, 1 was active smoker and 9 showed one or more comorbidities (chronic liver disease", "size": null, "x": 4.4611968994140625, "y": 222.9990692138672}}, {"key": "1088", "attributes": {"color": "#73E080", "label": "Eight patients were previously submitted to allogeneic HSCT, CAR T [n=1] or immunotherapy with monoclonal antibodies (inotuzumab, n=4) and 21 were receiving immunosuppressive drugs (corticosteroids in 11", "size": null, "x": 5.07022762298584, "y": 224.1885986328125}}, {"key": "1089", "attributes": {"color": "#73E080", "label": "The main clinical characteristics of COVID-19 infection were: fever (n=18), cough (n=16), shortness of breath (n=9) and asthenia (n=11) and 5 pts were asymptomatic. The most frequency therapies were hydroxychloroquine/ chloroquine (n=23), combined or not with lopinavir/ritonavir. Tocilizumab was given to 8 pts. Twelve pts required oxygen supply and 7 required ICU support (median stay 16 [1-47] days). COVID-19 was solved in 18 pts, although 5 pts showed PCR+ persistence (median 25 [16-91] days) after resolution of symptoms. The treatment of ALL was stopped", "size": null, "x": 4.203683853149414, "y": 224.43194580078125}}, {"key": "1090", "attributes": {"color": "#73E080", "label": "COVID-19 and ALL progression [n=2] and COVID-19 andPseudomonassepsis [n=1]). A trend for higher mortality was observed in patients with neutropenia <0", "size": null, "x": 4.803523063659668, "y": 223.6299285888672}}, {"key": "1091", "attributes": {"color": "#73E080", "label": "those with lymphocytopenia", "size": null, "x": 3.9152143001556396, "y": 223.4717559814453}}, {"key": "1092", "attributes": {"color": "#73E080", "label": "The frequency of adult patients with ALL and COVID-19 infection can be considered high, given the low incidence of adult ALL. COVID-19 infection was frequent in patients with advanced age and on ALL therapy. The frequency of severe COVID-19 infection and the mortality were high", "size": null, "x": 4.740967273712158, "y": 224.2435760498047}}, {"key": "1093", "attributes": {"color": "#B9ADCA", "label": "COVID-19: B-Cell Depletion and Sepsis Related Changes in Bone Marrow and Spleen", "size": null, "x": -33.41297912597656, "y": -78.63802337646484}}, {"key": "1094", "attributes": {"color": "#B9ADCA", "label": "Membership on an entity's Board of Directors or advisory committees; Hexal: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -33.90526580810547, "y": -78.70925903320312}}, {"key": "1095", "attributes": {"color": "#B9ADCA", "label": "Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -33.70920181274414, "y": -79.27461242675781}}, {"key": "1096", "attributes": {"color": "#B9ADCA", "label": "Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -33.2281494140625, "y": -78.26671600341797}}, {"key": "1097", "attributes": {"color": "#B9ADCA", "label": "Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -34.576072692871094, "y": -78.19209289550781}}, {"key": "1098", "attributes": {"color": "#5C01A9", "label": "On the Effects of Misclassification in Estimating Efficacy With Application to Recent COVID-19 Vaccine Trials", "size": null, "x": 47.58735275268555, "y": 223.23211669921875}}, {"key": "1099", "attributes": {"color": "#5C01A9", "label": "Fieller's Theorem", "size": null, "x": 47.78114318847656, "y": 222.64627075195312}}, {"key": "1100", "attributes": {"color": "#5C01A9", "label": "Measurement Error: Models, Methods and Applications", "size": null, "x": 47.91318130493164, "y": 223.73878479003906}}, {"key": "1101", "attributes": {"color": "#5C01A9", "label": "Bias due to differential and non-differential disease and exposure misclassification in studies of vaccine effectiveness", "size": null, "x": 47.01659393310547, "y": 223.35824584960938}}, {"key": "1102", "attributes": {"color": "#5C01A9", "label": "Introduction to the Theory of Statisitics", "size": null, "x": 48.026607513427734, "y": 223.19882202148438}}, {"key": "1103", "attributes": {"color": "#85D4B4", "label": "Worldwide Examination of Patients with CLL Hospitalized for COVID-19", "size": null, "x": -10.950960159301758, "y": -64.52157592773438}}, {"key": "1104", "attributes": {"color": "#85D4B4", "label": "Research Funding; Abbott Laboratories: Other: spouse with minority ownership interest ; AbbVie: Other: spouse with minority ownership interest . Scarfo: Janssen: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -11.413711547851562, "y": -66.14044952392578}}, {"key": "1105", "attributes": {"color": "#85D4B4", "label": "AstraZeneca: Honoraria; Gilead: Membership on an entity's Board of Directors or advisory committees. Abrisqueta: Celgene: Consultancy, Honoraria", "size": null, "x": -9.990957260131836, "y": -64.00946044921875}}, {"key": "1106", "attributes": {"color": "#85D4B4", "label": "Eyre: AbbVie: Consultancy, Honoraria, Other: travel support; Gilead: Consultancy, Honoraria, Other: travel support; Janssen: Consultancy, Honoraria, Other: travel support; KITE, AZ, Loxo Oncology at Lilly: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. MuntaÃ±ola Prat: Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel grants; participated in advisory boards; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel grants", "size": null, "x": -11.280613899230957, "y": -62.754398345947266}}, {"key": "1107", "attributes": {"color": "#85D4B4", "label": "AstraZeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Bayer: Consultancy, Membership on an entity's Board of Directors or advisory committees; ADC therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -11.821077346801758, "y": -65.17485046386719}}, {"key": "1108", "attributes": {"color": "#85D4B4", "label": "Seattle Genetics: Consultancy, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -11.305999755859375, "y": -65.24811553955078}}, {"key": "1109", "attributes": {"color": "#85D4B4", "label": "Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Epizyme: Speakers Bureau; Karyopharm: Speakers Bureau; TG Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -12.156440734863281, "y": -62.75935745239258}}, {"key": "1110", "attributes": {"color": "#85D4B4", "label": "Incyte: Consultancy; Genentech: Consultancy", "size": null, "x": -12.977166175842285, "y": -65.03506469726562}}, {"key": "1111", "attributes": {"color": "#85D4B4", "label": "Research Funding; Abbvie: Consultancy; Beigene: Consultancy", "size": null, "x": -10.251672744750977, "y": -65.00650024414062}}, {"key": "1112", "attributes": {"color": "#85D4B4", "label": "Gilead: Consultancy. Hernandez-Rivas: Gilead: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -11.611918449401855, "y": -64.86556243896484}}, {"key": "1113", "attributes": {"color": "#85D4B4", "label": "Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -12.442816734313965, "y": -64.71009063720703}}, {"key": "1114", "attributes": {"color": "#85D4B4", "label": "Membership on an entity's Board of Directors or advisory committees; BeiGene: Consultancy; Kite: Consultancy", "size": null, "x": -10.341585159301758, "y": -64.19471740722656}}, {"key": "1115", "attributes": {"color": "#85D4B4", "label": "Research Funding; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Genentech: Research Funding; Verastem: Research Funding; Bei-Gene: Research Funding; TG Therapeutics: Research Funding; Acerta: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche-Genentech: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -10.548029899597168, "y": -65.51839447021484}}, {"key": "1116", "attributes": {"color": "#85D4B4", "label": "Current Employment. Hanson: Janssen-Cilag: Research Funding; Gilead: Research Funding; AbbVie: Honoraria. Eichhorst: ArQule: Consultancy, Honoraria, Other: travel support", "size": null, "x": -11.56651782989502, "y": -66.55077362060547}}, {"key": "1117", "attributes": {"color": "#85D4B4", "label": "Research Funding; Gilead: Consultancy, Honoraria, Other: travel support, Research Funding; AstraZeneca: Consultancy, Honoraria, Other: travel support", "size": null, "x": -10.150182723999023, "y": -63.630123138427734}}, {"key": "1118", "attributes": {"color": "#85D4B4", "label": "Research Funding; AbbVie: Consultancy, Honoraria, Other: travel support", "size": null, "x": -12.278837203979492, "y": -65.34143829345703}}, {"key": "1119", "attributes": {"color": "#85D4B4", "label": "Varettoni: Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel/accommodations/expenses; AbbVie: Other: Travel/ accommodations/expenses; Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees. Marchetti: Gilead: Consultancy; Novartis: Speakers Bureau; Amgen: Speakers Bureau; AbbVie: Other: Sponsored meetings; Takeda: Other: Sponsored meetings; Pfeizer: Other: Sponsored meetings. Munir: F. Hoffmann-La Roche: Consultancy, Other: Medical writing support, furnished by Scott Battle, PhD, of Health Interactions", "size": null, "x": -12.819025993347168, "y": -63.02231216430664}}, {"key": "1120", "attributes": {"color": "#85D4B4", "label": "Other: travel grants; speaker fees; Gilead: Consultancy, Other: travel grants; speaker fees; Novartis: Consultancy, Other: travel grants; speaker fees", "size": null, "x": -10.666529655456543, "y": -64.64251708984375}}, {"key": "1121", "attributes": {"color": "#85D4B4", "label": "Other: travel grants; speaker fees; Roche: Consultancy, Other: travel grants; speaker fees. Niemann: AstraZeneca: Honoraria, Research Funding; CSL Behring: Honoraria", "size": null, "x": -11.409042358398438, "y": -64.57205200195312}}, {"key": "1122", "attributes": {"color": "#85D4B4", "label": "Sunesis: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding; Danish Cancer Society: Honoraria, Research Funding", "size": null, "x": -13.155750274658203, "y": -64.33466339111328}}, {"key": "1123", "attributes": {"color": "#85D4B4", "label": "Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -10.642352104187012, "y": -64.2186050415039}}, {"key": "1124", "attributes": {"color": "#85D4B4", "label": "Roche: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -9.842852592468262, "y": -64.50982666015625}}, {"key": "1125", "attributes": {"color": "#85D4B4", "label": "Roche: Other: Conference fees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees. Itchaki: Abbvie Inc: Consultancy, Research Funding. Ma: Novartis: Research Funding", "size": null, "x": -9.3930025100708, "y": -63.97053909301758}}, {"key": "1126", "attributes": {"color": "#85D4B4", "label": "Kite: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Research Funding", "size": null, "x": -10.500194549560547, "y": -64.80267333984375}}, {"key": "1127", "attributes": {"color": "#85D4B4", "label": "Seymour: Seattle Genetics: Research Funding; Merck: Research Funding; Karyopharm: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -12.744762420654297, "y": -63.945499420166016}}, {"key": "1128", "attributes": {"color": "#85D4B4", "label": "Board of Directors or advisory committees; Incyte: Research Funding; Genentech: Research Funding; Bristol-Myers Squibb: Research Funding. Rigolin: Gilead: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -10.937986373901367, "y": -65.6160888671875}}, {"key": "1129", "attributes": {"color": "#85D4B4", "label": "Janssen: Honoraria; Gilead: Honoraria; AbbVie: Honoraria; Roche: Honoraria. Levin: Janssen: Membership on an entity's Board of Directors or advisory committees, Other: travel compensation; Abbvie: Membership on an entity's Board of Directors or advisory committees, Other: travel compensation; Roche: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -9.791829109191895, "y": -65.46232604980469}}, {"key": "1130", "attributes": {"color": "#85D4B4", "label": "AbbVie: Other: sponsored for educational meetings", "size": null, "x": -11.537220001220703, "y": -65.89961242675781}}, {"key": "1131", "attributes": {"color": "#85D4B4", "label": "Other: sponsored for educational meetings", "size": null, "x": -11.056709289550781, "y": -64.4353256225586}}, {"key": "1132", "attributes": {"color": "#85D4B4", "label": "Membership on an entity's Board of Directors or advisory committees. Wiestner: Pharmacyclics LLC, an AbbVie Company", "size": null, "x": -11.63686466217041, "y": -62.50060272216797}}, {"key": "1133", "attributes": {"color": "#85D4B4", "label": "Kater: Abbvie: Research Funding; Roche: Research Funding; Janssen: Research Funding; Celgene: Research Funding", "size": null, "x": -11.031194686889648, "y": -65.2130126953125}}, {"key": "1134", "attributes": {"color": "#85D4B4", "label": "Verastem Oncology: Consultancy, Honoraria; Gilead/Kite: Consultancy, Research Funding", "size": null, "x": -10.23132038116455, "y": -65.39423370361328}}, {"key": "1135", "attributes": {"color": "#85D4B4", "label": "Abbvie: Other: travel grants, Research Funding; Janssen: Other: travel grants; Roche: Other: travel grants, Research Funding. Chong: Novartis: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -11.525485038757324, "y": -63.72603988647461}}, {"key": "1136", "attributes": {"color": "#85D4B4", "label": "BMS: Membership on an entity's Board of Directors or advisory committees; KITE Pharma: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -9.343545913696289, "y": -64.74150848388672}}, {"key": "1137", "attributes": {"color": "#85D4B4", "label": "Verastem: Consultancy. Trentin: Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -12.208524703979492, "y": -66.0510482788086}}, {"key": "1138", "attributes": {"color": "#85D4B4", "label": "Farina: Abbvie: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -9.56572151184082, "y": -62.97658920288086}}, {"key": "1139", "attributes": {"color": "#85D4B4", "label": "Sunesis, Beigene: Research Funding. Foglietta: Janssen: Honoraria; Gilead: Honoraria. Jaksic: Roche: Honoraria; Janssen: Honoraria; Abbvie: Honoraria. Sportoletti: AbbVie: Honoraria; Janssen: Honoraria. Barr: Morphosys: Consultancy", "size": null, "x": -10.607681274414062, "y": -63.318641662597656}}, {"key": "1140", "attributes": {"color": "#85D4B4", "label": "Verastem: Consultancy; Seattle Genetics: Consultancy; TG therapeutics: Consultancy", "size": null, "x": -9.471428871154785, "y": -63.497283935546875}}, {"key": "1141", "attributes": {"color": "#85D4B4", "label": "Celgene: Consultancy; Merck: Consultancy; Genentech: Consultancy; Janssen: Consultancy", "size": null, "x": -10.785421371459961, "y": -63.53632354736328}}, {"key": "1142", "attributes": {"color": "#85D4B4", "label": "Genentech: Consultancy; DTRM: Research Funding; Celgene: Consultancy, Research Funding; Bayer: Consultancy, Honoraria; Astrazeneca: Honoraria; TG Therapeutics: Research Funding. Herishanu: Roche: Honoraria; Sanofi: Honoraria; Medison: Honoraria; Janssen: Honoraria", "size": null, "x": -12.111359596252441, "y": -63.81185531616211}}, {"key": "1143", "attributes": {"color": "#85D4B4", "label": "AbbVie: Consultancy, Speakers Bureau; Pharmacyclics: Research Funding, Speakers Bureau; Seattle Genetics: Consultancy; Verastem: Consultancy", "size": null, "x": -10.063807487487793, "y": -66.32760620117188}}, {"key": "1144", "attributes": {"color": "#85D4B4", "label": "Research Funding; Xencor: Research Funding; Bayer: Consultancy; Amgen: Consultancy; Janssen: Consultancy; Kite: Consultancy", "size": null, "x": -11.45973014831543, "y": -63.11343002319336}}, {"key": "1145", "attributes": {"color": "#85D4B4", "label": "Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Astellas: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company)", "size": null, "x": -12.514920234680176, "y": -65.14557647705078}}, {"key": "1146", "attributes": {"color": "#85D4B4", "label": "Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company)", "size": null, "x": -11.016386032104492, "y": -66.05033874511719}}, {"key": "1147", "attributes": {"color": "#85D4B4", "label": "Membership on an entity's Board of Directors or advisory committees, Other: Support of parent study and funding of editorial support. Received travel support", "size": null, "x": -9.899290084838867, "y": -63.31440353393555}}, {"key": "1148", "attributes": {"color": "#85D4B4", "label": "Research grant from Amgen Inc.; Omeros: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -11.146931648254395, "y": -63.350196838378906}}, {"key": "1149", "attributes": {"color": "#85D4B4", "label": "Brander: Verastem: Consultancy, Honoraria, Other, Research Funding; NCCN: Other; Novartis: Consultancy, Other; Teva: Consultancy, Honoraria; Tolero: Research Funding; NCCN: Other; Novartis: Consultancy, Other; Teva: Consultancy, Honoraria; Tolero: Research Funding; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding; ArQule: Consultancy, Other, Research Funding; Ascentage: Other, Research Funding", "size": null, "x": -9.871757507324219, "y": -65.12401580810547}}, {"key": "1150", "attributes": {"color": "#85D4B4", "label": "Research Funding; Pharmacyclics LLC, an AbbVie Company: Consultancy, Honoraria, Other, Research Funding; Pfizer: Consultancy, Other; TG Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other", "size": null, "x": -11.030380249023438, "y": -64.97676849365234}}, {"key": "1151", "attributes": {"color": "#85D4B4", "label": "Board of Directors or advisory committees; Jazz: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Novartis: Other: Advisory board; Astellas: Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria; Pfizer: Membership on an entity's Board of Directors or advisory committees; Alexion: Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -10.992011070251465, "y": -63.85896682739258}}, {"key": "1152", "attributes": {"color": "#85D4B4", "label": "Membership on an entity's Board of Directors or advisory committees; Shire: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -10.617977142333984, "y": -66.34910583496094}}, {"key": "1153", "attributes": {"color": "#85D4B4", "label": "Coombs: Abbvie: Consultancy, Honoraria; Genentech: Honoraria; AstraZeneca: Honoraria; MEI Pharma: Honoraria; LOXO Oncology: Honoraria; Octapharma: Honoraria; Novartis: Honoraria", "size": null, "x": -11.880146026611328, "y": -64.31275939941406}}, {"key": "1154", "attributes": {"color": "#85D4B4", "label": "FoÃ : Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees; Novartis: Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees; Incyte: Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Cuneo: Astra Zeneca: Honoraria; Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -9.575145721435547, "y": -62.36342239379883}}, {"key": "1155", "attributes": {"color": "#85D4B4", "label": "Novartis: Honoraria", "size": null, "x": -10.870689392089844, "y": -62.5016975402832}}, {"key": "1156", "attributes": {"color": "#85D4B4", "label": "Honoraria; Takeda: Honoraria; Celgene: Honoraria; Roche: Honoraria. Stamatopoulos: AstraZeneca: Honoraria", "size": null, "x": -12.044452667236328, "y": -63.303466796875}}, {"key": "1157", "attributes": {"color": "#85D4B4", "label": "Dynamo: Consultancy, Honoraria; Novartis: Research Funding; BeiGene: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company)", "size": null, "x": -9.303414344787598, "y": -65.49805450439453}}, {"key": "1158", "attributes": {"color": "#85D4B4", "label": "Research Funding; Gilead: Consultancy, Honoraria, Research Funding; ArQule: Consultancy, Honoraria; Acerta/AstraZeneca: Consultancy, Honoraria. Mato: Adaptive: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; BeiGene: Consultancy; LOXO: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding; Pharmacyclics LLC, an AbbVie Company: Consultancy", "size": null, "x": -9.284850120544434, "y": -65.06117248535156}}, {"key": "1159", "attributes": {"color": "#45E73B", "label": "A Review of the Progress and Challenges of Developing a Vaccine for COVID-19", "size": null, "x": 151.60723876953125, "y": 31.367494583129883}}, {"key": "1160", "attributes": {"color": "#45E73B", "label": "Herd immunity: understanding COVID-19", "size": null, "x": 152.29364013671875, "y": 32.23168182373047}}, {"key": "1161", "attributes": {"color": "#45E73B", "label": "Herd immunity or suppression strategy to combat COVID-19", "size": null, "x": 150.05409240722656, "y": 32.31246566772461}}, {"key": "1162", "attributes": {"color": "#45E73B", "label": "Pandemic preparedness: developing vaccines and therapeutic antibodies for COVID-19", "size": null, "x": 153.66708374023438, "y": 30.73575210571289}}, {"key": "1163", "attributes": {"color": "#45E73B", "label": "The hallmarks of COVID-19 disease", "size": null, "x": 151.1637725830078, "y": 33.29084777832031}}, {"key": "1164", "attributes": {"color": "#45E73B", "label": "The proximal origin of SARS-CoV-2", "size": null, "x": 153.36802673339844, "y": 31.98495101928711}}, {"key": "1165", "attributes": {"color": "#45E73B", "label": "Bats as reservoirs of severe emerging infectious diseases", "size": null, "x": 152.46905517578125, "y": 33.6282844543457}}, {"key": "1166", "attributes": {"color": "#45E73B", "label": "Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis", "size": null, "x": 152.10777282714844, "y": 30.32836151123047}}, {"key": "1167", "attributes": {"color": "#45E73B", "label": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan", "size": null, "x": 151.0043487548828, "y": 29.798917770385742}}, {"key": "1168", "attributes": {"color": "#45E73B", "label": "The current and future state of vaccines, antivirals and gene therapies against emerging coronaviruses", "size": null, "x": 152.45761108398438, "y": 32.63334274291992}}, {"key": "1169", "attributes": {"color": "#45E73B", "label": "Rapid COVID-19 vaccine development", "size": null, "x": 152.04998779296875, "y": 29.284658432006836}}, {"key": "1170", "attributes": {"color": "#45E73B", "label": "The Mysterious Disappearance of the First SARS Virus, and Why we need a Vaccine for the Current One But Didn't for the Other", "size": null, "x": 152.6552734375, "y": 31.701414108276367}}, {"key": "1171", "attributes": {"color": "#45E73B", "label": "The reproductive number of COVID-19 is higher compared to SARS coronavirus", "size": null, "x": 152.83676147460938, "y": 32.28363800048828}}, {"key": "1172", "attributes": {"color": "#45E73B", "label": "Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals", "size": null, "x": 150.83349609375, "y": 32.33834457397461}}, {"key": "1173", "attributes": {"color": "#45E73B", "label": "Cells Found in COVID-19 Patients Bode Well for Long-Term Immunity", "size": null, "x": 150.59132385253906, "y": 31.424976348876953}}, {"key": "1174", "attributes": {"color": "#45E73B", "label": "Sentinel surveillance of SARS-CoV-2 in waste water anticipates the occurrence of COVID-19 cases. medRxiv", "size": null, "x": 151.66651916503906, "y": 29.13972282409668}}, {"key": "1175", "attributes": {"color": "#45E73B", "label": "SARS-CoV-2 specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls", "size": null, "x": 151.20074462890625, "y": 31.37749671936035}}, {"key": "1176", "attributes": {"color": "#45E73B", "label": "Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv", "size": null, "x": 152.3935089111328, "y": 31.128488540649414}}, {"key": "1177", "attributes": {"color": "#45E73B", "label": "Antibody testing for COVID-19: a report from the national COVID scientific advisory panel. medRxiv", "size": null, "x": 150.12741088867188, "y": 31.016469955444336}}, {"key": "1178", "attributes": {"color": "#45E73B", "label": "Immunology of COVID-19: current state of the science", "size": null, "x": 151.30606079101562, "y": 32.56882095336914}}, {"key": "1179", "attributes": {"color": "#45E73B", "label": "Twoyear prospective study of the humoral immune response of patients with severe acute respiratory syndrome", "size": null, "x": 152.7732696533203, "y": 32.51936340332031}}, {"key": "1180", "attributes": {"color": "#45E73B", "label": "Coronavirus vaccines leap through safety trials -but which will work is anybody's guess", "size": null, "x": 151.95407104492188, "y": 31.11459732055664}}, {"key": "1181", "attributes": {"color": "#45E73B", "label": "The clinical development process for a novel preventive vaccine: an overview", "size": null, "x": 151.65045166015625, "y": 30.95600700378418}}, {"key": "1182", "attributes": {"color": "#45E73B", "label": "Are genetic vaccines the right weapon against COVID-19?", "size": null, "x": 153.77923583984375, "y": 32.33980178833008}}, {"key": "1183", "attributes": {"color": "#45E73B", "label": "The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world", "size": null, "x": 150.9910888671875, "y": 30.400482177734375}}, {"key": "1184", "attributes": {"color": "#45E73B", "label": "Draft Landscape of COVID-19 Candidate Vaccines", "size": null, "x": 151.7660675048828, "y": 32.94514083862305}}, {"key": "1185", "attributes": {"color": "#45E73B", "label": "A strategic approach to COVID-19 vaccine R&D", "size": null, "x": 149.97206115722656, "y": 30.706239700317383}}, {"key": "1186", "attributes": {"color": "#45E73B", "label": "Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19", "size": null, "x": 151.75759887695312, "y": 33.36988830566406}}, {"key": "1187", "attributes": {"color": "#45E73B", "label": "Available online at", "size": null, "x": 151.65538024902344, "y": 30.086753845214844}}, {"key": "1188", "attributes": {"color": "#45E73B", "label": "COVID-19: learning from lessons to guide treatment and prevention interventions. mSphere", "size": null, "x": 151.40025329589844, "y": 31.624048233032227}}, {"key": "1189", "attributes": {"color": "#45E73B", "label": "SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness", "size": null, "x": 149.98329162597656, "y": 30.195573806762695}}, {"key": "1190", "attributes": {"color": "#45E73B", "label": "An mRNA vaccine against SARS-CoV-2 -preliminary report", "size": null, "x": 150.04103088378906, "y": 29.698183059692383}}, {"key": "1191", "attributes": {"color": "#45E73B", "label": "An Infectious Disease Expert Explains The Results from Moderna's Latest Vaccine Trials", "size": null, "x": 151.97804260253906, "y": 32.0383415222168}}, {"key": "1192", "attributes": {"color": "#45E73B", "label": "Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older", "size": null, "x": 149.35159301757812, "y": 31.205121994018555}}, {"key": "1193", "attributes": {"color": "#45E73B", "label": "Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older", "size": null, "x": 151.470947265625, "y": 32.26271438598633}}, {"key": "1194", "attributes": {"color": "#45E73B", "label": "Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report. medRxiv", "size": null, "x": 151.45208740234375, "y": 28.727447509765625}}, {"key": "1195", "attributes": {"color": "#45E73B", "label": "Studies at Pirbright Demonstrate Two Doses of Oxford University's COVID-19", "size": null, "x": 151.6409149169922, "y": 32.72150421142578}}, {"key": "1196", "attributes": {"color": "#45E73B", "label": "Vaccine Boosts Immune Response In Pigs", "size": null, "x": 151.30776977539062, "y": 30.651409149169922}}, {"key": "1197", "attributes": {"color": "#45E73B", "label": "A phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers", "size": null, "x": 150.37705993652344, "y": 31.806955337524414}}, {"key": "1198", "attributes": {"color": "#45E73B", "label": "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized control trial", "size": null, "x": 152.76878356933594, "y": 30.59760856628418}}, {"key": "1199", "attributes": {"color": "#45E73B", "label": "Vaccine (ChAdOx1 nCoV-19) trial in South African Adults with and without HIV-Infection", "size": null, "x": 150.81741333007812, "y": 32.614219665527344}}, {"key": "1200", "attributes": {"color": "#45E73B", "label": "Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19", "size": null, "x": 151.18768310546875, "y": 33.778602600097656}}, {"key": "1201", "attributes": {"color": "#45E73B", "label": "A Phase III Study to Investigate a Vaccine Against COVID-19", "size": null, "x": 153.06838989257812, "y": 31.38977813720703}}, {"key": "1202", "attributes": {"color": "#45E73B", "label": "Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19", "size": null, "x": 152.36891174316406, "y": 30.573070526123047}}, {"key": "1203", "attributes": {"color": "#45E73B", "label": "Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomized, first-in-human trial", "size": null, "x": 153.16958618164062, "y": 32.95198059082031}}, {"key": "1204", "attributes": {"color": "#45E73B", "label": "Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 2 trial", "size": null, "x": 150.27333068847656, "y": 31.320261001586914}}, {"key": "1205", "attributes": {"color": "#45E73B", "label": "CanSino's COVID-19 Vaccine Candidate Approved for Military use in China", "size": null, "x": 150.749755859375, "y": 30.86742401123047}}, {"key": "1206", "attributes": {"color": "#45E73B", "label": "Why One Vaccine is Already a Sure Loser, and also a Sure Winner, in the Race to Inoculate the World", "size": null, "x": 152.60379028320312, "y": 33.387550354003906}}, {"key": "1207", "attributes": {"color": "#45E73B", "label": "Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes", "size": null, "x": 152.6972198486328, "y": 29.718002319335938}}, {"key": "1208", "attributes": {"color": "#45E73B", "label": "Placebo Parallel-Controlled Phase I/II Clinical Trial for Inactivated Novel Coronavirus Pneumonia Vaccine (Vero cells). (2020)", "size": null, "x": 151.9220428466797, "y": 31.628875732421875}}, {"key": "1209", "attributes": {"color": "#45E73B", "label": "Sinopharm Says Second Covid Vaccine Found to Be Safe", "size": null, "x": 153.0187530517578, "y": 30.53310203552246}}, {"key": "1210", "attributes": {"color": "#45E73B", "label": "Chinese COVID-19 Vaccine Candidate the First to Start Phase 3 Clinical Trials Worldwide", "size": null, "x": 151.45933532714844, "y": 31.051130294799805}}, {"key": "1211", "attributes": {"color": "#45E73B", "label": "Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety in Healthcare Professionals of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac", "size": null, "x": 150.80941772460938, "y": 30.008615493774414}}, {"key": "1212", "attributes": {"color": "#45E73B", "label": "Indonesia Testing Location for China's Sinovac Phase 3 Clinical Trial", "size": null, "x": 153.50994873046875, "y": 31.224323272705078}}, {"key": "1213", "attributes": {"color": "#45E73B", "label": "Sinovac Says Early Data Show its Covid-19 Vaccine Generated Immune Responses", "size": null, "x": 153.1313018798828, "y": 31.11693000793457}}, {"key": "1214", "attributes": {"color": "#45E73B", "label": "Immunogenicity and Safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, double-blind, and placebo-controlled Phase 2 clinical trial. medRxiv", "size": null, "x": 152.13504028320312, "y": 31.302776336669922}}, {"key": "1215", "attributes": {"color": "#45E73B", "label": "Available online at: https:// www.gatesfoundation.org/Media-Center/Press-Releases/2020/04/Gates-Foundation-Expands-Commitment-to-COVID-19-Response-Calls-for-International-Collaboration", "size": null, "x": 151.56236267089844, "y": 31.961050033569336}}, {"key": "1216", "attributes": {"color": "#45E73B", "label": "Fear Mounts Trump May Pressure FDA to Rush Covid-19 Vaccine by Election", "size": null, "x": 150.3329620361328, "y": 32.734764099121094}}, {"key": "1217", "attributes": {"color": "#45E73B", "label": "Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees", "size": null, "x": 152.32273864746094, "y": 32.732017517089844}}, {"key": "1218", "attributes": {"color": "#45E73B", "label": "Russia's fast track coronavirus vaccine draws outrage over safety", "size": null, "x": 152.97842407226562, "y": 30.88180923461914}}, {"key": "1219", "attributes": {"color": "#45E73B", "label": "A review of Dengvaxia R : development to deployment", "size": null, "x": 151.884521484375, "y": 29.6382999420166}}, {"key": "1220", "attributes": {"color": "#45E73B", "label": "COVID-19 human challenge studies: ethical issues", "size": null, "x": 150.8597412109375, "y": 31.707998275756836}}, {"key": "1221", "attributes": {"color": "#45E73B", "label": "From Oxford to an Italian Lab, One Race for Coronavirus Vaccine is gaining Backers", "size": null, "x": 150.89569091796875, "y": 31.024789810180664}}, {"key": "1222", "attributes": {"color": "#45E73B", "label": "Multivalue ethical framework for fair global allocation of a COVID-19 vaccine", "size": null, "x": 150.00238037109375, "y": 32.91156768798828}}, {"key": "1223", "attributes": {"color": "#45E73B", "label": "Epidemiological impact of SARS-CoV-2 vaccination: mathematical modeling analyses. medRxiv", "size": null, "x": 152.5127410888672, "y": 30.156757354736328}}, {"key": "1224", "attributes": {"color": "#45E73B", "label": "Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv", "size": null, "x": 153.34815979003906, "y": 30.01017189025879}}, {"key": "1225", "attributes": {"color": "#45E73B", "label": "Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear", "size": null, "x": 150.88031005859375, "y": 29.51291847229004}}, {"key": "1226", "attributes": {"color": "#45E73B", "label": "The improbability of the rapid development of a vaccine for SARS-CoV-2", "size": null, "x": 150.4291229248047, "y": 30.115631103515625}}, {"key": "1227", "attributes": {"color": "#45E73B", "label": "Coronavirus Vaccine Developers Wary of Errant Antibodies", "size": null, "x": 151.6986541748047, "y": 30.317731857299805}}, {"key": "1228", "attributes": {"color": "#45E73B", "label": "US Anti-Vaxxers Aim to Spread Fear Over Future Coronavirus Vaccine", "size": null, "x": 151.11752319335938, "y": 29.425395965576172}}, {"key": "1229", "attributes": {"color": "#45E73B", "label": "Half of Americans would get a COVID-19 Vaccine", "size": null, "x": 151.63369750976562, "y": 30.722341537475586}}, {"key": "1230", "attributes": {"color": "#45E73B", "label": "Disruption of healthcare: Will the COVID pandemic worsen non-COVID outcomes and disease outbreaks?", "size": null, "x": 152.7747344970703, "y": 30.82015037536621}}, {"key": "1231", "attributes": {"color": "#45E73B", "label": "Ensuring uptake of vaccines against SARS-CoV-2", "size": null, "x": 152.8740997314453, "y": 29.995479583740234}}, {"key": "1232", "attributes": {"color": "#45E73B", "label": "Older Adults May Be Left Out Of Some COVID-19 Trials", "size": null, "x": 151.2017822265625, "y": 31.824968338012695}}, {"key": "1233", "attributes": {"color": "#45E73B", "label": "What you always needed to know about electroporation based DNA vaccines", "size": null, "x": 150.29763793945312, "y": 30.585651397705078}}, {"key": "1234", "attributes": {"color": "#45E73B", "label": "Global Vaccine Summit 2020", "size": null, "x": 151.36306762695312, "y": 30.02897071838379}}, {"key": "1235", "attributes": {"color": "#45E73B", "label": "Accelerating development of SARS-CoV-2 vaccines -the role for controlled human infection models", "size": null, "x": 151.23431396484375, "y": 30.353010177612305}}, {"key": "1236", "attributes": {"color": "#45E73B", "label": "Coronavirus disease pandemic (COVID-19): challenges and a global perspective", "size": null, "x": 151.99839782714844, "y": 32.31801223754883}}, {"key": "1237", "attributes": {"color": "#45E73B", "label": "A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS", "size": null, "x": 149.8951416015625, "y": 31.832571029663086}}, {"key": "1238", "attributes": {"color": "#6463D0", "label": "Human Reproduction Open", "size": null, "x": -82.45682525634766, "y": 55.682437896728516}}, {"key": "1239", "attributes": {"color": "#6463D0", "label": "Occasional involvement of the ovary in Ewing sarcoma", "size": null, "x": -82.43733215332031, "y": 52.71354675292969}}, {"key": "1240", "attributes": {"color": "#6463D0", "label": "Relationship between reproductive history, anthropometrics, lifestyle factors, and the likelihood of persistent chemotherapy-related amenorrhea in women with premenopausal breast cancer", "size": null, "x": -82.62743377685547, "y": 56.17753982543945}}, {"key": "1241", "attributes": {"color": "#6463D0", "label": "Prevalence of menstrual cycles and outcome of 50 pregnancies after high-dose chemotherapy and auto-SCT in non-Hodgkin and Hodgkin lymphoma patients younger than 40 years", "size": null, "x": -80.90323638916016, "y": 55.32135009765625}}, {"key": "1242", "attributes": {"color": "#6463D0", "label": "Fertility preservation in female oncology patients: the influence of the type of cancer on ovarian stimulation response", "size": null, "x": -81.3431167602539, "y": 54.72332000732422}}, {"key": "1243", "attributes": {"color": "#6463D0", "label": "How can we improve oncofertility care for patients? A systematic scoping review of current international practice and models of care", "size": null, "x": -80.42547607421875, "y": 56.03606414794922}}, {"key": "1244", "attributes": {"color": "#6463D0", "label": "Defining quality assurance and quality control measures in connection with ovarian tissue cryopreservation and transplantation: a call to action", "size": null, "x": -82.20191955566406, "y": 57.45744323730469}}, {"key": "1245", "attributes": {"color": "#6463D0", "label": "Cancer treatment and gonadal function: experimental and established strategies for fertility preservation in children and young adults", "size": null, "x": -82.07467651367188, "y": 58.118011474609375}}, {"key": "1246", "attributes": {"color": "#6463D0", "label": "Birth outcomes among adolescent and young adult cancer survivors", "size": null, "x": -81.03887176513672, "y": 57.35467529296875}}, {"key": "1247", "attributes": {"color": "#6463D0", "label": "Birth rates after radioactive iodine treatment for differentiated thyroid cancer", "size": null, "x": -80.96221923828125, "y": 54.28741455078125}}, {"key": "1248", "attributes": {"color": "#6463D0", "label": "Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer", "size": null, "x": -84.6265640258789, "y": 55.334293365478516}}, {"key": "1249", "attributes": {"color": "#6463D0", "label": "Elective egg freezing for non-medical reasons: scientific impact paper no. 63", "size": null, "x": -83.42884063720703, "y": 57.22395706176758}}, {"key": "1250", "attributes": {"color": "#6463D0", "label": "The utility of anti-Mullerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer", "size": null, "x": -82.70536041259766, "y": 57.312339782714844}}, {"key": "1251", "attributes": {"color": "#6463D0", "label": "Pretreatment anti-Mullerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer", "size": null, "x": -80.5985336303711, "y": 55.650997161865234}}, {"key": "1252", "attributes": {"color": "#6463D0", "label": "Ovarian tissue cryopreservation for fertility preservation: clinical and research perspectives", "size": null, "x": -82.07707977294922, "y": 55.56966781616211}}, {"key": "1253", "attributes": {"color": "#6463D0", "label": "Association of maternal age with severe maternal morbidity and mortality in Canada", "size": null, "x": -81.42708587646484, "y": 53.564640045166016}}, {"key": "1254", "attributes": {"color": "#6463D0", "label": "Transgender men's experiences of fertility preservation: a qualitative study", "size": null, "x": -82.84280395507812, "y": 55.960025787353516}}, {"key": "1255", "attributes": {"color": "#6463D0", "label": "The impact of the localisation of endometriosis lesions on ovarian reserve and assisted reproduction techniques outcomes", "size": null, "x": -83.52308654785156, "y": 55.64873504638672}}, {"key": "1256", "attributes": {"color": "#6463D0", "label": "Fifteen year follow-up of embryos cryopreserved in cancer patients for fertility preservation", "size": null, "x": -83.02638244628906, "y": 57.17573547363281}}, {"key": "1257", "attributes": {"color": "#6463D0", "label": "Predicting ovarian activity in women affected by early breast cancer: a meta-analysis-based nomogram", "size": null, "x": -81.24647521972656, "y": 57.25889587402344}}, {"key": "1258", "attributes": {"color": "#6463D0", "label": "Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review", "size": null, "x": -83.76268768310547, "y": 54.59600067138672}}, {"key": "1259", "attributes": {"color": "#6463D0", "label": "Operative techniques and complications of extraction and transplantation of ovarian tissue: the Erlangen experience", "size": null, "x": -80.02102661132812, "y": 55.3661003112793}}, {"key": "1260", "attributes": {"color": "#6463D0", "label": "Fertility protection: complications of surgery and results of removal and transplantation of ovarian tissue", "size": null, "x": -83.72750854492188, "y": 57.81526565551758}}, {"key": "1261", "attributes": {"color": "#6463D0", "label": "In vitro fertilization outcome in women with", "size": null, "x": -84.6769027709961, "y": 53.473960876464844}}, {"key": "1262", "attributes": {"color": "#6463D0", "label": "unoperated bilateral endometriomas", "size": null, "x": -84.78191375732422, "y": 57.020362854003906}}, {"key": "1263", "attributes": {"color": "#6463D0", "label": "Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis", "size": null, "x": -81.6821517944336, "y": 54.0694465637207}}, {"key": "1264", "attributes": {"color": "#6463D0", "label": "Fertility results and pregnancy outcomes after conservative treatment of cervical cancer: a systematic review of the literature", "size": null, "x": -80.78829193115234, "y": 53.57142639160156}}, {"key": "1265", "attributes": {"color": "#6463D0", "label": "Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients-the International Breast Cancer Study Group Trial VIII", "size": null, "x": -82.48651885986328, "y": 57.80966567993164}}, {"key": "1266", "attributes": {"color": "#6463D0", "label": "Detection of Hodgkin lymphoma within ovarian tissue", "size": null, "x": -80.8248062133789, "y": 53.829437255859375}}, {"key": "1267", "attributes": {"color": "#6463D0", "label": "Evaluation of quantitative polymerase chain reaction markers for the detection of breast cancer cells in ovarian tissue stored for fertility preservation", "size": null, "x": -80.61614990234375, "y": 55.14464569091797}}, {"key": "1268", "attributes": {"color": "#6463D0", "label": "Transgender men, pregnancy, and the \"new\" advanced paternal age: a review of the literature", "size": null, "x": -81.45313262939453, "y": 57.24708938598633}}, {"key": "1269", "attributes": {"color": "#6463D0", "label": "Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus", "size": null, "x": -82.05181884765625, "y": 56.935302734375}}, {"key": "1270", "attributes": {"color": "#6463D0", "label": "Obstetric outcomes of pregnancy after conservative treatment of endometrial cancer: case series and literature review", "size": null, "x": -82.77879333496094, "y": 54.65313720703125}}, {"key": "1271", "attributes": {"color": "#6463D0", "label": "Difficult choices for young patients with cancer: the supportive role of decisional counseling", "size": null, "x": -82.38851928710938, "y": 56.915218353271484}}, {"key": "1272", "attributes": {"color": "#6463D0", "label": "Elective and onco-fertility preservation: factors related to IVF outcomes", "size": null, "x": -83.51556396484375, "y": 56.715885162353516}}, {"key": "1273", "attributes": {"color": "#6463D0", "label": "Is vitrification of oocytes useful for fertility preservation for age-related fertility decline and in cancer patients?", "size": null, "x": -84.5086441040039, "y": 56.31898498535156}}, {"key": "1274", "attributes": {"color": "#6463D0", "label": "Emergency IVF for embryo freezing to preserve female fertility: a French multicentre cohort study", "size": null, "x": -83.20318603515625, "y": 54.114315032958984}}, {"key": "1275", "attributes": {"color": "#6463D0", "label": "Thirteen years' experience in fertility preservation for cancer patients after in vitro fertilization and in vitro maturation treatments", "size": null, "x": -80.59468841552734, "y": 54.015052795410156}}, {"key": "1276", "attributes": {"color": "#6463D0", "label": "Impact of cancer treatment on uterine function", "size": null, "x": -81.65653228759766, "y": 56.379432678222656}}, {"key": "1277", "attributes": {"color": "#6463D0", "label": "Slow freezing versus vitrification technique for human ovarian tissue cryopreservation: an evaluation of histological changes, WNT signaling pathway and apoptotic genes expression", "size": null, "x": -82.1011962890625, "y": 56.29928970336914}}, {"key": "1278", "attributes": {"color": "#6463D0", "label": "Vitrification of cleavage stage day 3 embryos results in higher live birth rates than conventional slow freezing: a RCT", "size": null, "x": -81.04181671142578, "y": 55.63884735107422}}, {"key": "1279", "attributes": {"color": "#6463D0", "label": "Prospective evaluation of serum anti-Mullerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer", "size": null, "x": -81.6341552734375, "y": 56.77494430541992}}, {"key": "1280", "attributes": {"color": "#6463D0", "label": "Oocyte vitrification versus ovarian cortex transplantation in fertility preservation for adult women undergoing gonadotoxic treatments: a prospective cohort study", "size": null, "x": -83.12081146240234, "y": 57.75127410888672}}, {"key": "1281", "attributes": {"color": "#6463D0", "label": "Pretreatment antimullerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy", "size": null, "x": -82.7511215209961, "y": 55.11022186279297}}, {"key": "1282", "attributes": {"color": "#6463D0", "label": "Oncofertility: combination of ovarian stimulation with subsequent ovarian tissue extraction on the day of oocyte retrieval", "size": null, "x": -83.9849624633789, "y": 56.19181442260742}}, {"key": "1283", "attributes": {"color": "#6463D0", "label": "Efficacy of in vitro fertilization after chemotherapy", "size": null, "x": -83.06014251708984, "y": 55.33330154418945}}, {"key": "1284", "attributes": {"color": "#6463D0", "label": "Utilization rates and results of long-term embryo cryopreservation before gonadotoxic treatment", "size": null, "x": -83.34346771240234, "y": 55.00368118286133}}, {"key": "1285", "attributes": {"color": "#6463D0", "label": "Evaluation of minimal disseminated disease in cryopreserved ovarian tissue from bone and soft tissue sarcoma patients", "size": null, "x": -84.20225524902344, "y": 55.773216247558594}}, {"key": "1286", "attributes": {"color": "#6463D0", "label": "Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue", "size": null, "x": -84.33800506591797, "y": 54.81671905517578}}, {"key": "1287", "attributes": {"color": "#6463D0", "label": "Ovarian tissue cryopreservation followed by controlled ovarian stimulation and pick-up of mature oocytes does not impair the number or quality of retrieved oocytes", "size": null, "x": -81.72884368896484, "y": 55.21238708496094}}, {"key": "1288", "attributes": {"color": "#6463D0", "label": "Successful oocyte cryopreservation in reproductive-aged cancer survivors", "size": null, "x": -83.99517059326172, "y": 54.231727600097656}}, {"key": "1289", "attributes": {"color": "#6463D0", "label": "Ethics Committee of the American Society for Reproductive Medicine. Planned oocyte cryopreservation for women seeking to preserve future reproductive potential: an Ethics Committee opinion", "size": null, "x": -84.26193237304688, "y": 53.04832458496094}}, {"key": "1290", "attributes": {"color": "#6463D0", "label": "Morphological, ultrastructural and functional imaging of frozen/ thawed and vitrified/warmed human ovarian tissue retrieved from oncological patients", "size": null, "x": -81.3080062866211, "y": 56.936302185058594}}, {"key": "1291", "attributes": {"color": "#6463D0", "label": "Cryopreservation of ovarian tissue in pediatric patients", "size": null, "x": -82.3103256225586, "y": 57.1437873840332}}, {"key": "1292", "attributes": {"color": "#6463D0", "label": "Parenthood in survivors after adulthood cancer and perinatal health in their offspring: a preliminary report", "size": null, "x": -84.01068115234375, "y": 55.89850616455078}}, {"key": "1293", "attributes": {"color": "#6463D0", "label": "Anti-mullerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy", "size": null, "x": -82.21771240234375, "y": 54.32611846923828}}, {"key": "1294", "attributes": {"color": "#6463D0", "label": "Transplantation of frozen-thawed ovarian tissue: an update on worldwide activity published in peer-reviewed papers and on the Danish cohort", "size": null, "x": -81.2951889038086, "y": 57.60029983520508}}, {"key": "1295", "attributes": {"color": "#6463D0", "label": "Ovarian preservation with gonadotropin-releasing hormone analog during chemotherapy", "size": null, "x": -82.94489288330078, "y": 58.238216400146484}}, {"key": "1296", "attributes": {"color": "#6463D0", "label": "Cancer patients' and professional caregivers' needs, preferences and factors associated with receiving and providing fertility-related information: a mixed-methods systematic review", "size": null, "x": -83.53801727294922, "y": 58.16288375854492}}, {"key": "1297", "attributes": {"color": "#6463D0", "label": "To freeze or not to freeze: decision regret and satisfaction following elective oocyte cryopreservation", "size": null, "x": -84.82569122314453, "y": 54.674076080322266}}, {"key": "1298", "attributes": {"color": "#6463D0", "label": "Cryopreserved ovarian cortex from patients with leukemia in complete remission contains no apparent viable malignant cells", "size": null, "x": -81.88752746582031, "y": 53.377132415771484}}, {"key": "1299", "attributes": {"color": "#6463D0", "label": "BRCA1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro", "size": null, "x": -82.25260162353516, "y": 57.59476852416992}}, {"key": "1300", "attributes": {"color": "#6463D0", "label": "Outcomes of ovarian transposition in gynaecological cancers; a systematic review and meta-analysis", "size": null, "x": -81.4428482055664, "y": 53.141822814941406}}, {"key": "1301", "attributes": {"color": "#6463D0", "label": "Maternal and neonatal outcomes in pregnancies following colorectal cancer", "size": null, "x": -80.17059326171875, "y": 53.81947326660156}}, {"key": "1302", "attributes": {"color": "#6463D0", "label": "Anti-Mullerian hormone in breast cancer patients treated with chemotherapy: a retrospective evaluation of subsequent pregnancies", "size": null, "x": -81.7230224609375, "y": 53.15680694580078}}, {"key": "1303", "attributes": {"color": "#6463D0", "label": "The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis", "size": null, "x": -83.89800262451172, "y": 56.661033630371094}}, {"key": "1304", "attributes": {"color": "#6463D0", "label": "Pregnancy after cancer: does timing of conception affect infant health?", "size": null, "x": -82.41861724853516, "y": 58.26075744628906}}, {"key": "1305", "attributes": {"color": "#6463D0", "label": "Ovarian function after ovarian transposition and additional pelvic radiotherapy: a systematic review", "size": null, "x": -80.01951599121094, "y": 54.77915954589844}}, {"key": "1306", "attributes": {"color": "#6463D0", "label": "Improving fertility preservation in cancer: ovarian tissue cryobanking followed by ovarian stimulation can be efficiently combined", "size": null, "x": -83.27536010742188, "y": 57.48176574707031}}, {"key": "1307", "attributes": {"color": "#6463D0", "label": "Bone marrow remission status predicts leukemia contamination in ovarian biopsies collected for fertility preservation", "size": null, "x": -84.0483627319336, "y": 57.37331008911133}}, {"key": "1308", "attributes": {"color": "#6463D0", "label": "Stillbirth and neonatal death among female cancer survivors: a national cohort study", "size": null, "x": -82.98869323730469, "y": 55.67100524902344}}, {"key": "1309", "attributes": {"color": "#6463D0", "label": "Fertility preservation toolkit: a clinician resource to assist clinical discussion and decision making in pediatric and adolescent oncology", "size": null, "x": -80.40692138671875, "y": 54.592899322509766}}, {"key": "1310", "attributes": {"color": "#6463D0", "label": "Fertility preservation and refreezing of transplanted ovarian tissue-a potential new way of managing patients with low risk of malignant cell recurrence", "size": null, "x": -79.61480712890625, "y": 55.59738540649414}}, {"key": "1311", "attributes": {"color": "#6463D0", "label": "Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease", "size": null, "x": -81.52534484863281, "y": 55.680931091308594}}, {"key": "1312", "attributes": {"color": "#6463D0", "label": "Adjuvant anti-HER2 therapy, treatment-related amenorrhea, and survival in premenopausal HER2-positive early breast cancer patients", "size": null, "x": -83.5898208618164, "y": 52.963722229003906}}, {"key": "1313", "attributes": {"color": "#6463D0", "label": "Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: a pooled analysis of the MIG1 and GIM2 phase III studies", "size": null, "x": -80.33879089355469, "y": 56.890602111816406}}, {"key": "1314", "attributes": {"color": "#6463D0", "label": "Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies", "size": null, "x": -82.55337524414062, "y": 55.562950134277344}}, {"key": "1315", "attributes": {"color": "#6463D0", "label": "Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in young BRCA-mutated breast cancer patients", "size": null, "x": -85.20800018310547, "y": 55.111419677734375}}, {"key": "1316", "attributes": {"color": "#6463D0", "label": "Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients", "size": null, "x": -80.8496322631836, "y": 56.85402297973633}}, {"key": "1317", "attributes": {"color": "#6463D0", "label": "Long-term safety of pregnancy following breast cancer according to estrogen receptor status", "size": null, "x": -84.28077697753906, "y": 56.196807861328125}}, {"key": "1318", "attributes": {"color": "#6463D0", "label": "Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials", "size": null, "x": -79.79638671875, "y": 54.413726806640625}}, {"key": "1319", "attributes": {"color": "#6463D0", "label": "Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and metaanalysis of individual patient-level data", "size": null, "x": -82.80870056152344, "y": 54.157596588134766}}, {"key": "1320", "attributes": {"color": "#6463D0", "label": "Impact of taxanes, endocrine therapy, and deleterious germline BRCA mutations on anti-mullerian hormone levels in early breast cancer patients treated with anthracycline-and cyclophosphamidebased chemotherapy", "size": null, "x": -82.98765563964844, "y": 56.46833801269531}}, {"key": "1321", "attributes": {"color": "#6463D0", "label": "ESMO Guidelines Committee. Fertility preservation and posttreatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines", "size": null, "x": -83.2300796508789, "y": 53.52848815917969}}, {"key": "1322", "attributes": {"color": "#6463D0", "label": "Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkinlymphoma-evaluation by using antimullerian hormone and retrieved oocytes", "size": null, "x": -82.07989501953125, "y": 55.86862564086914}}, {"key": "1323", "attributes": {"color": "#6463D0", "label": "Prospective study of depression and anxiety in female fertility preservation and infertility patients", "size": null, "x": -80.9202880859375, "y": 56.26689147949219}}, {"key": "1324", "attributes": {"color": "#6463D0", "label": "Childbirth in young Korean women with previously treated breast cancer: the SMARTSHIP study", "size": null, "x": -82.78245544433594, "y": 53.81546401977539}}, {"key": "1325", "attributes": {"color": "#6463D0", "label": "Female patients with lymphoma demonstrate diminished ovarian reserve even before initiation of chemotherapy when compared with healthy controls and patients with other malignancies", "size": null, "x": -83.124755859375, "y": 58.328582763671875}}, {"key": "1326", "attributes": {"color": "#6463D0", "label": "Transgender men who experienced pregnancy after female-to-male gender transitioning", "size": null, "x": -80.20033264160156, "y": 55.20077896118164}}, {"key": "1327", "attributes": {"color": "#6463D0", "label": "A systematic review of patient oncofertility support needs in reproductive cancer patients aged 14 to 45 years of age", "size": null, "x": -81.14797973632812, "y": 56.52207565307617}}, {"key": "1328", "attributes": {"color": "#6463D0", "label": "Systematic review of fertility-related psychological distress in cancer patients: informing on an improved model of care", "size": null, "x": -85.0128173828125, "y": 56.005165100097656}}, {"key": "1329", "attributes": {"color": "#6463D0", "label": "Reproductive functions in female patients treated with adjuvant and neoadjuvant chemotherapy for localized osteosarcoma of the extremity", "size": null, "x": -83.42976379394531, "y": 56.282772064208984}}, {"key": "1330", "attributes": {"color": "#6463D0", "label": "Is transplantation of cryopreserved ovarian tissue from patients with advanced-stage breast cancer safe? A pilot study", "size": null, "x": -81.9203872680664, "y": 57.31134033203125}}, {"key": "1331", "attributes": {"color": "#6463D0", "label": "Stillbirth, early death and neonatal morbidity among offspring of female cancer survivors", "size": null, "x": -84.59367370605469, "y": 55.085105895996094}}, {"key": "1332", "attributes": {"color": "#6463D0", "label": "Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients", "size": null, "x": -83.71572875976562, "y": 53.944095611572266}}, {"key": "1333", "attributes": {"color": "#6463D0", "label": "Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study", "size": null, "x": -84.07184600830078, "y": 56.48468017578125}}, {"key": "1334", "attributes": {"color": "#6463D0", "label": "Pregnancy achieved using donor eggs in cancer survivors with treatment-induced ovarian failure: obstetric and perinatal outcome", "size": null, "x": -80.92406463623047, "y": 56.509666442871094}}, {"key": "1335", "attributes": {"color": "#6463D0", "label": "Safety of ovarian tissue transplantation in patients with borderline ovarian tumors", "size": null, "x": -82.44081115722656, "y": 53.12350845336914}}, {"key": "1336", "attributes": {"color": "#6463D0", "label": "State of the art on oocyte cryopreservation in female cancer patients: a critical review of the literature", "size": null, "x": -82.97400665283203, "y": 55.123741149902344}}, {"key": "1337", "attributes": {"color": "#6463D0", "label": "Study of anti-MÃ¼llerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide", "size": null, "x": -82.2615737915039, "y": 55.47088623046875}}, {"key": "1338", "attributes": {"color": "#6463D0", "label": "Ovarian reserve and oocyte maturity in women with malignancy undergoing in vitro maturation treatment", "size": null, "x": -81.25634765625, "y": 54.84408950805664}}, {"key": "1339", "attributes": {"color": "#6463D0", "label": "Predictors of psychological distress and interest in mental health services in individuals with cancer", "size": null, "x": -81.76824188232422, "y": 57.85602569580078}}, {"key": "1340", "attributes": {"color": "#6463D0", "label": "Transgender men and pregnancy", "size": null, "x": -81.73202514648438, "y": 54.31332015991211}}, {"key": "1341", "attributes": {"color": "#6463D0", "label": "Current success and efficiency of autologous ovarian transplantation: a meta-analysis", "size": null, "x": -83.78157043457031, "y": 54.90177536010742}}, {"key": "1342", "attributes": {"color": "#6463D0", "label": "ESHRE guideline: female fertility preservation", "size": null, "x": -84.691162109375, "y": 57.005157470703125}}, {"key": "1343", "attributes": {"color": "#6463D0", "label": "New insights in the selection and management of cancer patients applicants for ovarian tissue cryopreservation", "size": null, "x": -83.66043853759766, "y": 55.64723205566406}}, {"key": "1344", "attributes": {"color": "#6463D0", "label": "Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer", "size": null, "x": -81.05770111083984, "y": 55.505043029785156}}, {"key": "1345", "attributes": {"color": "#6463D0", "label": "The fertility-related concerns, needs and preferences of younger women with breast cancer: a systematic review", "size": null, "x": -84.24596405029297, "y": 55.5573844909668}}, {"key": "1346", "attributes": {"color": "#6463D0", "label": "Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review", "size": null, "x": -81.74700164794922, "y": 52.84478759765625}}, {"key": "1347", "attributes": {"color": "#6463D0", "label": "for the CAROLÃ©LISA Cooperative Group. Impact of cancer chemotherapy before ovarian cortex cryopreservation on ovarian tissue transplantation", "size": null, "x": -82.2729263305664, "y": 56.6116828918457}}, {"key": "1348", "attributes": {"color": "#6463D0", "label": "Effects of ovarian endometrioma on embryo quality", "size": null, "x": -82.25747680664062, "y": 57.91628646850586}}, {"key": "1349", "attributes": {"color": "#6463D0", "label": "Consistent and predictable delivery rates after oocyte vitrification: an observational longitudinal cohort multicentric study", "size": null, "x": -80.70637512207031, "y": 57.60127258300781}}, {"key": "1350", "attributes": {"color": "#6463D0", "label": "Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance", "size": null, "x": -81.9598159790039, "y": 54.01301956176758}}, {"key": "1351", "attributes": {"color": "#6463D0", "label": "New methods to improve the safety assessment of cryopreserved ovarian tissue for fertility preservation in breast cancer patients", "size": null, "x": -80.96170806884766, "y": 54.47212219238281}}, {"key": "1352", "attributes": {"color": "#6463D0", "label": "A prospective study of women and girls undergoing fertility preservation due to oncologic and non-oncologic indications in Sweden-Trends in patients' choices and benefit of the chosen methods after long-term follow up", "size": null, "x": -81.31324005126953, "y": 56.723411560058594}}, {"key": "1353", "attributes": {"color": "#6463D0", "label": "Ice age: cryopreservation in assisted reproduction-an update", "size": null, "x": -81.92689514160156, "y": 58.33595275878906}}, {"key": "1354", "attributes": {"color": "#6463D0", "label": "Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation", "size": null, "x": -79.66818237304688, "y": 54.92289733886719}}, {"key": "1355", "attributes": {"color": "#6463D0", "label": "Autotransplantation of cryopreserved ovarian tissue in 12 women with chemotherapy-induced premature ovarian failure: the Danish experience", "size": null, "x": -82.3268814086914, "y": 55.687381744384766}}, {"key": "1356", "attributes": {"color": "#6463D0", "label": "Tamoxifen and pregnancy: an absolute contraindication?", "size": null, "x": -84.00335693359375, "y": 55.178627014160156}}, {"key": "1357", "attributes": {"color": "#6463D0", "label": "Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis", "size": null, "x": -83.21061706542969, "y": 55.96638107299805}}, {"key": "1358", "attributes": {"color": "#6463D0", "label": "The role of in-depth reproductive health counseling in addressing reproductive health concerns in female survivors of nongynecologic cancers", "size": null, "x": -82.19230651855469, "y": 53.1450309753418}}, {"key": "1359", "attributes": {"color": "#6463D0", "label": "First delivery in a leukemia survivor after transplantation of cryopreserved ovarian tissue, evaluated for leukemia cells contamination", "size": null, "x": -82.88688659667969, "y": 57.03946304321289}}, {"key": "1360", "attributes": {"color": "#6463D0", "label": "Vitrification versus slow freezing for human ovarian tissue cryopreservation: a systematic review and meta-anlaysis", "size": null, "x": -83.02669525146484, "y": 56.20689392089844}}, {"key": "1361", "attributes": {"color": "#6463D0", "label": "Stillbirth and neonatal death in relation to radiation exposure before conception: a retrospective cohort study", "size": null, "x": -82.33224487304688, "y": 54.988243103027344}}, {"key": "1362", "attributes": {"color": "#6463D0", "label": "Antineoplastic agents and (in)fertility: informing patients to improve decisions", "size": null, "x": -83.30127716064453, "y": 54.798545837402344}}, {"key": "1363", "attributes": {"color": "#6463D0", "label": "Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and meta-analysis", "size": null, "x": -82.93476867675781, "y": 53.205379486083984}}, {"key": "1364", "attributes": {"color": "#6463D0", "label": "Ovarian damage from chemotherapy and current approaches to its protection", "size": null, "x": -80.09397888183594, "y": 56.22716522216797}}, {"key": "1365", "attributes": {"color": "#6463D0", "label": "Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients", "size": null, "x": -83.45693969726562, "y": 55.619503021240234}}, {"key": "1366", "attributes": {"color": "#6463D0", "label": "Meta-analysis of associations between maternal breast cancer and the risk of adverse delivery outcomes", "size": null, "x": -83.98999786376953, "y": 53.66267395019531}}, {"key": "1367", "attributes": {"color": "#6463D0", "label": "Obstetric and offspring risks of women's morbid conditions linked to prior anticancer treatments", "size": null, "x": -84.46015167236328, "y": 57.037113189697266}}, {"key": "1368", "attributes": {"color": "#6463D0", "label": "Gonadal status in reproductive age women after haematopoietic stem cell transplantation for haematological malignancies", "size": null, "x": -80.77003479003906, "y": 55.09290313720703}}, {"key": "1369", "attributes": {"color": "#6463D0", "label": "The impact of uterine radiation on subsequent fertility and pregnancy outcomes", "size": null, "x": -82.59339904785156, "y": 56.59745788574219}}, {"key": "1370", "attributes": {"color": "#6463D0", "label": "ESHRE guideline: ovarian stimulation for IVF/ICSI", "size": null, "x": -83.5831298828125, "y": 53.30012893676758}}, {"key": "1371", "attributes": {"color": "#6463D0", "label": "Luteal phase after conventional stimulation in the same ovarian cycle might improve the management of poor responder patients fulfilling the Bologna criteria: a case series", "size": null, "x": -83.53350830078125, "y": 55.43794250488281}}, {"key": "1372", "attributes": {"color": "#6463D0", "label": "Premature ovarian failure and fertility in longterm survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study", "size": null, "x": -81.40647888183594, "y": 55.99536895751953}}, {"key": "1373", "attributes": {"color": "#6463D0", "label": "A picture of medically assisted reproduction activities during the COVID-19 pandemic in Europe", "size": null, "x": -82.27039337158203, "y": 53.853355407714844}}, {"key": "1374", "attributes": {"color": "#6463D0", "label": "Optimizing reproductive outcome in children and young people with cancer", "size": null, "x": -82.32389831542969, "y": 54.239437103271484}}, {"key": "1375", "attributes": {"color": "#6463D0", "label": "Systematic review of fertility preservation patient decision aids for cancer patients", "size": null, "x": -81.79206085205078, "y": 55.848358154296875}}, {"key": "1376", "attributes": {"color": "#6463D0", "label": "Levels of depression in transgender people and its predictors: results of a large matched control study with transgender people accessing clinical services", "size": null, "x": -83.20320129394531, "y": 55.23781204223633}}, {"key": "1377", "attributes": {"color": "#6463D0", "label": "Oncologic and obstetrical outcomes with fertility-sparing treatment of cervical cancer: a systematic review and meta-analysis", "size": null, "x": -84.14459228515625, "y": 54.48235321044922}}, {"key": "1378", "attributes": {"color": "#6463D0", "label": "Predictive value of the serum anti-Mullerian level for spontaneous pregnancy in women after endometriosis surgery", "size": null, "x": -81.24913024902344, "y": 54.02999496459961}}, {"key": "1379", "attributes": {"color": "#FF6AE4", "label": "The NTD Supply Chain Forum-Strengthening the backbone of NTD programs", "size": null, "x": -37.17014694213867, "y": -245.0410614013672}}, {"key": "1380", "attributes": {"color": "#FF6AE4", "label": "WHO | World Health Organization", "size": null, "x": -36.20804214477539, "y": -244.7082977294922}}, {"key": "1381", "attributes": {"color": "#FF6AE4", "label": "Uniting to Combat Neglected Tropical Diseases. The London Declaration on Neglected Tropical Diseases", "size": null, "x": -36.15272903442383, "y": -245.31980895996094}}, {"key": "1382", "attributes": {"color": "#FF6AE4", "label": "MECTIZAN Donation Program-MSD Responsibility", "size": null, "x": -37.90958786010742, "y": -245.38577270507812}}, {"key": "1383", "attributes": {"color": "#FF6AE4", "label": "requesting medicines and reporting", "size": null, "x": -36.42790222167969, "y": -244.3835906982422}}, {"key": "1384", "attributes": {"color": "#FF6AE4", "label": "Merck Commemorates 30 Years of MECTIZAN Donation Program Progress", "size": null, "x": -37.91687774658203, "y": -244.7177276611328}}, {"key": "1385", "attributes": {"color": "#FF6AE4", "label": "Initial five-year period 2012-2016 helminthiases in school-age children â¢ Donated through WHO", "size": null, "x": -37.13154220581055, "y": -245.94210815429688}}, {"key": "1386", "attributes": {"color": "#FF6AE4", "label": "GSK increases support for WHO strategy to improve children's health with new 5-year commitment to expand donations of albendazole medicine | GSK", "size": null, "x": -37.35765075683594, "y": -245.32247924804688}}, {"key": "1387", "attributes": {"color": "#FF6AE4", "label": "Progress and projections in the program to eliminate trachoma", "size": null, "x": -38.12830352783203, "y": -244.53982543945312}}, {"key": "1388", "attributes": {"color": "#FF6AE4", "label": "Home | International Trachoma Initiative", "size": null, "x": -37.71588897705078, "y": -243.90953063964844}}, {"key": "1389", "attributes": {"color": "#FF6AE4", "label": "Progress in public-private partnerships to fight neglected diseases", "size": null, "x": -36.86651611328125, "y": -245.50982666015625}}, {"key": "1390", "attributes": {"color": "#FF6AE4", "label": "Extends Long-Standing Donation Program to Support Global Effort to Tackle Intestinal Worms | Johnson & Johnson", "size": null, "x": -37.176788330078125, "y": -244.48446655273438}}, {"key": "1391", "attributes": {"color": "#FF6AE4", "label": "Schistosomiasis research and control since the retirement of Sir Patrick Manson in 1914", "size": null, "x": -36.972537994384766, "y": -244.03501892089844}}, {"key": "1392", "attributes": {"color": "#FF6AE4", "label": "Access to Medicines | Improving Access to Medicines | Eisai Co., Ltd", "size": null, "x": -37.19918441772461, "y": -246.42340087890625}}, {"key": "1393", "attributes": {"color": "#7E43A0", "label": "Banc de Sang i Teixits, Head of Clinical Hematology", "size": null, "x": 206.81427001953125, "y": 15.24581527709961}}, {"key": "1394", "attributes": {"color": "#7E43A0", "label": "Campoy: boehringer ingelheim: Consultancy", "size": null, "x": 206.18023681640625, "y": 15.367719650268555}}, {"key": "1395", "attributes": {"color": "#7E43A0", "label": "Speakers Bureau", "size": null, "x": 207.39512634277344, "y": 15.59072208404541}}, {"key": "1396", "attributes": {"color": "#7E43A0", "label": "Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Astellas: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": 207.1314697265625, "y": 14.921661376953125}}, {"key": "1397", "attributes": {"color": "#DA049E", "label": "Sistema renina-angiotensina-aldosterona y COVID19. Implicaciones clÃ­nicas Renin-angiotensin system Renin -angiotensin system inhibitors", "size": null, "x": -24.67162322998047, "y": 111.66421508789062}}, {"key": "1398", "attributes": {"color": "#DA049E", "label": "COVID-19 and the cardiovascular system", "size": null, "x": -23.03490447998047, "y": 112.0916519165039}}, {"key": "1399", "attributes": {"color": "#DA049E", "label": "Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?", "size": null, "x": -26.3704891204834, "y": 111.46507263183594}}, {"key": "1400", "attributes": {"color": "#DA049E", "label": "Controversy regarding ACEinhibitors/ ARBs in COVID-19", "size": null, "x": -24.937685012817383, "y": 111.55094146728516}}, {"key": "1401", "attributes": {"color": "#DA049E", "label": "Renin-angiotensin system and cardiovascular risk", "size": null, "x": -24.878799438476562, "y": 112.66565704345703}}, {"key": "1402", "attributes": {"color": "#DA049E", "label": "Counter-regulatory renin-angiotensin system in cardiovascular disease", "size": null, "x": -25.031967163085938, "y": 113.10905456542969}}, {"key": "1403", "attributes": {"color": "#DA049E", "label": "The ACE2/angiotensin-(1-7)/mas axis of the renin-angiotensin system: focus on angiotensin", "size": null, "x": -24.268508911132812, "y": 111.24530792236328}}, {"key": "1404", "attributes": {"color": "#DA049E", "label": "A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury", "size": null, "x": -23.449138641357422, "y": 110.38783264160156}}, {"key": "1405", "attributes": {"color": "#DA049E", "label": "The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice", "size": null, "x": -23.491052627563477, "y": 113.63318634033203}}, {"key": "1406", "attributes": {"color": "#DA049E", "label": "Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases", "size": null, "x": -26.222740173339844, "y": 112.40006256103516}}, {"key": "1407", "attributes": {"color": "#DA049E", "label": "Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease", "size": null, "x": -25.241064071655273, "y": 112.61583709716797}}, {"key": "1408", "attributes": {"color": "#DA049E", "label": "Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats", "size": null, "x": -23.3515567779541, "y": 109.94173431396484}}, {"key": "1409", "attributes": {"color": "#DA049E", "label": "Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2", "size": null, "x": -26.03851890563965, "y": 112.74408721923828}}, {"key": "1410", "attributes": {"color": "#DA049E", "label": "Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation", "size": null, "x": -25.34256362915039, "y": 111.06732177734375}}, {"key": "1411", "attributes": {"color": "#DA049E", "label": "Localization of ACE2 in the renal vasculature: Amplification by angiotensin II type 1 receptor blockade using telmisartan", "size": null, "x": -25.44647216796875, "y": 111.94090270996094}}, {"key": "1412", "attributes": {"color": "#DA049E", "label": "Tumor necrosis factor-Î± convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)", "size": null, "x": -24.470632553100586, "y": 113.46257781982422}}, {"key": "1413", "attributes": {"color": "#DA049E", "label": "Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors", "size": null, "x": -23.702592849731445, "y": 112.94657135009766}}, {"key": "1414", "attributes": {"color": "#DA049E", "label": "Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis", "size": null, "x": -24.685922622680664, "y": 110.5870132446289}}, {"key": "1415", "attributes": {"color": "#DA049E", "label": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study", "size": null, "x": -29.897140502929688, "y": 135.73997497558594}}, {"key": "1416", "attributes": {"color": "#DA049E", "label": "The presence of heart disease worsens prognosis in patients with COVID-19", "size": null, "x": -24.7261905670166, "y": 111.1103744506836}}, {"key": "1417", "attributes": {"color": "#DA049E", "label": "Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China", "size": null, "x": -23.955591201782227, "y": 111.93992614746094}}, {"key": "1418", "attributes": {"color": "#DA049E", "label": "Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic", "size": null, "x": -23.682924270629883, "y": 111.80140686035156}}, {"key": "1419", "attributes": {"color": "#DA049E", "label": "Drugs and the renin-angiotensin system in COVID-19", "size": null, "x": -26.398283004760742, "y": 111.99404907226562}}, {"key": "1420", "attributes": {"color": "#DA049E", "label": "HFSA/ACC/AHA statement addresses concerns Re: using RAAS antagonists in COVID-19. Disponible en", "size": null, "x": -26.217103958129883, "y": 112.5609359741211}}, {"key": "1421", "attributes": {"color": "#DA049E", "label": "Position statement of the ESC council on hypertension on ACE-inhibitors and angiotensin receptor blockers", "size": null, "x": -24.10060691833496, "y": 110.39506530761719}}, {"key": "1422", "attributes": {"color": "#DA049E", "label": "Medicamentos antihipertensivos que actÃºan sobre el sistema renina angiotensina e infecciÃ³n por COVID-19. Disponible en", "size": null, "x": -25.00627326965332, "y": 113.91969299316406}}, {"key": "1423", "attributes": {"color": "#DA049E", "label": "Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19", "size": null, "x": -25.52992820739746, "y": 112.94398498535156}}, {"key": "1424", "attributes": {"color": "#DA049E", "label": "Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19", "size": null, "x": -25.24934196472168, "y": 110.60783386230469}}, {"key": "1425", "attributes": {"color": "#DA049E", "label": "Renin-angiotensin-aldosterone system blockers and the risk of COVID-19", "size": null, "x": -24.700925827026367, "y": 112.07817077636719}}, {"key": "1426", "attributes": {"color": "#DA049E", "label": "Use of renin-angiotensinaldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study", "size": null, "x": -23.516931533813477, "y": 111.29619598388672}}, {"key": "1427", "attributes": {"color": "#DA049E", "label": "Ramipril in high risk patients with COVID-19", "size": null, "x": -22.903474807739258, "y": 111.1767349243164}}, {"key": "1428", "attributes": {"color": "#DA049E", "label": "Cardiovascular disease, drug therapy, and mortality in COVID-19", "size": null, "x": -25.212928771972656, "y": 111.90132141113281}}, {"key": "1429", "attributes": {"color": "#DA049E", "label": "Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19", "size": null, "x": -25.775175094604492, "y": 111.44863891601562}}, {"key": "1430", "attributes": {"color": "#DA049E", "label": "Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China", "size": null, "x": -24.46860694885254, "y": 112.76742553710938}}, {"key": "1431", "attributes": {"color": "#DA049E", "label": "Potential interventions for novel coronavirus in China: A systematic review", "size": null, "x": -25.417999267578125, "y": 111.70523834228516}}, {"key": "1432", "attributes": {"color": "#DA049E", "label": "Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction", "size": null, "x": -22.636856079101562, "y": 111.8355484008789}}, {"key": "1433", "attributes": {"color": "#DA049E", "label": "Nicotianamine is a novel angiotensin-converting enzyme 2 inhibitor in soybean", "size": null, "x": -25.871532440185547, "y": 113.37471008300781}}, {"key": "1434", "attributes": {"color": "#DA049E", "label": "Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs", "size": null, "x": -24.356075286865234, "y": 111.55034637451172}}, {"key": "1435", "attributes": {"color": "#DA049E", "label": "Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg", "size": null, "x": -24.889841079711914, "y": 109.93592834472656}}, {"key": "1436", "attributes": {"color": "#DA049E", "label": "Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries", "size": null, "x": -23.647459030151367, "y": 110.75785827636719}}, {"key": "1437", "attributes": {"color": "#DA049E", "label": "ESC/ESH guidelines for the management of arterial hypertension", "size": null, "x": -23.26729965209961, "y": 112.90605926513672}}, {"key": "1438", "attributes": {"color": "#DA049E", "label": "Q&A: The novel coronavirus outbreak causing COVID-19", "size": null, "x": -24.192691802978516, "y": 110.92306518554688}}, {"key": "1439", "attributes": {"color": "#DA049E", "label": "Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy", "size": null, "x": -24.357149124145508, "y": 111.99542999267578}}, {"key": "1440", "attributes": {"color": "#DA049E", "label": "Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19", "size": null, "x": -23.99374771118164, "y": 111.62615203857422}}, {"key": "1441", "attributes": {"color": "#DA049E", "label": "Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy", "size": null, "x": -26.104530334472656, "y": 111.83975982666016}}, {"key": "1442", "attributes": {"color": "#DA049E", "label": "Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study", "size": null, "x": -23.636695861816406, "y": 112.30936431884766}}, {"key": "1443", "attributes": {"color": "#DA049E", "label": "COVID 19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease", "size": null, "x": -22.95886993408203, "y": 112.76720428466797}}, {"key": "1444", "attributes": {"color": "#DA049E", "label": "Neurohormonal activation in heart failure with reduced ejection fraction", "size": null, "x": -24.244707107543945, "y": 113.1331787109375}}, {"key": "1445", "attributes": {"color": "#DA049E", "label": "ACE2 gene expression is up-regulated in the human failing heart", "size": null, "x": -25.632524490356445, "y": 111.87484741210938}}, {"key": "1446", "attributes": {"color": "#DA049E", "label": "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure", "size": null, "x": -23.09174919128418, "y": 111.55134582519531}}, {"key": "1447", "attributes": {"color": "#DA049E", "label": "Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial", "size": null, "x": -25.680320739746094, "y": 110.43404388427734}}, {"key": "1448", "attributes": {"color": "#DA049E", "label": "Management of heart failure patients with COVID-19. A joint position paper of the Chinese Heart Failure Association; National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. Intergovernmental Panel on Climate Change", "size": null, "x": -24.05616569519043, "y": 112.68077087402344}}, {"key": "1449", "attributes": {"color": "#A701CD", "label": "Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era-Data from the Sarah Cannon Blood Cancer Network (SCBCN)", "size": null, "x": -87.10765075683594, "y": -212.2517547607422}}, {"key": "1450", "attributes": {"color": "#A701CD", "label": "AlloVir: Honoraria; CRISPR: Honoraria", "size": null, "x": -87.7670669555664, "y": -211.92861938476562}}, {"key": "1451", "attributes": {"color": "#A701CD", "label": "Squibb Company: Honoraria. Kambhampati: AbbVie: Other: Investigator in AbbViesponsored clinical trials.. McSweeney: Kite, a Gilead Company: Consultancy", "size": null, "x": -87.00587463378906, "y": -212.7707061767578}}, {"key": "1452", "attributes": {"color": "#A701CD", "label": "Ramakrishnan: Amgen: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Cigna: Honoraria. Safah: Verastem: Honoraria", "size": null, "x": -87.72991943359375, "y": -212.6600799560547}}, {"key": "1453", "attributes": {"color": "#9163E2", "label": "Evaluation and Treatment Coronavirus", "size": null, "x": -50.49091720581055, "y": -19.756975173950195}}, {"key": "1454", "attributes": {"color": "#9163E2", "label": "StatPearls; StatPearls Publishing: Treasure Island (FL)", "size": null, "x": -53.12068557739258, "y": -19.908119201660156}}, {"key": "1455", "attributes": {"color": "#9163E2", "label": "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An Overview of Viral Structure and Host Response", "size": null, "x": -52.333168029785156, "y": -20.647127151489258}}, {"key": "1456", "attributes": {"color": "#9163E2", "label": "WHO Coronavirus Disease", "size": null, "x": -51.84764862060547, "y": -19.37735366821289}}, {"key": "1457", "attributes": {"color": "#9163E2", "label": "Accurately Says that Other Countries that Reopened Saw an Increase in Coronavirus Infections", "size": null, "x": -52.69868469238281, "y": -17.779762268066406}}, {"key": "1458", "attributes": {"color": "#9163E2", "label": "Projecting the Transmission Dynamics of SARS-CoV-2 through the Postpandemic Period", "size": null, "x": -53.92845916748047, "y": -19.97797966003418}}, {"key": "1459", "attributes": {"color": "#9163E2", "label": "Genome Composition and Divergence of the Novel Coronavirus (2019-NCoV) Originating in China", "size": null, "x": -53.69180679321289, "y": -20.653654098510742}}, {"key": "1460", "attributes": {"color": "#9163E2", "label": "Work on a COVID-19 Vaccine Candidate, Moderna", "size": null, "x": -54.333866119384766, "y": -22.614646911621094}}, {"key": "1461", "attributes": {"color": "#9163E2", "label": "Chinese Clinical Trial Register (ChiCTR) -The World Health Organization International Clinical Trials Registered Organization Registered Platform", "size": null, "x": -51.48824691772461, "y": -23.091449737548828}}, {"key": "1462", "attributes": {"color": "#9163E2", "label": "Dose-Ranging Study of the Safety and Immunogenicity of 2019-NCoV Vaccine (MRNA-1273) in Healthy Adults -Full Text View", "size": null, "x": -54.335845947265625, "y": -20.603303909301758}}, {"key": "1463", "attributes": {"color": "#9163E2", "label": "COVID-19 Vaccines: Breaking Record Times to First-in-Human Trials", "size": null, "x": -51.42258834838867, "y": -18.375782012939453}}, {"key": "1464", "attributes": {"color": "#9163E2", "label": "The Clinical Development Process for a Novel Preventive Vaccine: An Overview", "size": null, "x": -53.82465744018555, "y": -20.460819244384766}}, {"key": "1465", "attributes": {"color": "#9163E2", "label": "Antibody-Dependent Enhancement and SARS-CoV-2 Vaccines and Therapies", "size": null, "x": -53.17997741699219, "y": -20.35432243347168}}, {"key": "1466", "attributes": {"color": "#9163E2", "label": "Developing MRNA-Vaccine Technologies", "size": null, "x": -52.95353698730469, "y": -19.04904556274414}}, {"key": "1467", "attributes": {"color": "#9163E2", "label": "Coronavirus Vaccines Get a Biotech Boost", "size": null, "x": -54.4610481262207, "y": -18.403644561767578}}, {"key": "1468", "attributes": {"color": "#9163E2", "label": "Will Pay $1.6 Billion to Novavax for Coronavirus Vaccine", "size": null, "x": -52.251766204833984, "y": -19.864410400390625}}, {"key": "1469", "attributes": {"color": "#9163E2", "label": "An MRNA Vaccine against SARS-CoV-2 î Preliminary Report", "size": null, "x": -53.92160415649414, "y": -20.969043731689453}}, {"key": "1470", "attributes": {"color": "#9163E2", "label": "Novavax Announces Positive Phase 1 Data for Its", "size": null, "x": -52.291866302490234, "y": -22.483518600463867}}, {"key": "1471", "attributes": {"color": "#9163E2", "label": "Vaccine Candidate", "size": null, "x": -50.143795013427734, "y": -20.074617385864258}}, {"key": "1472", "attributes": {"color": "#9163E2", "label": "Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report", "size": null, "x": -50.02745056152344, "y": -20.418203353881836}}, {"key": "1473", "attributes": {"color": "#9163E2", "label": "Concurrent Human Antibody and TH1 Type T-Cell Responses Elicited by a COVID-19 RNA Vaccine", "size": null, "x": -50.70062255859375, "y": -20.55646324157715}}, {"key": "1474", "attributes": {"color": "#9163E2", "label": "Tolerability, and Immunogenicity of a Recombinant Adenovirus Type-5 Vectored COVID-19 Vaccine: A Dose-Escalation", "size": null, "x": -51.43765640258789, "y": -21.70734977722168}}, {"key": "1475", "attributes": {"color": "#9163E2", "label": "Immunogenicity and Safety of a Recombinant Adenovirus Type-5-Vectored COVID-19 Vaccine in Healthy Adults Aged 18 Years or Older: A Randomised, Double-Blind", "size": null, "x": -53.10209655761719, "y": -17.72815704345703}}, {"key": "1476", "attributes": {"color": "#9163E2", "label": "Safety and Immunogenicity of the ChAdOx1 NCoV-19 Vaccine against SARS-CoV-2: A Preliminary Report of a Phase 1/2, Single-Blind, Randomised Controlled Trial", "size": null, "x": -51.8956298828125, "y": -21.89032745361328}}, {"key": "1477", "attributes": {"color": "#9163E2", "label": "Immunity and Immunopathology to Viruses: What Decides the Outcome?", "size": null, "x": -52.000587463378906, "y": -19.57045555114746}}, {"key": "1478", "attributes": {"color": "#9163E2", "label": "The Xs and Y of Immune Responses to Viral Vaccines", "size": null, "x": -49.660091400146484, "y": -20.608762741088867}}, {"key": "1479", "attributes": {"color": "#9163E2", "label": "Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease", "size": null, "x": -52.62519454956055, "y": -22.58699607849121}}, {"key": "1480", "attributes": {"color": "#9163E2", "label": "Cell Responses in Patients with COVID-19", "size": null, "x": -52.30687713623047, "y": -17.590055465698242}}, {"key": "1481", "attributes": {"color": "#9163E2", "label": "Humoral and Circulating Follicular Helper T Cell Responses in Recovered Patients with COVID-19", "size": null, "x": -52.97718048095703, "y": -21.676515579223633}}, {"key": "1482", "attributes": {"color": "#9163E2", "label": "Smallpox Vaccine: The Good, the Bad, and the Ugly", "size": null, "x": -51.6000862121582, "y": -18.78822898864746}}, {"key": "1483", "attributes": {"color": "#9163E2", "label": "An Introduction to Poliovirus: Pathogenesis, Vaccination, and the Endgame for Global Eradication", "size": null, "x": -51.84951400756836, "y": -21.60593605041504}}, {"key": "1484", "attributes": {"color": "#9163E2", "label": "Advances in HIV-1", "size": null, "x": -53.592308044433594, "y": -20.9422550201416}}, {"key": "1485", "attributes": {"color": "#9163E2", "label": "Respiratory Syncytial Virus Vaccines", "size": null, "x": -52.189823150634766, "y": -21.187089920043945}}, {"key": "1486", "attributes": {"color": "#9163E2", "label": "Multi-Faceted Functions of Secretory IgA at Mucosal Surfaces", "size": null, "x": -52.86936950683594, "y": -22.08631706237793}}, {"key": "1487", "attributes": {"color": "#9163E2", "label": "The Role of IgA in COVID-19", "size": null, "x": -53.296878814697266, "y": -21.325883865356445}}, {"key": "1488", "attributes": {"color": "#9163E2", "label": "Effect of Vaccine Administration Modality on Immunogenicity and Efficacy", "size": null, "x": -51.11317825317383, "y": -18.026878356933594}}, {"key": "1489", "attributes": {"color": "#9163E2", "label": "Altimmune COVID-19 Vaccine Candidate Tested at UAB Shows Positive Preclinical Results -News", "size": null, "x": -53.36983108520508, "y": -22.481273651123047}}, {"key": "1490", "attributes": {"color": "#9163E2", "label": "Quadram Researchers Working on COVID-19 Vaccine Join WHO Expert Groups", "size": null, "x": -54.58807373046875, "y": -19.96424102783203}}, {"key": "1491", "attributes": {"color": "#9163E2", "label": "New Understanding of the Damage of SARS-CoV-2 Infection Outside the Respiratory System", "size": null, "x": -53.817138671875, "y": -22.136972427368164}}, {"key": "1492", "attributes": {"color": "#9163E2", "label": "Angiotensin-Converting Enzyme 2 in Lung Diseases", "size": null, "x": -51.734764099121094, "y": -19.6807918548584}}, {"key": "1493", "attributes": {"color": "#9163E2", "label": "Angiotensin-converting Enzyme 2 in the Brain: Properties and Future Directions", "size": null, "x": -51.423179626464844, "y": -22.12473487854004}}, {"key": "1494", "attributes": {"color": "#9163E2", "label": "ACE2 Expression by Colonic Epithelial Cells Is Associated with Viral Infection", "size": null, "x": -51.022823333740234, "y": -20.09888458251953}}, {"key": "1495", "attributes": {"color": "#9163E2", "label": "The Distribution and Functions of Immunoglobulin Isotypes. Immunobiology: The Immune System in Health and Disease, 5; Garland Science", "size": null, "x": -52.62430953979492, "y": -21.64372444152832}}, {"key": "1496", "attributes": {"color": "#9163E2", "label": "T-Cell-Inducing Vaccines â What's the Future", "size": null, "x": -54.3558349609375, "y": -21.476224899291992}}, {"key": "1497", "attributes": {"color": "#9163E2", "label": "Immunoglobulin Class Switching Appears to Be Regulated by B Cell Antigen Receptor-Specific T Cell Action", "size": null, "x": -54.14301300048828, "y": -20.852153778076172}}, {"key": "1498", "attributes": {"color": "#9163E2", "label": "Duration of Serum Neutralizing Antibodies for SARS-CoV-2: Lessons from SARS-CoV Infection", "size": null, "x": -51.1366081237793, "y": -20.70534896850586}}, {"key": "1499", "attributes": {"color": "#9163E2", "label": "Vaccine Adjuvants: Putting Innate Immunity to Work", "size": null, "x": -51.473228454589844, "y": -18.529218673706055}}, {"key": "1500", "attributes": {"color": "#9163E2", "label": "Immune Mechanisms of Protection: Can Adjuvants Rise to the Challenge?", "size": null, "x": -52.1833381652832, "y": -22.655439376831055}}, {"key": "1501", "attributes": {"color": "#9163E2", "label": "Antibody-Antigen-Adjuvant Conjugates Enable Co-Delivery of Antigen and Adjuvant to Dendritic Cells in Cis but Only Have Partial Targeting Specificity", "size": null, "x": -53.43400192260742, "y": -19.761436462402344}}, {"key": "1502", "attributes": {"color": "#9163E2", "label": "Better Adjuvants for Better Vaccines", "size": null, "x": -52.92028045654297, "y": -20.961864471435547}}, {"key": "1503", "attributes": {"color": "#9163E2", "label": "Nanoparticle Vaccines against Infectious Diseases", "size": null, "x": -52.057350158691406, "y": -23.235885620117188}}, {"key": "1504", "attributes": {"color": "#9163E2", "label": "Nanoparticle Vaccines Adopting Virus-Like Features for Enhanced Immune Potentiation", "size": null, "x": -53.92334747314453, "y": -21.938079833984375}}, {"key": "1505", "attributes": {"color": "#9163E2", "label": "Cryo-EM Structure of the 2019-NCoV Spike in the Prefusion Conformation", "size": null, "x": -51.22453308105469, "y": -20.96338653564453}}, {"key": "1506", "attributes": {"color": "#9163E2", "label": "Mosaic Nanoparticle Display of Diverse Influenza Virus Hemagglutinins Elicits Broad B Cell Responses", "size": null, "x": -52.750213623046875, "y": -19.113922119140625}}, {"key": "1507", "attributes": {"color": "#9163E2", "label": "The Lymphatic System in Health and Disease", "size": null, "x": -53.20552444458008, "y": -19.25088119506836}}, {"key": "1508", "attributes": {"color": "#9163E2", "label": "Lymphatic Drug Delivery Using Engineered Liposomes and Solid Lipid Nanoparticles", "size": null, "x": -54.397647857666016, "y": -21.177722930908203}}, {"key": "1509", "attributes": {"color": "#9163E2", "label": "eTheRNA Launches an International Consortium and Starts Development of Cross-Strain Protective CoV-2 mRNA Vaccine for High Risk Populations", "size": null, "x": -51.838375091552734, "y": -20.2469482421875}}, {"key": "1510", "attributes": {"color": "#9163E2", "label": "Intravacc Partners with Wageningen Bioveterinary Research and Utrecht University to Develop an Intranasal", "size": null, "x": -51.05253982543945, "y": -21.388696670532227}}, {"key": "1511", "attributes": {"color": "#9163E2", "label": "COVID-19 Vaccine Development and a Potential Nanomaterial Path Forward", "size": null, "x": -54.63363265991211, "y": -19.312902450561523}}, {"key": "1512", "attributes": {"color": "#9163E2", "label": "Milken Institute's COVID-19 Treatment and Vaccine Tracker Tracks the Development of Treatments and Vaccines for COVID-19", "size": null, "x": -51.63977813720703, "y": -20.850202560424805}}, {"key": "1513", "attributes": {"color": "#9163E2", "label": "Inactivated Virus Vaccines from Chemistry to Prophylaxis: Merits, Risks and Challenges", "size": null, "x": -50.62139892578125, "y": -21.72279930114746}}, {"key": "1514", "attributes": {"color": "#9163E2", "label": "Recent Advances in Subunit Vaccine Carriers. Vaccines (Basel, Switz", "size": null, "x": -51.30198669433594, "y": -21.88438606262207}}, {"key": "1515", "attributes": {"color": "#9163E2", "label": "Nucleic Acid Vaccines", "size": null, "x": -52.54623794555664, "y": -21.316776275634766}}, {"key": "1516", "attributes": {"color": "#9163E2", "label": "Viral Vectors for Vaccine Applications", "size": null, "x": -54.870697021484375, "y": -21.59806251525879}}, {"key": "1517", "attributes": {"color": "#9163E2", "label": "Viruses as Vaccine Vectors for Infectious Diseases and Cancer", "size": null, "x": -50.231239318847656, "y": -20.637916564941406}}, {"key": "1518", "attributes": {"color": "#9163E2", "label": "Developments in Viral Vector-Based Vaccines. Vaccines (Basel, Switz", "size": null, "x": -53.40801239013672, "y": -18.611072540283203}}, {"key": "1519", "attributes": {"color": "#9163E2", "label": "Expression Kinetics of Nucleoside-Modified MRNA Delivered in Lipid Nanoparticles to Mice by Various Routes", "size": null, "x": -55.580596923828125, "y": -20.61625099182129}}, {"key": "1520", "attributes": {"color": "#9163E2", "label": "RNA Mediated Toll-Like Receptor Stimulation in Health and Disease", "size": null, "x": -53.05284881591797, "y": -19.79974365234375}}, {"key": "1521", "attributes": {"color": "#9163E2", "label": "Species-Specific Recognition of Single-Stranded RNA via Toll-Like Receptor 7 and 8", "size": null, "x": -53.48704147338867, "y": -20.14288902282715}}, {"key": "1522", "attributes": {"color": "#9163E2", "label": "Advances in MRNA Vaccines for Infectious Diseases. Front. Immunol. 2019, 10, 594. (75) Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection -Full Text View", "size": null, "x": -50.73810958862305, "y": -18.76239013671875}}, {"key": "1523", "attributes": {"color": "#9163E2", "label": "Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates against COVID-19 in Healthy Adults -Full Text View", "size": null, "x": -54.61992645263672, "y": -21.192350387573242}}, {"key": "1524", "attributes": {"color": "#9163E2", "label": "Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines against COVID-2019 Using Different Dosing Regimens in Healthy Adults -Full Text View", "size": null, "x": -53.89927291870117, "y": -19.2491512298584}}, {"key": "1525", "attributes": {"color": "#9163E2", "label": "A Phase I/II Study to Determine Efficacy", "size": null, "x": -52.5622444152832, "y": -19.69971466064453}}, {"key": "1526", "attributes": {"color": "#9163E2", "label": "Vaccine ChAdOx1 NCoV-19 in UK Healthy Adult Volunteers -Full Text View", "size": null, "x": -52.23590850830078, "y": -20.230958938598633}}, {"key": "1527", "attributes": {"color": "#9163E2", "label": "Phase I Clinical Trial of a COVID-19 Vaccine", "size": null, "x": -52.83666229248047, "y": -21.250303268432617}}, {"key": "1528", "attributes": {"color": "#9163E2", "label": "Healthy Adults -Full Text View", "size": null, "x": -53.88529586791992, "y": -19.445648193359375}}, {"key": "1529", "attributes": {"color": "#9163E2", "label": "A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) -Full Text View", "size": null, "x": -50.73788070678711, "y": -22.239952087402344}}, {"key": "1530", "attributes": {"color": "#9163E2", "label": "Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers -Full Text View", "size": null, "x": -49.9447135925293, "y": -19.685380935668945}}, {"key": "1531", "attributes": {"color": "#9163E2", "label": "INOVIO-Announces-Positive-Interim-Phase-1-Data-For-INO-4800-Vaccine-for", "size": null, "x": -50.871604919433594, "y": -20.931013107299805}}, {"key": "1532", "attributes": {"color": "#9163E2", "label": "Double-Blinded, Placebo-Controlled, Phase I/ II Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged â¥ 60 Years -Full Text View", "size": null, "x": -53.58226013183594, "y": -20.276521682739258}}, {"key": "1533", "attributes": {"color": "#9163E2", "label": "Sinovac Reports Positive Data from Phase I/II trials of CoronaVac", "size": null, "x": -53.69677734375, "y": -21.634620666503906}}, {"key": "1534", "attributes": {"color": "#9163E2", "label": "Novel Coronavirus (2019-CoV) Inactivated Vaccine (Vero Cell) Phase I/II Clinical Trial", "size": null, "x": -51.98574447631836, "y": -21.01441764831543}}, {"key": "1535", "attributes": {"color": "#9163E2", "label": "First COVID-19 Inactivated Vaccine Performs Well in Clinical Trials", "size": null, "x": -52.35645294189453, "y": -18.573694229125977}}, {"key": "1536", "attributes": {"color": "#9163E2", "label": "Vaccine against COVID-19 -Full Text View", "size": null, "x": -53.989749908447266, "y": -21.68921661376953}}, {"key": "1537", "attributes": {"color": "#9163E2", "label": "China's Zhifei Starts Phase II Trial of COVID-19 Vaccine. Reuters", "size": null, "x": -52.03190612792969, "y": -18.349040985107422}}, {"key": "1538", "attributes": {"color": "#9163E2", "label": "Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine -Full Text View", "size": null, "x": -49.986122131347656, "y": -20.854080200195312}}, {"key": "1539", "attributes": {"color": "#9163E2", "label": "A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS", "size": null, "x": -51.28615951538086, "y": -19.836580276489258}}, {"key": "1540", "attributes": {"color": "#9163E2", "label": "Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2", "size": null, "x": -53.33827590942383, "y": -20.93062400817871}}, {"key": "1541", "attributes": {"color": "#9163E2", "label": "RS) with or without MATRIX-M TM Adjuvant in Healthy Subjects -Full Text View. ClinicalTrials.gov", "size": null, "x": -53.155662536621094, "y": -22.838279724121094}}, {"key": "1542", "attributes": {"color": "#9163E2", "label": "Vaxine Expects to Start Phase II Trials for Potential COVID-19 Vaccine in Weeks. Reuters", "size": null, "x": -52.313804626464844, "y": -20.56403350830078}}, {"key": "1543", "attributes": {"color": "#9163E2", "label": "Zydus Cadila's COVID-19 Vaccine Passes Phase I Safety Trials", "size": null, "x": -51.60691833496094, "y": -21.05580711364746}}, {"key": "1544", "attributes": {"color": "#9163E2", "label": "Phase II to Test Efficiency Begins 6 August -Health News", "size": null, "x": -51.359249114990234, "y": -19.340185165405273}}, {"key": "1545", "attributes": {"color": "#9163E2", "label": "COVID-19 Vaccine: A Comprehensive Status Report. Virus Res. 2020, 288, 198114. (98) COVID-19 Vaccine Reaches Phase-2 Trials in China", "size": null, "x": -52.85865783691406, "y": -22.70205307006836}}, {"key": "1546", "attributes": {"color": "#9163E2", "label": "Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing against COVID-19 in People Aged â©¾60 Years -Full Text View", "size": null, "x": -51.15899658203125, "y": -20.363910675048828}}, {"key": "1547", "attributes": {"color": "#9163E2", "label": "Modified MRNA Vaccines Protect against Zika Virus Infection", "size": null, "x": -54.82899856567383, "y": -20.329914093017578}}, {"key": "1548", "attributes": {"color": "#9163E2", "label": "Designing Liposomal Adjuvants for the Next Generation of Vaccines", "size": null, "x": -54.5662841796875, "y": -18.8262939453125}}, {"key": "1549", "attributes": {"color": "#9163E2", "label": "Incorporation of Pseudouridine into MRNA Yields Superior Nonimmunogenic Vector with Increased Translational Capacity and Biological Stability", "size": null, "x": -51.87631607055664, "y": -20.54197120666504}}, {"key": "1550", "attributes": {"color": "#9163E2", "label": "Selective Chemical Modifications of Uridine and Pseudouridine in Polynucleotides and Their Effect on the Specificities of Ribonuclease and Phosphodiesterases", "size": null, "x": -52.957523345947266, "y": -19.36982536315918}}, {"key": "1551", "attributes": {"color": "#9163E2", "label": "Stabilization of RNA Stacking by Pseudouridine", "size": null, "x": -54.95244598388672, "y": -18.97635841369629}}, {"key": "1552", "attributes": {"color": "#9163E2", "label": "A Recombinant Receptor-Binding Domain of MERS-CoV in Trimeric Form Protects Human Dipeptidyl Peptidase 4 (HDPP4) Transgenic Mice from MERS-CoV Infection", "size": null, "x": -51.72345733642578, "y": -21.331655502319336}}, {"key": "1553", "attributes": {"color": "#9163E2", "label": "A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 -Full Text View", "size": null, "x": -51.80397033691406, "y": -22.625764846801758}}, {"key": "1554", "attributes": {"color": "#9163E2", "label": "Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates against COVID-19 in Healthy Adults -Full Text View", "size": null, "x": -52.650943756103516, "y": -20.664947509765625}}, {"key": "1555", "attributes": {"color": "#9163E2", "label": "INO-4800 DNA Coronavirus Vaccine", "size": null, "x": -53.5856819152832, "y": -22.473180770874023}}, {"key": "1556", "attributes": {"color": "#9163E2", "label": "with Record-Setting Speed, Vaccinemakers Take Their First Shots at the New Coronavirus", "size": null, "x": -50.249629974365234, "y": -22.3874454498291}}, {"key": "1557", "attributes": {"color": "#9163E2", "label": "Skepticism Greets Putin's Announcement Of Russian Coronavirus Vaccine", "size": null, "x": -53.033329010009766, "y": -22.40101432800293}}, {"key": "1558", "attributes": {"color": "#9163E2", "label": "A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity", "size": null, "x": -52.43698501586914, "y": -19.240942001342773}}, {"key": "1559", "attributes": {"color": "#9163E2", "label": "Molecular Mechanisms for Enhanced DNA Vaccine Immunogenicity", "size": null, "x": -52.75114822387695, "y": -19.480730056762695}}, {"key": "1560", "attributes": {"color": "#9163E2", "label": "Factors Which Contribute to the Immunogenicity of Non-Replicating Adenoviral Vectored Vaccines", "size": null, "x": -50.903717041015625, "y": -20.758806228637695}}, {"key": "1561", "attributes": {"color": "#9163E2", "label": "CanSino to Conduct Phase III Covid-19 Vaccine Trial in Saudi Arabia", "size": null, "x": -54.715301513671875, "y": -18.364885330200195}}, {"key": "1562", "attributes": {"color": "#9163E2", "label": "A Phase III Study to Investigate a Vaccine against COVID-19", "size": null, "x": -52.59354019165039, "y": -19.422679901123047}}, {"key": "1563", "attributes": {"color": "#9163E2", "label": "Vaccine: Light at the End of the Tunnel", "size": null, "x": -53.205657958984375, "y": -18.135591506958008}}, {"key": "1564", "attributes": {"color": "#9163E2", "label": "Japan's AnGes Speeds Toward 2021 Rollout in Coronavirus", "size": null, "x": -50.450958251953125, "y": -21.076631546020508}}, {"key": "1565", "attributes": {"color": "#9163E2", "label": "RNA-Based Vaccination: Sending a Strong Message", "size": null, "x": -52.18767547607422, "y": -21.580556869506836}}, {"key": "1566", "attributes": {"color": "#9163E2", "label": "Site-Specific Glycan Analysis of the SARS-CoV-2 Spike", "size": null, "x": -53.71786117553711, "y": -23.09795570373535}}, {"key": "1567", "attributes": {"color": "#9163E2", "label": "DNA Vaccines: Technology and Application as Anti-Parasite and Anti-Microbial Agents", "size": null, "x": -52.54029083251953, "y": -18.168838500976562}}, {"key": "1568", "attributes": {"color": "#9163E2", "label": "Nonviral Delivery of Self-Amplifying RNA Vaccines", "size": null, "x": -51.04046630859375, "y": -18.92762565612793}}, {"key": "1569", "attributes": {"color": "#9163E2", "label": "Lab to Sidestep Drug Industry to Sell Potential Virus Vaccine", "size": null, "x": -50.484336853027344, "y": -21.363826751708984}}, {"key": "1570", "attributes": {"color": "#9163E2", "label": "Protective Efficacy of in Vitro Synthesized, Specific MRNA Vaccines against Influenza A Virus Infection", "size": null, "x": -51.896995544433594, "y": -22.200815200805664}}, {"key": "1571", "attributes": {"color": "#9163E2", "label": "Messenger RNA-Based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity", "size": null, "x": -54.05099105834961, "y": -18.62857437133789}}, {"key": "1572", "attributes": {"color": "#9163E2", "label": "Development of Nonhuman Adenoviruses as Vaccine Vectors", "size": null, "x": -53.15004348754883, "y": -18.951112747192383}}, {"key": "1573", "attributes": {"color": "#9163E2", "label": "Analysis of 15 Adenovirus Hexon Proteins Reveals the Location and Structure of Seven Hypervariable Regions Containing Serotype-Specific Residues", "size": null, "x": -54.552040100097656, "y": -20.363765716552734}}, {"key": "1574", "attributes": {"color": "#9163E2", "label": "Recombinant Bovine Adenovirus Type 3 Expressing Bovine Viral Diarrhea Virus Glycoprotein E2 Induces an Immune Response in Cotton Rats", "size": null, "x": -53.56810760498047, "y": -19.358821868896484}}, {"key": "1575", "attributes": {"color": "#9163E2", "label": "Vaccination of Puppies Born to Immune Dams with a Canine Adenovirus-Based Vaccine Protects against a Canine Distemper Virus Challenge", "size": null, "x": -51.13611602783203, "y": -19.889068603515625}}, {"key": "1576", "attributes": {"color": "#9163E2", "label": "Recombinant Ovine Atadenovirus Induces a Strong and Sustained T Cell Response against the Hepatitis C Virus NS3 Antigen in Mice", "size": null, "x": -51.41862106323242, "y": -20.50787353515625}}, {"key": "1577", "attributes": {"color": "#9163E2", "label": "Porcine Adenoviral Vectors Evade Preexisting Humoral Immunity to Adenoviruses and Efficiently Infect Both Human and Murine Cells in Culture", "size": null, "x": -50.71397018432617, "y": -21.416980743408203}}, {"key": "1578", "attributes": {"color": "#9163E2", "label": "Novel Human Gene Transfer Vectors: Evaluation of Wild-Type and Recombinant Animal Adenoviruses in Human-Derived Cells", "size": null, "x": -50.59138488769531, "y": -19.38880157470703}}, {"key": "1579", "attributes": {"color": "#9163E2", "label": "Comparative Transduction Efficiencies of Human and Nonhuman Adenoviral Vectors in Human, Murine, Bovine, and Porcine Cells in Culture", "size": null, "x": -52.13548278808594, "y": -20.429763793945312}}, {"key": "1580", "attributes": {"color": "#9163E2", "label": "Biology of Ovine Adenovirus Infection of Nonpermissive Cells", "size": null, "x": -53.075843811035156, "y": -20.30646324157715}}, {"key": "1581", "attributes": {"color": "#9163E2", "label": "Sinovac Says Its Covid-19 Vaccine Generated Immune Responses", "size": null, "x": -52.03447723388672, "y": -18.935115814208984}}, {"key": "1582", "attributes": {"color": "#9163E2", "label": "China's Sinopharm Touts 100% Antibody Response for COVID-19 Vaccine It's Already Giving to Workers", "size": null, "x": -50.59170913696289, "y": -22.702556610107422}}, {"key": "1583", "attributes": {"color": "#9163E2", "label": "Chinese Researchers Launch Phase-2 Human Test for Possible Coronavirus Vaccine", "size": null, "x": -49.88871383666992, "y": -21.46775245666504}}, {"key": "1584", "attributes": {"color": "#9163E2", "label": "Zydus to Start Second Phase of Covid-19 Vaccine Candidate Trials Today", "size": null, "x": -54.92753982543945, "y": -21.04947853088379}}, {"key": "1585", "attributes": {"color": "#9163E2", "label": "Phase 1â2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine", "size": null, "x": -52.218929290771484, "y": -22.805931091308594}}, {"key": "1586", "attributes": {"color": "#9163E2", "label": "Registered\" COVID-19 Vaccine from Russia's Gamaleya Institute; His Daughter among Those Inoculated -Health News", "size": null, "x": -53.20062255859375, "y": -21.55718421936035}}, {"key": "1587", "attributes": {"color": "#9163E2", "label": "But Questions Over Its Safety Remain", "size": null, "x": -54.18548583984375, "y": -19.837411880493164}}, {"key": "1588", "attributes": {"color": "#9163E2", "label": "a Delta Inulin Microparticle, Potentiates In-Built Adjuvant Property of Co-Administered Vaccines", "size": null, "x": -54.6275749206543, "y": -21.31806755065918}}, {"key": "1589", "attributes": {"color": "#9163E2", "label": "The Virosomal Adjuvanted Influenza Vaccine", "size": null, "x": -54.41628646850586, "y": -18.146825790405273}}, {"key": "1590", "attributes": {"color": "#9163E2", "label": "Development and Evaluation of AS03, an Adjuvant System Containing Î±-Tocopherol and Squalene in an Oil-in-Water Emulsion", "size": null, "x": -52.9647102355957, "y": -18.62189292907715}}, {"key": "1591", "attributes": {"color": "#9163E2", "label": "Placebo-Controlled, First-in-Human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers -Full Text View", "size": null, "x": -51.24714279174805, "y": -22.80910873413086}}, {"key": "1592", "attributes": {"color": "#9163E2", "label": "Partially-Blinded, Dose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID 19 Vaccine in Adults 18â55 Years of Age -Full Text View", "size": null, "x": -54.03221130371094, "y": -22.243587493896484}}, {"key": "1593", "attributes": {"color": "#9163E2", "label": "Sanofi: Press Releases, Tuesday", "size": null, "x": -55.19024658203125, "y": -20.474170684814453}}, {"key": "1594", "attributes": {"color": "#9163E2", "label": "GSK Allies with Innovax for COVID-19 Vaccine R&D Project", "size": null, "x": -53.50114059448242, "y": -21.933818817138672}}, {"key": "1595", "attributes": {"color": "#9163E2", "label": "GSK Makes Adjuvant Available to Coronavirus Vaccine Project", "size": null, "x": -52.21141052246094, "y": -21.098886489868164}}, {"key": "1596", "attributes": {"color": "#9163E2", "label": "Development of the CpG Adjuvant 1018: A Case Study", "size": null, "x": -49.324134826660156, "y": -21.219453811645508}}, {"key": "1597", "attributes": {"color": "#9163E2", "label": "A Phase I, Prospective, Open-Labeled Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 -Full Text View", "size": null, "x": -52.54602813720703, "y": -21.990970611572266}}, {"key": "1598", "attributes": {"color": "#9163E2", "label": "Announce Collaboration to Develop a Coronavirus (COVID-19) Vaccine. Dynavax Technologies Corp", "size": null, "x": -51.13478469848633, "y": -19.527088165283203}}, {"key": "1599", "attributes": {"color": "#9163E2", "label": "Announce Collaboration to Advance Vaccine Development for COVID-19", "size": null, "x": -50.640560150146484, "y": -20.185590744018555}}, {"key": "1600", "attributes": {"color": "#7CB165", "label": "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Hematologic Patients: Experience at the Hospital Attending More Patients in Spain", "size": null, "x": 124.08747863769531, "y": -237.14373779296875}}, {"key": "1601", "attributes": {"color": "#7CB165", "label": "IL-6 values were associated with higher mortality. Furthermore, it was observed that active hematologic disease is a factor of poor prognosis of COVID-19. Disclosures Salamero: Daichii Sankyo:Honoraria;Celgene:Consultancy, Honoraria;Novartis:Consultancy, Honoraria;Jazz Pharmaceuticals:Consultancy, Honoraria", "size": null, "x": 124.13450622558594, "y": -236.61447143554688}}, {"key": "1602", "attributes": {"color": "#C6AED4", "label": "Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective", "size": null, "x": 155.2296600341797, "y": 82.94355773925781}}, {"key": "1603", "attributes": {"color": "#C6AED4", "label": "Guideline on good pharmacovigilance practices (GVP): Annex I -Definitions (Rev 4)", "size": null, "x": 154.6800537109375, "y": 82.14920806884766}}, {"key": "1604", "attributes": {"color": "#C6AED4", "label": "COVID-19): people with certain medical conditions", "size": null, "x": 155.10028076171875, "y": 83.4155502319336}}, {"key": "1605", "attributes": {"color": "#C6AED4", "label": "JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis", "size": null, "x": 155.0862274169922, "y": 81.92768859863281}}, {"key": "1606", "attributes": {"color": "#C6AED4", "label": "COVID-19 in a high-risk dual heart and kidney transplant recipient", "size": null, "x": 154.80125427246094, "y": 82.62551879882812}}, {"key": "1607", "attributes": {"color": "#C6AED4", "label": "Case report of a SARS-CoV-2 infection in a patient with ulcerative colitis on tofacitinib", "size": null, "x": 156.41958618164062, "y": 82.85343933105469}}, {"key": "1608", "attributes": {"color": "#C6AED4", "label": "COVID-19 in rheumatic disease patients on immunosuppressive agents", "size": null, "x": 156.0846710205078, "y": 82.92442321777344}}, {"key": "1609", "attributes": {"color": "#C6AED4", "label": "Novel coronavirus (SARS-CoV-2) infection in a renal transplant recipient: case report", "size": null, "x": 155.34495544433594, "y": 83.99882507324219}}, {"key": "1610", "attributes": {"color": "#C6AED4", "label": "Covid-19 in immune-mediated inflammatory diseases: case series from New York", "size": null, "x": 154.87628173828125, "y": 82.92993927001953}}, {"key": "1611", "attributes": {"color": "#C6AED4", "label": "Dexamethasone in hospitalized patients with Covid-19: preliminary report", "size": null, "x": 155.79119873046875, "y": 81.94108581542969}}, {"key": "1612", "attributes": {"color": "#C6AED4", "label": "Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the Cremona experience", "size": null, "x": 155.5292510986328, "y": 82.56803894042969}}, {"key": "1613", "attributes": {"color": "#C6AED4", "label": "Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis", "size": null, "x": 156.41387939453125, "y": 81.97392272949219}}, {"key": "1614", "attributes": {"color": "#C6AED4", "label": "Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial", "size": null, "x": 156.35009765625, "y": 83.5481948852539}}, {"key": "1615", "attributes": {"color": "#C6AED4", "label": "Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomised trial", "size": null, "x": 155.4886016845703, "y": 81.60910034179688}}, {"key": "1616", "attributes": {"color": "#C6AED4", "label": "Cardiovascular complications in patients with COVID-19: consequences of viral toxicities and host immune response", "size": null, "x": 155.6590576171875, "y": 83.36558532714844}}, {"key": "1617", "attributes": {"color": "#C6AED4", "label": "Potential effects of coronaviruses on the cardiovascular system: a review", "size": null, "x": 155.73831176757812, "y": 82.86500549316406}}, {"key": "1618", "attributes": {"color": "#C6AED4", "label": "Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis", "size": null, "x": 154.4915313720703, "y": 83.45814514160156}}, {"key": "1619", "attributes": {"color": "#FD578D", "label": "A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts", "size": null, "x": -149.16989135742188, "y": -192.927978515625}}, {"key": "1620", "attributes": {"color": "#FD578D", "label": "Nadeem: Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -149.30245971679688, "y": -193.66746520996094}}, {"key": "1621", "attributes": {"color": "#FD578D", "label": "Membership on an entity's Board of Directors or advisory committees; Adaptive: Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -149.83189392089844, "y": -192.36508178710938}}, {"key": "1622", "attributes": {"color": "#FD578D", "label": "Celgene: Membership on an entity's Board of Directors or advisory committees. Barth: Sanofi: Membership on an entity's Board of Directors or advisory committees. Sanchorawala: Takeda: Research Funding; Celgene: Research Funding; Prothena: Research Funding; Caelum: Research Funding; Oncopeptide: Research Funding; Regeneron: Other: advisory board; Caleum: Other: advisory board; Proclara: Other: advisory board; Abbvie: Other: advisory board", "size": null, "x": -149.29359436035156, "y": -192.42698669433594}}, {"key": "1623", "attributes": {"color": "#FD578D", "label": "OncoPep: Consultancy, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties; C4: Current equity holder in private company", "size": null, "x": -148.68406677246094, "y": -193.291748046875}}, {"key": "1624", "attributes": {"color": "#FD578D", "label": "Adaptive: Consultancy; Legend: Consultancy; Amgen: Consultancy; AbbVie: Consultancy; Karyopharm: Consultancy; Takeda: Consultancy. Ghobrial: Celgene: Consultancy, Honoraria; GlaxoSmithKline: Consultancy; Genentech: Consultancy; Novartis: Consultancy; Noxxon Pharma: Consultancy; Adaptive Biotechnologies: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria", "size": null, "x": -148.2247772216797, "y": -193.73863220214844}}, {"key": "1625", "attributes": {"color": "#FD578D", "label": "Karyopharm Therapeutics: Consultancy, Honoraria; GNS Healthcare: Consultancy; Janssen: Consultancy, Honoraria; Amgen: Consultancy, Honoraria", "size": null, "x": -148.75320434570312, "y": -192.15081787109375}}, {"key": "1626", "attributes": {"color": "#FD578D", "label": "Other: Scientific Founder of Oncopep and C4 Therapeutics.; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Sanofi-Aventis: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -149.70281982421875, "y": -192.92288208007812}}, {"key": "1627", "attributes": {"color": "#FD578D", "label": "Celgene: Membership on an entity's Board of Directors or advisory committees", "size": null, "x": -148.68386840820312, "y": -192.716064453125}}, {"key": "1628", "attributes": {"color": "#0E95E4", "label": "Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey", "size": null, "x": -217.78805541992188, "y": -0.7111856937408447}}, {"key": "1629", "attributes": {"color": "#0E95E4", "label": "Sanchorawala: Oncopeptide: Research Funding; Abbvie: Other: advisory board; Proclara: Other: advisory board; Caleum: Other: advisory board; Regeneron: Other: advisory board; Prothena: Research Funding; Takeda: Research Funding; Janssen: Research Funding; UpToDate: Patents & Royalties; Caelum: Research Funding; Celgene: Research Funding. Cibeira: Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Educational lectures; Akcea Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Other: Educational lectures", "size": null, "x": -218.2633056640625, "y": -0.29363399744033813}}, {"key": "1630", "attributes": {"color": "#0E95E4", "label": "Other: travel support to meetings", "size": null, "x": -217.68508911132812, "y": -1.2956126928329468}}, {"key": "1631", "attributes": {"color": "#A36913", "label": "Journal Pre-proof Trombosis y COVID-19: revisiÃ³n de alcance Title: Thrombosis and COVID-19: a scoping review", "size": null, "x": -35.04157638549805, "y": 159.27589416503906}}, {"key": "1632", "attributes": {"color": "#A36913", "label": "Novel Coronavirus ( 2019-nCoV ) Situation Report -1 21", "size": null, "x": -36.81012725830078, "y": 160.85324096679688}}, {"key": "1633", "attributes": {"color": "#A36913", "label": "Effect of dexamethasone in hospitalized patients with COVID-19 -preliminary report", "size": null, "x": -33.59963607788086, "y": 160.022705078125}}, {"key": "1634", "attributes": {"color": "#A36913", "label": "A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)", "size": null, "x": -36.65427780151367, "y": 160.20327758789062}}, {"key": "1635", "attributes": {"color": "#A36913", "label": "ISTH interim guidance on recognition and management of coagulopathy in COVID-19", "size": null, "x": -34.49542999267578, "y": 160.2874298095703}}, {"key": "1636", "attributes": {"color": "#A36913", "label": "Coagulation, fibrinolysis, and fibrin deposition in acute lung injury", "size": null, "x": -35.60174560546875, "y": 158.9825897216797}}, {"key": "1637", "attributes": {"color": "#A36913", "label": "Autopsy Findings and Venous Thromboembolism in Patients With COVID-19", "size": null, "x": -35.74184799194336, "y": 160.95835876464844}}, {"key": "1638", "attributes": {"color": "#A36913", "label": "Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past", "size": null, "x": -34.385009765625, "y": 160.57464599609375}}, {"key": "1639", "attributes": {"color": "#A36913", "label": "Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19", "size": null, "x": -35.65805435180664, "y": 161.37071228027344}}, {"key": "1640", "attributes": {"color": "#A36913", "label": "Incidence of thrombotic complications in critically ill ICU patients with COVID-19", "size": null, "x": -36.23674011230469, "y": 161.44921875}}, {"key": "1641", "attributes": {"color": "#A36913", "label": "High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study", "size": null, "x": -35.96051788330078, "y": 159.97821044921875}}, {"key": "1642", "attributes": {"color": "#A36913", "label": "Scoping studies: towards a methodological framework", "size": null, "x": -34.612083435058594, "y": 161.2935333251953}}, {"key": "1643", "attributes": {"color": "#A36913", "label": "Clinical Characteristics of Coronavirus Disease 2019 in China", "size": null, "x": -34.55949020385742, "y": 159.30450439453125}}, {"key": "1644", "attributes": {"color": "#A36913", "label": "Clinical features of patients with 2019 novel coronavirus in Wuhan", "size": null, "x": -34.63404846191406, "y": 160.4411163330078}}, {"key": "1645", "attributes": {"color": "#A36913", "label": "Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia", "size": null, "x": -35.259891510009766, "y": 159.66799926757812}}, {"key": "1646", "attributes": {"color": "#A36913", "label": "Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia", "size": null, "x": -35.48357009887695, "y": 160.2481689453125}}, {"key": "1647", "attributes": {"color": "#A36913", "label": "Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan", "size": null, "x": -35.458431243896484, "y": 161.8031005859375}}, {"key": "1648", "attributes": {"color": "#A36913", "label": "Prominent changes in blood coagulation of patients with SARS-CoV-2 infection", "size": null, "x": -36.51268005371094, "y": 159.49139404296875}}, {"key": "1649", "attributes": {"color": "#A36913", "label": "COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure", "size": null, "x": -34.13338088989258, "y": 159.77806091308594}}, {"key": "1650", "attributes": {"color": "#A36913", "label": "Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy", "size": null, "x": -35.86980056762695, "y": 160.8154754638672}}, {"key": "1651", "attributes": {"color": "#A36913", "label": "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study", "size": null, "x": -35.400943756103516, "y": 160.6292724609375}}, {"key": "1652", "attributes": {"color": "#A36913", "label": "Attention should be paid to", "size": null, "x": -34.1823616027832, "y": 161.0363006591797}}, {"key": "1653", "attributes": {"color": "#A36913", "label": "Figura 1. Diagrama de flujo de los estudios/artÃ­culos incluidos en la scope review", "size": null, "x": -35.13313293457031, "y": 158.6414337158203}}, {"key": "1654", "attributes": {"color": "#292F8F", "label": "E cacy and safety of COVID-19 vaccines in older people", "size": null, "x": 120.32090759277344, "y": -44.97900390625}}, {"key": "1655", "attributes": {"color": "#292F8F", "label": "Excess mortality in England and Wales during the first wave of the COVID-19 pandemic", "size": null, "x": 123.24455261230469, "y": -45.49870300292969}}, {"key": "1656", "attributes": {"color": "#292F8F", "label": "Government's vaccine taskforce: strategy for protecting the UK and the world", "size": null, "x": 121.36528778076172, "y": -44.861106872558594}}, {"key": "1657", "attributes": {"color": "#292F8F", "label": "Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults", "size": null, "x": 123.44538116455078, "y": -45.783721923828125}}, {"key": "1658", "attributes": {"color": "#292F8F", "label": "Viruses -from pathogens to vaccine carriers", "size": null, "x": 123.8313980102539, "y": -45.32844924926758}}, {"key": "1659", "attributes": {"color": "#292F8F", "label": "Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial", "size": null, "x": 122.02587127685547, "y": -44.843685150146484}}, {"key": "1660", "attributes": {"color": "#292F8F", "label": "Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial", "size": null, "x": 121.69483947753906, "y": -44.34267044067383}}, {"key": "1661", "attributes": {"color": "#292F8F", "label": "Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine", "size": null, "x": 123.90709686279297, "y": -44.62053298950195}}, {"key": "1662", "attributes": {"color": "#292F8F", "label": "COVID-19 vaccine development landscape", "size": null, "x": 121.79915618896484, "y": -46.15849685668945}}, {"key": "1663", "attributes": {"color": "#292F8F", "label": "e generation of memory B cells is maintained, but the antibody response is not, in the elderly after repeated influenza immunizations", "size": null, "x": 122.2199478149414, "y": -46.35080337524414}}, {"key": "1664", "attributes": {"color": "#292F8F", "label": "SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates", "size": null, "x": 121.16593933105469, "y": -44.652801513671875}}, {"key": "1665", "attributes": {"color": "#292F8F", "label": "As if expendable: e UK Government's failure to protect older people in care homes during the COVID-19 pandemic", "size": null, "x": 122.82054138183594, "y": -46.81004333496094}}, {"key": "1666", "attributes": {"color": "#292F8F", "label": "Underrepresentation of the elderly in clinical trials, time for action", "size": null, "x": 122.65706634521484, "y": -44.63213348388672}}, {"key": "1667", "attributes": {"color": "#292F8F", "label": "Will covid-19 vaccines save lives? Current trials aren't designed to tell us", "size": null, "x": 121.4217758178711, "y": -45.63931655883789}}, {"key": "1668", "attributes": {"color": "#2406AE", "label": "COVID-19 optimal vaccination policies: a modeling study on efficacy, natural and vaccine-induced immunity responses", "size": null, "x": 27.689075469970703, "y": -106.24999237060547}}, {"key": "1669", "attributes": {"color": "#2406AE", "label": "World of Health Organization, Novel Coronavirus (2019-nCoV)-SITUATION REPORT -1", "size": null, "x": 27.79861068725586, "y": -106.91197967529297}}, {"key": "1670", "attributes": {"color": "#2406AE", "label": "Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-ncov) outbreak", "size": null, "x": 26.60915756225586, "y": -104.76494598388672}}, {"key": "1671", "attributes": {"color": "#2406AE", "label": "The effect of control measures on COVID-19 transmission in Italy: Comparison with Guangdong province in China", "size": null, "x": 26.36465835571289, "y": -107.246337890625}}, {"key": "1672", "attributes": {"color": "#2406AE", "label": "A review on Promising vaccine development progress for COVID-19 disease", "size": null, "x": 27.377643585205078, "y": -105.1600570678711}}, {"key": "1673", "attributes": {"color": "#2406AE", "label": "COVID-19 Vaccine: A comprehensive status report", "size": null, "x": 27.80155372619629, "y": -107.80488586425781}}, {"key": "1674", "attributes": {"color": "#2406AE", "label": "Unwavering Regulatory Safeguards for COVID-19 Vaccines", "size": null, "x": 28.320859909057617, "y": -104.97105407714844}}, {"key": "1675", "attributes": {"color": "#2406AE", "label": "A vaccination model for transmission dynamics of influenza", "size": null, "x": 27.512279510498047, "y": -106.47538757324219}}, {"key": "1676", "attributes": {"color": "#2406AE", "label": "Modelling the evolution trajectory of COVID-19 in Wuhan, China: experience and suggestions", "size": null, "x": 26.924163818359375, "y": -107.25086975097656}}, {"key": "1677", "attributes": {"color": "#2406AE", "label": "Modeling and forecasting the COVID-19 pandemic in India", "size": null, "x": 27.98862648010254, "y": -106.19223022460938}}, {"key": "1678", "attributes": {"color": "#2406AE", "label": "Modeling behavioral change and COVID-19 containment in Mexico: A trade-off between lockdown and compliance", "size": null, "x": 26.396259307861328, "y": -105.72100830078125}}, {"key": "1679", "attributes": {"color": "#2406AE", "label": "Lifting mobility restrictions and the effect of superspreading events on the short-term dynamics of COVID-19", "size": null, "x": 27.674102783203125, "y": -108.04432678222656}}, {"key": "1680", "attributes": {"color": "#2406AE", "label": "Mathematical assessment of the impact of non-pharmaceutical interventions on curtailing the 2019 novel Coronavirus", "size": null, "x": 29.498016357421875, "y": -105.98028564453125}}, {"key": "1681", "attributes": {"color": "#2406AE", "label": "A mathematical model of COVID-19 using fractional derivative: outbreak in India with dynamics of transmission and control", "size": null, "x": 28.596853256225586, "y": -105.8353500366211}}, {"key": "1682", "attributes": {"color": "#2406AE", "label": "The COVID-19 pandemic: model-based evaluation of nonpharmaceutical interventions and prognoses", "size": null, "x": 27.726869583129883, "y": -105.13666534423828}}, {"key": "1683", "attributes": {"color": "#2406AE", "label": "Optimal control of vaccine distribution in a rabies metapopulation model", "size": null, "x": 28.910924911499023, "y": -105.20156860351562}}, {"key": "1684", "attributes": {"color": "#2406AE", "label": "Vaccination models and optimal control strategies to dengue", "size": null, "x": 26.395296096801758, "y": -105.5363998413086}}, {"key": "1685", "attributes": {"color": "#2406AE", "label": "Optimal control with multiple human papillomavirus vaccines", "size": null, "x": 27.34079933166504, "y": -106.02616119384766}}, {"key": "1686", "attributes": {"color": "#2406AE", "label": "Optimal control of vaccination dynamics during an influenza epidemic", "size": null, "x": 29.293128967285156, "y": -105.5750732421875}}, {"key": "1687", "attributes": {"color": "#2406AE", "label": "Controlling the Spread of COVID-19: Optimal Control Analysis", "size": null, "x": 27.579559326171875, "y": -104.65945434570312}}, {"key": "1688", "attributes": {"color": "#2406AE", "label": "Optimal Control of the COVID-19 Pandemic with non-pharmaceutical Interventions", "size": null, "x": 25.973745346069336, "y": -105.36653137207031}}, {"key": "1689", "attributes": {"color": "#2406AE", "label": "Modeling the impact of non-pharmaceutical interventions on the dynamics of novel coronavirus with optimal control analysis with a case study", "size": null, "x": 26.868928909301758, "y": -106.19342041015625}}, {"key": "1690", "attributes": {"color": "#2406AE", "label": "Determination of an optimal control strategy for vaccine administration in COVID-19 pandemic treatment", "size": null, "x": 27.37915802001953, "y": -105.88252258300781}}, {"key": "1691", "attributes": {"color": "#2406AE", "label": "World Health Organization", "size": null, "x": 27.92930793762207, "y": -107.07137298583984}}, {"key": "1692", "attributes": {"color": "#2406AE", "label": "World of Health Organization, WHO methods and data sources for global burden of disease estimates", "size": null, "x": 26.708009719848633, "y": -106.80850982666016}}, {"key": "1693", "attributes": {"color": "#2406AE", "label": "Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission", "size": null, "x": 26.346424102783203, "y": -105.16145324707031}}, {"key": "1694", "attributes": {"color": "#2406AE", "label": "The Burden of Disease due to COVID-19 in Korea Using Disability-Adjusted Life Years", "size": null, "x": 27.98229217529297, "y": -105.96969604492188}}, {"key": "1695", "attributes": {"color": "#2406AE", "label": "Functional analysis, calculus of variations and optimal control", "size": null, "x": 27.2381591796875, "y": -106.98915100097656}}, {"key": "1696", "attributes": {"color": "#2406AE", "label": "A survey of the maximum principles for optimal control problems with state constraints", "size": null, "x": 28.57935905456543, "y": -105.15531158447266}}, {"key": "1697", "attributes": {"color": "#2406AE", "label": "Optimal control applied to biological models", "size": null, "x": 28.470016479492188, "y": -106.82646179199219}}, {"key": "1698", "attributes": {"color": "#2406AE", "label": "Datos abiertos", "size": null, "x": 27.089584350585938, "y": -106.58004760742188}}, {"key": "1699", "attributes": {"color": "#2406AE", "label": "Jump: A modeling language for mathematical optimization", "size": null, "x": 28.81184959411621, "y": -106.380126953125}}, {"key": "1700", "attributes": {"color": "#2406AE", "label": "Computing in operations research using julia", "size": null, "x": 29.063745498657227, "y": -104.79653930664062}}, {"key": "1701", "attributes": {"color": "#2406AE", "label": "Mathworks, fmincon interior point algorithm", "size": null, "x": 28.680030822753906, "y": -106.75360107421875}}, {"key": "1702", "attributes": {"color": "#2406AE", "label": "Practical Methods for Optimal Control Using Nonlinear Programming, Third Edition", "size": null, "x": 26.99086570739746, "y": -105.61029815673828}}, {"key": "1703", "attributes": {"color": "#2406AE", "label": "Goddard problem in presence of a dynamic pressure limit", "size": null, "x": 27.359336853027344, "y": -107.31343841552734}}, {"key": "1704", "attributes": {"color": "#2406AE", "label": "Team Commands, Bocop: an open source toolbox for optimal control", "size": null, "x": 28.483999252319336, "y": -106.07846069335938}}, {"key": "1705", "attributes": {"color": "#2406AE", "label": "Bocop -A collection of examples", "size": null, "x": 28.424283981323242, "y": -107.20562744140625}}, {"key": "1706", "attributes": {"color": "#2406AE", "label": "Source code for the manuscript Optimal Vaccine Policies for COVID-19", "size": null, "x": 28.350915908813477, "y": -106.3656005859375}}, {"key": "1707", "attributes": {"color": "#2406AE", "label": "Collaborative data science", "size": null, "x": 26.197689056396484, "y": -106.35761260986328}}, {"key": "1708", "attributes": {"color": "#2406AE", "label": "Pfizer says early analysis shows its Covid-19 vaccine is more than 90% effective", "size": null, "x": 26.747411727905273, "y": -107.58031463623047}}, {"key": "1709", "attributes": {"color": "#2406AE", "label": "Russia says its sputnik v covid-19 vaccine is 92% effective", "size": null, "x": 26.486595153808594, "y": -106.14362335205078}}, {"key": "1710", "attributes": {"color": "#2406AE", "label": "Moderna's coronavirus vaccine is 94.5% effective, according to company data", "size": null, "x": 27.029434204101562, "y": -104.84935760498047}}, {"key": "1711", "attributes": {"color": "#2406AE", "label": "Coronavirus reinfections: three questions scientists are asking", "size": null, "x": 28.09795570373535, "y": -104.84619140625}}, {"key": "1712", "attributes": {"color": "#2406AE", "label": "Contemporary statistical inference for infectious disease models using stan", "size": null, "x": 28.41982650756836, "y": -105.52289581298828}}, {"key": "1713", "attributes": {"color": "#2406AE", "label": "An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China", "size": null, "x": 29.455036163330078, "y": -106.40486907958984}}, {"key": "1714", "attributes": {"color": "#2406AE", "label": "Parameter estimation Mathematical models for COVID-19 have shown that the parameters' values are not necessarily the same in each country. We use COVID-19 data from Mexico City plus Mexico state to follow the epidemic curve's initial growth in this work. Consequently, we estimate some parameter values of system in Equation", "size": null, "x": 27.721845626831055, "y": -105.5210189819336}}, {"key": "1715", "attributes": {"color": "#2406AE", "label": "i) before and ii) after mitigation measures were implemented. For both stages, we use model in Equation (1) with no vaccination dynamics (Î» V = 0 and V (0) = 0), and STAN R-package. This package is used for statistical inference by the Bayesian approach. For the code implementation of our system, we follow ideas of [46], and it is made freely available at [39]. For this section", "size": null, "x": 29.072193145751953, "y": -105.90336608886719}}, {"key": "1716", "attributes": {"color": "#68CF99", "label": "Biotechnology, nanotechnology and medicine", "size": null, "x": 138.1835174560547, "y": 142.15618896484375}}, {"key": "1717", "attributes": {"color": "#68CF99", "label": "Nano comes to life: How nanotechnology is transforming medicine and the future of biology", "size": null, "x": 137.55816650390625, "y": 141.6713104248047}}, {"key": "1718", "attributes": {"color": "#68CF99", "label": "2020) The history of nanoscience and nanotechnology: from chemical-physical applications to nanomedicine", "size": null, "x": 138.8568572998047, "y": 142.04147338867188}}, {"key": "1719", "attributes": {"color": "#68CF99", "label": "Biomaterials: been there, done that, and evolving into the future", "size": null, "x": 138.39930725097656, "y": 142.77603149414062}}, {"key": "1720", "attributes": {"color": "#68CF99", "label": "Review of emerging cocepts in nanotoxicology: opportunities and challenges for safer nanomaterial design", "size": null, "x": 137.72137451171875, "y": 142.14642333984375}}, {"key": "1721", "attributes": {"color": "#3005C7", "label": "Viral Pandemics of the Last Four Decades: Pathophysiology, Health Impacts and Perspectives", "size": null, "x": 83.8171157836914, "y": 87.16817474365234}}, {"key": "1722", "attributes": {"color": "#3005C7", "label": "Features, evaluation and treatment coronavirus (COVID-19). In Statpearls", "size": null, "x": 83.641845703125, "y": 88.19471740722656}}, {"key": "1723", "attributes": {"color": "#3005C7", "label": "Infectious disease threats in the twenty-first century: Strengthening the global response", "size": null, "x": 82.22364807128906, "y": 85.65015411376953}}, {"key": "1724", "attributes": {"color": "#3005C7", "label": "Tracking virus outbreaks in twenty-first century", "size": null, "x": 82.30160522460938, "y": 86.58600616455078}}, {"key": "1725", "attributes": {"color": "#3005C7", "label": "Emerging and re-emerging viruses in the era of globalization", "size": null, "x": 86.9957504272461, "y": 86.52680206298828}}, {"key": "1726", "attributes": {"color": "#3005C7", "label": "Sustainable development must account for pandemic risk", "size": null, "x": 86.11126708984375, "y": 88.51335906982422}}, {"key": "1727", "attributes": {"color": "#3005C7", "label": "Report on the Global HIV/AIDS Epidemic", "size": null, "x": 84.89542388916016, "y": 87.6744155883789}}, {"key": "1728", "attributes": {"color": "#3005C7", "label": "Global impacts of human immunodeficiency virus and AIDS", "size": null, "x": 84.75494384765625, "y": 86.92739868164062}}, {"key": "1729", "attributes": {"color": "#3005C7", "label": "Inadequate Plumbing Systems Likely Contributed to SARS Transmission", "size": null, "x": 80.7150650024414, "y": 86.50973510742188}}, {"key": "1730", "attributes": {"color": "#3005C7", "label": "Impacts of SARS on health care systems and strategies for combating future outbreaks of emerging infectious diseases", "size": null, "x": 82.0162124633789, "y": 87.03608703613281}}, {"key": "1731", "attributes": {"color": "#3005C7", "label": "Two tears after pandemic influenza A/2009/H1N1: What have we learned?", "size": null, "x": 82.91236877441406, "y": 87.64935302734375}}, {"key": "1732", "attributes": {"color": "#3005C7", "label": "Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Update. Disease Outbreak News", "size": null, "x": 81.76039123535156, "y": 88.35491180419922}}, {"key": "1733", "attributes": {"color": "#3005C7", "label": "The response to and impact of the ebola epidemic: Towards an agenda for interdisciplinary research", "size": null, "x": 85.10413360595703, "y": 88.73799896240234}}, {"key": "1734", "attributes": {"color": "#3005C7", "label": "The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak: An update on the status", "size": null, "x": 84.51484680175781, "y": 89.8896255493164}}, {"key": "1735", "attributes": {"color": "#3005C7", "label": "Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia", "size": null, "x": 86.32539367675781, "y": 87.8218994140625}}, {"key": "1736", "attributes": {"color": "#3005C7", "label": "WHO Coronavirus Disease (COVID-19) Dashboard", "size": null, "x": 83.36521911621094, "y": 90.00370788574219}}, {"key": "1737", "attributes": {"color": "#3005C7", "label": "Sex differences in immune responses", "size": null, "x": 84.33686828613281, "y": 87.91386413574219}}, {"key": "1738", "attributes": {"color": "#3005C7", "label": "The immunobiology of SARS", "size": null, "x": 85.987060546875, "y": 86.13294982910156}}, {"key": "1739", "attributes": {"color": "#3005C7", "label": "Do men have a higher case fatality rate of severe acute respiratory syndrome than women do?", "size": null, "x": 85.5263442993164, "y": 86.97114562988281}}, {"key": "1740", "attributes": {"color": "#3005C7", "label": "The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: A descriptive epidemiological analysis of data from the Saudi Ministry of Health", "size": null, "x": 81.41954040527344, "y": 87.03600311279297}}, {"key": "1741", "attributes": {"color": "#3005C7", "label": "Demographic variation of MERS-CoV infection among suspected and confirmed cases: An epidemiological analysis of laboratory-based data from Riyadh Regional Laboratory", "size": null, "x": 83.06053161621094, "y": 90.36833953857422}}, {"key": "1742", "attributes": {"color": "#3005C7", "label": "Women and health: Women's dual roles as both recipients and providers of healthcare", "size": null, "x": 82.86202239990234, "y": 90.24665832519531}}, {"key": "1743", "attributes": {"color": "#3005C7", "label": "COVID-19: Low skilled men have highest death rate of working age adults", "size": null, "x": 82.62052154541016, "y": 85.087158203125}}, {"key": "1744", "attributes": {"color": "#3005C7", "label": "Men: Good health and high mortality", "size": null, "x": 81.16768646240234, "y": 87.7228775024414}}, {"key": "1745", "attributes": {"color": "#3005C7", "label": "The impact of sex, gender and pregnancy on 2009 H1N1 disease", "size": null, "x": 83.24583435058594, "y": 86.88680267333984}}, {"key": "1746", "attributes": {"color": "#3005C7", "label": "Sex-and age-related differences in morbidity rates of 2009 ppandemic influenza A H1N1 virus of swine origin in Japan", "size": null, "x": 84.19345092773438, "y": 89.75396728515625}}, {"key": "1747", "attributes": {"color": "#3005C7", "label": "World Health Organization (WHO). Sex, Gender and Influenza", "size": null, "x": 84.30931091308594, "y": 85.92816925048828}}, {"key": "1748", "attributes": {"color": "#3005C7", "label": "Women's access to healthcare in developing countries", "size": null, "x": 85.6427230834961, "y": 85.02984619140625}}, {"key": "1749", "attributes": {"color": "#3005C7", "label": "Public knowledge, attitude and behavioural changes in an Indian population during the influenza A (H1N1) outbreak", "size": null, "x": 85.5210952758789, "y": 88.48014831542969}}, {"key": "1750", "attributes": {"color": "#3005C7", "label": "Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection", "size": null, "x": 82.81182861328125, "y": 90.34027862548828}}, {"key": "1751", "attributes": {"color": "#3005C7", "label": "Racial disparities in exposure, susceptibility, and access to healthcare in the US H1N1 influenza pandemic", "size": null, "x": 83.33776092529297, "y": 86.59901428222656}}, {"key": "1752", "attributes": {"color": "#3005C7", "label": "Agency for Haelthcare Research and Quality", "size": null, "x": 85.14767456054688, "y": 88.3707504272461}}, {"key": "1753", "attributes": {"color": "#3005C7", "label": "Exposure-specific and age-specific attack rates for ebola virus disease in ebola-affected households", "size": null, "x": 84.36192321777344, "y": 86.2928237915039}}, {"key": "1754", "attributes": {"color": "#3005C7", "label": "The perspective of gender on ebola virus using a risk management and population health framework: A scoping review", "size": null, "x": 85.35841369628906, "y": 88.04856872558594}}, {"key": "1755", "attributes": {"color": "#3005C7", "label": "Gender Inequality Index, UN Dev. Programme", "size": null, "x": 86.14995574951172, "y": 90.12257385253906}}, {"key": "1756", "attributes": {"color": "#3005C7", "label": "West Africa: Respect Rights in Ebola Response", "size": null, "x": 84.90713500976562, "y": 85.62342834472656}}, {"key": "1757", "attributes": {"color": "#3005C7", "label": "Addressing Sex and Gender in Epidemic-Prone Infectious Diseases", "size": null, "x": 85.21075439453125, "y": 85.57328033447266}}, {"key": "1758", "attributes": {"color": "#3005C7", "label": "Better Engagement of Women at the Grassroots Level Who Are Midwives, Who Are Death Attendants, Who Are Traditional Healers, Who Were Not Aware of All the Details. Just Respecting Their Leadership and Engagement Could Have Decreased the Number of People Who Died", "size": null, "x": 84.28982543945312, "y": 86.86837768554688}}, {"key": "1759", "attributes": {"color": "#3005C7", "label": "Immigrant health inequalities in the United States: Use of eight major national data systems", "size": null, "x": 84.50410461425781, "y": 87.453857421875}}, {"key": "1760", "attributes": {"color": "#3005C7", "label": "Ebola Virus Disease Epidemic: What Can the World Learn and Not Learn from West Africa?", "size": null, "x": 83.73542785644531, "y": 85.18099975585938}}, {"key": "1761", "attributes": {"color": "#3005C7", "label": "Marked ethnic, nativity, and socioeconomic disparities in disability and health insurance among US children and adults: The 2008-2010 American community survey", "size": null, "x": 82.1700210571289, "y": 87.20708465576172}}, {"key": "1762", "attributes": {"color": "#3005C7", "label": "Gender disparity in epidemiological trend of HIV/AIDS infection and treatment in Ethiopia", "size": null, "x": 85.94313049316406, "y": 90.4216079711914}}, {"key": "1763", "attributes": {"color": "#3005C7", "label": "Understanding the gender disparity in HIV infection across countries in sub-Saharan Africa: Evidence from the demographic and health surveys. Sociol. Health Illn", "size": null, "x": 85.08609008789062, "y": 85.21110534667969}}, {"key": "1764", "attributes": {"color": "#3005C7", "label": "Gender inequality and HIV transmission: A global analysis", "size": null, "x": 84.31936645507812, "y": 83.77481842041016}}, {"key": "1765", "attributes": {"color": "#3005C7", "label": "WHO (World Health Organization)", "size": null, "x": 82.95059967041016, "y": 88.53592681884766}}, {"key": "1766", "attributes": {"color": "#3005C7", "label": "The HIV epidemic among women in the United States: A persistent puzzle", "size": null, "x": 82.78641510009766, "y": 86.23592376708984}}, {"key": "1767", "attributes": {"color": "#3005C7", "label": "Socio-cultural factors in the access of women to HIV/AIDS prevention and treatment services in South-southern Nigeria", "size": null, "x": 82.09945678710938, "y": 87.94252014160156}}, {"key": "1768", "attributes": {"color": "#3005C7", "label": "Racial and ethnic disparities in access to physicians with HIV-related expertise", "size": null, "x": 85.77310943603516, "y": 86.03273010253906}}, {"key": "1769", "attributes": {"color": "#3005C7", "label": "Diagnoses of HIV Infection in the United States and Dependent Areas", "size": null, "x": 84.0878677368164, "y": 84.01126098632812}}, {"key": "1770", "attributes": {"color": "#3005C7", "label": "Association between age and clinical characteristics and outcomes of COVID-19", "size": null, "x": 85.49632263183594, "y": 86.30574798583984}}, {"key": "1771", "attributes": {"color": "#3005C7", "label": "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study", "size": null, "x": 83.98754119873047, "y": 87.81643676757812}}, {"key": "1772", "attributes": {"color": "#3005C7", "label": "Biological sex impacts COVID-19 outcomes", "size": null, "x": 86.01641082763672, "y": 86.46832275390625}}, {"key": "1773", "attributes": {"color": "#3005C7", "label": "Impact of sex and gender on COVID-19 outcomes in Europe", "size": null, "x": 85.36090850830078, "y": 87.52069091796875}}, {"key": "1774", "attributes": {"color": "#3005C7", "label": "Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study", "size": null, "x": 82.40412139892578, "y": 86.74451446533203}}, {"key": "1775", "attributes": {"color": "#3005C7", "label": "Disparities in age-specific morbidity and mortality from SARS-CoV-2 in China and the Republic of Korea", "size": null, "x": 84.99639129638672, "y": 89.33710479736328}}, {"key": "1776", "attributes": {"color": "#3005C7", "label": "Radiographic severity index in COVID-19 pneumonia: Relationship to age and sex in 783 Italian patients", "size": null, "x": 81.72196960449219, "y": 86.82693481445312}}, {"key": "1777", "attributes": {"color": "#3005C7", "label": "COVID-19 and Individual Genetic susceptibility/receptivity: Role of ACE1/ACE2 genes, immunity, inflammation and coagulation. might the double X-chromosome in females be protective against SARS-CoV-2 compared to the single X-chromosome in males?", "size": null, "x": 85.91053771972656, "y": 88.50577545166016}}, {"key": "1778", "attributes": {"color": "#3005C7", "label": "Gender differences in patients with COVID-19: Focus on severity and mortality. Front", "size": null, "x": 83.66777038574219, "y": 87.53294372558594}}, {"key": "1779", "attributes": {"color": "#3005C7", "label": "Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: A retrospective study of 168 severe patients", "size": null, "x": 85.93550109863281, "y": 85.23220825195312}}, {"key": "1780", "attributes": {"color": "#3005C7", "label": "Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019", "size": null, "x": 81.78199768066406, "y": 88.9610366821289}}, {"key": "1781", "attributes": {"color": "#3005C7", "label": "How viruses invade cells", "size": null, "x": 84.1954116821289, "y": 86.57962799072266}}, {"key": "1782", "attributes": {"color": "#3005C7", "label": "The energetic of membrane fusion from binding, through hemifusion, pore formation, and pore enlargement", "size": null, "x": 82.72138977050781, "y": 88.92225646972656}}, {"key": "1783", "attributes": {"color": "#3005C7", "label": "Receptor determinants of human and animal influenza virus isolates: Differences in receptor specificity of the H3 hemagglutinin based on species of origin", "size": null, "x": 84.44860076904297, "y": 89.4498062133789}}, {"key": "1784", "attributes": {"color": "#3005C7", "label": "Influenza hemagglutinin and neuraminidase membrane glycoproteins", "size": null, "x": 83.97325134277344, "y": 88.17642211914062}}, {"key": "1785", "attributes": {"color": "#3005C7", "label": "Early stages of influenza virus entry into Mv-1 lung cells: Involvement of dynamin", "size": null, "x": 82.25431060791016, "y": 84.995849609375}}, {"key": "1786", "attributes": {"color": "#3005C7", "label": "Assembly of endocytic machinery around individual influenza viruses during viral entry", "size": null, "x": 82.10639953613281, "y": 89.77588653564453}}, {"key": "1787", "attributes": {"color": "#3005C7", "label": "Nuclear transport of influenza virus ribonucleoproteins: The viral matrix protein (M1) promotes export and inhibits import", "size": null, "x": 83.98387908935547, "y": 89.11617279052734}}, {"key": "1788", "attributes": {"color": "#3005C7", "label": "Emerging targets and novel approaches to ebola virus prophylaxis and treatment", "size": null, "x": 83.01761627197266, "y": 85.32537078857422}}, {"key": "1789", "attributes": {"color": "#3005C7", "label": "C-type lectins DC-SIGN and L-SIGN mediate cellular entry by ebola virus in cis and in trans", "size": null, "x": 83.95136260986328, "y": 89.74496459960938}}, {"key": "1790", "attributes": {"color": "#3005C7", "label": "Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner", "size": null, "x": 86.07667541503906, "y": 87.16622161865234}}, {"key": "1791", "attributes": {"color": "#3005C7", "label": "Phosphatidylserine receptors: Enhancers of enveloped virus entry and infection", "size": null, "x": 83.35863494873047, "y": 88.30953216552734}}, {"key": "1792", "attributes": {"color": "#3005C7", "label": "The roles of histidines and charged residues as potential triggers of a conformational change in the fusion loop of ebola virus glycoprotein", "size": null, "x": 82.96698760986328, "y": 83.83888244628906}}, {"key": "1793", "attributes": {"color": "#3005C7", "label": "Infection of vaginal and colonic epithelial cells by the human immunodeficiency virus type 1 is neutralized by antibodies raised against conserved epitopes in the envelope glycoprotein gp 120", "size": null, "x": 85.31864929199219, "y": 87.33753967285156}}, {"key": "1794", "attributes": {"color": "#3005C7", "label": "Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier", "size": null, "x": 84.04728698730469, "y": 90.19210815429688}}, {"key": "1795", "attributes": {"color": "#3005C7", "label": "Chemokine receptor expression in the human ectocervix: Implications for infection by the human immunodeficiency virus-type 1", "size": null, "x": 83.56681060791016, "y": 88.55897521972656}}, {"key": "1796", "attributes": {"color": "#3005C7", "label": "Setting the stage-HIV host invasion", "size": null, "x": 83.15848541259766, "y": 88.33216857910156}}, {"key": "1797", "attributes": {"color": "#3005C7", "label": "Chemokines and chemokine receptors in HIV infection: Role in pathogenesis and therapeutics", "size": null, "x": 84.76113891601562, "y": 86.32218933105469}}, {"key": "1798", "attributes": {"color": "#3005C7", "label": "Human diseases caused by viruses and prions", "size": null, "x": 84.02210998535156, "y": 85.49173736572266}}, {"key": "1799", "attributes": {"color": "#3005C7", "label": "Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome", "size": null, "x": 84.50324249267578, "y": 85.19499969482422}}, {"key": "1800", "attributes": {"color": "#3005C7", "label": "Trilogy of ACE2: A peptidase in the rennin-angiotensin system, a SARS receptor, and a partner for the amino acid transporters", "size": null, "x": 85.11324310302734, "y": 86.02281188964844}}, {"key": "1801", "attributes": {"color": "#3005C7", "label": "Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC", "size": null, "x": 83.66462707519531, "y": 85.91133117675781}}, {"key": "1802", "attributes": {"color": "#3005C7", "label": "The coronavirus spike protein is a class I virus fusion protein: Structural and functional characterization of the fusion core complex", "size": null, "x": 83.47935485839844, "y": 88.9637680053711}}, {"key": "1803", "attributes": {"color": "#3005C7", "label": "An overview of their replication and pathogenesis", "size": null, "x": 84.13848876953125, "y": 87.54695129394531}}, {"key": "1804", "attributes": {"color": "#3005C7", "label": "SARS-CoV-2 and coronavirus disease 2019: What we know so far", "size": null, "x": 83.34137725830078, "y": 90.27452850341797}}, {"key": "1805", "attributes": {"color": "#3005C7", "label": "Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein", "size": null, "x": 86.59300994873047, "y": 87.20355987548828}}, {"key": "1806", "attributes": {"color": "#3005C7", "label": "Proteolytic activation of the SARS-coronavirus spike protein: Cutting enzymes at the cutting edge of antiviral research", "size": null, "x": 85.41165924072266, "y": 87.80691528320312}}, {"key": "1807", "attributes": {"color": "#3005C7", "label": "SARS-CoV-2 entry genes are most highly expressed in nasal goblet and ciliated cells within human airways", "size": null, "x": 84.22236633300781, "y": 84.5987548828125}}, {"key": "1808", "attributes": {"color": "#3005C7", "label": "SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract", "size": null, "x": 83.09210968017578, "y": 87.89614868164062}}, {"key": "1809", "attributes": {"color": "#3005C7", "label": "New understanding of the damage of SARS-CoV-2 infection outside the respiratory system", "size": null, "x": 81.14070129394531, "y": 85.85372161865234}}, {"key": "1810", "attributes": {"color": "#3005C7", "label": "Inflammation triggered by SARS-CoV-2 and ACE2 augment deives multiple organ failure of severe COVID-19: Molecular mechanisms and implications", "size": null, "x": 86.12287139892578, "y": 89.1235122680664}}, {"key": "1811", "attributes": {"color": "#3005C7", "label": "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response", "size": null, "x": 83.01031494140625, "y": 87.00504302978516}}, {"key": "1812", "attributes": {"color": "#3005C7", "label": "Structural basis for RNA replication by the SARS-CoV-2 polymerase", "size": null, "x": 83.0235824584961, "y": 88.83317565917969}}, {"key": "1813", "attributes": {"color": "#3005C7", "label": "Coronaviruses pathogenesis, comorbidities and multiple-organ damage-A review", "size": null, "x": 87.07352447509766, "y": 87.32015991210938}}, {"key": "1814", "attributes": {"color": "#3005C7", "label": "Long-term respiratory follow-up of H1N1 infection", "size": null, "x": 81.55441284179688, "y": 86.49767303466797}}, {"key": "1815", "attributes": {"color": "#3005C7", "label": "Severe ebola virus disease with vascular leakage and multiorgan failure: Treatment of a patient in intensive care", "size": null, "x": 86.81407165527344, "y": 87.89521789550781}}, {"key": "1816", "attributes": {"color": "#3005C7", "label": "Tissue and cellular tropism, pathology and pathogenesis of ebola and Marburg viruses", "size": null, "x": 81.8362808227539, "y": 85.70220947265625}}, {"key": "1817", "attributes": {"color": "#3005C7", "label": "Pulmonary disease in HIV-infected adults in the era of antiretroviral therapy", "size": null, "x": 86.13871002197266, "y": 86.69938659667969}}, {"key": "1818", "attributes": {"color": "#3005C7", "label": "Multiple organ infection and the pathogenesis of SARS", "size": null, "x": 83.5908432006836, "y": 87.01326751708984}}, {"key": "1819", "attributes": {"color": "#3005C7", "label": "Middle east respiratory syndrome coronavirus (MERS-CoV): A review. Germs", "size": null, "x": 81.5277099609375, "y": 87.36339569091797}}, {"key": "1820", "attributes": {"color": "#3005C7", "label": "Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19)-anatomic pathology perspective on current knowledge", "size": null, "x": 83.11461639404297, "y": 87.60001373291016}}, {"key": "1821", "attributes": {"color": "#3005C7", "label": "Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): An atypical acute respiratory distress syndrome working hypothesis", "size": null, "x": 84.50235748291016, "y": 84.82490539550781}}, {"key": "1822", "attributes": {"color": "#3005C7", "label": "Coronavirus disease 2019 and the cardiovascular system: Impacts and implications", "size": null, "x": 81.74146270751953, "y": 87.13052368164062}}, {"key": "1823", "attributes": {"color": "#3005C7", "label": "Reprt of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies", "size": null, "x": 80.51250457763672, "y": 87.46941375732422}}, {"key": "1824", "attributes": {"color": "#3005C7", "label": "Clinical manifestations of influenza a myocarditis during the influenza epidemic of winter 1998-1999", "size": null, "x": 80.67189025878906, "y": 86.02747344970703}}, {"key": "1825", "attributes": {"color": "#3005C7", "label": "What every cardiologist should know about H1N1? ARYA Atheroscler", "size": null, "x": 85.65046691894531, "y": 88.68775177001953}}, {"key": "1826", "attributes": {"color": "#3005C7", "label": "Real-time monitoring of cardiovascular function in rhesus macaques infected with Zaire ebolavirus", "size": null, "x": 84.05095672607422, "y": 88.71772003173828}}, {"key": "1827", "attributes": {"color": "#3005C7", "label": "HIV infection and risk of cardiovascular diseases beyond coronary artery disease", "size": null, "x": 83.33748626708984, "y": 85.03759002685547}}, {"key": "1828", "attributes": {"color": "#3005C7", "label": "Cardiovascular complications of severe acute respiratory syndrome", "size": null, "x": 86.439453125, "y": 85.94011688232422}}, {"key": "1829", "attributes": {"color": "#3005C7", "label": "Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study", "size": null, "x": 83.13409423828125, "y": 85.27290344238281}}, {"key": "1830", "attributes": {"color": "#3005C7", "label": "Clinical features of patients infected with 2019 novel coronavirus in", "size": null, "x": 84.87935638427734, "y": 84.5058364868164}}, {"key": "1831", "attributes": {"color": "#3005C7", "label": "Sudden death in toddlers caused by influenza B infection: A report of two cases and a review of the literature", "size": null, "x": 82.30796813964844, "y": 85.86860656738281}}, {"key": "1832", "attributes": {"color": "#3005C7", "label": "Original antigenic sin and pandemic (H1N1)", "size": null, "x": 81.44690704345703, "y": 88.40723419189453}}, {"key": "1833", "attributes": {"color": "#3005C7", "label": "Ebola virus causes intestinal tract architecrural disruption and bacterial invasion in non-human primates", "size": null, "x": 84.64080810546875, "y": 87.16806030273438}}, {"key": "1834", "attributes": {"color": "#3005C7", "label": "Chronic diarrhea and AIDS: Insights into studies with non-human primates", "size": null, "x": 82.38109588623047, "y": 89.02368927001953}}, {"key": "1835", "attributes": {"color": "#3005C7", "label": "Severe acute respiratory syndrome and its lesions in digestive system", "size": null, "x": 84.03162384033203, "y": 85.81393432617188}}, {"key": "1836", "attributes": {"color": "#3005C7", "label": "Middle East respiratory syndrome coronavirus: Another zoonotic betacoronavirus causing SARS-like disease", "size": null, "x": 82.45375061035156, "y": 89.56085205078125}}, {"key": "1837", "attributes": {"color": "#3005C7", "label": "Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus", "size": null, "x": 82.75169372558594, "y": 85.84364318847656}}, {"key": "1838", "attributes": {"color": "#3005C7", "label": "SARS-CoV-2-infection (coronavirus disease 2019) for the gastrointestinal consultant", "size": null, "x": 84.335205078125, "y": 85.05535125732422}}, {"key": "1839", "attributes": {"color": "#3005C7", "label": "Post-influenzal encephalitis during the influenza A outbreak in 1979/1980", "size": null, "x": 84.72188568115234, "y": 87.04592895507812}}, {"key": "1840", "attributes": {"color": "#3005C7", "label": "The neurological manifestations of H1N1 influenza infection; diagnostic challenges and recommendations", "size": null, "x": 86.72291564941406, "y": 86.25955200195312}}, {"key": "1841", "attributes": {"color": "#3005C7", "label": "Clinical presentation and management of severe ebola virus disease", "size": null, "x": 82.56143188476562, "y": 84.6563949584961}}, {"key": "1842", "attributes": {"color": "#3005C7", "label": "Neurological complications of ebola virus infection", "size": null, "x": 85.73497772216797, "y": 85.57418060302734}}, {"key": "1843", "attributes": {"color": "#3005C7", "label": "HIV infection and the central nervous system: A primer", "size": null, "x": 84.96563720703125, "y": 84.0639877319336}}, {"key": "1844", "attributes": {"color": "#3005C7", "label": "Possible central nervous system infection by SARS coronavirus", "size": null, "x": 87.2113265991211, "y": 87.6933822631836}}, {"key": "1845", "attributes": {"color": "#3005C7", "label": "Detection of severe acute respiratory syndrome coronavirus in the brain: Potential role of the chemokine mig in pathogenesis", "size": null, "x": 83.34270477294922, "y": 86.01350402832031}}, {"key": "1846", "attributes": {"color": "#3005C7", "label": "Neurological complications during treatment of Middle East respiratory syndrome", "size": null, "x": 85.15647888183594, "y": 85.7889404296875}}, {"key": "1847", "attributes": {"color": "#3005C7", "label": "A first case of meningitis/ encephalitis associated with SARS-coronavirus-2", "size": null, "x": 84.59659576416016, "y": 86.61151885986328}}, {"key": "1848", "attributes": {"color": "#3005C7", "label": "Neurologic manifestations of hospitalized patients with coronavirus disease", "size": null, "x": 83.48110961914062, "y": 87.88384246826172}}, {"key": "1849", "attributes": {"color": "#3005C7", "label": "Renal complications of seasonal and pandemic influenza A virus infections", "size": null, "x": 80.67404174804688, "y": 86.86070251464844}}, {"key": "1850", "attributes": {"color": "#3005C7", "label": "Kidney diseases associated with parvovirus B19, hanta, ebola, and dengue virus infection: A brief review", "size": null, "x": 85.62588500976562, "y": 84.59366607666016}}, {"key": "1851", "attributes": {"color": "#3005C7", "label": "Kidney diseases and HIV infection. Top Antivir", "size": null, "x": 82.50829315185547, "y": 87.63276672363281}}, {"key": "1852", "attributes": {"color": "#3005C7", "label": "Acute renal failure in patients with severe acute respiratory syndrome", "size": null, "x": 82.04179382324219, "y": 86.24675750732422}}, {"key": "1853", "attributes": {"color": "#3005C7", "label": "Family cluster of Middle East respiratory syndrome coronavirus infections", "size": null, "x": 83.95533752441406, "y": 86.99040985107422}}, {"key": "1854", "attributes": {"color": "#3005C7", "label": "Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China", "size": null, "x": 82.7412338256836, "y": 88.36788940429688}}, {"key": "1855", "attributes": {"color": "#3005C7", "label": "Is the kidney a target of SARS-CoV-2?", "size": null, "x": 81.17585754394531, "y": 88.70346069335938}}, {"key": "1856", "attributes": {"color": "#3005C7", "label": "Characteristics of human sperm chromatin structure following an episode of influenza and high fever: A case study", "size": null, "x": 86.60318756103516, "y": 88.66946411132812}}, {"key": "1857", "attributes": {"color": "#3005C7", "label": "High risk of temporary alteration of semen parameters after recent acute febrile illness", "size": null, "x": 81.79678344726562, "y": 87.1662826538086}}, {"key": "1858", "attributes": {"color": "#3005C7", "label": "Triple-reassortant swine influenza A (H1) in humans in the United States", "size": null, "x": 84.04054260253906, "y": 86.49846649169922}}, {"key": "1859", "attributes": {"color": "#3005C7", "label": "Pandemic influenza and pregnant women: Summary of a meeting of experts", "size": null, "x": 82.84757995605469, "y": 84.27642822265625}}, {"key": "1860", "attributes": {"color": "#3005C7", "label": "Ebola virus localization in the macaque reproductive tract during acute ebola virus disease", "size": null, "x": 85.41593933105469, "y": 89.8089370727539}}, {"key": "1861", "attributes": {"color": "#3005C7", "label": "Pathogenesis of experimental ebola virus infection in guinea pig", "size": null, "x": 83.06011199951172, "y": 87.52201080322266}}, {"key": "1862", "attributes": {"color": "#3005C7", "label": "Ebola virus disease in pregnancy: Clinical, histopathologic, and immunohistochemical findings", "size": null, "x": 84.04862213134766, "y": 87.3250503540039}}, {"key": "1863", "attributes": {"color": "#3005C7", "label": "Ebola virus persistence in breast milk after no reported illness: A likely source of virus transmission from mother to child", "size": null, "x": 84.49085235595703, "y": 88.59481048583984}}, {"key": "1864", "attributes": {"color": "#3005C7", "label": "Asssited reproduction in HIV-1 serodifferent couples: The need for viral validation of processed semen", "size": null, "x": 81.6717758178711, "y": 85.21354675292969}}, {"key": "1865", "attributes": {"color": "#3005C7", "label": "Sexual dysfunction in advanced HIV disease", "size": null, "x": 84.90795135498047, "y": 85.43546295166016}}, {"key": "1866", "attributes": {"color": "#3005C7", "label": "Effects of human immunodeficiency virus on protracted amenorrhea and ovarian dysfunction", "size": null, "x": 82.1540756225586, "y": 86.42235565185547}}, {"key": "1867", "attributes": {"color": "#3005C7", "label": "Community based study of treatment seeking among subjects with symptoms of sexually transmitted disease in rural Uganda", "size": null, "x": 83.50265502929688, "y": 86.71117401123047}}, {"key": "1868", "attributes": {"color": "#3005C7", "label": "Population-based study of fertility in women with HIV-1 infection in Uganda", "size": null, "x": 82.80783081054688, "y": 85.12493896484375}}, {"key": "1869", "attributes": {"color": "#3005C7", "label": "Stillbirth during infection with Middle East respiratory syndrome coronavirus", "size": null, "x": 85.34870910644531, "y": 86.72295379638672}}, {"key": "1870", "attributes": {"color": "#3005C7", "label": "Orchitis: A complication of severe acute respiratory syndrome (SARS)", "size": null, "x": 83.83943939208984, "y": 88.82915496826172}}, {"key": "1871", "attributes": {"color": "#3005C7", "label": "Study of SARS-CoV-2 in semen and urine samples of a volunteer with positive naso-pharyngeal swab", "size": null, "x": 86.51567840576172, "y": 86.37232208251953}}, {"key": "1872", "attributes": {"color": "#3005C7", "label": "Assessment of SARS-CoV-2 in human semen-a cohort study", "size": null, "x": 85.35507202148438, "y": 87.15316009521484}}, {"key": "1873", "attributes": {"color": "#3005C7", "label": "Clinical characteristics and results of semen tests among men with coronavirus disease 2019", "size": null, "x": 83.4193344116211, "y": 84.57698822021484}}, {"key": "1874", "attributes": {"color": "#3005C7", "label": "Effect of SARS-CoV-2 infection upon male gonadal function: A single center-based study", "size": null, "x": 82.2079849243164, "y": 88.75564575195312}}, {"key": "1875", "attributes": {"color": "#3005C7", "label": "The majority of male patients with COVID-19 present low testosterone levels on admission to intensive care in", "size": null, "x": 84.63072967529297, "y": 87.84041595458984}}, {"key": "1876", "attributes": {"color": "#3005C7", "label": "SARS-CoV-2 and male infertility: Possible multifaceted pathology", "size": null, "x": 85.77368927001953, "y": 87.01322174072266}}, {"key": "1877", "attributes": {"color": "#3005C7", "label": "The public's response to severe acute respiratory syndrome in Toronto and the United States", "size": null, "x": 82.2516098022461, "y": 88.3381118774414}}, {"key": "1878", "attributes": {"color": "#3005C7", "label": "Molecular mimicry of ACTH in SARS-implications for corticosteroid treatment and prophylaxis", "size": null, "x": 81.27566528320312, "y": 86.55465698242188}}, {"key": "1879", "attributes": {"color": "#3005C7", "label": "SARS-CoV-2 infection, oxidative stress and male reproductive hormones: Can testicular-adrenal crosstalks be ruled out?", "size": null, "x": 83.77188110351562, "y": 86.43952941894531}}, {"key": "1880", "attributes": {"color": "#3005C7", "label": "Oxidative stress and anxiety", "size": null, "x": 80.96734619140625, "y": 88.1878433227539}}, {"key": "1881", "attributes": {"color": "#3005C7", "label": "Does SARS-CoV-2 infection cause sperm DNA fragmentation? Possible link with oxidative stress", "size": null, "x": 86.0813217163086, "y": 86.28135681152344}}, {"key": "1882", "attributes": {"color": "#3005C7", "label": "Mental health, psychotropic medication use, and menstrual cycle characteristics", "size": null, "x": 85.4798583984375, "y": 84.03357696533203}}, {"key": "1883", "attributes": {"color": "#3005C7", "label": "Prior and novel coronaviruses, coronavirus disease 2019 (COVID-19), and human reproduction: What is known?", "size": null, "x": 84.7527847290039, "y": 90.29044342041016}}, {"key": "1884", "attributes": {"color": "#3005C7", "label": "Potential risk of SARS-CoV-2 infection on reproductive health", "size": null, "x": 84.31510162353516, "y": 84.17208099365234}}, {"key": "1885", "attributes": {"color": "#3005C7", "label": "MERS-CoV and SARS-CoV-2 infections in pregnancy and fetal development", "size": null, "x": 84.96815490722656, "y": 89.15744018554688}}, {"key": "1886", "attributes": {"color": "#3005C7", "label": "Risk factors associated with the increasing prevalence of pneumonia during pregnancy", "size": null, "x": 82.2658462524414, "y": 87.83414459228516}}, {"key": "1887", "attributes": {"color": "#3005C7", "label": "Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: A retrospective review of medical records", "size": null, "x": 84.9354476928711, "y": 83.74288177490234}}, {"key": "1888", "attributes": {"color": "#3005C7", "label": "Clinical analysis of 10 neonates born to mother with 2019-nCoV pneumonia", "size": null, "x": 83.69385528564453, "y": 89.46806335449219}}, {"key": "1889", "attributes": {"color": "#3005C7", "label": "Major depression, antidepressant use and male and female infertility", "size": null, "x": 81.36965942382812, "y": 88.19884490966797}}, {"key": "1890", "attributes": {"color": "#3005C7", "label": "Effects of psychological stress on male fertility", "size": null, "x": 84.2769546508789, "y": 87.01769256591797}}, {"key": "1891", "attributes": {"color": "#3005C7", "label": "A history of AIDS: Looking back to see ahead", "size": null, "x": 86.61083221435547, "y": 86.72420501708984}}, {"key": "1892", "attributes": {"color": "#3005C7", "label": "Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence", "size": null, "x": 81.73575592041016, "y": 86.10576629638672}}, {"key": "1893", "attributes": {"color": "#3005C7", "label": "Central Intelligence Agency (CIA)", "size": null, "x": 81.94351959228516, "y": 88.20951080322266}}, {"key": "1894", "attributes": {"color": "#3005C7", "label": "The evolution of HIV-1 and the origin of", "size": null, "x": 82.58309936523438, "y": 87.1444091796875}}, {"key": "1895", "attributes": {"color": "#3005C7", "label": "Structural basis for human coronavirus attachment to sialic acid receptors", "size": null, "x": 86.60356903076172, "y": 88.24837493896484}}, {"key": "1896", "attributes": {"color": "#3005C7", "label": "Sialic acid receptors of viruses", "size": null, "x": 86.11396789550781, "y": 85.4757080078125}}, {"key": "1897", "attributes": {"color": "#3005C7", "label": "HIV: Cell binding and entry. Cold Spring Harb", "size": null, "x": 85.20327758789062, "y": 88.04214477539062}}, {"key": "1898", "attributes": {"color": "#3005C7", "label": "Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses. Microbes Infect", "size": null, "x": 84.14594268798828, "y": 87.0032730102539}}, {"key": "1899", "attributes": {"color": "#3005C7", "label": "A novel coronavirus (COVID-19) outbreak: A call for action", "size": null, "x": 82.26846313476562, "y": 85.383544921875}}, {"key": "1900", "attributes": {"color": "#3005C7", "label": "The US Centres for Disease Control and Prevention (CDC)", "size": null, "x": 85.42769622802734, "y": 89.14459228515625}}, {"key": "1901", "attributes": {"color": "#3005C7", "label": "World Health Organization (WHO)", "size": null, "x": 81.16284942626953, "y": 88.85185241699219}}, {"key": "1902", "attributes": {"color": "#3005C7", "label": "Rate of hospitalization and inpatient care costs for HIV-1-infected patients in Pune", "size": null, "x": 83.52835083007812, "y": 89.28904724121094}}, {"key": "1903", "attributes": {"color": "#3005C7", "label": "Molecular analysis of HIV strains from a cluster of worker infections in the adult film industry", "size": null, "x": 83.05570983886719, "y": 86.91657257080078}}, {"key": "1904", "attributes": {"color": "#3005C7", "label": "Estimation of the HIV basic reproduction number in rural south west Uganda", "size": null, "x": 83.97441101074219, "y": 88.50069427490234}}, {"key": "1905", "attributes": {"color": "#3005C7", "label": "The novel Chinese coronavirus (2019-nCoV) infections: Challenges for fighting the storm", "size": null, "x": 85.73077392578125, "y": 89.38795471191406}}, {"key": "1906", "attributes": {"color": "#3005C7", "label": "Incubation time of acute human immunodeficiency virus (HIV) infection and duration of acute HIV infection are independent prognostic factors of progression to AIDS", "size": null, "x": 83.47346496582031, "y": 88.35132598876953}}, {"key": "1907", "attributes": {"color": "#3005C7", "label": "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges", "size": null, "x": 82.39474487304688, "y": 87.05872344970703}}, {"key": "1908", "attributes": {"color": "#3005C7", "label": "Focus on Middle East respiratory syndrome coronavirus (MERS-CoV)", "size": null, "x": 81.46363067626953, "y": 85.49165344238281}}, {"key": "1909", "attributes": {"color": "#3005C7", "label": "Identifying symptom patterns in people living with HIV disease", "size": null, "x": 82.41471862792969, "y": 86.55368041992188}}, {"key": "1910", "attributes": {"color": "#3005C7", "label": "Imaging lung manifestation of HIV/AIDS", "size": null, "x": 83.7390365600586, "y": 87.95970153808594}}, {"key": "1911", "attributes": {"color": "#3005C7", "label": "The cytokine response profile of ebola virus disease in a large cohort of rhesus macaques treated with monoclonal antibodies", "size": null, "x": 81.00958251953125, "y": 89.48731994628906}}, {"key": "1912", "attributes": {"color": "#3005C7", "label": "Cytokine and chemokine profiles in lung tissues from fatal cases of 2009 pandemic influenza A (H1N1): Role of the host immune response in pathogenesis", "size": null, "x": 82.3050537109375, "y": 88.86032104492188}}, {"key": "1913", "attributes": {"color": "#3005C7", "label": "Cytokine and HIV-1: Interaction and clinical implications", "size": null, "x": 81.92628479003906, "y": 89.39082336425781}}, {"key": "1914", "attributes": {"color": "#3005C7", "label": "Systematic review of treatment effects", "size": null, "x": 83.4359130859375, "y": 88.82694244384766}}, {"key": "1915", "attributes": {"color": "#3005C7", "label": "HIV antiretroviral therapy", "size": null, "x": 83.49755859375, "y": 85.5115966796875}}, {"key": "1916", "attributes": {"color": "#3005C7", "label": "Vaccines for SARS-CoV-2: Lessons from other coronavirus strains", "size": null, "x": 85.89312744140625, "y": 89.8713150024414}}, {"key": "1917", "attributes": {"color": "#3005C7", "label": "Phase I SARS vaccine trial in China", "size": null, "x": 82.43375396728516, "y": 88.60152435302734}}, {"key": "1918", "attributes": {"color": "#3005C7", "label": "Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice", "size": null, "x": 84.99896240234375, "y": 87.98260498046875}}, {"key": "1919", "attributes": {"color": "#3005C7", "label": "Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine", "size": null, "x": 84.89258575439453, "y": 89.66412353515625}}, {"key": "1920", "attributes": {"color": "#3005C7", "label": "A double-inacivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge", "size": null, "x": 83.84019470214844, "y": 87.58616638183594}}, {"key": "1921", "attributes": {"color": "#3005C7", "label": "Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: A phase I, open-label, single-arm, dose-escalation trial", "size": null, "x": 86.46989440917969, "y": 86.84786987304688}}, {"key": "1922", "attributes": {"color": "#3005C7", "label": "Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus", "size": null, "x": 83.19022369384766, "y": 84.32352447509766}}, {"key": "1923", "attributes": {"color": "#3005C7", "label": "Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease", "size": null, "x": 86.70722961425781, "y": 89.06781005859375}}, {"key": "1924", "attributes": {"color": "#3005C7", "label": "Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: A six-year follow-up study", "size": null, "x": 81.74665832519531, "y": 89.92304992675781}}, {"key": "1925", "attributes": {"color": "#3005C7", "label": "Persistence of antibodies against Middle East respiratory syndrome coronavirus", "size": null, "x": 82.86750030517578, "y": 89.81666564941406}}, {"key": "1926", "attributes": {"color": "#3005C7", "label": "Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell response", "size": null, "x": 83.28363037109375, "y": 89.1922378540039}}, {"key": "1927", "attributes": {"color": "#3005C7", "label": "DRAFT Landscape of COVID-19 Candidate Vaccines-3", "size": null, "x": 82.5959243774414, "y": 88.182861328125}}, {"key": "1928", "attributes": {"color": "#3005C7", "label": "Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved in First Interim Analysis from Phase 3 Study", "size": null, "x": 83.57271575927734, "y": 90.48931884765625}}, {"key": "1929", "attributes": {"color": "#3005C7", "label": "Moderna's Fully Phase 3 COVE Study of mRNA-1273", "size": null, "x": 83.19403839111328, "y": 85.67379760742188}}, {"key": "1930", "attributes": {"color": "#3005C7", "label": "Dozens of COVID-19 Vaccines Are in Development. Here Are the Ones to Follow-3", "size": null, "x": 86.37866973876953, "y": 89.44860076904297}}, {"key": "1931", "attributes": {"color": "#3005C7", "label": "Covid-19 Vaccine: First Person Receives Pfizer Jab in UK", "size": null, "x": 83.05664825439453, "y": 88.28486633300781}}, {"key": "1932", "attributes": {"color": "#3005C7", "label": "Novavax Announces COVID-19 Vaccine Clinical Development Progress", "size": null, "x": 84.53855895996094, "y": 88.18295288085938}}, {"key": "1933", "attributes": {"color": "#3005C7", "label": "A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF 2001 for Prevention of COVID-19", "size": null, "x": 81.51545715332031, "y": 89.87850189208984}}, {"key": "1934", "attributes": {"color": "#3005C7", "label": "China's Zhifei Finishes Covid-19 Vaccine's Phase II Clinical Trial in Three Months in Race to the Market", "size": null, "x": 81.90921020507812, "y": 87.62874603271484}}, {"key": "1935", "attributes": {"color": "#3005C7", "label": "COVID-19 Vaccine Tracker", "size": null, "x": 85.97918701171875, "y": 87.48625946044922}}, {"key": "1936", "attributes": {"color": "#3005C7", "label": "COVID-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows", "size": null, "x": 87.61283874511719, "y": 87.28003692626953}}, {"key": "1937", "attributes": {"color": "#3005C7", "label": "COVID-19: Oxford vaccine is up to 90% effective, interim analysis indicates", "size": null, "x": 84.01268005371094, "y": 85.13038635253906}}, {"key": "1938", "attributes": {"color": "#3005C7", "label": "Covaxin and ZyCoV-D: Recent Update of Covid-19 Vaccine Candidates in India", "size": null, "x": 83.07134246826172, "y": 86.34779357910156}}, {"key": "1939", "attributes": {"color": "#3005C7", "label": "Lessons from a new disease", "size": null, "x": 81.41988372802734, "y": 84.75625610351562}}, {"key": "1940", "attributes": {"color": "#3005C7", "label": "Global Health Security Agenda (GHSA)", "size": null, "x": 82.82274627685547, "y": 85.59104919433594}}, {"key": "1941", "attributes": {"color": "#3005C7", "label": "COVID-19 and the UN Sustainable Development Goals: Threat to solidarity or an opportunity", "size": null, "x": 84.1946029663086, "y": 86.05217742919922}}, {"key": "1942", "attributes": {"color": "#3005C7", "label": "Reversing Setbacks to Poverty Reduction Requires Nations to Work Together for a Resilient Recovery", "size": null, "x": 81.63143157958984, "y": 87.70086669921875}}, {"key": "1943", "attributes": {"color": "#3005C7", "label": "The Impact of COVID-19 on Global Poverty under Worsening Growth and Inequality", "size": null, "x": 84.19049835205078, "y": 88.30378723144531}}, {"key": "1944", "attributes": {"color": "#3005C7", "label": "COVID-19 pandemic: Lessons learned and future directions", "size": null, "x": 87.35607147216797, "y": 86.7481918334961}}, {"key": "1945", "attributes": {"color": "#3005C7", "label": "WHO Statement on the Tenth Meeting of the IHR Emergency Committee Regarding MERS", "size": null, "x": 83.06748962402344, "y": 84.7154769897461}}, {"key": "1946", "attributes": {"color": "#3005C7", "label": "Surveillance and testing for Middle East respiratory syndrome coronavirus, Saudi Arabia", "size": null, "x": 83.8949966430664, "y": 89.33464813232422}}, {"key": "1947", "attributes": {"color": "#3005C7", "label": "WHO ad hoc Scientific Teleconference on the Current Influenza A (H1N1) Situation", "size": null, "x": 81.76707458496094, "y": 86.53863525390625}}, {"key": "1948", "attributes": {"color": "#3005C7", "label": "Estimating the incidence reporting rates of new influenza pandemics at an early stage using travel data from the source country", "size": null, "x": 83.3132095336914, "y": 89.66268920898438}}, {"key": "1949", "attributes": {"color": "#3005C7", "label": "Lessons from ebola: Improving infectious disease surveillance to inform outbreak management", "size": null, "x": 84.99768829345703, "y": 86.48648834228516}}, {"key": "1950", "attributes": {"color": "#3005C7", "label": "Routine use of point-of-care tests: Usefulness and application in clinical microbiology", "size": null, "x": 80.71525573730469, "y": 87.97229766845703}}, {"key": "1951", "attributes": {"color": "#3005C7", "label": "Shifting the paradigm: Using HIV surveillance data as a foundation for improving HIV care and preventing HIV infection", "size": null, "x": 80.67842864990234, "y": 88.24140930175781}}, {"key": "1952", "attributes": {"color": "#3005C7", "label": "Ethics in the time of coronavirus: Recommendations in the COVID-19 pandemic", "size": null, "x": 83.7455062866211, "y": 84.17752838134766}}, {"key": "1953", "attributes": {"color": "#3005C7", "label": "The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: Implication for infection prevention and control measures", "size": null, "x": 86.54454040527344, "y": 85.27857971191406}}, {"key": "1954", "attributes": {"color": "#3005C7", "label": "2019-nCOV CDC response team initial public health response and interim clinical guidance for the 2019 novel coronavirus outbreak-United States", "size": null, "x": 83.9190902709961, "y": 89.16854095458984}}, {"key": "1955", "attributes": {"color": "#3005C7", "label": "Coronavirus-This Is How the World Is Responding", "size": null, "x": 83.98091888427734, "y": 84.70209503173828}}, {"key": "1956", "attributes": {"color": "#3005C7", "label": "Novel Coronavirus (2019-nCOV) Situation Report 1", "size": null, "x": 84.86415100097656, "y": 88.52753448486328}}, {"key": "1957", "attributes": {"color": "#3005C7", "label": "Global research trends of Middle East respiratory syndrome coronavirus: A bibliometric analysis", "size": null, "x": 82.73536682128906, "y": 84.15393829345703}}, {"key": "1958", "attributes": {"color": "#3005C7", "label": "Golbal strategies and response measures to the influenza A (H1N1) pandemic. In A Comprehensive Evaluation on Emergency Response in China. Research Series on the Chinese Dream and China's Development Path", "size": null, "x": 80.2928237915039, "y": 87.27959442138672}}, {"key": "1959", "attributes": {"color": "#3005C7", "label": "Developed Countries Rush to Buy Influenza (H1N1) Vaccines, Leaving Poor Countries Worried about Epidemic Control", "size": null, "x": 85.45716857910156, "y": 83.69094848632812}}, {"key": "1960", "attributes": {"color": "#3005C7", "label": "Integrating Clinical Research into Epidemic Response: The Ebola Experience", "size": null, "x": 80.75337219238281, "y": 88.77535247802734}}, {"key": "1961", "attributes": {"color": "#3005C7", "label": "International collaboration in HIV prevention research: Evidence from a research seminar in Russia", "size": null, "x": 87.16460418701172, "y": 88.49175262451172}}, {"key": "1962", "attributes": {"color": "#3005C7", "label": "Evolution of an international research collaborative in HIV and rehabilitation: Community engaged process, lessons learned, and recommendations", "size": null, "x": 83.62299346923828, "y": 86.5034408569336}}, {"key": "1963", "attributes": {"color": "#3005C7", "label": "Collaboration in the war against viruses: A multidisciplinary international effort", "size": null, "x": 81.035400390625, "y": 86.70234680175781}}, {"key": "1964", "attributes": {"color": "#3005C7", "label": "The urgent need for integrated science to fight COVID-19 pandemic and beyond", "size": null, "x": 84.61052703857422, "y": 85.94970703125}}, {"key": "1965", "attributes": {"color": "#3005C7", "label": "COVID-19: Collaboration Is the Engine of Global Science-Especially for Developing Countries", "size": null, "x": 83.35612487792969, "y": 84.8484878540039}}, {"key": "1966", "attributes": {"color": "#3005C7", "label": "Agent-based modeling in molecular systems biology", "size": null, "x": 84.89665222167969, "y": 86.7506103515625}}, {"key": "1967", "attributes": {"color": "#3005C7", "label": "Stochastic modeling of infectious diseases for heterogeneous populations", "size": null, "x": 82.26307678222656, "y": 87.47943115234375}}, {"key": "1968", "attributes": {"color": "#3005C7", "label": "Mathematical modeling using improved SIR model with more realistic assumptions", "size": null, "x": 82.52709197998047, "y": 88.01858520507812}}, {"key": "1969", "attributes": {"color": "#3005C7", "label": "Personal protective equipment for preventing highly infectious disease due to exposure to contaminated body fluids in healthcare staff", "size": null, "x": 81.16502380371094, "y": 86.14202117919922}}, {"key": "1970", "attributes": {"color": "#3005C7", "label": "Impact of the fall 2009 influenza A(H1N1)pdm09 pandemic on US hospitals", "size": null, "x": 85.32231140136719, "y": 90.18209075927734}}, {"key": "1971", "attributes": {"color": "#3005C7", "label": "Ebola and the global governance of health", "size": null, "x": 87.01241302490234, "y": 89.12086486816406}}, {"key": "1972", "attributes": {"color": "#3005C7", "label": "Impact and Implications of the Ebola Crisis", "size": null, "x": 81.8337173461914, "y": 84.50703430175781}}, {"key": "1973", "attributes": {"color": "#3005C7", "label": "Ebola Threatens Social and Political Stability in Affected Countries", "size": null, "x": 86.11119079589844, "y": 89.68073272705078}}, {"key": "1974", "attributes": {"color": "#3005C7", "label": "How can health systems be strengthened to control and prevent an ebola outbreak? A narrative review", "size": null, "x": 85.48175811767578, "y": 88.9790267944336}}, {"key": "1975", "attributes": {"color": "#3005C7", "label": "Difficulties facing healthcare workers in the era of AIDS treatment in Lesotho", "size": null, "x": 84.04766845703125, "y": 85.99935150146484}}, {"key": "1976", "attributes": {"color": "#3005C7", "label": "Medication management and adherence during the COVID-19 pandemic: Perspectives and experiences from low-and middle-income countries", "size": null, "x": 82.78640747070312, "y": 89.4132080078125}}, {"key": "1977", "attributes": {"color": "#3005C7", "label": "COVID-19 Quickly Becomes Most Important US Problem", "size": null, "x": 81.25111389160156, "y": 90.0639877319336}}, {"key": "1978", "attributes": {"color": "#3005C7", "label": "?amp_js_v=a6& amp_gsa=1&usqp=mq331AQHKAFQArABIA%3D%3D#aoh=16081908079024&referrer=https%3A% 2F%2Fwww.google.com&amp_tf=From%20%251%24s&ampshare=https%3A%2F%2Fnews.cgtn.com% 2Fnews%2F2020-05-04%2FCOVID-19-UK-Roundup-Latest-developments-and-challenges-QdglVgctEs% 2Findex.html", "size": null, "x": 83.41761016845703, "y": 85.54432678222656}}, {"key": "1979", "attributes": {"color": "#3005C7", "label": "Key COVID-19 Challenges Facing UK Businesses Today", "size": null, "x": 83.6617660522461, "y": 83.77177429199219}}, {"key": "1980", "attributes": {"color": "#3005C7", "label": "Primary health care facility preparedness for outpatient service provision during the COVID-19 pandemic in India: Cross-sectional study", "size": null, "x": 83.13426971435547, "y": 87.56076049804688}}, {"key": "1981", "attributes": {"color": "#3005C7", "label": "Analysis of the effectiveness of interventions used during the 2009 A/H1N1 influenza pandemic", "size": null, "x": 80.86581420898438, "y": 85.13196563720703}}, {"key": "1982", "attributes": {"color": "#3005C7", "label": "Impact of interventions and the incidence of ebola virus disease in Liberia-implications for future epidemics", "size": null, "x": 85.09403991699219, "y": 84.84465789794922}}, {"key": "1983", "attributes": {"color": "#3005C7", "label": "Combination HIV prevention interventions: The potential of integrated behavioral and biomedical approaches", "size": null, "x": 82.95296478271484, "y": 86.53656005859375}}, {"key": "1984", "attributes": {"color": "#3005C7", "label": "Effective containment explains subexponential growth in recent confirmed COVID-19 cases in China", "size": null, "x": 84.34077453613281, "y": 85.47393035888672}}, {"key": "1985", "attributes": {"color": "#3005C7", "label": "Remdesivir and its antiviral activity against COVID-19: A systematic review", "size": null, "x": 84.21176147460938, "y": 89.40876770019531}}, {"key": "1986", "attributes": {"color": "#3005C7", "label": "Remdesivir for the treatment of Covid-19-preliminary report", "size": null, "x": 83.45675659179688, "y": 87.1774673461914}}, {"key": "1987", "attributes": {"color": "#3005C7", "label": "Remdesivir in adults with severe COVID-19: A randomized, double-bling, placebo-controlled, multicentre trial", "size": null, "x": 83.41522979736328, "y": 87.0545425415039}}, {"key": "1988", "attributes": {"color": "#3005C7", "label": "NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19", "size": null, "x": 85.22825622558594, "y": 85.26513671875}}, {"key": "1989", "attributes": {"color": "#3005C7", "label": "Coronavirus Disease (COVID-19): Dexamethasone", "size": null, "x": 85.7294692993164, "y": 88.0441665649414}}, {"key": "1990", "attributes": {"color": "#3005C7", "label": "Savetsky, I. The COVID-19 pandemic: Changing lives and lessons learned", "size": null, "x": 84.68363952636719, "y": 88.2334213256836}}, {"key": "1991", "attributes": {"color": "#3005C7", "label": "The COVID-19 pandemic: Effects on low-and middle-income countries", "size": null, "x": 85.5888900756836, "y": 85.87621307373047}}, {"key": "1992", "attributes": {"color": "#3005C7", "label": "Coronavirus disease 2019 (COVID-19): Current status and future perspectives", "size": null, "x": 84.91913604736328, "y": 87.32176208496094}}, {"key": "1993", "attributes": {"color": "#3005C7", "label": "An evidence based perspective on mRNA-SARS-CoV-2 vaccine development", "size": null, "x": 81.03477478027344, "y": 87.11693572998047}}, {"key": "1994", "attributes": {"color": "#3005C7", "label": "Coronavirus disease (COVID-19) current status and future perspectives: A narrative review", "size": null, "x": 82.24577331542969, "y": 84.45559692382812}}], "edges": [{"key": "0", "source": "0", "target": "1", "attributes": {"size": null, "type": "arrow"}}, {"key": "1", "source": "0", "target": "2", "attributes": {"size": null, "type": "arrow"}}, {"key": "2", "source": "0", "target": "3", "attributes": {"size": null, "type": "arrow"}}, {"key": "3", "source": "0", "target": "4", "attributes": {"size": null, "type": "arrow"}}, {"key": "4", "source": "0", "target": "5", "attributes": {"size": null, "type": "arrow"}}, {"key": "5", "source": "0", "target": "6", "attributes": {"size": null, "type": "arrow"}}, {"key": "6", "source": "0", "target": "7", "attributes": {"size": null, "type": "arrow"}}, {"key": "7", "source": "0", "target": "8", "attributes": {"size": null, "type": "arrow"}}, {"key": "8", "source": "0", "target": "9", "attributes": {"size": null, "type": "arrow"}}, {"key": "9", "source": "0", "target": "10", "attributes": {"size": null, "type": "arrow"}}, {"key": "10", "source": "0", "target": "11", "attributes": {"size": null, "type": "arrow"}}, {"key": "11", "source": "0", "target": "12", "attributes": {"size": null, "type": "arrow"}}, {"key": "12", "source": "0", "target": "13", "attributes": {"size": null, "type": "arrow"}}, {"key": "13", "source": "0", "target": "14", "attributes": {"size": null, "type": "arrow"}}, {"key": "14", "source": "0", "target": "15", "attributes": {"size": null, "type": "arrow"}}, {"key": "15", "source": "0", "target": "16", "attributes": {"size": null, "type": "arrow"}}, {"key": "16", "source": "0", "target": "17", "attributes": {"size": null, "type": "arrow"}}, {"key": "17", "source": "0", "target": "18", "attributes": {"size": null, "type": "arrow"}}, {"key": "18", "source": "0", "target": "19", "attributes": {"size": null, "type": "arrow"}}, {"key": "19", "source": "0", "target": "20", "attributes": {"size": null, "type": "arrow"}}, {"key": "20", "source": "0", "target": "21", "attributes": {"size": null, "type": "arrow"}}, {"key": "21", "source": "0", "target": "22", "attributes": {"size": null, "type": "arrow"}}, {"key": "22", "source": "0", "target": "23", "attributes": {"size": null, "type": "arrow"}}, {"key": "23", "source": "0", "target": "24", "attributes": {"size": null, "type": "arrow"}}, {"key": "24", "source": "0", "target": "25", "attributes": {"size": null, "type": "arrow"}}, {"key": "25", "source": "0", "target": "26", "attributes": {"size": null, "type": "arrow"}}, {"key": "26", "source": "0", "target": "27", "attributes": {"size": null, "type": "arrow"}}, {"key": "27", "source": "0", "target": "28", "attributes": {"size": null, "type": "arrow"}}, {"key": "28", "source": "0", "target": "29", "attributes": {"size": null, "type": "arrow"}}, {"key": "29", "source": "0", "target": "30", "attributes": {"size": null, "type": "arrow"}}, {"key": "30", "source": "0", "target": "31", "attributes": {"size": null, "type": "arrow"}}, {"key": "31", "source": "0", "target": "32", "attributes": {"size": null, "type": "arrow"}}, {"key": "32", "source": "0", "target": "33", "attributes": {"size": null, "type": "arrow"}}, {"key": "33", "source": "0", "target": "34", "attributes": {"size": null, "type": "arrow"}}, {"key": "34", "source": "0", "target": "35", "attributes": {"size": null, "type": "arrow"}}, {"key": "35", "source": "0", "target": "36", "attributes": {"size": null, "type": "arrow"}}, {"key": "36", "source": "0", "target": "37", "attributes": {"size": null, "type": "arrow"}}, {"key": "37", "source": "0", "target": "38", "attributes": {"size": null, "type": "arrow"}}, {"key": "38", "source": "0", "target": "39", "attributes": {"size": null, "type": "arrow"}}, {"key": "39", "source": "0", "target": "40", "attributes": {"size": null, "type": "arrow"}}, {"key": "40", "source": "0", "target": "41", "attributes": {"size": null, "type": "arrow"}}, {"key": "41", "source": "0", "target": "42", "attributes": {"size": null, "type": "arrow"}}, {"key": "42", "source": "0", "target": "43", "attributes": {"size": null, "type": "arrow"}}, {"key": "43", "source": "0", "target": "44", "attributes": {"size": null, "type": "arrow"}}, {"key": "44", "source": "0", "target": "45", "attributes": {"size": null, "type": "arrow"}}, {"key": "45", "source": "0", "target": "46", "attributes": {"size": null, "type": "arrow"}}, {"key": "46", "source": "0", "target": "47", "attributes": {"size": null, "type": "arrow"}}, {"key": "47", "source": "0", "target": "48", "attributes": {"size": null, "type": "arrow"}}, {"key": "48", "source": "0", "target": "49", "attributes": {"size": null, "type": "arrow"}}, {"key": "49", "source": "0", "target": "50", "attributes": {"size": null, "type": "arrow"}}, {"key": "50", "source": "0", "target": "51", "attributes": {"size": null, "type": "arrow"}}, {"key": "51", "source": "0", "target": "52", "attributes": {"size": null, "type": "arrow"}}, {"key": "52", "source": "0", "target": "53", "attributes": {"size": null, "type": "arrow"}}, {"key": "53", "source": "0", "target": "54", "attributes": {"size": null, "type": "arrow"}}, {"key": "54", "source": "0", "target": "55", "attributes": {"size": null, "type": "arrow"}}, {"key": "55", "source": "0", "target": "56", "attributes": {"size": null, "type": "arrow"}}, {"key": "56", "source": "0", "target": "57", "attributes": {"size": null, "type": "arrow"}}, {"key": "57", "source": "0", "target": "58", "attributes": {"size": null, "type": "arrow"}}, {"key": "58", "source": "0", "target": "59", "attributes": {"size": null, "type": "arrow"}}, {"key": "59", "source": "0", "target": "60", "attributes": {"size": null, "type": "arrow"}}, {"key": "60", "source": "0", "target": "61", "attributes": {"size": null, "type": "arrow"}}, {"key": "61", "source": "0", "target": "62", "attributes": {"size": null, "type": "arrow"}}, {"key": "62", "source": "0", "target": "63", "attributes": {"size": null, "type": "arrow"}}, {"key": "63", "source": "0", "target": "64", "attributes": {"size": null, "type": "arrow"}}, {"key": "64", "source": "0", "target": "65", "attributes": {"size": null, "type": "arrow"}}, {"key": "65", "source": "0", "target": "66", "attributes": {"size": null, "type": "arrow"}}, {"key": "66", "source": "0", "target": "67", "attributes": {"size": null, "type": "arrow"}}, {"key": "67", "source": "0", "target": "68", "attributes": {"size": null, "type": "arrow"}}, {"key": "68", "source": "0", "target": "69", "attributes": {"size": null, "type": "arrow"}}, {"key": "69", "source": "0", "target": "70", "attributes": {"size": null, "type": "arrow"}}, {"key": "70", "source": "0", "target": "71", "attributes": {"size": null, "type": "arrow"}}, {"key": "71", "source": "0", "target": "72", "attributes": {"size": null, "type": "arrow"}}, {"key": "72", "source": "0", "target": "73", "attributes": {"size": null, "type": "arrow"}}, {"key": "73", "source": "0", "target": "74", "attributes": {"size": null, "type": "arrow"}}, {"key": "74", "source": "0", "target": "75", "attributes": {"size": null, "type": "arrow"}}, {"key": "75", "source": "0", "target": "76", "attributes": {"size": null, "type": "arrow"}}, {"key": "76", "source": "0", "target": "77", "attributes": {"size": null, "type": "arrow"}}, {"key": "77", "source": "0", "target": "78", "attributes": {"size": null, "type": "arrow"}}, {"key": "78", "source": "0", "target": "79", "attributes": {"size": null, "type": "arrow"}}, {"key": "79", "source": "0", "target": "80", "attributes": {"size": null, "type": "arrow"}}, {"key": "80", "source": "0", "target": "81", "attributes": {"size": null, "type": "arrow"}}, {"key": "81", "source": "0", "target": "82", "attributes": {"size": null, "type": "arrow"}}, {"key": "82", "source": "0", "target": "83", "attributes": {"size": null, "type": "arrow"}}, {"key": "83", "source": "0", "target": "84", "attributes": {"size": null, "type": "arrow"}}, {"key": "84", "source": "0", "target": "85", "attributes": {"size": null, "type": "arrow"}}, {"key": "85", "source": "0", "target": "86", "attributes": {"size": null, "type": "arrow"}}, {"key": "86", "source": "0", "target": "87", "attributes": {"size": null, "type": "arrow"}}, {"key": "87", "source": "0", "target": "88", "attributes": {"size": null, "type": "arrow"}}, {"key": "88", "source": "0", "target": "89", "attributes": {"size": null, "type": "arrow"}}, {"key": "89", "source": "0", "target": "90", "attributes": {"size": null, "type": "arrow"}}, {"key": "90", "source": "0", "target": "91", "attributes": {"size": null, "type": "arrow"}}, {"key": "91", "source": "0", "target": "92", "attributes": {"size": null, "type": "arrow"}}, {"key": "92", "source": "0", "target": "93", "attributes": {"size": null, "type": "arrow"}}, {"key": "93", "source": "0", "target": "94", "attributes": {"size": null, "type": "arrow"}}, {"key": "94", "source": "0", "target": "95", "attributes": {"size": null, "type": "arrow"}}, {"key": "95", "source": "0", "target": "96", "attributes": {"size": null, "type": "arrow"}}, {"key": "96", "source": "0", "target": "97", "attributes": {"size": null, "type": "arrow"}}, {"key": "97", "source": "0", "target": "98", "attributes": {"size": null, "type": "arrow"}}, {"key": "98", "source": "0", "target": "99", "attributes": {"size": null, "type": "arrow"}}, {"key": "99", "source": "0", "target": "100", "attributes": {"size": null, "type": "arrow"}}, {"key": "100", "source": "101", "target": "102", "attributes": {"size": null, "type": "arrow"}}, {"key": "101", "source": "101", "target": "103", "attributes": {"size": null, "type": "arrow"}}, {"key": "102", "source": "101", "target": "104", "attributes": {"size": null, "type": "arrow"}}, {"key": "103", "source": "101", "target": "105", "attributes": {"size": null, "type": "arrow"}}, {"key": "104", "source": "101", "target": "106", "attributes": {"size": null, "type": "arrow"}}, {"key": "105", "source": "101", "target": "107", "attributes": {"size": null, "type": "arrow"}}, {"key": "106", "source": "101", "target": "108", "attributes": {"size": null, "type": "arrow"}}, {"key": "107", "source": "101", "target": "109", "attributes": {"size": null, "type": "arrow"}}, {"key": "108", "source": "101", "target": "110", "attributes": {"size": null, "type": "arrow"}}, {"key": "109", "source": "101", "target": "111", "attributes": {"size": null, "type": "arrow"}}, {"key": "110", "source": "101", "target": "112", "attributes": {"size": null, "type": "arrow"}}, {"key": "111", "source": "101", "target": "113", "attributes": {"size": null, "type": "arrow"}}, {"key": "112", "source": "101", "target": "114", "attributes": {"size": null, "type": "arrow"}}, {"key": "113", "source": "101", "target": "115", "attributes": {"size": null, "type": "arrow"}}, {"key": "114", "source": "101", "target": "116", "attributes": {"size": null, "type": "arrow"}}, {"key": "115", "source": "101", "target": "117", "attributes": {"size": null, "type": "arrow"}}, {"key": "116", "source": "101", "target": "118", "attributes": {"size": null, "type": "arrow"}}, {"key": "117", "source": "101", "target": "119", "attributes": {"size": null, "type": "arrow"}}, {"key": "118", "source": "120", "target": "128", "attributes": {"size": null, "type": "arrow"}}, {"key": "119", "source": "120", "target": "129", "attributes": {"size": null, "type": "arrow"}}, {"key": "120", "source": "120", "target": "130", "attributes": {"size": null, "type": "arrow"}}, {"key": "121", "source": "120", "target": "131", "attributes": {"size": null, "type": "arrow"}}, {"key": "122", "source": "120", "target": "132", "attributes": {"size": null, "type": "arrow"}}, {"key": "123", "source": "120", "target": "133", "attributes": {"size": null, "type": "arrow"}}, {"key": "124", "source": "120", "target": "134", "attributes": {"size": null, "type": "arrow"}}, {"key": "125", "source": "120", "target": "135", "attributes": {"size": null, "type": "arrow"}}, {"key": "126", "source": "120", "target": "136", "attributes": {"size": null, "type": "arrow"}}, {"key": "127", "source": "120", "target": "121", "attributes": {"size": null, "type": "arrow"}}, {"key": "128", "source": "120", "target": "122", "attributes": {"size": null, "type": "arrow"}}, {"key": "129", "source": "120", "target": "123", "attributes": {"size": null, "type": "arrow"}}, {"key": "130", "source": "120", "target": "124", "attributes": {"size": null, "type": "arrow"}}, {"key": "131", "source": "120", "target": "125", "attributes": {"size": null, "type": "arrow"}}, {"key": "132", "source": "120", "target": "126", "attributes": {"size": null, "type": "arrow"}}, {"key": "133", "source": "120", "target": "127", "attributes": {"size": null, "type": "arrow"}}, {"key": "134", "source": "137", "target": "138", "attributes": {"size": null, "type": "arrow"}}, {"key": "135", "source": "137", "target": "139", "attributes": {"size": null, "type": "arrow"}}, {"key": "136", "source": "137", "target": "140", "attributes": {"size": null, "type": "arrow"}}, {"key": "137", "source": "137", "target": "141", "attributes": {"size": null, "type": "arrow"}}, {"key": "138", "source": "137", "target": "142", "attributes": {"size": null, "type": "arrow"}}, {"key": "139", "source": "137", "target": "143", "attributes": {"size": null, "type": "arrow"}}, {"key": "140", "source": "137", "target": "144", "attributes": {"size": null, "type": "arrow"}}, {"key": "141", "source": "137", "target": "145", "attributes": {"size": null, "type": "arrow"}}, {"key": "142", "source": "137", "target": "146", "attributes": {"size": null, "type": "arrow"}}, {"key": "143", "source": "137", "target": "147", "attributes": {"size": null, "type": "arrow"}}, {"key": "144", "source": "137", "target": "148", "attributes": {"size": null, "type": "arrow"}}, {"key": "145", "source": "137", "target": "149", "attributes": {"size": null, "type": "arrow"}}, {"key": "146", "source": "137", "target": "150", "attributes": {"size": null, "type": "arrow"}}, {"key": "147", "source": "137", "target": "151", "attributes": {"size": null, "type": "arrow"}}, {"key": "148", "source": "137", "target": "152", "attributes": {"size": null, "type": "arrow"}}, {"key": "149", "source": "137", "target": "153", "attributes": {"size": null, "type": "arrow"}}, {"key": "150", "source": "137", "target": "154", "attributes": {"size": null, "type": "arrow"}}, {"key": "151", "source": "137", "target": "155", "attributes": {"size": null, "type": "arrow"}}, {"key": "152", "source": "137", "target": "156", "attributes": {"size": null, "type": "arrow"}}, {"key": "153", "source": "137", "target": "157", "attributes": {"size": null, "type": "arrow"}}, {"key": "154", "source": "137", "target": "158", "attributes": {"size": null, "type": "arrow"}}, {"key": "155", "source": "137", "target": "159", "attributes": {"size": null, "type": "arrow"}}, {"key": "156", "source": "137", "target": "160", "attributes": {"size": null, "type": "arrow"}}, {"key": "157", "source": "137", "target": "161", "attributes": {"size": null, "type": "arrow"}}, {"key": "158", "source": "137", "target": "162", "attributes": {"size": null, "type": "arrow"}}, {"key": "159", "source": "137", "target": "163", "attributes": {"size": null, "type": "arrow"}}, {"key": "160", "source": "137", "target": "164", "attributes": {"size": null, "type": "arrow"}}, {"key": "161", "source": "137", "target": "165", "attributes": {"size": null, "type": "arrow"}}, {"key": "162", "source": "137", "target": "166", "attributes": {"size": null, "type": "arrow"}}, {"key": "163", "source": "137", "target": "167", "attributes": {"size": null, "type": "arrow"}}, {"key": "164", "source": "137", "target": "168", "attributes": {"size": null, "type": "arrow"}}, {"key": "165", "source": "137", "target": "169", "attributes": {"size": null, "type": "arrow"}}, {"key": "166", "source": "137", "target": "170", "attributes": {"size": null, "type": "arrow"}}, {"key": "167", "source": "137", "target": "171", "attributes": {"size": null, "type": "arrow"}}, {"key": "168", "source": "137", "target": "172", "attributes": {"size": null, "type": "arrow"}}, {"key": "169", "source": "173", "target": "176", "attributes": {"size": null, "type": "arrow"}}, {"key": "170", "source": "173", "target": "177", "attributes": {"size": null, "type": "arrow"}}, {"key": "171", "source": "173", "target": "174", "attributes": {"size": null, "type": "arrow"}}, {"key": "172", "source": "173", "target": "175", "attributes": {"size": null, "type": "arrow"}}, {"key": "173", "source": "178", "target": "192", "attributes": {"size": null, "type": "arrow"}}, {"key": "174", "source": "178", "target": "193", "attributes": {"size": null, "type": "arrow"}}, {"key": "175", "source": "178", "target": "194", "attributes": {"size": null, "type": "arrow"}}, {"key": "176", "source": "178", "target": "195", "attributes": {"size": null, "type": "arrow"}}, {"key": "177", "source": "178", "target": "196", "attributes": {"size": null, "type": "arrow"}}, {"key": "178", "source": "178", "target": "179", "attributes": {"size": null, "type": "arrow"}}, {"key": "179", "source": "178", "target": "180", "attributes": {"size": null, "type": "arrow"}}, {"key": "180", "source": "178", "target": "181", "attributes": {"size": null, "type": "arrow"}}, {"key": "181", "source": "178", "target": "182", "attributes": {"size": null, "type": "arrow"}}, {"key": "182", "source": "178", "target": "183", "attributes": {"size": null, "type": "arrow"}}, {"key": "183", "source": "178", "target": "184", "attributes": {"size": null, "type": "arrow"}}, {"key": "184", "source": "178", "target": "185", "attributes": {"size": null, "type": "arrow"}}, {"key": "185", "source": "178", "target": "186", "attributes": {"size": null, "type": "arrow"}}, {"key": "186", "source": "178", "target": "187", "attributes": {"size": null, "type": "arrow"}}, {"key": "187", "source": "178", "target": "188", "attributes": {"size": null, "type": "arrow"}}, {"key": "188", "source": "178", "target": "189", "attributes": {"size": null, "type": "arrow"}}, {"key": "189", "source": "178", "target": "190", "attributes": {"size": null, "type": "arrow"}}, {"key": "190", "source": "178", "target": "191", "attributes": {"size": null, "type": "arrow"}}, {"key": "191", "source": "197", "target": "198", "attributes": {"size": null, "type": "arrow"}}, {"key": "192", "source": "199", "target": "200", "attributes": {"size": null, "type": "arrow"}}, {"key": "193", "source": "199", "target": "201", "attributes": {"size": null, "type": "arrow"}}, {"key": "194", "source": "199", "target": "202", "attributes": {"size": null, "type": "arrow"}}, {"key": "195", "source": "199", "target": "203", "attributes": {"size": null, "type": "arrow"}}, {"key": "196", "source": "199", "target": "204", "attributes": {"size": null, "type": "arrow"}}, {"key": "197", "source": "199", "target": "205", "attributes": {"size": null, "type": "arrow"}}, {"key": "198", "source": "199", "target": "206", "attributes": {"size": null, "type": "arrow"}}, {"key": "199", "source": "199", "target": "207", "attributes": {"size": null, "type": "arrow"}}, {"key": "200", "source": "199", "target": "208", "attributes": {"size": null, "type": "arrow"}}, {"key": "201", "source": "199", "target": "209", "attributes": {"size": null, "type": "arrow"}}, {"key": "202", "source": "199", "target": "210", "attributes": {"size": null, "type": "arrow"}}, {"key": "203", "source": "199", "target": "211", "attributes": {"size": null, "type": "arrow"}}, {"key": "204", "source": "199", "target": "212", "attributes": {"size": null, "type": "arrow"}}, {"key": "205", "source": "213", "target": "214", "attributes": {"size": null, "type": "arrow"}}, {"key": "206", "source": "213", "target": "215", "attributes": {"size": null, "type": "arrow"}}, {"key": "207", "source": "213", "target": "216", "attributes": {"size": null, "type": "arrow"}}, {"key": "208", "source": "213", "target": "217", "attributes": {"size": null, "type": "arrow"}}, {"key": "209", "source": "213", "target": "218", "attributes": {"size": null, "type": "arrow"}}, {"key": "210", "source": "213", "target": "219", "attributes": {"size": null, "type": "arrow"}}, {"key": "211", "source": "213", "target": "220", "attributes": {"size": null, "type": "arrow"}}, {"key": "212", "source": "213", "target": "221", "attributes": {"size": null, "type": "arrow"}}, {"key": "213", "source": "222", "target": "224", "attributes": {"size": null, "type": "arrow"}}, {"key": "214", "source": "222", "target": "225", "attributes": {"size": null, "type": "arrow"}}, {"key": "215", "source": "222", "target": "226", "attributes": {"size": null, "type": "arrow"}}, {"key": "216", "source": "222", "target": "227", "attributes": {"size": null, "type": "arrow"}}, {"key": "217", "source": "222", "target": "202", "attributes": {"size": null, "type": "arrow"}}, {"key": "218", "source": "222", "target": "223", "attributes": {"size": null, "type": "arrow"}}, {"key": "219", "source": "228", "target": "229", "attributes": {"size": null, "type": "arrow"}}, {"key": "220", "source": "228", "target": "230", "attributes": {"size": null, "type": "arrow"}}, {"key": "221", "source": "228", "target": "231", "attributes": {"size": null, "type": "arrow"}}, {"key": "222", "source": "228", "target": "232", "attributes": {"size": null, "type": "arrow"}}, {"key": "223", "source": "228", "target": "233", "attributes": {"size": null, "type": "arrow"}}, {"key": "224", "source": "234", "target": "235", "attributes": {"size": null, "type": "arrow"}}, {"key": "225", "source": "234", "target": "236", "attributes": {"size": null, "type": "arrow"}}, {"key": "226", "source": "234", "target": "237", "attributes": {"size": null, "type": "arrow"}}, {"key": "227", "source": "234", "target": "238", "attributes": {"size": null, "type": "arrow"}}, {"key": "228", "source": "234", "target": "239", "attributes": {"size": null, "type": "arrow"}}, {"key": "229", "source": "234", "target": "240", "attributes": {"size": null, "type": "arrow"}}, {"key": "230", "source": "234", "target": "241", "attributes": {"size": null, "type": "arrow"}}, {"key": "231", "source": "234", "target": "242", "attributes": {"size": null, "type": "arrow"}}, {"key": "232", "source": "234", "target": "243", "attributes": {"size": null, "type": "arrow"}}, {"key": "233", "source": "234", "target": "244", "attributes": {"size": null, "type": "arrow"}}, {"key": "234", "source": "234", "target": "245", "attributes": {"size": null, "type": "arrow"}}, {"key": "235", "source": "234", "target": "123", "attributes": {"size": null, "type": "arrow"}}, {"key": "236", "source": "246", "target": "247", "attributes": {"size": null, "type": "arrow"}}, {"key": "237", "source": "246", "target": "248", "attributes": {"size": null, "type": "arrow"}}, {"key": "238", "source": "246", "target": "249", "attributes": {"size": null, "type": "arrow"}}, {"key": "239", "source": "246", "target": "250", "attributes": {"size": null, "type": "arrow"}}, {"key": "240", "source": "246", "target": "251", "attributes": {"size": null, "type": "arrow"}}, {"key": "241", "source": "246", "target": "252", "attributes": {"size": null, "type": "arrow"}}, {"key": "242", "source": "246", "target": "253", "attributes": {"size": null, "type": "arrow"}}, {"key": "243", "source": "246", "target": "254", "attributes": {"size": null, "type": "arrow"}}, {"key": "244", "source": "255", "target": "256", "attributes": {"size": null, "type": "arrow"}}, {"key": "245", "source": "255", "target": "257", "attributes": {"size": null, "type": "arrow"}}, {"key": "246", "source": "255", "target": "258", "attributes": {"size": null, "type": "arrow"}}, {"key": "247", "source": "255", "target": "259", "attributes": {"size": null, "type": "arrow"}}, {"key": "248", "source": "255", "target": "260", "attributes": {"size": null, "type": "arrow"}}, {"key": "249", "source": "255", "target": "261", "attributes": {"size": null, "type": "arrow"}}, {"key": "250", "source": "255", "target": "262", "attributes": {"size": null, "type": "arrow"}}, {"key": "251", "source": "263", "target": "264", "attributes": {"size": null, "type": "arrow"}}, {"key": "252", "source": "263", "target": "265", "attributes": {"size": null, "type": "arrow"}}, {"key": "253", "source": "263", "target": "266", "attributes": {"size": null, "type": "arrow"}}, {"key": "254", "source": "263", "target": "267", "attributes": {"size": null, "type": "arrow"}}, {"key": "255", "source": "263", "target": "268", "attributes": {"size": null, "type": "arrow"}}, {"key": "256", "source": "263", "target": "269", "attributes": {"size": null, "type": "arrow"}}, {"key": "257", "source": "263", "target": "270", "attributes": {"size": null, "type": "arrow"}}, {"key": "258", "source": "263", "target": "271", "attributes": {"size": null, "type": "arrow"}}, {"key": "259", "source": "263", "target": "272", "attributes": {"size": null, "type": "arrow"}}, {"key": "260", "source": "273", "target": "274", "attributes": {"size": null, "type": "arrow"}}, {"key": "261", "source": "273", "target": "275", "attributes": {"size": null, "type": "arrow"}}, {"key": "262", "source": "273", "target": "276", "attributes": {"size": null, "type": "arrow"}}, {"key": "263", "source": "273", "target": "277", "attributes": {"size": null, "type": "arrow"}}, {"key": "264", "source": "273", "target": "278", "attributes": {"size": null, "type": "arrow"}}, {"key": "265", "source": "273", "target": "279", "attributes": {"size": null, "type": "arrow"}}, {"key": "266", "source": "273", "target": "280", "attributes": {"size": null, "type": "arrow"}}, {"key": "267", "source": "273", "target": "281", "attributes": {"size": null, "type": "arrow"}}, {"key": "268", "source": "273", "target": "282", "attributes": {"size": null, "type": "arrow"}}, {"key": "269", "source": "273", "target": "283", "attributes": {"size": null, "type": "arrow"}}, {"key": "270", "source": "273", "target": "284", "attributes": {"size": null, "type": "arrow"}}, {"key": "271", "source": "273", "target": "285", "attributes": {"size": null, "type": "arrow"}}, {"key": "272", "source": "273", "target": "286", "attributes": {"size": null, "type": "arrow"}}, {"key": "273", "source": "273", "target": "287", "attributes": {"size": null, "type": "arrow"}}, {"key": "274", "source": "273", "target": "288", "attributes": {"size": null, "type": "arrow"}}, {"key": "275", "source": "273", "target": "289", "attributes": {"size": null, "type": "arrow"}}, {"key": "276", "source": "273", "target": "290", "attributes": {"size": null, "type": "arrow"}}, {"key": "277", "source": "273", "target": "291", "attributes": {"size": null, "type": "arrow"}}, {"key": "278", "source": "273", "target": "292", "attributes": {"size": null, "type": "arrow"}}, {"key": "279", "source": "273", "target": "293", "attributes": {"size": null, "type": "arrow"}}, {"key": "280", "source": "273", "target": "294", "attributes": {"size": null, "type": "arrow"}}, {"key": "281", "source": "273", "target": "295", "attributes": {"size": null, "type": "arrow"}}, {"key": "282", "source": "273", "target": "296", "attributes": {"size": null, "type": "arrow"}}, {"key": "283", "source": "273", "target": "297", "attributes": {"size": null, "type": "arrow"}}, {"key": "284", "source": "273", "target": "298", "attributes": {"size": null, "type": "arrow"}}, {"key": "285", "source": "273", "target": "299", "attributes": {"size": null, "type": "arrow"}}, {"key": "286", "source": "273", "target": "300", "attributes": {"size": null, "type": "arrow"}}, {"key": "287", "source": "273", "target": "301", "attributes": {"size": null, "type": "arrow"}}, {"key": "288", "source": "273", "target": "302", "attributes": {"size": null, "type": "arrow"}}, {"key": "289", "source": "273", "target": "303", "attributes": {"size": null, "type": "arrow"}}, {"key": "290", "source": "273", "target": "304", "attributes": {"size": null, "type": "arrow"}}, {"key": "291", "source": "273", "target": "305", "attributes": {"size": null, "type": "arrow"}}, {"key": "292", "source": "273", "target": "306", "attributes": {"size": null, "type": "arrow"}}, {"key": "293", "source": "273", "target": "307", "attributes": {"size": null, "type": "arrow"}}, {"key": "294", "source": "273", "target": "308", "attributes": {"size": null, "type": "arrow"}}, {"key": "295", "source": "273", "target": "309", "attributes": {"size": null, "type": "arrow"}}, {"key": "296", "source": "273", "target": "310", "attributes": {"size": null, "type": "arrow"}}, {"key": "297", "source": "273", "target": "311", "attributes": {"size": null, "type": "arrow"}}, {"key": "298", "source": "273", "target": "312", "attributes": {"size": null, "type": "arrow"}}, {"key": "299", "source": "273", "target": "313", "attributes": {"size": null, "type": "arrow"}}, {"key": "300", "source": "273", "target": "314", "attributes": {"size": null, "type": "arrow"}}, {"key": "301", "source": "273", "target": "315", "attributes": {"size": null, "type": "arrow"}}, {"key": "302", "source": "273", "target": "316", "attributes": {"size": null, "type": "arrow"}}, {"key": "303", "source": "273", "target": "317", "attributes": {"size": null, "type": "arrow"}}, {"key": "304", "source": "273", "target": "318", "attributes": {"size": null, "type": "arrow"}}, {"key": "305", "source": "273", "target": "319", "attributes": {"size": null, "type": "arrow"}}, {"key": "306", "source": "273", "target": "320", "attributes": {"size": null, "type": "arrow"}}, {"key": "307", "source": "273", "target": "321", "attributes": {"size": null, "type": "arrow"}}, {"key": "308", "source": "273", "target": "322", "attributes": {"size": null, "type": "arrow"}}, {"key": "309", "source": "273", "target": "323", "attributes": {"size": null, "type": "arrow"}}, {"key": "310", "source": "273", "target": "324", "attributes": {"size": null, "type": "arrow"}}, {"key": "311", "source": "273", "target": "325", "attributes": {"size": null, "type": "arrow"}}, {"key": "312", "source": "273", "target": "326", "attributes": {"size": null, "type": "arrow"}}, {"key": "313", "source": "273", "target": "327", "attributes": {"size": null, "type": "arrow"}}, {"key": "314", "source": "273", "target": "328", "attributes": {"size": null, "type": "arrow"}}, {"key": "315", "source": "273", "target": "329", "attributes": {"size": null, "type": "arrow"}}, {"key": "316", "source": "273", "target": "330", "attributes": {"size": null, "type": "arrow"}}, {"key": "317", "source": "273", "target": "331", "attributes": {"size": null, "type": "arrow"}}, {"key": "318", "source": "273", "target": "332", "attributes": {"size": null, "type": "arrow"}}, {"key": "319", "source": "273", "target": "333", "attributes": {"size": null, "type": "arrow"}}, {"key": "320", "source": "273", "target": "334", "attributes": {"size": null, "type": "arrow"}}, {"key": "321", "source": "335", "target": "336", "attributes": {"size": null, "type": "arrow"}}, {"key": "322", "source": "335", "target": "337", "attributes": {"size": null, "type": "arrow"}}, {"key": "323", "source": "335", "target": "338", "attributes": {"size": null, "type": "arrow"}}, {"key": "324", "source": "335", "target": "339", "attributes": {"size": null, "type": "arrow"}}, {"key": "325", "source": "335", "target": "340", "attributes": {"size": null, "type": "arrow"}}, {"key": "326", "source": "335", "target": "341", "attributes": {"size": null, "type": "arrow"}}, {"key": "327", "source": "335", "target": "342", "attributes": {"size": null, "type": "arrow"}}, {"key": "328", "source": "335", "target": "343", "attributes": {"size": null, "type": "arrow"}}, {"key": "329", "source": "335", "target": "344", "attributes": {"size": null, "type": "arrow"}}, {"key": "330", "source": "335", "target": "345", "attributes": {"size": null, "type": "arrow"}}, {"key": "331", "source": "335", "target": "346", "attributes": {"size": null, "type": "arrow"}}, {"key": "332", "source": "335", "target": "347", "attributes": {"size": null, "type": "arrow"}}, {"key": "333", "source": "335", "target": "348", "attributes": {"size": null, "type": "arrow"}}, {"key": "334", "source": "335", "target": "349", "attributes": {"size": null, "type": "arrow"}}, {"key": "335", "source": "335", "target": "350", "attributes": {"size": null, "type": "arrow"}}, {"key": "336", "source": "335", "target": "351", "attributes": {"size": null, "type": "arrow"}}, {"key": "337", "source": "335", "target": "352", "attributes": {"size": null, "type": "arrow"}}, {"key": "338", "source": "335", "target": "353", "attributes": {"size": null, "type": "arrow"}}, {"key": "339", "source": "335", "target": "354", "attributes": {"size": null, "type": "arrow"}}, {"key": "340", "source": "335", "target": "355", "attributes": {"size": null, "type": "arrow"}}, {"key": "341", "source": "335", "target": "356", "attributes": {"size": null, "type": "arrow"}}, {"key": "342", "source": "335", "target": "357", "attributes": {"size": null, "type": "arrow"}}, {"key": "343", "source": "335", "target": "358", "attributes": {"size": null, "type": "arrow"}}, {"key": "344", "source": "335", "target": "359", "attributes": {"size": null, "type": "arrow"}}, {"key": "345", "source": "335", "target": "360", "attributes": {"size": null, "type": "arrow"}}, {"key": "346", "source": "335", "target": "361", "attributes": {"size": null, "type": "arrow"}}, {"key": "347", "source": "335", "target": "362", "attributes": {"size": null, "type": "arrow"}}, {"key": "348", "source": "335", "target": "363", "attributes": {"size": null, "type": "arrow"}}, {"key": "349", "source": "335", "target": "364", "attributes": {"size": null, "type": "arrow"}}, {"key": "350", "source": "335", "target": "365", "attributes": {"size": null, "type": "arrow"}}, {"key": "351", "source": "335", "target": "366", "attributes": {"size": null, "type": "arrow"}}, {"key": "352", "source": "335", "target": "367", "attributes": {"size": null, "type": "arrow"}}, {"key": "353", "source": "335", "target": "368", "attributes": {"size": null, "type": "arrow"}}, {"key": "354", "source": "335", "target": "369", "attributes": {"size": null, "type": "arrow"}}, {"key": "355", "source": "335", "target": "370", "attributes": {"size": null, "type": "arrow"}}, {"key": "356", "source": "335", "target": "371", "attributes": {"size": null, "type": "arrow"}}, {"key": "357", "source": "335", "target": "372", "attributes": {"size": null, "type": "arrow"}}, {"key": "358", "source": "335", "target": "373", "attributes": {"size": null, "type": "arrow"}}, {"key": "359", "source": "374", "target": "375", "attributes": {"size": null, "type": "arrow"}}, {"key": "360", "source": "374", "target": "376", "attributes": {"size": null, "type": "arrow"}}, {"key": "361", "source": "377", "target": "378", "attributes": {"size": null, "type": "arrow"}}, {"key": "362", "source": "377", "target": "379", "attributes": {"size": null, "type": "arrow"}}, {"key": "363", "source": "377", "target": "380", "attributes": {"size": null, "type": "arrow"}}, {"key": "364", "source": "377", "target": "381", "attributes": {"size": null, "type": "arrow"}}, {"key": "365", "source": "377", "target": "382", "attributes": {"size": null, "type": "arrow"}}, {"key": "366", "source": "377", "target": "383", "attributes": {"size": null, "type": "arrow"}}, {"key": "367", "source": "377", "target": "384", "attributes": {"size": null, "type": "arrow"}}, {"key": "368", "source": "377", "target": "385", "attributes": {"size": null, "type": "arrow"}}, {"key": "369", "source": "377", "target": "386", "attributes": {"size": null, "type": "arrow"}}, {"key": "370", "source": "377", "target": "387", "attributes": {"size": null, "type": "arrow"}}, {"key": "371", "source": "377", "target": "388", "attributes": {"size": null, "type": "arrow"}}, {"key": "372", "source": "377", "target": "389", "attributes": {"size": null, "type": "arrow"}}, {"key": "373", "source": "377", "target": "390", "attributes": {"size": null, "type": "arrow"}}, {"key": "374", "source": "377", "target": "391", "attributes": {"size": null, "type": "arrow"}}, {"key": "375", "source": "377", "target": "392", "attributes": {"size": null, "type": "arrow"}}, {"key": "376", "source": "377", "target": "393", "attributes": {"size": null, "type": "arrow"}}, {"key": "377", "source": "377", "target": "394", "attributes": {"size": null, "type": "arrow"}}, {"key": "378", "source": "377", "target": "395", "attributes": {"size": null, "type": "arrow"}}, {"key": "379", "source": "377", "target": "396", "attributes": {"size": null, "type": "arrow"}}, {"key": "380", "source": "377", "target": "397", "attributes": {"size": null, "type": "arrow"}}, {"key": "381", "source": "377", "target": "398", "attributes": {"size": null, "type": "arrow"}}, {"key": "382", "source": "377", "target": "399", "attributes": {"size": null, "type": "arrow"}}, {"key": "383", "source": "377", "target": "400", "attributes": {"size": null, "type": "arrow"}}, {"key": "384", "source": "377", "target": "401", "attributes": {"size": null, "type": "arrow"}}, {"key": "385", "source": "377", "target": "402", "attributes": {"size": null, "type": "arrow"}}, {"key": "386", "source": "377", "target": "403", "attributes": {"size": null, "type": "arrow"}}, {"key": "387", "source": "377", "target": "404", "attributes": {"size": null, "type": "arrow"}}, {"key": "388", "source": "377", "target": "405", "attributes": {"size": null, "type": "arrow"}}, {"key": "389", "source": "377", "target": "406", "attributes": {"size": null, "type": "arrow"}}, {"key": "390", "source": "377", "target": "407", "attributes": {"size": null, "type": "arrow"}}, {"key": "391", "source": "377", "target": "408", "attributes": {"size": null, "type": "arrow"}}, {"key": "392", "source": "377", "target": "409", "attributes": {"size": null, "type": "arrow"}}, {"key": "393", "source": "377", "target": "410", "attributes": {"size": null, "type": "arrow"}}, {"key": "394", "source": "377", "target": "411", "attributes": {"size": null, "type": "arrow"}}, {"key": "395", "source": "377", "target": "412", "attributes": {"size": null, "type": "arrow"}}, {"key": "396", "source": "377", "target": "413", "attributes": {"size": null, "type": "arrow"}}, {"key": "397", "source": "377", "target": "414", "attributes": {"size": null, "type": "arrow"}}, {"key": "398", "source": "377", "target": "415", "attributes": {"size": null, "type": "arrow"}}, {"key": "399", "source": "377", "target": "416", "attributes": {"size": null, "type": "arrow"}}, {"key": "400", "source": "377", "target": "417", "attributes": {"size": null, "type": "arrow"}}, {"key": "401", "source": "377", "target": "418", "attributes": {"size": null, "type": "arrow"}}, {"key": "402", "source": "377", "target": "419", "attributes": {"size": null, "type": "arrow"}}, {"key": "403", "source": "377", "target": "420", "attributes": {"size": null, "type": "arrow"}}, {"key": "404", "source": "377", "target": "421", "attributes": {"size": null, "type": "arrow"}}, {"key": "405", "source": "422", "target": "423", "attributes": {"size": null, "type": "arrow"}}, {"key": "406", "source": "422", "target": "424", "attributes": {"size": null, "type": "arrow"}}, {"key": "407", "source": "422", "target": "425", "attributes": {"size": null, "type": "arrow"}}, {"key": "408", "source": "422", "target": "426", "attributes": {"size": null, "type": "arrow"}}, {"key": "409", "source": "422", "target": "427", "attributes": {"size": null, "type": "arrow"}}, {"key": "410", "source": "422", "target": "428", "attributes": {"size": null, "type": "arrow"}}, {"key": "411", "source": "422", "target": "429", "attributes": {"size": null, "type": "arrow"}}, {"key": "412", "source": "422", "target": "430", "attributes": {"size": null, "type": "arrow"}}, {"key": "413", "source": "422", "target": "431", "attributes": {"size": null, "type": "arrow"}}, {"key": "414", "source": "422", "target": "432", "attributes": {"size": null, "type": "arrow"}}, {"key": "415", "source": "422", "target": "433", "attributes": {"size": null, "type": "arrow"}}, {"key": "416", "source": "422", "target": "434", "attributes": {"size": null, "type": "arrow"}}, {"key": "417", "source": "422", "target": "435", "attributes": {"size": null, "type": "arrow"}}, {"key": "418", "source": "422", "target": "436", "attributes": {"size": null, "type": "arrow"}}, {"key": "419", "source": "422", "target": "437", "attributes": {"size": null, "type": "arrow"}}, {"key": "420", "source": "422", "target": "438", "attributes": {"size": null, "type": "arrow"}}, {"key": "421", "source": "422", "target": "439", "attributes": {"size": null, "type": "arrow"}}, {"key": "422", "source": "422", "target": "440", "attributes": {"size": null, "type": "arrow"}}, {"key": "423", "source": "422", "target": "441", "attributes": {"size": null, "type": "arrow"}}, {"key": "424", "source": "422", "target": "442", "attributes": {"size": null, "type": "arrow"}}, {"key": "425", "source": "422", "target": "443", "attributes": {"size": null, "type": "arrow"}}, {"key": "426", "source": "422", "target": "444", "attributes": {"size": null, "type": "arrow"}}, {"key": "427", "source": "422", "target": "445", "attributes": {"size": null, "type": "arrow"}}, {"key": "428", "source": "422", "target": "446", "attributes": {"size": null, "type": "arrow"}}, {"key": "429", "source": "422", "target": "447", "attributes": {"size": null, "type": "arrow"}}, {"key": "430", "source": "422", "target": "448", "attributes": {"size": null, "type": "arrow"}}, {"key": "431", "source": "422", "target": "449", "attributes": {"size": null, "type": "arrow"}}, {"key": "432", "source": "422", "target": "450", "attributes": {"size": null, "type": "arrow"}}, {"key": "433", "source": "451", "target": "452", "attributes": {"size": null, "type": "arrow"}}, {"key": "434", "source": "451", "target": "453", "attributes": {"size": null, "type": "arrow"}}, {"key": "435", "source": "451", "target": "454", "attributes": {"size": null, "type": "arrow"}}, {"key": "436", "source": "451", "target": "455", "attributes": {"size": null, "type": "arrow"}}, {"key": "437", "source": "451", "target": "456", "attributes": {"size": null, "type": "arrow"}}, {"key": "438", "source": "451", "target": "457", "attributes": {"size": null, "type": "arrow"}}, {"key": "439", "source": "451", "target": "458", "attributes": {"size": null, "type": "arrow"}}, {"key": "440", "source": "459", "target": "328", "attributes": {"size": null, "type": "arrow"}}, {"key": "441", "source": "459", "target": "460", "attributes": {"size": null, "type": "arrow"}}, {"key": "442", "source": "459", "target": "461", "attributes": {"size": null, "type": "arrow"}}, {"key": "443", "source": "459", "target": "462", "attributes": {"size": null, "type": "arrow"}}, {"key": "444", "source": "459", "target": "463", "attributes": {"size": null, "type": "arrow"}}, {"key": "445", "source": "459", "target": "464", "attributes": {"size": null, "type": "arrow"}}, {"key": "446", "source": "459", "target": "465", "attributes": {"size": null, "type": "arrow"}}, {"key": "447", "source": "459", "target": "466", "attributes": {"size": null, "type": "arrow"}}, {"key": "448", "source": "459", "target": "467", "attributes": {"size": null, "type": "arrow"}}, {"key": "449", "source": "459", "target": "468", "attributes": {"size": null, "type": "arrow"}}, {"key": "450", "source": "459", "target": "469", "attributes": {"size": null, "type": "arrow"}}, {"key": "451", "source": "470", "target": "471", "attributes": {"size": null, "type": "arrow"}}, {"key": "452", "source": "470", "target": "472", "attributes": {"size": null, "type": "arrow"}}, {"key": "453", "source": "470", "target": "254", "attributes": {"size": null, "type": "arrow"}}, {"key": "454", "source": "473", "target": "474", "attributes": {"size": null, "type": "arrow"}}, {"key": "455", "source": "473", "target": "475", "attributes": {"size": null, "type": "arrow"}}, {"key": "456", "source": "473", "target": "476", "attributes": {"size": null, "type": "arrow"}}, {"key": "457", "source": "477", "target": "478", "attributes": {"size": null, "type": "arrow"}}, {"key": "458", "source": "477", "target": "479", "attributes": {"size": null, "type": "arrow"}}, {"key": "459", "source": "477", "target": "480", "attributes": {"size": null, "type": "arrow"}}, {"key": "460", "source": "477", "target": "481", "attributes": {"size": null, "type": "arrow"}}, {"key": "461", "source": "477", "target": "482", "attributes": {"size": null, "type": "arrow"}}, {"key": "462", "source": "477", "target": "483", "attributes": {"size": null, "type": "arrow"}}, {"key": "463", "source": "484", "target": "485", "attributes": {"size": null, "type": "arrow"}}, {"key": "464", "source": "484", "target": "486", "attributes": {"size": null, "type": "arrow"}}, {"key": "465", "source": "487", "target": "488", "attributes": {"size": null, "type": "arrow"}}, {"key": "466", "source": "489", "target": "346", "attributes": {"size": null, "type": "arrow"}}, {"key": "467", "source": "489", "target": "353", "attributes": {"size": null, "type": "arrow"}}, {"key": "468", "source": "489", "target": "355", "attributes": {"size": null, "type": "arrow"}}, {"key": "469", "source": "489", "target": "356", "attributes": {"size": null, "type": "arrow"}}, {"key": "470", "source": "489", "target": "370", "attributes": {"size": null, "type": "arrow"}}, {"key": "471", "source": "489", "target": "490", "attributes": {"size": null, "type": "arrow"}}, {"key": "472", "source": "489", "target": "491", "attributes": {"size": null, "type": "arrow"}}, {"key": "473", "source": "489", "target": "492", "attributes": {"size": null, "type": "arrow"}}, {"key": "474", "source": "489", "target": "493", "attributes": {"size": null, "type": "arrow"}}, {"key": "475", "source": "489", "target": "494", "attributes": {"size": null, "type": "arrow"}}, {"key": "476", "source": "489", "target": "495", "attributes": {"size": null, "type": "arrow"}}, {"key": "477", "source": "489", "target": "496", "attributes": {"size": null, "type": "arrow"}}, {"key": "478", "source": "489", "target": "497", "attributes": {"size": null, "type": "arrow"}}, {"key": "479", "source": "489", "target": "498", "attributes": {"size": null, "type": "arrow"}}, {"key": "480", "source": "489", "target": "499", "attributes": {"size": null, "type": "arrow"}}, {"key": "481", "source": "489", "target": "500", "attributes": {"size": null, "type": "arrow"}}, {"key": "482", "source": "489", "target": "501", "attributes": {"size": null, "type": "arrow"}}, {"key": "483", "source": "489", "target": "502", "attributes": {"size": null, "type": "arrow"}}, {"key": "484", "source": "489", "target": "503", "attributes": {"size": null, "type": "arrow"}}, {"key": "485", "source": "489", "target": "504", "attributes": {"size": null, "type": "arrow"}}, {"key": "486", "source": "489", "target": "505", "attributes": {"size": null, "type": "arrow"}}, {"key": "487", "source": "489", "target": "506", "attributes": {"size": null, "type": "arrow"}}, {"key": "488", "source": "489", "target": "507", "attributes": {"size": null, "type": "arrow"}}, {"key": "489", "source": "489", "target": "508", "attributes": {"size": null, "type": "arrow"}}, {"key": "490", "source": "489", "target": "509", "attributes": {"size": null, "type": "arrow"}}, {"key": "491", "source": "489", "target": "510", "attributes": {"size": null, "type": "arrow"}}, {"key": "492", "source": "489", "target": "511", "attributes": {"size": null, "type": "arrow"}}, {"key": "493", "source": "489", "target": "512", "attributes": {"size": null, "type": "arrow"}}, {"key": "494", "source": "489", "target": "513", "attributes": {"size": null, "type": "arrow"}}, {"key": "495", "source": "489", "target": "514", "attributes": {"size": null, "type": "arrow"}}, {"key": "496", "source": "489", "target": "515", "attributes": {"size": null, "type": "arrow"}}, {"key": "497", "source": "489", "target": "516", "attributes": {"size": null, "type": "arrow"}}, {"key": "498", "source": "489", "target": "517", "attributes": {"size": null, "type": "arrow"}}, {"key": "499", "source": "489", "target": "518", "attributes": {"size": null, "type": "arrow"}}, {"key": "500", "source": "489", "target": "519", "attributes": {"size": null, "type": "arrow"}}, {"key": "501", "source": "489", "target": "520", "attributes": {"size": null, "type": "arrow"}}, {"key": "502", "source": "489", "target": "521", "attributes": {"size": null, "type": "arrow"}}, {"key": "503", "source": "489", "target": "522", "attributes": {"size": null, "type": "arrow"}}, {"key": "504", "source": "489", "target": "523", "attributes": {"size": null, "type": "arrow"}}, {"key": "505", "source": "489", "target": "524", "attributes": {"size": null, "type": "arrow"}}, {"key": "506", "source": "489", "target": "525", "attributes": {"size": null, "type": "arrow"}}, {"key": "507", "source": "489", "target": "526", "attributes": {"size": null, "type": "arrow"}}, {"key": "508", "source": "489", "target": "527", "attributes": {"size": null, "type": "arrow"}}, {"key": "509", "source": "489", "target": "528", "attributes": {"size": null, "type": "arrow"}}, {"key": "510", "source": "489", "target": "529", "attributes": {"size": null, "type": "arrow"}}, {"key": "511", "source": "489", "target": "530", "attributes": {"size": null, "type": "arrow"}}, {"key": "512", "source": "489", "target": "531", "attributes": {"size": null, "type": "arrow"}}, {"key": "513", "source": "489", "target": "532", "attributes": {"size": null, "type": "arrow"}}, {"key": "514", "source": "489", "target": "533", "attributes": {"size": null, "type": "arrow"}}, {"key": "515", "source": "489", "target": "534", "attributes": {"size": null, "type": "arrow"}}, {"key": "516", "source": "489", "target": "535", "attributes": {"size": null, "type": "arrow"}}, {"key": "517", "source": "489", "target": "536", "attributes": {"size": null, "type": "arrow"}}, {"key": "518", "source": "489", "target": "537", "attributes": {"size": null, "type": "arrow"}}, {"key": "519", "source": "489", "target": "538", "attributes": {"size": null, "type": "arrow"}}, {"key": "520", "source": "489", "target": "539", "attributes": {"size": null, "type": "arrow"}}, {"key": "521", "source": "489", "target": "540", "attributes": {"size": null, "type": "arrow"}}, {"key": "522", "source": "489", "target": "541", "attributes": {"size": null, "type": "arrow"}}, {"key": "523", "source": "489", "target": "542", "attributes": {"size": null, "type": "arrow"}}, {"key": "524", "source": "489", "target": "543", "attributes": {"size": null, "type": "arrow"}}, {"key": "525", "source": "489", "target": "544", "attributes": {"size": null, "type": "arrow"}}, {"key": "526", "source": "489", "target": "545", "attributes": {"size": null, "type": "arrow"}}, {"key": "527", "source": "489", "target": "546", "attributes": {"size": null, "type": "arrow"}}, {"key": "528", "source": "489", "target": "547", "attributes": {"size": null, "type": "arrow"}}, {"key": "529", "source": "489", "target": "548", "attributes": {"size": null, "type": "arrow"}}, {"key": "530", "source": "489", "target": "549", "attributes": {"size": null, "type": "arrow"}}, {"key": "531", "source": "489", "target": "550", "attributes": {"size": null, "type": "arrow"}}, {"key": "532", "source": "489", "target": "551", "attributes": {"size": null, "type": "arrow"}}, {"key": "533", "source": "489", "target": "552", "attributes": {"size": null, "type": "arrow"}}, {"key": "534", "source": "489", "target": "553", "attributes": {"size": null, "type": "arrow"}}, {"key": "535", "source": "489", "target": "554", "attributes": {"size": null, "type": "arrow"}}, {"key": "536", "source": "489", "target": "555", "attributes": {"size": null, "type": "arrow"}}, {"key": "537", "source": "489", "target": "556", "attributes": {"size": null, "type": "arrow"}}, {"key": "538", "source": "489", "target": "557", "attributes": {"size": null, "type": "arrow"}}, {"key": "539", "source": "489", "target": "558", "attributes": {"size": null, "type": "arrow"}}, {"key": "540", "source": "489", "target": "559", "attributes": {"size": null, "type": "arrow"}}, {"key": "541", "source": "489", "target": "560", "attributes": {"size": null, "type": "arrow"}}, {"key": "542", "source": "489", "target": "561", "attributes": {"size": null, "type": "arrow"}}, {"key": "543", "source": "489", "target": "562", "attributes": {"size": null, "type": "arrow"}}, {"key": "544", "source": "489", "target": "563", "attributes": {"size": null, "type": "arrow"}}, {"key": "545", "source": "489", "target": "564", "attributes": {"size": null, "type": "arrow"}}, {"key": "546", "source": "489", "target": "565", "attributes": {"size": null, "type": "arrow"}}, {"key": "547", "source": "489", "target": "566", "attributes": {"size": null, "type": "arrow"}}, {"key": "548", "source": "489", "target": "567", "attributes": {"size": null, "type": "arrow"}}, {"key": "549", "source": "489", "target": "568", "attributes": {"size": null, "type": "arrow"}}, {"key": "550", "source": "489", "target": "569", "attributes": {"size": null, "type": "arrow"}}, {"key": "551", "source": "489", "target": "570", "attributes": {"size": null, "type": "arrow"}}, {"key": "552", "source": "489", "target": "571", "attributes": {"size": null, "type": "arrow"}}, {"key": "553", "source": "489", "target": "572", "attributes": {"size": null, "type": "arrow"}}, {"key": "554", "source": "489", "target": "573", "attributes": {"size": null, "type": "arrow"}}, {"key": "555", "source": "489", "target": "574", "attributes": {"size": null, "type": "arrow"}}, {"key": "556", "source": "489", "target": "575", "attributes": {"size": null, "type": "arrow"}}, {"key": "557", "source": "489", "target": "576", "attributes": {"size": null, "type": "arrow"}}, {"key": "558", "source": "489", "target": "577", "attributes": {"size": null, "type": "arrow"}}, {"key": "559", "source": "489", "target": "578", "attributes": {"size": null, "type": "arrow"}}, {"key": "560", "source": "489", "target": "579", "attributes": {"size": null, "type": "arrow"}}, {"key": "561", "source": "489", "target": "580", "attributes": {"size": null, "type": "arrow"}}, {"key": "562", "source": "489", "target": "581", "attributes": {"size": null, "type": "arrow"}}, {"key": "563", "source": "489", "target": "582", "attributes": {"size": null, "type": "arrow"}}, {"key": "564", "source": "489", "target": "583", "attributes": {"size": null, "type": "arrow"}}, {"key": "565", "source": "489", "target": "584", "attributes": {"size": null, "type": "arrow"}}, {"key": "566", "source": "489", "target": "585", "attributes": {"size": null, "type": "arrow"}}, {"key": "567", "source": "489", "target": "586", "attributes": {"size": null, "type": "arrow"}}, {"key": "568", "source": "489", "target": "587", "attributes": {"size": null, "type": "arrow"}}, {"key": "569", "source": "489", "target": "588", "attributes": {"size": null, "type": "arrow"}}, {"key": "570", "source": "489", "target": "589", "attributes": {"size": null, "type": "arrow"}}, {"key": "571", "source": "489", "target": "590", "attributes": {"size": null, "type": "arrow"}}, {"key": "572", "source": "489", "target": "591", "attributes": {"size": null, "type": "arrow"}}, {"key": "573", "source": "489", "target": "592", "attributes": {"size": null, "type": "arrow"}}, {"key": "574", "source": "489", "target": "593", "attributes": {"size": null, "type": "arrow"}}, {"key": "575", "source": "489", "target": "594", "attributes": {"size": null, "type": "arrow"}}, {"key": "576", "source": "489", "target": "595", "attributes": {"size": null, "type": "arrow"}}, {"key": "577", "source": "489", "target": "596", "attributes": {"size": null, "type": "arrow"}}, {"key": "578", "source": "489", "target": "597", "attributes": {"size": null, "type": "arrow"}}, {"key": "579", "source": "489", "target": "598", "attributes": {"size": null, "type": "arrow"}}, {"key": "580", "source": "489", "target": "599", "attributes": {"size": null, "type": "arrow"}}, {"key": "581", "source": "489", "target": "600", "attributes": {"size": null, "type": "arrow"}}, {"key": "582", "source": "489", "target": "601", "attributes": {"size": null, "type": "arrow"}}, {"key": "583", "source": "489", "target": "602", "attributes": {"size": null, "type": "arrow"}}, {"key": "584", "source": "489", "target": "603", "attributes": {"size": null, "type": "arrow"}}, {"key": "585", "source": "489", "target": "604", "attributes": {"size": null, "type": "arrow"}}, {"key": "586", "source": "489", "target": "605", "attributes": {"size": null, "type": "arrow"}}, {"key": "587", "source": "489", "target": "606", "attributes": {"size": null, "type": "arrow"}}, {"key": "588", "source": "489", "target": "607", "attributes": {"size": null, "type": "arrow"}}, {"key": "589", "source": "489", "target": "608", "attributes": {"size": null, "type": "arrow"}}, {"key": "590", "source": "489", "target": "609", "attributes": {"size": null, "type": "arrow"}}, {"key": "591", "source": "489", "target": "610", "attributes": {"size": null, "type": "arrow"}}, {"key": "592", "source": "489", "target": "611", "attributes": {"size": null, "type": "arrow"}}, {"key": "593", "source": "489", "target": "612", "attributes": {"size": null, "type": "arrow"}}, {"key": "594", "source": "489", "target": "613", "attributes": {"size": null, "type": "arrow"}}, {"key": "595", "source": "489", "target": "614", "attributes": {"size": null, "type": "arrow"}}, {"key": "596", "source": "489", "target": "615", "attributes": {"size": null, "type": "arrow"}}, {"key": "597", "source": "489", "target": "616", "attributes": {"size": null, "type": "arrow"}}, {"key": "598", "source": "489", "target": "617", "attributes": {"size": null, "type": "arrow"}}, {"key": "599", "source": "489", "target": "618", "attributes": {"size": null, "type": "arrow"}}, {"key": "600", "source": "489", "target": "619", "attributes": {"size": null, "type": "arrow"}}, {"key": "601", "source": "489", "target": "620", "attributes": {"size": null, "type": "arrow"}}, {"key": "602", "source": "489", "target": "621", "attributes": {"size": null, "type": "arrow"}}, {"key": "603", "source": "489", "target": "622", "attributes": {"size": null, "type": "arrow"}}, {"key": "604", "source": "489", "target": "623", "attributes": {"size": null, "type": "arrow"}}, {"key": "605", "source": "489", "target": "624", "attributes": {"size": null, "type": "arrow"}}, {"key": "606", "source": "489", "target": "625", "attributes": {"size": null, "type": "arrow"}}, {"key": "607", "source": "489", "target": "626", "attributes": {"size": null, "type": "arrow"}}, {"key": "608", "source": "489", "target": "627", "attributes": {"size": null, "type": "arrow"}}, {"key": "609", "source": "489", "target": "628", "attributes": {"size": null, "type": "arrow"}}, {"key": "610", "source": "489", "target": "629", "attributes": {"size": null, "type": "arrow"}}, {"key": "611", "source": "489", "target": "630", "attributes": {"size": null, "type": "arrow"}}, {"key": "612", "source": "489", "target": "631", "attributes": {"size": null, "type": "arrow"}}, {"key": "613", "source": "489", "target": "632", "attributes": {"size": null, "type": "arrow"}}, {"key": "614", "source": "489", "target": "633", "attributes": {"size": null, "type": "arrow"}}, {"key": "615", "source": "489", "target": "634", "attributes": {"size": null, "type": "arrow"}}, {"key": "616", "source": "489", "target": "635", "attributes": {"size": null, "type": "arrow"}}, {"key": "617", "source": "489", "target": "636", "attributes": {"size": null, "type": "arrow"}}, {"key": "618", "source": "489", "target": "637", "attributes": {"size": null, "type": "arrow"}}, {"key": "619", "source": "489", "target": "638", "attributes": {"size": null, "type": "arrow"}}, {"key": "620", "source": "489", "target": "639", "attributes": {"size": null, "type": "arrow"}}, {"key": "621", "source": "489", "target": "640", "attributes": {"size": null, "type": "arrow"}}, {"key": "622", "source": "489", "target": "641", "attributes": {"size": null, "type": "arrow"}}, {"key": "623", "source": "489", "target": "642", "attributes": {"size": null, "type": "arrow"}}, {"key": "624", "source": "489", "target": "643", "attributes": {"size": null, "type": "arrow"}}, {"key": "625", "source": "489", "target": "644", "attributes": {"size": null, "type": "arrow"}}, {"key": "626", "source": "489", "target": "645", "attributes": {"size": null, "type": "arrow"}}, {"key": "627", "source": "489", "target": "646", "attributes": {"size": null, "type": "arrow"}}, {"key": "628", "source": "489", "target": "647", "attributes": {"size": null, "type": "arrow"}}, {"key": "629", "source": "489", "target": "648", "attributes": {"size": null, "type": "arrow"}}, {"key": "630", "source": "489", "target": "649", "attributes": {"size": null, "type": "arrow"}}, {"key": "631", "source": "489", "target": "650", "attributes": {"size": null, "type": "arrow"}}, {"key": "632", "source": "489", "target": "651", "attributes": {"size": null, "type": "arrow"}}, {"key": "633", "source": "489", "target": "652", "attributes": {"size": null, "type": "arrow"}}, {"key": "634", "source": "489", "target": "653", "attributes": {"size": null, "type": "arrow"}}, {"key": "635", "source": "489", "target": "654", "attributes": {"size": null, "type": "arrow"}}, {"key": "636", "source": "489", "target": "655", "attributes": {"size": null, "type": "arrow"}}, {"key": "637", "source": "489", "target": "656", "attributes": {"size": null, "type": "arrow"}}, {"key": "638", "source": "489", "target": "657", "attributes": {"size": null, "type": "arrow"}}, {"key": "639", "source": "489", "target": "658", "attributes": {"size": null, "type": "arrow"}}, {"key": "640", "source": "489", "target": "659", "attributes": {"size": null, "type": "arrow"}}, {"key": "641", "source": "489", "target": "660", "attributes": {"size": null, "type": "arrow"}}, {"key": "642", "source": "489", "target": "661", "attributes": {"size": null, "type": "arrow"}}, {"key": "643", "source": "489", "target": "662", "attributes": {"size": null, "type": "arrow"}}, {"key": "644", "source": "489", "target": "663", "attributes": {"size": null, "type": "arrow"}}, {"key": "645", "source": "489", "target": "664", "attributes": {"size": null, "type": "arrow"}}, {"key": "646", "source": "489", "target": "665", "attributes": {"size": null, "type": "arrow"}}, {"key": "647", "source": "489", "target": "666", "attributes": {"size": null, "type": "arrow"}}, {"key": "648", "source": "489", "target": "667", "attributes": {"size": null, "type": "arrow"}}, {"key": "649", "source": "489", "target": "668", "attributes": {"size": null, "type": "arrow"}}, {"key": "650", "source": "489", "target": "669", "attributes": {"size": null, "type": "arrow"}}, {"key": "651", "source": "489", "target": "670", "attributes": {"size": null, "type": "arrow"}}, {"key": "652", "source": "489", "target": "671", "attributes": {"size": null, "type": "arrow"}}, {"key": "653", "source": "489", "target": "672", "attributes": {"size": null, "type": "arrow"}}, {"key": "654", "source": "489", "target": "673", "attributes": {"size": null, "type": "arrow"}}, {"key": "655", "source": "489", "target": "674", "attributes": {"size": null, "type": "arrow"}}, {"key": "656", "source": "489", "target": "675", "attributes": {"size": null, "type": "arrow"}}, {"key": "657", "source": "489", "target": "676", "attributes": {"size": null, "type": "arrow"}}, {"key": "658", "source": "489", "target": "677", "attributes": {"size": null, "type": "arrow"}}, {"key": "659", "source": "489", "target": "678", "attributes": {"size": null, "type": "arrow"}}, {"key": "660", "source": "489", "target": "679", "attributes": {"size": null, "type": "arrow"}}, {"key": "661", "source": "489", "target": "680", "attributes": {"size": null, "type": "arrow"}}, {"key": "662", "source": "489", "target": "681", "attributes": {"size": null, "type": "arrow"}}, {"key": "663", "source": "489", "target": "682", "attributes": {"size": null, "type": "arrow"}}, {"key": "664", "source": "489", "target": "683", "attributes": {"size": null, "type": "arrow"}}, {"key": "665", "source": "489", "target": "684", "attributes": {"size": null, "type": "arrow"}}, {"key": "666", "source": "489", "target": "685", "attributes": {"size": null, "type": "arrow"}}, {"key": "667", "source": "489", "target": "686", "attributes": {"size": null, "type": "arrow"}}, {"key": "668", "source": "489", "target": "687", "attributes": {"size": null, "type": "arrow"}}, {"key": "669", "source": "489", "target": "688", "attributes": {"size": null, "type": "arrow"}}, {"key": "670", "source": "489", "target": "689", "attributes": {"size": null, "type": "arrow"}}, {"key": "671", "source": "489", "target": "690", "attributes": {"size": null, "type": "arrow"}}, {"key": "672", "source": "489", "target": "691", "attributes": {"size": null, "type": "arrow"}}, {"key": "673", "source": "489", "target": "692", "attributes": {"size": null, "type": "arrow"}}, {"key": "674", "source": "489", "target": "693", "attributes": {"size": null, "type": "arrow"}}, {"key": "675", "source": "489", "target": "694", "attributes": {"size": null, "type": "arrow"}}, {"key": "676", "source": "489", "target": "695", "attributes": {"size": null, "type": "arrow"}}, {"key": "677", "source": "489", "target": "696", "attributes": {"size": null, "type": "arrow"}}, {"key": "678", "source": "489", "target": "697", "attributes": {"size": null, "type": "arrow"}}, {"key": "679", "source": "489", "target": "698", "attributes": {"size": null, "type": "arrow"}}, {"key": "680", "source": "489", "target": "699", "attributes": {"size": null, "type": "arrow"}}, {"key": "681", "source": "489", "target": "700", "attributes": {"size": null, "type": "arrow"}}, {"key": "682", "source": "489", "target": "701", "attributes": {"size": null, "type": "arrow"}}, {"key": "683", "source": "489", "target": "702", "attributes": {"size": null, "type": "arrow"}}, {"key": "684", "source": "489", "target": "703", "attributes": {"size": null, "type": "arrow"}}, {"key": "685", "source": "489", "target": "704", "attributes": {"size": null, "type": "arrow"}}, {"key": "686", "source": "489", "target": "705", "attributes": {"size": null, "type": "arrow"}}, {"key": "687", "source": "489", "target": "706", "attributes": {"size": null, "type": "arrow"}}, {"key": "688", "source": "489", "target": "707", "attributes": {"size": null, "type": "arrow"}}, {"key": "689", "source": "489", "target": "708", "attributes": {"size": null, "type": "arrow"}}, {"key": "690", "source": "489", "target": "709", "attributes": {"size": null, "type": "arrow"}}, {"key": "691", "source": "489", "target": "710", "attributes": {"size": null, "type": "arrow"}}, {"key": "692", "source": "489", "target": "711", "attributes": {"size": null, "type": "arrow"}}, {"key": "693", "source": "489", "target": "712", "attributes": {"size": null, "type": "arrow"}}, {"key": "694", "source": "489", "target": "713", "attributes": {"size": null, "type": "arrow"}}, {"key": "695", "source": "489", "target": "714", "attributes": {"size": null, "type": "arrow"}}, {"key": "696", "source": "489", "target": "715", "attributes": {"size": null, "type": "arrow"}}, {"key": "697", "source": "489", "target": "716", "attributes": {"size": null, "type": "arrow"}}, {"key": "698", "source": "489", "target": "717", "attributes": {"size": null, "type": "arrow"}}, {"key": "699", "source": "489", "target": "718", "attributes": {"size": null, "type": "arrow"}}, {"key": "700", "source": "489", "target": "719", "attributes": {"size": null, "type": "arrow"}}, {"key": "701", "source": "489", "target": "720", "attributes": {"size": null, "type": "arrow"}}, {"key": "702", "source": "489", "target": "721", "attributes": {"size": null, "type": "arrow"}}, {"key": "703", "source": "489", "target": "722", "attributes": {"size": null, "type": "arrow"}}, {"key": "704", "source": "489", "target": "723", "attributes": {"size": null, "type": "arrow"}}, {"key": "705", "source": "489", "target": "724", "attributes": {"size": null, "type": "arrow"}}, {"key": "706", "source": "489", "target": "725", "attributes": {"size": null, "type": "arrow"}}, {"key": "707", "source": "489", "target": "726", "attributes": {"size": null, "type": "arrow"}}, {"key": "708", "source": "489", "target": "727", "attributes": {"size": null, "type": "arrow"}}, {"key": "709", "source": "489", "target": "728", "attributes": {"size": null, "type": "arrow"}}, {"key": "710", "source": "489", "target": "729", "attributes": {"size": null, "type": "arrow"}}, {"key": "711", "source": "489", "target": "730", "attributes": {"size": null, "type": "arrow"}}, {"key": "712", "source": "489", "target": "731", "attributes": {"size": null, "type": "arrow"}}, {"key": "713", "source": "489", "target": "732", "attributes": {"size": null, "type": "arrow"}}, {"key": "714", "source": "489", "target": "733", "attributes": {"size": null, "type": "arrow"}}, {"key": "715", "source": "489", "target": "734", "attributes": {"size": null, "type": "arrow"}}, {"key": "716", "source": "489", "target": "735", "attributes": {"size": null, "type": "arrow"}}, {"key": "717", "source": "489", "target": "736", "attributes": {"size": null, "type": "arrow"}}, {"key": "718", "source": "489", "target": "737", "attributes": {"size": null, "type": "arrow"}}, {"key": "719", "source": "489", "target": "738", "attributes": {"size": null, "type": "arrow"}}, {"key": "720", "source": "489", "target": "739", "attributes": {"size": null, "type": "arrow"}}, {"key": "721", "source": "489", "target": "740", "attributes": {"size": null, "type": "arrow"}}, {"key": "722", "source": "489", "target": "741", "attributes": {"size": null, "type": "arrow"}}, {"key": "723", "source": "489", "target": "742", "attributes": {"size": null, "type": "arrow"}}, {"key": "724", "source": "489", "target": "743", "attributes": {"size": null, "type": "arrow"}}, {"key": "725", "source": "489", "target": "744", "attributes": {"size": null, "type": "arrow"}}, {"key": "726", "source": "489", "target": "745", "attributes": {"size": null, "type": "arrow"}}, {"key": "727", "source": "489", "target": "746", "attributes": {"size": null, "type": "arrow"}}, {"key": "728", "source": "489", "target": "747", "attributes": {"size": null, "type": "arrow"}}, {"key": "729", "source": "489", "target": "748", "attributes": {"size": null, "type": "arrow"}}, {"key": "730", "source": "489", "target": "749", "attributes": {"size": null, "type": "arrow"}}, {"key": "731", "source": "489", "target": "750", "attributes": {"size": null, "type": "arrow"}}, {"key": "732", "source": "489", "target": "751", "attributes": {"size": null, "type": "arrow"}}, {"key": "733", "source": "489", "target": "752", "attributes": {"size": null, "type": "arrow"}}, {"key": "734", "source": "489", "target": "753", "attributes": {"size": null, "type": "arrow"}}, {"key": "735", "source": "489", "target": "754", "attributes": {"size": null, "type": "arrow"}}, {"key": "736", "source": "489", "target": "755", "attributes": {"size": null, "type": "arrow"}}, {"key": "737", "source": "489", "target": "756", "attributes": {"size": null, "type": "arrow"}}, {"key": "738", "source": "489", "target": "757", "attributes": {"size": null, "type": "arrow"}}, {"key": "739", "source": "489", "target": "758", "attributes": {"size": null, "type": "arrow"}}, {"key": "740", "source": "489", "target": "759", "attributes": {"size": null, "type": "arrow"}}, {"key": "741", "source": "489", "target": "760", "attributes": {"size": null, "type": "arrow"}}, {"key": "742", "source": "489", "target": "761", "attributes": {"size": null, "type": "arrow"}}, {"key": "743", "source": "489", "target": "762", "attributes": {"size": null, "type": "arrow"}}, {"key": "744", "source": "489", "target": "763", "attributes": {"size": null, "type": "arrow"}}, {"key": "745", "source": "489", "target": "764", "attributes": {"size": null, "type": "arrow"}}, {"key": "746", "source": "489", "target": "765", "attributes": {"size": null, "type": "arrow"}}, {"key": "747", "source": "489", "target": "766", "attributes": {"size": null, "type": "arrow"}}, {"key": "748", "source": "489", "target": "767", "attributes": {"size": null, "type": "arrow"}}, {"key": "749", "source": "489", "target": "768", "attributes": {"size": null, "type": "arrow"}}, {"key": "750", "source": "489", "target": "769", "attributes": {"size": null, "type": "arrow"}}, {"key": "751", "source": "489", "target": "770", "attributes": {"size": null, "type": "arrow"}}, {"key": "752", "source": "489", "target": "771", "attributes": {"size": null, "type": "arrow"}}, {"key": "753", "source": "489", "target": "772", "attributes": {"size": null, "type": "arrow"}}, {"key": "754", "source": "489", "target": "773", "attributes": {"size": null, "type": "arrow"}}, {"key": "755", "source": "489", "target": "774", "attributes": {"size": null, "type": "arrow"}}, {"key": "756", "source": "489", "target": "775", "attributes": {"size": null, "type": "arrow"}}, {"key": "757", "source": "489", "target": "776", "attributes": {"size": null, "type": "arrow"}}, {"key": "758", "source": "489", "target": "777", "attributes": {"size": null, "type": "arrow"}}, {"key": "759", "source": "489", "target": "778", "attributes": {"size": null, "type": "arrow"}}, {"key": "760", "source": "489", "target": "779", "attributes": {"size": null, "type": "arrow"}}, {"key": "761", "source": "489", "target": "780", "attributes": {"size": null, "type": "arrow"}}, {"key": "762", "source": "489", "target": "781", "attributes": {"size": null, "type": "arrow"}}, {"key": "763", "source": "489", "target": "782", "attributes": {"size": null, "type": "arrow"}}, {"key": "764", "source": "489", "target": "783", "attributes": {"size": null, "type": "arrow"}}, {"key": "765", "source": "489", "target": "784", "attributes": {"size": null, "type": "arrow"}}, {"key": "766", "source": "489", "target": "785", "attributes": {"size": null, "type": "arrow"}}, {"key": "767", "source": "489", "target": "786", "attributes": {"size": null, "type": "arrow"}}, {"key": "768", "source": "489", "target": "787", "attributes": {"size": null, "type": "arrow"}}, {"key": "769", "source": "489", "target": "788", "attributes": {"size": null, "type": "arrow"}}, {"key": "770", "source": "489", "target": "789", "attributes": {"size": null, "type": "arrow"}}, {"key": "771", "source": "489", "target": "790", "attributes": {"size": null, "type": "arrow"}}, {"key": "772", "source": "489", "target": "791", "attributes": {"size": null, "type": "arrow"}}, {"key": "773", "source": "489", "target": "792", "attributes": {"size": null, "type": "arrow"}}, {"key": "774", "source": "489", "target": "793", "attributes": {"size": null, "type": "arrow"}}, {"key": "775", "source": "489", "target": "794", "attributes": {"size": null, "type": "arrow"}}, {"key": "776", "source": "489", "target": "795", "attributes": {"size": null, "type": "arrow"}}, {"key": "777", "source": "489", "target": "796", "attributes": {"size": null, "type": "arrow"}}, {"key": "778", "source": "489", "target": "797", "attributes": {"size": null, "type": "arrow"}}, {"key": "779", "source": "489", "target": "798", "attributes": {"size": null, "type": "arrow"}}, {"key": "780", "source": "489", "target": "799", "attributes": {"size": null, "type": "arrow"}}, {"key": "781", "source": "489", "target": "800", "attributes": {"size": null, "type": "arrow"}}, {"key": "782", "source": "489", "target": "801", "attributes": {"size": null, "type": "arrow"}}, {"key": "783", "source": "489", "target": "802", "attributes": {"size": null, "type": "arrow"}}, {"key": "784", "source": "489", "target": "803", "attributes": {"size": null, "type": "arrow"}}, {"key": "785", "source": "489", "target": "804", "attributes": {"size": null, "type": "arrow"}}, {"key": "786", "source": "489", "target": "805", "attributes": {"size": null, "type": "arrow"}}, {"key": "787", "source": "489", "target": "806", "attributes": {"size": null, "type": "arrow"}}, {"key": "788", "source": "489", "target": "807", "attributes": {"size": null, "type": "arrow"}}, {"key": "789", "source": "489", "target": "808", "attributes": {"size": null, "type": "arrow"}}, {"key": "790", "source": "489", "target": "809", "attributes": {"size": null, "type": "arrow"}}, {"key": "791", "source": "489", "target": "810", "attributes": {"size": null, "type": "arrow"}}, {"key": "792", "source": "489", "target": "811", "attributes": {"size": null, "type": "arrow"}}, {"key": "793", "source": "489", "target": "812", "attributes": {"size": null, "type": "arrow"}}, {"key": "794", "source": "489", "target": "813", "attributes": {"size": null, "type": "arrow"}}, {"key": "795", "source": "489", "target": "814", "attributes": {"size": null, "type": "arrow"}}, {"key": "796", "source": "489", "target": "815", "attributes": {"size": null, "type": "arrow"}}, {"key": "797", "source": "489", "target": "816", "attributes": {"size": null, "type": "arrow"}}, {"key": "798", "source": "489", "target": "817", "attributes": {"size": null, "type": "arrow"}}, {"key": "799", "source": "489", "target": "818", "attributes": {"size": null, "type": "arrow"}}, {"key": "800", "source": "489", "target": "819", "attributes": {"size": null, "type": "arrow"}}, {"key": "801", "source": "489", "target": "820", "attributes": {"size": null, "type": "arrow"}}, {"key": "802", "source": "489", "target": "821", "attributes": {"size": null, "type": "arrow"}}, {"key": "803", "source": "489", "target": "822", "attributes": {"size": null, "type": "arrow"}}, {"key": "804", "source": "489", "target": "823", "attributes": {"size": null, "type": "arrow"}}, {"key": "805", "source": "489", "target": "824", "attributes": {"size": null, "type": "arrow"}}, {"key": "806", "source": "489", "target": "825", "attributes": {"size": null, "type": "arrow"}}, {"key": "807", "source": "489", "target": "826", "attributes": {"size": null, "type": "arrow"}}, {"key": "808", "source": "489", "target": "827", "attributes": {"size": null, "type": "arrow"}}, {"key": "809", "source": "489", "target": "828", "attributes": {"size": null, "type": "arrow"}}, {"key": "810", "source": "489", "target": "829", "attributes": {"size": null, "type": "arrow"}}, {"key": "811", "source": "489", "target": "830", "attributes": {"size": null, "type": "arrow"}}, {"key": "812", "source": "489", "target": "831", "attributes": {"size": null, "type": "arrow"}}, {"key": "813", "source": "489", "target": "832", "attributes": {"size": null, "type": "arrow"}}, {"key": "814", "source": "489", "target": "833", "attributes": {"size": null, "type": "arrow"}}, {"key": "815", "source": "489", "target": "834", "attributes": {"size": null, "type": "arrow"}}, {"key": "816", "source": "489", "target": "835", "attributes": {"size": null, "type": "arrow"}}, {"key": "817", "source": "489", "target": "836", "attributes": {"size": null, "type": "arrow"}}, {"key": "818", "source": "489", "target": "837", "attributes": {"size": null, "type": "arrow"}}, {"key": "819", "source": "489", "target": "838", "attributes": {"size": null, "type": "arrow"}}, {"key": "820", "source": "489", "target": "839", "attributes": {"size": null, "type": "arrow"}}, {"key": "821", "source": "489", "target": "840", "attributes": {"size": null, "type": "arrow"}}, {"key": "822", "source": "489", "target": "841", "attributes": {"size": null, "type": "arrow"}}, {"key": "823", "source": "489", "target": "842", "attributes": {"size": null, "type": "arrow"}}, {"key": "824", "source": "489", "target": "843", "attributes": {"size": null, "type": "arrow"}}, {"key": "825", "source": "489", "target": "844", "attributes": {"size": null, "type": "arrow"}}, {"key": "826", "source": "489", "target": "845", "attributes": {"size": null, "type": "arrow"}}, {"key": "827", "source": "846", "target": "890", "attributes": {"size": null, "type": "arrow"}}, {"key": "828", "source": "846", "target": "891", "attributes": {"size": null, "type": "arrow"}}, {"key": "829", "source": "846", "target": "892", "attributes": {"size": null, "type": "arrow"}}, {"key": "830", "source": "846", "target": "893", "attributes": {"size": null, "type": "arrow"}}, {"key": "831", "source": "846", "target": "894", "attributes": {"size": null, "type": "arrow"}}, {"key": "832", "source": "846", "target": "889", "attributes": {"size": null, "type": "arrow"}}, {"key": "833", "source": "846", "target": "577", "attributes": {"size": null, "type": "arrow"}}, {"key": "834", "source": "846", "target": "847", "attributes": {"size": null, "type": "arrow"}}, {"key": "835", "source": "846", "target": "848", "attributes": {"size": null, "type": "arrow"}}, {"key": "836", "source": "846", "target": "849", "attributes": {"size": null, "type": "arrow"}}, {"key": "837", "source": "846", "target": "850", "attributes": {"size": null, "type": "arrow"}}, {"key": "838", "source": "846", "target": "851", "attributes": {"size": null, "type": "arrow"}}, {"key": "839", "source": "846", "target": "852", "attributes": {"size": null, "type": "arrow"}}, {"key": "840", "source": "846", "target": "853", "attributes": {"size": null, "type": "arrow"}}, {"key": "841", "source": "846", "target": "854", "attributes": {"size": null, "type": "arrow"}}, {"key": "842", "source": "846", "target": "855", "attributes": {"size": null, "type": "arrow"}}, {"key": "843", "source": "846", "target": "856", "attributes": {"size": null, "type": "arrow"}}, {"key": "844", "source": "846", "target": "857", "attributes": {"size": null, "type": "arrow"}}, {"key": "845", "source": "846", "target": "858", "attributes": {"size": null, "type": "arrow"}}, {"key": "846", "source": "846", "target": "859", "attributes": {"size": null, "type": "arrow"}}, {"key": "847", "source": "846", "target": "860", "attributes": {"size": null, "type": "arrow"}}, {"key": "848", "source": "846", "target": "861", "attributes": {"size": null, "type": "arrow"}}, {"key": "849", "source": "846", "target": "862", "attributes": {"size": null, "type": "arrow"}}, {"key": "850", "source": "846", "target": "863", "attributes": {"size": null, "type": "arrow"}}, {"key": "851", "source": "846", "target": "864", "attributes": {"size": null, "type": "arrow"}}, {"key": "852", "source": "846", "target": "865", "attributes": {"size": null, "type": "arrow"}}, {"key": "853", "source": "846", "target": "866", "attributes": {"size": null, "type": "arrow"}}, {"key": "854", "source": "846", "target": "867", "attributes": {"size": null, "type": "arrow"}}, {"key": "855", "source": "846", "target": "868", "attributes": {"size": null, "type": "arrow"}}, {"key": "856", "source": "846", "target": "869", "attributes": {"size": null, "type": "arrow"}}, {"key": "857", "source": "846", "target": "870", "attributes": {"size": null, "type": "arrow"}}, {"key": "858", "source": "846", "target": "871", "attributes": {"size": null, "type": "arrow"}}, {"key": "859", "source": "846", "target": "872", "attributes": {"size": null, "type": "arrow"}}, {"key": "860", "source": "846", "target": "873", "attributes": {"size": null, "type": "arrow"}}, {"key": "861", "source": "846", "target": "874", "attributes": {"size": null, "type": "arrow"}}, {"key": "862", "source": "846", "target": "875", "attributes": {"size": null, "type": "arrow"}}, {"key": "863", "source": "846", "target": "876", "attributes": {"size": null, "type": "arrow"}}, {"key": "864", "source": "846", "target": "877", "attributes": {"size": null, "type": "arrow"}}, {"key": "865", "source": "846", "target": "878", "attributes": {"size": null, "type": "arrow"}}, {"key": "866", "source": "846", "target": "879", "attributes": {"size": null, "type": "arrow"}}, {"key": "867", "source": "846", "target": "880", "attributes": {"size": null, "type": "arrow"}}, {"key": "868", "source": "846", "target": "881", "attributes": {"size": null, "type": "arrow"}}, {"key": "869", "source": "846", "target": "882", "attributes": {"size": null, "type": "arrow"}}, {"key": "870", "source": "846", "target": "883", "attributes": {"size": null, "type": "arrow"}}, {"key": "871", "source": "846", "target": "884", "attributes": {"size": null, "type": "arrow"}}, {"key": "872", "source": "846", "target": "885", "attributes": {"size": null, "type": "arrow"}}, {"key": "873", "source": "846", "target": "886", "attributes": {"size": null, "type": "arrow"}}, {"key": "874", "source": "846", "target": "887", "attributes": {"size": null, "type": "arrow"}}, {"key": "875", "source": "846", "target": "888", "attributes": {"size": null, "type": "arrow"}}, {"key": "876", "source": "846", "target": "505", "attributes": {"size": null, "type": "arrow"}}, {"key": "877", "source": "895", "target": "1018", "attributes": {"size": null, "type": "arrow"}}, {"key": "878", "source": "895", "target": "1019", "attributes": {"size": null, "type": "arrow"}}, {"key": "879", "source": "895", "target": "1020", "attributes": {"size": null, "type": "arrow"}}, {"key": "880", "source": "895", "target": "524", "attributes": {"size": null, "type": "arrow"}}, {"key": "881", "source": "895", "target": "547", "attributes": {"size": null, "type": "arrow"}}, {"key": "882", "source": "895", "target": "617", "attributes": {"size": null, "type": "arrow"}}, {"key": "883", "source": "895", "target": "626", "attributes": {"size": null, "type": "arrow"}}, {"key": "884", "source": "895", "target": "629", "attributes": {"size": null, "type": "arrow"}}, {"key": "885", "source": "895", "target": "676", "attributes": {"size": null, "type": "arrow"}}, {"key": "886", "source": "895", "target": "719", "attributes": {"size": null, "type": "arrow"}}, {"key": "887", "source": "895", "target": "1010", "attributes": {"size": null, "type": "arrow"}}, {"key": "888", "source": "895", "target": "368", "attributes": {"size": null, "type": "arrow"}}, {"key": "889", "source": "895", "target": "896", "attributes": {"size": null, "type": "arrow"}}, {"key": "890", "source": "895", "target": "897", "attributes": {"size": null, "type": "arrow"}}, {"key": "891", "source": "895", "target": "898", "attributes": {"size": null, "type": "arrow"}}, {"key": "892", "source": "895", "target": "899", "attributes": {"size": null, "type": "arrow"}}, {"key": "893", "source": "895", "target": "900", "attributes": {"size": null, "type": "arrow"}}, {"key": "894", "source": "895", "target": "901", "attributes": {"size": null, "type": "arrow"}}, {"key": "895", "source": "895", "target": "902", "attributes": {"size": null, "type": "arrow"}}, {"key": "896", "source": "895", "target": "903", "attributes": {"size": null, "type": "arrow"}}, {"key": "897", "source": "895", "target": "904", "attributes": {"size": null, "type": "arrow"}}, {"key": "898", "source": "895", "target": "905", "attributes": {"size": null, "type": "arrow"}}, {"key": "899", "source": "895", "target": "906", "attributes": {"size": null, "type": "arrow"}}, {"key": "900", "source": "895", "target": "907", "attributes": {"size": null, "type": "arrow"}}, {"key": "901", "source": "895", "target": "908", "attributes": {"size": null, "type": "arrow"}}, {"key": "902", "source": "895", "target": "909", "attributes": {"size": null, "type": "arrow"}}, {"key": "903", "source": "895", "target": "910", "attributes": {"size": null, "type": "arrow"}}, {"key": "904", "source": "895", "target": "911", "attributes": {"size": null, "type": "arrow"}}, {"key": "905", "source": "895", "target": "912", "attributes": {"size": null, "type": "arrow"}}, {"key": "906", "source": "895", "target": "913", "attributes": {"size": null, "type": "arrow"}}, {"key": "907", "source": "895", "target": "914", "attributes": {"size": null, "type": "arrow"}}, {"key": "908", "source": "895", "target": "915", "attributes": {"size": null, "type": "arrow"}}, {"key": "909", "source": "895", "target": "916", "attributes": {"size": null, "type": "arrow"}}, {"key": "910", "source": "895", "target": "917", "attributes": {"size": null, "type": "arrow"}}, {"key": "911", "source": "895", "target": "918", "attributes": {"size": null, "type": "arrow"}}, {"key": "912", "source": "895", "target": "919", "attributes": {"size": null, "type": "arrow"}}, {"key": "913", "source": "895", "target": "920", "attributes": {"size": null, "type": "arrow"}}, {"key": "914", "source": "895", "target": "921", "attributes": {"size": null, "type": "arrow"}}, {"key": "915", "source": "895", "target": "922", "attributes": {"size": null, "type": "arrow"}}, {"key": "916", "source": "895", "target": "923", "attributes": {"size": null, "type": "arrow"}}, {"key": "917", "source": "895", "target": "924", "attributes": {"size": null, "type": "arrow"}}, {"key": "918", "source": "895", "target": "925", "attributes": {"size": null, "type": "arrow"}}, {"key": "919", "source": "895", "target": "926", "attributes": {"size": null, "type": "arrow"}}, {"key": "920", "source": "895", "target": "927", "attributes": {"size": null, "type": "arrow"}}, {"key": "921", "source": "895", "target": "928", "attributes": {"size": null, "type": "arrow"}}, {"key": "922", "source": "895", "target": "929", "attributes": {"size": null, "type": "arrow"}}, {"key": "923", "source": "895", "target": "930", "attributes": {"size": null, "type": "arrow"}}, {"key": "924", "source": "895", "target": "931", "attributes": {"size": null, "type": "arrow"}}, {"key": "925", "source": "895", "target": "932", "attributes": {"size": null, "type": "arrow"}}, {"key": "926", "source": "895", "target": "933", "attributes": {"size": null, "type": "arrow"}}, {"key": "927", "source": "895", "target": "934", "attributes": {"size": null, "type": "arrow"}}, {"key": "928", "source": "895", "target": "935", "attributes": {"size": null, "type": "arrow"}}, {"key": "929", "source": "895", "target": "936", "attributes": {"size": null, "type": "arrow"}}, {"key": "930", "source": "895", "target": "937", "attributes": {"size": null, "type": "arrow"}}, {"key": "931", "source": "895", "target": "938", "attributes": {"size": null, "type": "arrow"}}, {"key": "932", "source": "895", "target": "939", "attributes": {"size": null, "type": "arrow"}}, {"key": "933", "source": "895", "target": "940", "attributes": {"size": null, "type": "arrow"}}, {"key": "934", "source": "895", "target": "941", "attributes": {"size": null, "type": "arrow"}}, {"key": "935", "source": "895", "target": "942", "attributes": {"size": null, "type": "arrow"}}, {"key": "936", "source": "895", "target": "943", "attributes": {"size": null, "type": "arrow"}}, {"key": "937", "source": "895", "target": "944", "attributes": {"size": null, "type": "arrow"}}, {"key": "938", "source": "895", "target": "945", "attributes": {"size": null, "type": "arrow"}}, {"key": "939", "source": "895", "target": "946", "attributes": {"size": null, "type": "arrow"}}, {"key": "940", "source": "895", "target": "947", "attributes": {"size": null, "type": "arrow"}}, {"key": "941", "source": "895", "target": "948", "attributes": {"size": null, "type": "arrow"}}, {"key": "942", "source": "895", "target": "949", "attributes": {"size": null, "type": "arrow"}}, {"key": "943", "source": "895", "target": "950", "attributes": {"size": null, "type": "arrow"}}, {"key": "944", "source": "895", "target": "951", "attributes": {"size": null, "type": "arrow"}}, {"key": "945", "source": "895", "target": "952", "attributes": {"size": null, "type": "arrow"}}, {"key": "946", "source": "895", "target": "953", "attributes": {"size": null, "type": "arrow"}}, {"key": "947", "source": "895", "target": "954", "attributes": {"size": null, "type": "arrow"}}, {"key": "948", "source": "895", "target": "955", "attributes": {"size": null, "type": "arrow"}}, {"key": "949", "source": "895", "target": "956", "attributes": {"size": null, "type": "arrow"}}, {"key": "950", "source": "895", "target": "957", "attributes": {"size": null, "type": "arrow"}}, {"key": "951", "source": "895", "target": "958", "attributes": {"size": null, "type": "arrow"}}, {"key": "952", "source": "895", "target": "959", "attributes": {"size": null, "type": "arrow"}}, {"key": "953", "source": "895", "target": "960", "attributes": {"size": null, "type": "arrow"}}, {"key": "954", "source": "895", "target": "961", "attributes": {"size": null, "type": "arrow"}}, {"key": "955", "source": "895", "target": "962", "attributes": {"size": null, "type": "arrow"}}, {"key": "956", "source": "895", "target": "963", "attributes": {"size": null, "type": "arrow"}}, {"key": "957", "source": "895", "target": "964", "attributes": {"size": null, "type": "arrow"}}, {"key": "958", "source": "895", "target": "965", "attributes": {"size": null, "type": "arrow"}}, {"key": "959", "source": "895", "target": "966", "attributes": {"size": null, "type": "arrow"}}, {"key": "960", "source": "895", "target": "967", "attributes": {"size": null, "type": "arrow"}}, {"key": "961", "source": "895", "target": "968", "attributes": {"size": null, "type": "arrow"}}, {"key": "962", "source": "895", "target": "969", "attributes": {"size": null, "type": "arrow"}}, {"key": "963", "source": "895", "target": "970", "attributes": {"size": null, "type": "arrow"}}, {"key": "964", "source": "895", "target": "971", "attributes": {"size": null, "type": "arrow"}}, {"key": "965", "source": "895", "target": "972", "attributes": {"size": null, "type": "arrow"}}, {"key": "966", "source": "895", "target": "973", "attributes": {"size": null, "type": "arrow"}}, {"key": "967", "source": "895", "target": "974", "attributes": {"size": null, "type": "arrow"}}, {"key": "968", "source": "895", "target": "975", "attributes": {"size": null, "type": "arrow"}}, {"key": "969", "source": "895", "target": "976", "attributes": {"size": null, "type": "arrow"}}, {"key": "970", "source": "895", "target": "977", "attributes": {"size": null, "type": "arrow"}}, {"key": "971", "source": "895", "target": "978", "attributes": {"size": null, "type": "arrow"}}, {"key": "972", "source": "895", "target": "979", "attributes": {"size": null, "type": "arrow"}}, {"key": "973", "source": "895", "target": "980", "attributes": {"size": null, "type": "arrow"}}, {"key": "974", "source": "895", "target": "981", "attributes": {"size": null, "type": "arrow"}}, {"key": "975", "source": "895", "target": "982", "attributes": {"size": null, "type": "arrow"}}, {"key": "976", "source": "895", "target": "983", "attributes": {"size": null, "type": "arrow"}}, {"key": "977", "source": "895", "target": "984", "attributes": {"size": null, "type": "arrow"}}, {"key": "978", "source": "895", "target": "985", "attributes": {"size": null, "type": "arrow"}}, {"key": "979", "source": "895", "target": "986", "attributes": {"size": null, "type": "arrow"}}, {"key": "980", "source": "895", "target": "987", "attributes": {"size": null, "type": "arrow"}}, {"key": "981", "source": "895", "target": "988", "attributes": {"size": null, "type": "arrow"}}, {"key": "982", "source": "895", "target": "989", "attributes": {"size": null, "type": "arrow"}}, {"key": "983", "source": "895", "target": "990", "attributes": {"size": null, "type": "arrow"}}, {"key": "984", "source": "895", "target": "991", "attributes": {"size": null, "type": "arrow"}}, {"key": "985", "source": "895", "target": "992", "attributes": {"size": null, "type": "arrow"}}, {"key": "986", "source": "895", "target": "993", "attributes": {"size": null, "type": "arrow"}}, {"key": "987", "source": "895", "target": "994", "attributes": {"size": null, "type": "arrow"}}, {"key": "988", "source": "895", "target": "995", "attributes": {"size": null, "type": "arrow"}}, {"key": "989", "source": "895", "target": "996", "attributes": {"size": null, "type": "arrow"}}, {"key": "990", "source": "895", "target": "997", "attributes": {"size": null, "type": "arrow"}}, {"key": "991", "source": "895", "target": "998", "attributes": {"size": null, "type": "arrow"}}, {"key": "992", "source": "895", "target": "999", "attributes": {"size": null, "type": "arrow"}}, {"key": "993", "source": "895", "target": "1000", "attributes": {"size": null, "type": "arrow"}}, {"key": "994", "source": "895", "target": "1001", "attributes": {"size": null, "type": "arrow"}}, {"key": "995", "source": "895", "target": "1002", "attributes": {"size": null, "type": "arrow"}}, {"key": "996", "source": "895", "target": "491", "attributes": {"size": null, "type": "arrow"}}, {"key": "997", "source": "895", "target": "1003", "attributes": {"size": null, "type": "arrow"}}, {"key": "998", "source": "895", "target": "1004", "attributes": {"size": null, "type": "arrow"}}, {"key": "999", "source": "895", "target": "1005", "attributes": {"size": null, "type": "arrow"}}, {"key": "1000", "source": "895", "target": "1006", "attributes": {"size": null, "type": "arrow"}}, {"key": "1001", "source": "895", "target": "1007", "attributes": {"size": null, "type": "arrow"}}, {"key": "1002", "source": "895", "target": "1008", "attributes": {"size": null, "type": "arrow"}}, {"key": "1003", "source": "895", "target": "1009", "attributes": {"size": null, "type": "arrow"}}, {"key": "1004", "source": "895", "target": "1011", "attributes": {"size": null, "type": "arrow"}}, {"key": "1005", "source": "895", "target": "1012", "attributes": {"size": null, "type": "arrow"}}, {"key": "1006", "source": "895", "target": "1013", "attributes": {"size": null, "type": "arrow"}}, {"key": "1007", "source": "895", "target": "1014", "attributes": {"size": null, "type": "arrow"}}, {"key": "1008", "source": "895", "target": "1015", "attributes": {"size": null, "type": "arrow"}}, {"key": "1009", "source": "895", "target": "1016", "attributes": {"size": null, "type": "arrow"}}, {"key": "1010", "source": "895", "target": "1017", "attributes": {"size": null, "type": "arrow"}}, {"key": "1011", "source": "1025", "target": "1026", "attributes": {"size": null, "type": "arrow"}}, {"key": "1012", "source": "1025", "target": "1027", "attributes": {"size": null, "type": "arrow"}}, {"key": "1013", "source": "1025", "target": "1028", "attributes": {"size": null, "type": "arrow"}}, {"key": "1014", "source": "1025", "target": "1029", "attributes": {"size": null, "type": "arrow"}}, {"key": "1015", "source": "1025", "target": "1030", "attributes": {"size": null, "type": "arrow"}}, {"key": "1016", "source": "1025", "target": "1031", "attributes": {"size": null, "type": "arrow"}}, {"key": "1017", "source": "1025", "target": "1032", "attributes": {"size": null, "type": "arrow"}}, {"key": "1018", "source": "1025", "target": "1033", "attributes": {"size": null, "type": "arrow"}}, {"key": "1019", "source": "1025", "target": "1034", "attributes": {"size": null, "type": "arrow"}}, {"key": "1020", "source": "1025", "target": "1035", "attributes": {"size": null, "type": "arrow"}}, {"key": "1021", "source": "1025", "target": "1036", "attributes": {"size": null, "type": "arrow"}}, {"key": "1022", "source": "1025", "target": "1037", "attributes": {"size": null, "type": "arrow"}}, {"key": "1023", "source": "1025", "target": "1038", "attributes": {"size": null, "type": "arrow"}}, {"key": "1024", "source": "1025", "target": "1039", "attributes": {"size": null, "type": "arrow"}}, {"key": "1025", "source": "1025", "target": "1040", "attributes": {"size": null, "type": "arrow"}}, {"key": "1026", "source": "1025", "target": "1041", "attributes": {"size": null, "type": "arrow"}}, {"key": "1027", "source": "1025", "target": "1042", "attributes": {"size": null, "type": "arrow"}}, {"key": "1028", "source": "1025", "target": "1043", "attributes": {"size": null, "type": "arrow"}}, {"key": "1029", "source": "1025", "target": "1044", "attributes": {"size": null, "type": "arrow"}}, {"key": "1030", "source": "1025", "target": "1045", "attributes": {"size": null, "type": "arrow"}}, {"key": "1031", "source": "1025", "target": "1046", "attributes": {"size": null, "type": "arrow"}}, {"key": "1032", "source": "1025", "target": "1047", "attributes": {"size": null, "type": "arrow"}}, {"key": "1033", "source": "1025", "target": "1048", "attributes": {"size": null, "type": "arrow"}}, {"key": "1034", "source": "1025", "target": "1049", "attributes": {"size": null, "type": "arrow"}}, {"key": "1035", "source": "1025", "target": "1050", "attributes": {"size": null, "type": "arrow"}}, {"key": "1036", "source": "1025", "target": "202", "attributes": {"size": null, "type": "arrow"}}, {"key": "1037", "source": "1025", "target": "1051", "attributes": {"size": null, "type": "arrow"}}, {"key": "1038", "source": "1025", "target": "1052", "attributes": {"size": null, "type": "arrow"}}, {"key": "1039", "source": "1025", "target": "1053", "attributes": {"size": null, "type": "arrow"}}, {"key": "1040", "source": "1025", "target": "1054", "attributes": {"size": null, "type": "arrow"}}, {"key": "1041", "source": "1025", "target": "1055", "attributes": {"size": null, "type": "arrow"}}, {"key": "1042", "source": "1056", "target": "1064", "attributes": {"size": null, "type": "arrow"}}, {"key": "1043", "source": "1056", "target": "1057", "attributes": {"size": null, "type": "arrow"}}, {"key": "1044", "source": "1056", "target": "1058", "attributes": {"size": null, "type": "arrow"}}, {"key": "1045", "source": "1056", "target": "1059", "attributes": {"size": null, "type": "arrow"}}, {"key": "1046", "source": "1056", "target": "1060", "attributes": {"size": null, "type": "arrow"}}, {"key": "1047", "source": "1056", "target": "1061", "attributes": {"size": null, "type": "arrow"}}, {"key": "1048", "source": "1056", "target": "1062", "attributes": {"size": null, "type": "arrow"}}, {"key": "1049", "source": "1056", "target": "1063", "attributes": {"size": null, "type": "arrow"}}, {"key": "1050", "source": "1056", "target": "223", "attributes": {"size": null, "type": "arrow"}}, {"key": "1051", "source": "1065", "target": "1066", "attributes": {"size": null, "type": "arrow"}}, {"key": "1052", "source": "1065", "target": "1067", "attributes": {"size": null, "type": "arrow"}}, {"key": "1053", "source": "1065", "target": "1068", "attributes": {"size": null, "type": "arrow"}}, {"key": "1054", "source": "1065", "target": "1069", "attributes": {"size": null, "type": "arrow"}}, {"key": "1055", "source": "1065", "target": "348", "attributes": {"size": null, "type": "arrow"}}, {"key": "1056", "source": "1065", "target": "1070", "attributes": {"size": null, "type": "arrow"}}, {"key": "1057", "source": "1065", "target": "1071", "attributes": {"size": null, "type": "arrow"}}, {"key": "1058", "source": "1065", "target": "1072", "attributes": {"size": null, "type": "arrow"}}, {"key": "1059", "source": "1065", "target": "1073", "attributes": {"size": null, "type": "arrow"}}, {"key": "1060", "source": "1065", "target": "1074", "attributes": {"size": null, "type": "arrow"}}, {"key": "1061", "source": "1065", "target": "1075", "attributes": {"size": null, "type": "arrow"}}, {"key": "1062", "source": "1065", "target": "1076", "attributes": {"size": null, "type": "arrow"}}, {"key": "1063", "source": "1065", "target": "1077", "attributes": {"size": null, "type": "arrow"}}, {"key": "1064", "source": "1065", "target": "1078", "attributes": {"size": null, "type": "arrow"}}, {"key": "1065", "source": "1065", "target": "1079", "attributes": {"size": null, "type": "arrow"}}, {"key": "1066", "source": "1065", "target": "1080", "attributes": {"size": null, "type": "arrow"}}, {"key": "1067", "source": "1065", "target": "1081", "attributes": {"size": null, "type": "arrow"}}, {"key": "1068", "source": "1065", "target": "1082", "attributes": {"size": null, "type": "arrow"}}, {"key": "1069", "source": "1065", "target": "1083", "attributes": {"size": null, "type": "arrow"}}, {"key": "1070", "source": "1065", "target": "1084", "attributes": {"size": null, "type": "arrow"}}, {"key": "1071", "source": "1065", "target": "1085", "attributes": {"size": null, "type": "arrow"}}, {"key": "1072", "source": "1086", "target": "1087", "attributes": {"size": null, "type": "arrow"}}, {"key": "1073", "source": "1086", "target": "1088", "attributes": {"size": null, "type": "arrow"}}, {"key": "1074", "source": "1086", "target": "1089", "attributes": {"size": null, "type": "arrow"}}, {"key": "1075", "source": "1086", "target": "1090", "attributes": {"size": null, "type": "arrow"}}, {"key": "1076", "source": "1086", "target": "1091", "attributes": {"size": null, "type": "arrow"}}, {"key": "1077", "source": "1086", "target": "1092", "attributes": {"size": null, "type": "arrow"}}, {"key": "1078", "source": "1093", "target": "1094", "attributes": {"size": null, "type": "arrow"}}, {"key": "1079", "source": "1093", "target": "1095", "attributes": {"size": null, "type": "arrow"}}, {"key": "1080", "source": "1093", "target": "1096", "attributes": {"size": null, "type": "arrow"}}, {"key": "1081", "source": "1093", "target": "1097", "attributes": {"size": null, "type": "arrow"}}, {"key": "1082", "source": "1093", "target": "202", "attributes": {"size": null, "type": "arrow"}}, {"key": "1083", "source": "1098", "target": "1101", "attributes": {"size": null, "type": "arrow"}}, {"key": "1084", "source": "1098", "target": "1102", "attributes": {"size": null, "type": "arrow"}}, {"key": "1085", "source": "1098", "target": "1099", "attributes": {"size": null, "type": "arrow"}}, {"key": "1086", "source": "1098", "target": "1100", "attributes": {"size": null, "type": "arrow"}}, {"key": "1087", "source": "1103", "target": "1104", "attributes": {"size": null, "type": "arrow"}}, {"key": "1088", "source": "1103", "target": "1105", "attributes": {"size": null, "type": "arrow"}}, {"key": "1089", "source": "1103", "target": "1106", "attributes": {"size": null, "type": "arrow"}}, {"key": "1090", "source": "1103", "target": "1107", "attributes": {"size": null, "type": "arrow"}}, {"key": "1091", "source": "1103", "target": "1108", "attributes": {"size": null, "type": "arrow"}}, {"key": "1092", "source": "1103", "target": "1109", "attributes": {"size": null, "type": "arrow"}}, {"key": "1093", "source": "1103", "target": "1110", "attributes": {"size": null, "type": "arrow"}}, {"key": "1094", "source": "1103", "target": "1111", "attributes": {"size": null, "type": "arrow"}}, {"key": "1095", "source": "1103", "target": "1112", "attributes": {"size": null, "type": "arrow"}}, {"key": "1096", "source": "1103", "target": "1113", "attributes": {"size": null, "type": "arrow"}}, {"key": "1097", "source": "1103", "target": "1114", "attributes": {"size": null, "type": "arrow"}}, {"key": "1098", "source": "1103", "target": "1115", "attributes": {"size": null, "type": "arrow"}}, {"key": "1099", "source": "1103", "target": "1116", "attributes": {"size": null, "type": "arrow"}}, {"key": "1100", "source": "1103", "target": "1117", "attributes": {"size": null, "type": "arrow"}}, {"key": "1101", "source": "1103", "target": "1118", "attributes": {"size": null, "type": "arrow"}}, {"key": "1102", "source": "1103", "target": "1119", "attributes": {"size": null, "type": "arrow"}}, {"key": "1103", "source": "1103", "target": "1120", "attributes": {"size": null, "type": "arrow"}}, {"key": "1104", "source": "1103", "target": "1121", "attributes": {"size": null, "type": "arrow"}}, {"key": "1105", "source": "1103", "target": "1122", "attributes": {"size": null, "type": "arrow"}}, {"key": "1106", "source": "1103", "target": "1123", "attributes": {"size": null, "type": "arrow"}}, {"key": "1107", "source": "1103", "target": "1124", "attributes": {"size": null, "type": "arrow"}}, {"key": "1108", "source": "1103", "target": "1125", "attributes": {"size": null, "type": "arrow"}}, {"key": "1109", "source": "1103", "target": "1126", "attributes": {"size": null, "type": "arrow"}}, {"key": "1110", "source": "1103", "target": "1127", "attributes": {"size": null, "type": "arrow"}}, {"key": "1111", "source": "1103", "target": "1128", "attributes": {"size": null, "type": "arrow"}}, {"key": "1112", "source": "1103", "target": "1129", "attributes": {"size": null, "type": "arrow"}}, {"key": "1113", "source": "1103", "target": "1130", "attributes": {"size": null, "type": "arrow"}}, {"key": "1114", "source": "1103", "target": "1131", "attributes": {"size": null, "type": "arrow"}}, {"key": "1115", "source": "1103", "target": "1132", "attributes": {"size": null, "type": "arrow"}}, {"key": "1116", "source": "1103", "target": "1133", "attributes": {"size": null, "type": "arrow"}}, {"key": "1117", "source": "1103", "target": "1134", "attributes": {"size": null, "type": "arrow"}}, {"key": "1118", "source": "1103", "target": "1135", "attributes": {"size": null, "type": "arrow"}}, {"key": "1119", "source": "1103", "target": "1136", "attributes": {"size": null, "type": "arrow"}}, {"key": "1120", "source": "1103", "target": "1137", "attributes": {"size": null, "type": "arrow"}}, {"key": "1121", "source": "1103", "target": "1138", "attributes": {"size": null, "type": "arrow"}}, {"key": "1122", "source": "1103", "target": "1139", "attributes": {"size": null, "type": "arrow"}}, {"key": "1123", "source": "1103", "target": "1140", "attributes": {"size": null, "type": "arrow"}}, {"key": "1124", "source": "1103", "target": "1141", "attributes": {"size": null, "type": "arrow"}}, {"key": "1125", "source": "1103", "target": "1142", "attributes": {"size": null, "type": "arrow"}}, {"key": "1126", "source": "1103", "target": "1143", "attributes": {"size": null, "type": "arrow"}}, {"key": "1127", "source": "1103", "target": "1144", "attributes": {"size": null, "type": "arrow"}}, {"key": "1128", "source": "1103", "target": "1145", "attributes": {"size": null, "type": "arrow"}}, {"key": "1129", "source": "1103", "target": "1146", "attributes": {"size": null, "type": "arrow"}}, {"key": "1130", "source": "1103", "target": "1147", "attributes": {"size": null, "type": "arrow"}}, {"key": "1131", "source": "1103", "target": "1148", "attributes": {"size": null, "type": "arrow"}}, {"key": "1132", "source": "1103", "target": "1149", "attributes": {"size": null, "type": "arrow"}}, {"key": "1133", "source": "1103", "target": "1150", "attributes": {"size": null, "type": "arrow"}}, {"key": "1134", "source": "1103", "target": "186", "attributes": {"size": null, "type": "arrow"}}, {"key": "1135", "source": "1103", "target": "1151", "attributes": {"size": null, "type": "arrow"}}, {"key": "1136", "source": "1103", "target": "1152", "attributes": {"size": null, "type": "arrow"}}, {"key": "1137", "source": "1103", "target": "1153", "attributes": {"size": null, "type": "arrow"}}, {"key": "1138", "source": "1103", "target": "1154", "attributes": {"size": null, "type": "arrow"}}, {"key": "1139", "source": "1103", "target": "1155", "attributes": {"size": null, "type": "arrow"}}, {"key": "1140", "source": "1103", "target": "1156", "attributes": {"size": null, "type": "arrow"}}, {"key": "1141", "source": "1103", "target": "1157", "attributes": {"size": null, "type": "arrow"}}, {"key": "1142", "source": "1103", "target": "1158", "attributes": {"size": null, "type": "arrow"}}, {"key": "1143", "source": "1103", "target": "202", "attributes": {"size": null, "type": "arrow"}}, {"key": "1144", "source": "1103", "target": "230", "attributes": {"size": null, "type": "arrow"}}, {"key": "1145", "source": "1159", "target": "518", "attributes": {"size": null, "type": "arrow"}}, {"key": "1146", "source": "1159", "target": "616", "attributes": {"size": null, "type": "arrow"}}, {"key": "1147", "source": "1159", "target": "155", "attributes": {"size": null, "type": "arrow"}}, {"key": "1148", "source": "1159", "target": "1160", "attributes": {"size": null, "type": "arrow"}}, {"key": "1149", "source": "1159", "target": "1161", "attributes": {"size": null, "type": "arrow"}}, {"key": "1150", "source": "1159", "target": "1162", "attributes": {"size": null, "type": "arrow"}}, {"key": "1151", "source": "1159", "target": "1163", "attributes": {"size": null, "type": "arrow"}}, {"key": "1152", "source": "1159", "target": "1164", "attributes": {"size": null, "type": "arrow"}}, {"key": "1153", "source": "1159", "target": "1165", "attributes": {"size": null, "type": "arrow"}}, {"key": "1154", "source": "1159", "target": "1166", "attributes": {"size": null, "type": "arrow"}}, {"key": "1155", "source": "1159", "target": "1167", "attributes": {"size": null, "type": "arrow"}}, {"key": "1156", "source": "1159", "target": "1168", "attributes": {"size": null, "type": "arrow"}}, {"key": "1157", "source": "1159", "target": "1169", "attributes": {"size": null, "type": "arrow"}}, {"key": "1158", "source": "1159", "target": "1170", "attributes": {"size": null, "type": "arrow"}}, {"key": "1159", "source": "1159", "target": "1171", "attributes": {"size": null, "type": "arrow"}}, {"key": "1160", "source": "1159", "target": "1172", "attributes": {"size": null, "type": "arrow"}}, {"key": "1161", "source": "1159", "target": "1173", "attributes": {"size": null, "type": "arrow"}}, {"key": "1162", "source": "1159", "target": "1174", "attributes": {"size": null, "type": "arrow"}}, {"key": "1163", "source": "1159", "target": "1175", "attributes": {"size": null, "type": "arrow"}}, {"key": "1164", "source": "1159", "target": "1176", "attributes": {"size": null, "type": "arrow"}}, {"key": "1165", "source": "1159", "target": "1177", "attributes": {"size": null, "type": "arrow"}}, {"key": "1166", "source": "1159", "target": "1178", "attributes": {"size": null, "type": "arrow"}}, {"key": "1167", "source": "1159", "target": "1179", "attributes": {"size": null, "type": "arrow"}}, {"key": "1168", "source": "1159", "target": "1180", "attributes": {"size": null, "type": "arrow"}}, {"key": "1169", "source": "1159", "target": "1181", "attributes": {"size": null, "type": "arrow"}}, {"key": "1170", "source": "1159", "target": "1182", "attributes": {"size": null, "type": "arrow"}}, {"key": "1171", "source": "1159", "target": "1183", "attributes": {"size": null, "type": "arrow"}}, {"key": "1172", "source": "1159", "target": "1184", "attributes": {"size": null, "type": "arrow"}}, {"key": "1173", "source": "1159", "target": "1185", "attributes": {"size": null, "type": "arrow"}}, {"key": "1174", "source": "1159", "target": "1186", "attributes": {"size": null, "type": "arrow"}}, {"key": "1175", "source": "1159", "target": "1187", "attributes": {"size": null, "type": "arrow"}}, {"key": "1176", "source": "1159", "target": "1188", "attributes": {"size": null, "type": "arrow"}}, {"key": "1177", "source": "1159", "target": "1189", "attributes": {"size": null, "type": "arrow"}}, {"key": "1178", "source": "1159", "target": "1190", "attributes": {"size": null, "type": "arrow"}}, {"key": "1179", "source": "1159", "target": "1191", "attributes": {"size": null, "type": "arrow"}}, {"key": "1180", "source": "1159", "target": "1192", "attributes": {"size": null, "type": "arrow"}}, {"key": "1181", "source": "1159", "target": "1193", "attributes": {"size": null, "type": "arrow"}}, {"key": "1182", "source": "1159", "target": "1194", "attributes": {"size": null, "type": "arrow"}}, {"key": "1183", "source": "1159", "target": "1195", "attributes": {"size": null, "type": "arrow"}}, {"key": "1184", "source": "1159", "target": "1196", "attributes": {"size": null, "type": "arrow"}}, {"key": "1185", "source": "1159", "target": "1197", "attributes": {"size": null, "type": "arrow"}}, {"key": "1186", "source": "1159", "target": "1198", "attributes": {"size": null, "type": "arrow"}}, {"key": "1187", "source": "1159", "target": "1199", "attributes": {"size": null, "type": "arrow"}}, {"key": "1188", "source": "1159", "target": "1200", "attributes": {"size": null, "type": "arrow"}}, {"key": "1189", "source": "1159", "target": "1201", "attributes": {"size": null, "type": "arrow"}}, {"key": "1190", "source": "1159", "target": "1202", "attributes": {"size": null, "type": "arrow"}}, {"key": "1191", "source": "1159", "target": "1203", "attributes": {"size": null, "type": "arrow"}}, {"key": "1192", "source": "1159", "target": "1204", "attributes": {"size": null, "type": "arrow"}}, {"key": "1193", "source": "1159", "target": "1205", "attributes": {"size": null, "type": "arrow"}}, {"key": "1194", "source": "1159", "target": "1206", "attributes": {"size": null, "type": "arrow"}}, {"key": "1195", "source": "1159", "target": "1207", "attributes": {"size": null, "type": "arrow"}}, {"key": "1196", "source": "1159", "target": "1208", "attributes": {"size": null, "type": "arrow"}}, {"key": "1197", "source": "1159", "target": "1209", "attributes": {"size": null, "type": "arrow"}}, {"key": "1198", "source": "1159", "target": "1210", "attributes": {"size": null, "type": "arrow"}}, {"key": "1199", "source": "1159", "target": "1211", "attributes": {"size": null, "type": "arrow"}}, {"key": "1200", "source": "1159", "target": "1212", "attributes": {"size": null, "type": "arrow"}}, {"key": "1201", "source": "1159", "target": "1213", "attributes": {"size": null, "type": "arrow"}}, {"key": "1202", "source": "1159", "target": "1214", "attributes": {"size": null, "type": "arrow"}}, {"key": "1203", "source": "1159", "target": "1215", "attributes": {"size": null, "type": "arrow"}}, {"key": "1204", "source": "1159", "target": "1216", "attributes": {"size": null, "type": "arrow"}}, {"key": "1205", "source": "1159", "target": "1217", "attributes": {"size": null, "type": "arrow"}}, {"key": "1206", "source": "1159", "target": "1218", "attributes": {"size": null, "type": "arrow"}}, {"key": "1207", "source": "1159", "target": "1219", "attributes": {"size": null, "type": "arrow"}}, {"key": "1208", "source": "1159", "target": "1220", "attributes": {"size": null, "type": "arrow"}}, {"key": "1209", "source": "1159", "target": "1221", "attributes": {"size": null, "type": "arrow"}}, {"key": "1210", "source": "1159", "target": "1222", "attributes": {"size": null, "type": "arrow"}}, {"key": "1211", "source": "1159", "target": "1223", "attributes": {"size": null, "type": "arrow"}}, {"key": "1212", "source": "1159", "target": "1224", "attributes": {"size": null, "type": "arrow"}}, {"key": "1213", "source": "1159", "target": "1225", "attributes": {"size": null, "type": "arrow"}}, {"key": "1214", "source": "1159", "target": "1226", "attributes": {"size": null, "type": "arrow"}}, {"key": "1215", "source": "1159", "target": "1227", "attributes": {"size": null, "type": "arrow"}}, {"key": "1216", "source": "1159", "target": "1228", "attributes": {"size": null, "type": "arrow"}}, {"key": "1217", "source": "1159", "target": "770", "attributes": {"size": null, "type": "arrow"}}, {"key": "1218", "source": "1159", "target": "1229", "attributes": {"size": null, "type": "arrow"}}, {"key": "1219", "source": "1159", "target": "1230", "attributes": {"size": null, "type": "arrow"}}, {"key": "1220", "source": "1159", "target": "1231", "attributes": {"size": null, "type": "arrow"}}, {"key": "1221", "source": "1159", "target": "1232", "attributes": {"size": null, "type": "arrow"}}, {"key": "1222", "source": "1159", "target": "1233", "attributes": {"size": null, "type": "arrow"}}, {"key": "1223", "source": "1159", "target": "1234", "attributes": {"size": null, "type": "arrow"}}, {"key": "1224", "source": "1159", "target": "1235", "attributes": {"size": null, "type": "arrow"}}, {"key": "1225", "source": "1159", "target": "1236", "attributes": {"size": null, "type": "arrow"}}, {"key": "1226", "source": "1159", "target": "1237", "attributes": {"size": null, "type": "arrow"}}, {"key": "1227", "source": "1159", "target": "931", "attributes": {"size": null, "type": "arrow"}}, {"key": "1228", "source": "1159", "target": "988", "attributes": {"size": null, "type": "arrow"}}, {"key": "1229", "source": "1159", "target": "1007", "attributes": {"size": null, "type": "arrow"}}, {"key": "1230", "source": "1159", "target": "1014", "attributes": {"size": null, "type": "arrow"}}, {"key": "1231", "source": "1238", "target": "1239", "attributes": {"size": null, "type": "arrow"}}, {"key": "1232", "source": "1238", "target": "1240", "attributes": {"size": null, "type": "arrow"}}, {"key": "1233", "source": "1238", "target": "1241", "attributes": {"size": null, "type": "arrow"}}, {"key": "1234", "source": "1238", "target": "1242", "attributes": {"size": null, "type": "arrow"}}, {"key": "1235", "source": "1238", "target": "1243", "attributes": {"size": null, "type": "arrow"}}, {"key": "1236", "source": "1238", "target": "1244", "attributes": {"size": null, "type": "arrow"}}, {"key": "1237", "source": "1238", "target": "1245", "attributes": {"size": null, "type": "arrow"}}, {"key": "1238", "source": "1238", "target": "1246", "attributes": {"size": null, "type": "arrow"}}, {"key": "1239", "source": "1238", "target": "1247", "attributes": {"size": null, "type": "arrow"}}, {"key": "1240", "source": "1238", "target": "1248", "attributes": {"size": null, "type": "arrow"}}, {"key": "1241", "source": "1238", "target": "1249", "attributes": {"size": null, "type": "arrow"}}, {"key": "1242", "source": "1238", "target": "1250", "attributes": {"size": null, "type": "arrow"}}, {"key": "1243", "source": "1238", "target": "1251", "attributes": {"size": null, "type": "arrow"}}, {"key": "1244", "source": "1238", "target": "1252", "attributes": {"size": null, "type": "arrow"}}, {"key": "1245", "source": "1238", "target": "1253", "attributes": {"size": null, "type": "arrow"}}, {"key": "1246", "source": "1238", "target": "1254", "attributes": {"size": null, "type": "arrow"}}, {"key": "1247", "source": "1238", "target": "1255", "attributes": {"size": null, "type": "arrow"}}, {"key": "1248", "source": "1238", "target": "1256", "attributes": {"size": null, "type": "arrow"}}, {"key": "1249", "source": "1238", "target": "1257", "attributes": {"size": null, "type": "arrow"}}, {"key": "1250", "source": "1238", "target": "1258", "attributes": {"size": null, "type": "arrow"}}, {"key": "1251", "source": "1238", "target": "1259", "attributes": {"size": null, "type": "arrow"}}, {"key": "1252", "source": "1238", "target": "1260", "attributes": {"size": null, "type": "arrow"}}, {"key": "1253", "source": "1238", "target": "1261", "attributes": {"size": null, "type": "arrow"}}, {"key": "1254", "source": "1238", "target": "1262", "attributes": {"size": null, "type": "arrow"}}, {"key": "1255", "source": "1238", "target": "1263", "attributes": {"size": null, "type": "arrow"}}, {"key": "1256", "source": "1238", "target": "1264", "attributes": {"size": null, "type": "arrow"}}, {"key": "1257", "source": "1238", "target": "1265", "attributes": {"size": null, "type": "arrow"}}, {"key": "1258", "source": "1238", "target": "1266", "attributes": {"size": null, "type": "arrow"}}, {"key": "1259", "source": "1238", "target": "1267", "attributes": {"size": null, "type": "arrow"}}, {"key": "1260", "source": "1238", "target": "1268", "attributes": {"size": null, "type": "arrow"}}, {"key": "1261", "source": "1238", "target": "1269", "attributes": {"size": null, "type": "arrow"}}, {"key": "1262", "source": "1238", "target": "1270", "attributes": {"size": null, "type": "arrow"}}, {"key": "1263", "source": "1238", "target": "1271", "attributes": {"size": null, "type": "arrow"}}, {"key": "1264", "source": "1238", "target": "1272", "attributes": {"size": null, "type": "arrow"}}, {"key": "1265", "source": "1238", "target": "1273", "attributes": {"size": null, "type": "arrow"}}, {"key": "1266", "source": "1238", "target": "1274", "attributes": {"size": null, "type": "arrow"}}, {"key": "1267", "source": "1238", "target": "1275", "attributes": {"size": null, "type": "arrow"}}, {"key": "1268", "source": "1238", "target": "1276", "attributes": {"size": null, "type": "arrow"}}, {"key": "1269", "source": "1238", "target": "1277", "attributes": {"size": null, "type": "arrow"}}, {"key": "1270", "source": "1238", "target": "1278", "attributes": {"size": null, "type": "arrow"}}, {"key": "1271", "source": "1238", "target": "1279", "attributes": {"size": null, "type": "arrow"}}, {"key": "1272", "source": "1238", "target": "1280", "attributes": {"size": null, "type": "arrow"}}, {"key": "1273", "source": "1238", "target": "1281", "attributes": {"size": null, "type": "arrow"}}, {"key": "1274", "source": "1238", "target": "1282", "attributes": {"size": null, "type": "arrow"}}, {"key": "1275", "source": "1238", "target": "1283", "attributes": {"size": null, "type": "arrow"}}, {"key": "1276", "source": "1238", "target": "1284", "attributes": {"size": null, "type": "arrow"}}, {"key": "1277", "source": "1238", "target": "1285", "attributes": {"size": null, "type": "arrow"}}, {"key": "1278", "source": "1238", "target": "1286", "attributes": {"size": null, "type": "arrow"}}, {"key": "1279", "source": "1238", "target": "1287", "attributes": {"size": null, "type": "arrow"}}, {"key": "1280", "source": "1238", "target": "1288", "attributes": {"size": null, "type": "arrow"}}, {"key": "1281", "source": "1238", "target": "1289", "attributes": {"size": null, "type": "arrow"}}, {"key": "1282", "source": "1238", "target": "1290", "attributes": {"size": null, "type": "arrow"}}, {"key": "1283", "source": "1238", "target": "1291", "attributes": {"size": null, "type": "arrow"}}, {"key": "1284", "source": "1238", "target": "1292", "attributes": {"size": null, "type": "arrow"}}, {"key": "1285", "source": "1238", "target": "1293", "attributes": {"size": null, "type": "arrow"}}, {"key": "1286", "source": "1238", "target": "1294", "attributes": {"size": null, "type": "arrow"}}, {"key": "1287", "source": "1238", "target": "1295", "attributes": {"size": null, "type": "arrow"}}, {"key": "1288", "source": "1238", "target": "1296", "attributes": {"size": null, "type": "arrow"}}, {"key": "1289", "source": "1238", "target": "1297", "attributes": {"size": null, "type": "arrow"}}, {"key": "1290", "source": "1238", "target": "1298", "attributes": {"size": null, "type": "arrow"}}, {"key": "1291", "source": "1238", "target": "1299", "attributes": {"size": null, "type": "arrow"}}, {"key": "1292", "source": "1238", "target": "1300", "attributes": {"size": null, "type": "arrow"}}, {"key": "1293", "source": "1238", "target": "1301", "attributes": {"size": null, "type": "arrow"}}, {"key": "1294", "source": "1238", "target": "1302", "attributes": {"size": null, "type": "arrow"}}, {"key": "1295", "source": "1238", "target": "1303", "attributes": {"size": null, "type": "arrow"}}, {"key": "1296", "source": "1238", "target": "1304", "attributes": {"size": null, "type": "arrow"}}, {"key": "1297", "source": "1238", "target": "1305", "attributes": {"size": null, "type": "arrow"}}, {"key": "1298", "source": "1238", "target": "1306", "attributes": {"size": null, "type": "arrow"}}, {"key": "1299", "source": "1238", "target": "1307", "attributes": {"size": null, "type": "arrow"}}, {"key": "1300", "source": "1238", "target": "1308", "attributes": {"size": null, "type": "arrow"}}, {"key": "1301", "source": "1238", "target": "1309", "attributes": {"size": null, "type": "arrow"}}, {"key": "1302", "source": "1238", "target": "1310", "attributes": {"size": null, "type": "arrow"}}, {"key": "1303", "source": "1238", "target": "1311", "attributes": {"size": null, "type": "arrow"}}, {"key": "1304", "source": "1238", "target": "1312", "attributes": {"size": null, "type": "arrow"}}, {"key": "1305", "source": "1238", "target": "1313", "attributes": {"size": null, "type": "arrow"}}, {"key": "1306", "source": "1238", "target": "1314", "attributes": {"size": null, "type": "arrow"}}, {"key": "1307", "source": "1238", "target": "1315", "attributes": {"size": null, "type": "arrow"}}, {"key": "1308", "source": "1238", "target": "1316", "attributes": {"size": null, "type": "arrow"}}, {"key": "1309", "source": "1238", "target": "1317", "attributes": {"size": null, "type": "arrow"}}, {"key": "1310", "source": "1238", "target": "1318", "attributes": {"size": null, "type": "arrow"}}, {"key": "1311", "source": "1238", "target": "1319", "attributes": {"size": null, "type": "arrow"}}, {"key": "1312", "source": "1238", "target": "1320", "attributes": {"size": null, "type": "arrow"}}, {"key": "1313", "source": "1238", "target": "1321", "attributes": {"size": null, "type": "arrow"}}, {"key": "1314", "source": "1238", "target": "1322", "attributes": {"size": null, "type": "arrow"}}, {"key": "1315", "source": "1238", "target": "1323", "attributes": {"size": null, "type": "arrow"}}, {"key": "1316", "source": "1238", "target": "1324", "attributes": {"size": null, "type": "arrow"}}, {"key": "1317", "source": "1238", "target": "1325", "attributes": {"size": null, "type": "arrow"}}, {"key": "1318", "source": "1238", "target": "1326", "attributes": {"size": null, "type": "arrow"}}, {"key": "1319", "source": "1238", "target": "1327", "attributes": {"size": null, "type": "arrow"}}, {"key": "1320", "source": "1238", "target": "1328", "attributes": {"size": null, "type": "arrow"}}, {"key": "1321", "source": "1238", "target": "1329", "attributes": {"size": null, "type": "arrow"}}, {"key": "1322", "source": "1238", "target": "1330", "attributes": {"size": null, "type": "arrow"}}, {"key": "1323", "source": "1238", "target": "1331", "attributes": {"size": null, "type": "arrow"}}, {"key": "1324", "source": "1238", "target": "1332", "attributes": {"size": null, "type": "arrow"}}, {"key": "1325", "source": "1238", "target": "1333", "attributes": {"size": null, "type": "arrow"}}, {"key": "1326", "source": "1238", "target": "1334", "attributes": {"size": null, "type": "arrow"}}, {"key": "1327", "source": "1238", "target": "1335", "attributes": {"size": null, "type": "arrow"}}, {"key": "1328", "source": "1238", "target": "1336", "attributes": {"size": null, "type": "arrow"}}, {"key": "1329", "source": "1238", "target": "1337", "attributes": {"size": null, "type": "arrow"}}, {"key": "1330", "source": "1238", "target": "1338", "attributes": {"size": null, "type": "arrow"}}, {"key": "1331", "source": "1238", "target": "1339", "attributes": {"size": null, "type": "arrow"}}, {"key": "1332", "source": "1238", "target": "1340", "attributes": {"size": null, "type": "arrow"}}, {"key": "1333", "source": "1238", "target": "1341", "attributes": {"size": null, "type": "arrow"}}, {"key": "1334", "source": "1238", "target": "1342", "attributes": {"size": null, "type": "arrow"}}, {"key": "1335", "source": "1238", "target": "1343", "attributes": {"size": null, "type": "arrow"}}, {"key": "1336", "source": "1238", "target": "1344", "attributes": {"size": null, "type": "arrow"}}, {"key": "1337", "source": "1238", "target": "1345", "attributes": {"size": null, "type": "arrow"}}, {"key": "1338", "source": "1238", "target": "1346", "attributes": {"size": null, "type": "arrow"}}, {"key": "1339", "source": "1238", "target": "1347", "attributes": {"size": null, "type": "arrow"}}, {"key": "1340", "source": "1238", "target": "1348", "attributes": {"size": null, "type": "arrow"}}, {"key": "1341", "source": "1238", "target": "1349", "attributes": {"size": null, "type": "arrow"}}, {"key": "1342", "source": "1238", "target": "1350", "attributes": {"size": null, "type": "arrow"}}, {"key": "1343", "source": "1238", "target": "1351", "attributes": {"size": null, "type": "arrow"}}, {"key": "1344", "source": "1238", "target": "1352", "attributes": {"size": null, "type": "arrow"}}, {"key": "1345", "source": "1238", "target": "1353", "attributes": {"size": null, "type": "arrow"}}, {"key": "1346", "source": "1238", "target": "1354", "attributes": {"size": null, "type": "arrow"}}, {"key": "1347", "source": "1238", "target": "1355", "attributes": {"size": null, "type": "arrow"}}, {"key": "1348", "source": "1238", "target": "1356", "attributes": {"size": null, "type": "arrow"}}, {"key": "1349", "source": "1238", "target": "1357", "attributes": {"size": null, "type": "arrow"}}, {"key": "1350", "source": "1238", "target": "1358", "attributes": {"size": null, "type": "arrow"}}, {"key": "1351", "source": "1238", "target": "1359", "attributes": {"size": null, "type": "arrow"}}, {"key": "1352", "source": "1238", "target": "1360", "attributes": {"size": null, "type": "arrow"}}, {"key": "1353", "source": "1238", "target": "1361", "attributes": {"size": null, "type": "arrow"}}, {"key": "1354", "source": "1238", "target": "1362", "attributes": {"size": null, "type": "arrow"}}, {"key": "1355", "source": "1238", "target": "1363", "attributes": {"size": null, "type": "arrow"}}, {"key": "1356", "source": "1238", "target": "1364", "attributes": {"size": null, "type": "arrow"}}, {"key": "1357", "source": "1238", "target": "1365", "attributes": {"size": null, "type": "arrow"}}, {"key": "1358", "source": "1238", "target": "1366", "attributes": {"size": null, "type": "arrow"}}, {"key": "1359", "source": "1238", "target": "1367", "attributes": {"size": null, "type": "arrow"}}, {"key": "1360", "source": "1238", "target": "1368", "attributes": {"size": null, "type": "arrow"}}, {"key": "1361", "source": "1238", "target": "1369", "attributes": {"size": null, "type": "arrow"}}, {"key": "1362", "source": "1238", "target": "1370", "attributes": {"size": null, "type": "arrow"}}, {"key": "1363", "source": "1238", "target": "1371", "attributes": {"size": null, "type": "arrow"}}, {"key": "1364", "source": "1238", "target": "1372", "attributes": {"size": null, "type": "arrow"}}, {"key": "1365", "source": "1238", "target": "1373", "attributes": {"size": null, "type": "arrow"}}, {"key": "1366", "source": "1238", "target": "1374", "attributes": {"size": null, "type": "arrow"}}, {"key": "1367", "source": "1238", "target": "1375", "attributes": {"size": null, "type": "arrow"}}, {"key": "1368", "source": "1238", "target": "1376", "attributes": {"size": null, "type": "arrow"}}, {"key": "1369", "source": "1238", "target": "1377", "attributes": {"size": null, "type": "arrow"}}, {"key": "1370", "source": "1238", "target": "1378", "attributes": {"size": null, "type": "arrow"}}, {"key": "1371", "source": "1379", "target": "1381", "attributes": {"size": null, "type": "arrow"}}, {"key": "1372", "source": "1379", "target": "1382", "attributes": {"size": null, "type": "arrow"}}, {"key": "1373", "source": "1379", "target": "1383", "attributes": {"size": null, "type": "arrow"}}, {"key": "1374", "source": "1379", "target": "1384", "attributes": {"size": null, "type": "arrow"}}, {"key": "1375", "source": "1379", "target": "1385", "attributes": {"size": null, "type": "arrow"}}, {"key": "1376", "source": "1379", "target": "1386", "attributes": {"size": null, "type": "arrow"}}, {"key": "1377", "source": "1379", "target": "1387", "attributes": {"size": null, "type": "arrow"}}, {"key": "1378", "source": "1379", "target": "1388", "attributes": {"size": null, "type": "arrow"}}, {"key": "1379", "source": "1379", "target": "1389", "attributes": {"size": null, "type": "arrow"}}, {"key": "1380", "source": "1379", "target": "1390", "attributes": {"size": null, "type": "arrow"}}, {"key": "1381", "source": "1379", "target": "1391", "attributes": {"size": null, "type": "arrow"}}, {"key": "1382", "source": "1379", "target": "1392", "attributes": {"size": null, "type": "arrow"}}, {"key": "1383", "source": "1379", "target": "1380", "attributes": {"size": null, "type": "arrow"}}, {"key": "1384", "source": "1393", "target": "1394", "attributes": {"size": null, "type": "arrow"}}, {"key": "1385", "source": "1393", "target": "1395", "attributes": {"size": null, "type": "arrow"}}, {"key": "1386", "source": "1393", "target": "1396", "attributes": {"size": null, "type": "arrow"}}, {"key": "1387", "source": "1397", "target": "1022", "attributes": {"size": null, "type": "arrow"}}, {"key": "1388", "source": "1397", "target": "1023", "attributes": {"size": null, "type": "arrow"}}, {"key": "1389", "source": "1397", "target": "526", "attributes": {"size": null, "type": "arrow"}}, {"key": "1390", "source": "1397", "target": "914", "attributes": {"size": null, "type": "arrow"}}, {"key": "1391", "source": "1397", "target": "926", "attributes": {"size": null, "type": "arrow"}}, {"key": "1392", "source": "1397", "target": "928", "attributes": {"size": null, "type": "arrow"}}, {"key": "1393", "source": "1397", "target": "930", "attributes": {"size": null, "type": "arrow"}}, {"key": "1394", "source": "1397", "target": "1398", "attributes": {"size": null, "type": "arrow"}}, {"key": "1395", "source": "1397", "target": "1399", "attributes": {"size": null, "type": "arrow"}}, {"key": "1396", "source": "1397", "target": "1400", "attributes": {"size": null, "type": "arrow"}}, {"key": "1397", "source": "1397", "target": "1401", "attributes": {"size": null, "type": "arrow"}}, {"key": "1398", "source": "1397", "target": "1402", "attributes": {"size": null, "type": "arrow"}}, {"key": "1399", "source": "1397", "target": "1403", "attributes": {"size": null, "type": "arrow"}}, {"key": "1400", "source": "1397", "target": "1404", "attributes": {"size": null, "type": "arrow"}}, {"key": "1401", "source": "1397", "target": "1405", "attributes": {"size": null, "type": "arrow"}}, {"key": "1402", "source": "1397", "target": "1406", "attributes": {"size": null, "type": "arrow"}}, {"key": "1403", "source": "1397", "target": "1407", "attributes": {"size": null, "type": "arrow"}}, {"key": "1404", "source": "1397", "target": "1408", "attributes": {"size": null, "type": "arrow"}}, {"key": "1405", "source": "1397", "target": "1409", "attributes": {"size": null, "type": "arrow"}}, {"key": "1406", "source": "1397", "target": "1410", "attributes": {"size": null, "type": "arrow"}}, {"key": "1407", "source": "1397", "target": "1411", "attributes": {"size": null, "type": "arrow"}}, {"key": "1408", "source": "1397", "target": "1412", "attributes": {"size": null, "type": "arrow"}}, {"key": "1409", "source": "1397", "target": "1413", "attributes": {"size": null, "type": "arrow"}}, {"key": "1410", "source": "1397", "target": "1414", "attributes": {"size": null, "type": "arrow"}}, {"key": "1411", "source": "1397", "target": "1415", "attributes": {"size": null, "type": "arrow"}}, {"key": "1412", "source": "1397", "target": "1416", "attributes": {"size": null, "type": "arrow"}}, {"key": "1413", "source": "1397", "target": "1417", "attributes": {"size": null, "type": "arrow"}}, {"key": "1414", "source": "1397", "target": "1418", "attributes": {"size": null, "type": "arrow"}}, {"key": "1415", "source": "1397", "target": "1419", "attributes": {"size": null, "type": "arrow"}}, {"key": "1416", "source": "1397", "target": "1420", "attributes": {"size": null, "type": "arrow"}}, {"key": "1417", "source": "1397", "target": "1421", "attributes": {"size": null, "type": "arrow"}}, {"key": "1418", "source": "1397", "target": "1422", "attributes": {"size": null, "type": "arrow"}}, {"key": "1419", "source": "1397", "target": "1423", "attributes": {"size": null, "type": "arrow"}}, {"key": "1420", "source": "1397", "target": "1424", "attributes": {"size": null, "type": "arrow"}}, {"key": "1421", "source": "1397", "target": "1425", "attributes": {"size": null, "type": "arrow"}}, {"key": "1422", "source": "1397", "target": "1426", "attributes": {"size": null, "type": "arrow"}}, {"key": "1423", "source": "1397", "target": "1427", "attributes": {"size": null, "type": "arrow"}}, {"key": "1424", "source": "1397", "target": "1428", "attributes": {"size": null, "type": "arrow"}}, {"key": "1425", "source": "1397", "target": "1429", "attributes": {"size": null, "type": "arrow"}}, {"key": "1426", "source": "1397", "target": "1430", "attributes": {"size": null, "type": "arrow"}}, {"key": "1427", "source": "1397", "target": "1431", "attributes": {"size": null, "type": "arrow"}}, {"key": "1428", "source": "1397", "target": "1432", "attributes": {"size": null, "type": "arrow"}}, {"key": "1429", "source": "1397", "target": "1433", "attributes": {"size": null, "type": "arrow"}}, {"key": "1430", "source": "1397", "target": "1434", "attributes": {"size": null, "type": "arrow"}}, {"key": "1431", "source": "1397", "target": "1435", "attributes": {"size": null, "type": "arrow"}}, {"key": "1432", "source": "1397", "target": "1436", "attributes": {"size": null, "type": "arrow"}}, {"key": "1433", "source": "1397", "target": "1437", "attributes": {"size": null, "type": "arrow"}}, {"key": "1434", "source": "1397", "target": "1438", "attributes": {"size": null, "type": "arrow"}}, {"key": "1435", "source": "1397", "target": "1439", "attributes": {"size": null, "type": "arrow"}}, {"key": "1436", "source": "1397", "target": "1440", "attributes": {"size": null, "type": "arrow"}}, {"key": "1437", "source": "1397", "target": "1441", "attributes": {"size": null, "type": "arrow"}}, {"key": "1438", "source": "1397", "target": "1442", "attributes": {"size": null, "type": "arrow"}}, {"key": "1439", "source": "1397", "target": "1443", "attributes": {"size": null, "type": "arrow"}}, {"key": "1440", "source": "1397", "target": "1444", "attributes": {"size": null, "type": "arrow"}}, {"key": "1441", "source": "1397", "target": "1445", "attributes": {"size": null, "type": "arrow"}}, {"key": "1442", "source": "1397", "target": "1446", "attributes": {"size": null, "type": "arrow"}}, {"key": "1443", "source": "1397", "target": "1447", "attributes": {"size": null, "type": "arrow"}}, {"key": "1444", "source": "1397", "target": "1448", "attributes": {"size": null, "type": "arrow"}}, {"key": "1445", "source": "1397", "target": "1007", "attributes": {"size": null, "type": "arrow"}}, {"key": "1446", "source": "1449", "target": "1450", "attributes": {"size": null, "type": "arrow"}}, {"key": "1447", "source": "1449", "target": "1451", "attributes": {"size": null, "type": "arrow"}}, {"key": "1448", "source": "1449", "target": "1452", "attributes": {"size": null, "type": "arrow"}}, {"key": "1449", "source": "515", "target": "1477", "attributes": {"size": null, "type": "arrow"}}, {"key": "1450", "source": "515", "target": "1478", "attributes": {"size": null, "type": "arrow"}}, {"key": "1451", "source": "515", "target": "1479", "attributes": {"size": null, "type": "arrow"}}, {"key": "1452", "source": "515", "target": "1480", "attributes": {"size": null, "type": "arrow"}}, {"key": "1453", "source": "515", "target": "1481", "attributes": {"size": null, "type": "arrow"}}, {"key": "1454", "source": "515", "target": "1482", "attributes": {"size": null, "type": "arrow"}}, {"key": "1455", "source": "515", "target": "1483", "attributes": {"size": null, "type": "arrow"}}, {"key": "1456", "source": "515", "target": "1484", "attributes": {"size": null, "type": "arrow"}}, {"key": "1457", "source": "515", "target": "1485", "attributes": {"size": null, "type": "arrow"}}, {"key": "1458", "source": "515", "target": "1486", "attributes": {"size": null, "type": "arrow"}}, {"key": "1459", "source": "515", "target": "1487", "attributes": {"size": null, "type": "arrow"}}, {"key": "1460", "source": "515", "target": "1488", "attributes": {"size": null, "type": "arrow"}}, {"key": "1461", "source": "515", "target": "1489", "attributes": {"size": null, "type": "arrow"}}, {"key": "1462", "source": "515", "target": "1490", "attributes": {"size": null, "type": "arrow"}}, {"key": "1463", "source": "515", "target": "1491", "attributes": {"size": null, "type": "arrow"}}, {"key": "1464", "source": "515", "target": "1492", "attributes": {"size": null, "type": "arrow"}}, {"key": "1465", "source": "515", "target": "1493", "attributes": {"size": null, "type": "arrow"}}, {"key": "1466", "source": "515", "target": "1494", "attributes": {"size": null, "type": "arrow"}}, {"key": "1467", "source": "515", "target": "1495", "attributes": {"size": null, "type": "arrow"}}, {"key": "1468", "source": "515", "target": "1496", "attributes": {"size": null, "type": "arrow"}}, {"key": "1469", "source": "515", "target": "1497", "attributes": {"size": null, "type": "arrow"}}, {"key": "1470", "source": "515", "target": "1498", "attributes": {"size": null, "type": "arrow"}}, {"key": "1471", "source": "515", "target": "1499", "attributes": {"size": null, "type": "arrow"}}, {"key": "1472", "source": "515", "target": "1500", "attributes": {"size": null, "type": "arrow"}}, {"key": "1473", "source": "515", "target": "1501", "attributes": {"size": null, "type": "arrow"}}, {"key": "1474", "source": "515", "target": "1502", "attributes": {"size": null, "type": "arrow"}}, {"key": "1475", "source": "515", "target": "1503", "attributes": {"size": null, "type": "arrow"}}, {"key": "1476", "source": "515", "target": "1504", "attributes": {"size": null, "type": "arrow"}}, {"key": "1477", "source": "515", "target": "1505", "attributes": {"size": null, "type": "arrow"}}, {"key": "1478", "source": "515", "target": "1506", "attributes": {"size": null, "type": "arrow"}}, {"key": "1479", "source": "515", "target": "1507", "attributes": {"size": null, "type": "arrow"}}, {"key": "1480", "source": "515", "target": "1508", "attributes": {"size": null, "type": "arrow"}}, {"key": "1481", "source": "515", "target": "1509", "attributes": {"size": null, "type": "arrow"}}, {"key": "1482", "source": "515", "target": "1510", "attributes": {"size": null, "type": "arrow"}}, {"key": "1483", "source": "515", "target": "1511", "attributes": {"size": null, "type": "arrow"}}, {"key": "1484", "source": "515", "target": "1512", "attributes": {"size": null, "type": "arrow"}}, {"key": "1485", "source": "515", "target": "1513", "attributes": {"size": null, "type": "arrow"}}, {"key": "1486", "source": "515", "target": "1514", "attributes": {"size": null, "type": "arrow"}}, {"key": "1487", "source": "515", "target": "1515", "attributes": {"size": null, "type": "arrow"}}, {"key": "1488", "source": "515", "target": "1516", "attributes": {"size": null, "type": "arrow"}}, {"key": "1489", "source": "515", "target": "1517", "attributes": {"size": null, "type": "arrow"}}, {"key": "1490", "source": "515", "target": "1518", "attributes": {"size": null, "type": "arrow"}}, {"key": "1491", "source": "515", "target": "1519", "attributes": {"size": null, "type": "arrow"}}, {"key": "1492", "source": "515", "target": "1520", "attributes": {"size": null, "type": "arrow"}}, {"key": "1493", "source": "515", "target": "1521", "attributes": {"size": null, "type": "arrow"}}, {"key": "1494", "source": "515", "target": "1522", "attributes": {"size": null, "type": "arrow"}}, {"key": "1495", "source": "515", "target": "1523", "attributes": {"size": null, "type": "arrow"}}, {"key": "1496", "source": "515", "target": "1524", "attributes": {"size": null, "type": "arrow"}}, {"key": "1497", "source": "515", "target": "1525", "attributes": {"size": null, "type": "arrow"}}, {"key": "1498", "source": "515", "target": "1526", "attributes": {"size": null, "type": "arrow"}}, {"key": "1499", "source": "515", "target": "1527", "attributes": {"size": null, "type": "arrow"}}, {"key": "1500", "source": "515", "target": "1528", "attributes": {"size": null, "type": "arrow"}}, {"key": "1501", "source": "515", "target": "1529", "attributes": {"size": null, "type": "arrow"}}, {"key": "1502", "source": "515", "target": "1530", "attributes": {"size": null, "type": "arrow"}}, {"key": "1503", "source": "515", "target": "1531", "attributes": {"size": null, "type": "arrow"}}, {"key": "1504", "source": "515", "target": "1532", "attributes": {"size": null, "type": "arrow"}}, {"key": "1505", "source": "515", "target": "1533", "attributes": {"size": null, "type": "arrow"}}, {"key": "1506", "source": "515", "target": "1534", "attributes": {"size": null, "type": "arrow"}}, {"key": "1507", "source": "515", "target": "1535", "attributes": {"size": null, "type": "arrow"}}, {"key": "1508", "source": "515", "target": "1536", "attributes": {"size": null, "type": "arrow"}}, {"key": "1509", "source": "515", "target": "1537", "attributes": {"size": null, "type": "arrow"}}, {"key": "1510", "source": "515", "target": "1538", "attributes": {"size": null, "type": "arrow"}}, {"key": "1511", "source": "515", "target": "1539", "attributes": {"size": null, "type": "arrow"}}, {"key": "1512", "source": "515", "target": "1540", "attributes": {"size": null, "type": "arrow"}}, {"key": "1513", "source": "515", "target": "1541", "attributes": {"size": null, "type": "arrow"}}, {"key": "1514", "source": "515", "target": "1542", "attributes": {"size": null, "type": "arrow"}}, {"key": "1515", "source": "515", "target": "1543", "attributes": {"size": null, "type": "arrow"}}, {"key": "1516", "source": "515", "target": "1544", "attributes": {"size": null, "type": "arrow"}}, {"key": "1517", "source": "515", "target": "1545", "attributes": {"size": null, "type": "arrow"}}, {"key": "1518", "source": "515", "target": "1546", "attributes": {"size": null, "type": "arrow"}}, {"key": "1519", "source": "515", "target": "1547", "attributes": {"size": null, "type": "arrow"}}, {"key": "1520", "source": "515", "target": "1548", "attributes": {"size": null, "type": "arrow"}}, {"key": "1521", "source": "515", "target": "1549", "attributes": {"size": null, "type": "arrow"}}, {"key": "1522", "source": "515", "target": "1550", "attributes": {"size": null, "type": "arrow"}}, {"key": "1523", "source": "515", "target": "1551", "attributes": {"size": null, "type": "arrow"}}, {"key": "1524", "source": "515", "target": "1552", "attributes": {"size": null, "type": "arrow"}}, {"key": "1525", "source": "515", "target": "1553", "attributes": {"size": null, "type": "arrow"}}, {"key": "1526", "source": "515", "target": "1554", "attributes": {"size": null, "type": "arrow"}}, {"key": "1527", "source": "515", "target": "1555", "attributes": {"size": null, "type": "arrow"}}, {"key": "1528", "source": "515", "target": "1556", "attributes": {"size": null, "type": "arrow"}}, {"key": "1529", "source": "515", "target": "1557", "attributes": {"size": null, "type": "arrow"}}, {"key": "1530", "source": "515", "target": "1558", "attributes": {"size": null, "type": "arrow"}}, {"key": "1531", "source": "515", "target": "1559", "attributes": {"size": null, "type": "arrow"}}, {"key": "1532", "source": "515", "target": "1560", "attributes": {"size": null, "type": "arrow"}}, {"key": "1533", "source": "515", "target": "1561", "attributes": {"size": null, "type": "arrow"}}, {"key": "1534", "source": "515", "target": "1562", "attributes": {"size": null, "type": "arrow"}}, {"key": "1535", "source": "515", "target": "1563", "attributes": {"size": null, "type": "arrow"}}, {"key": "1536", "source": "515", "target": "1564", "attributes": {"size": null, "type": "arrow"}}, {"key": "1537", "source": "515", "target": "1565", "attributes": {"size": null, "type": "arrow"}}, {"key": "1538", "source": "515", "target": "1566", "attributes": {"size": null, "type": "arrow"}}, {"key": "1539", "source": "515", "target": "1567", "attributes": {"size": null, "type": "arrow"}}, {"key": "1540", "source": "515", "target": "1568", "attributes": {"size": null, "type": "arrow"}}, {"key": "1541", "source": "515", "target": "1569", "attributes": {"size": null, "type": "arrow"}}, {"key": "1542", "source": "515", "target": "1570", "attributes": {"size": null, "type": "arrow"}}, {"key": "1543", "source": "515", "target": "1571", "attributes": {"size": null, "type": "arrow"}}, {"key": "1544", "source": "515", "target": "1572", "attributes": {"size": null, "type": "arrow"}}, {"key": "1545", "source": "515", "target": "1573", "attributes": {"size": null, "type": "arrow"}}, {"key": "1546", "source": "515", "target": "1574", "attributes": {"size": null, "type": "arrow"}}, {"key": "1547", "source": "515", "target": "1575", "attributes": {"size": null, "type": "arrow"}}, {"key": "1548", "source": "515", "target": "1576", "attributes": {"size": null, "type": "arrow"}}, {"key": "1549", "source": "515", "target": "1577", "attributes": {"size": null, "type": "arrow"}}, {"key": "1550", "source": "515", "target": "1578", "attributes": {"size": null, "type": "arrow"}}, {"key": "1551", "source": "515", "target": "1579", "attributes": {"size": null, "type": "arrow"}}, {"key": "1552", "source": "515", "target": "1580", "attributes": {"size": null, "type": "arrow"}}, {"key": "1553", "source": "515", "target": "1581", "attributes": {"size": null, "type": "arrow"}}, {"key": "1554", "source": "515", "target": "1582", "attributes": {"size": null, "type": "arrow"}}, {"key": "1555", "source": "515", "target": "1583", "attributes": {"size": null, "type": "arrow"}}, {"key": "1556", "source": "515", "target": "1584", "attributes": {"size": null, "type": "arrow"}}, {"key": "1557", "source": "515", "target": "1585", "attributes": {"size": null, "type": "arrow"}}, {"key": "1558", "source": "515", "target": "1586", "attributes": {"size": null, "type": "arrow"}}, {"key": "1559", "source": "515", "target": "1587", "attributes": {"size": null, "type": "arrow"}}, {"key": "1560", "source": "515", "target": "1588", "attributes": {"size": null, "type": "arrow"}}, {"key": "1561", "source": "515", "target": "1589", "attributes": {"size": null, "type": "arrow"}}, {"key": "1562", "source": "515", "target": "1590", "attributes": {"size": null, "type": "arrow"}}, {"key": "1563", "source": "515", "target": "1591", "attributes": {"size": null, "type": "arrow"}}, {"key": "1564", "source": "515", "target": "1592", "attributes": {"size": null, "type": "arrow"}}, {"key": "1565", "source": "515", "target": "1593", "attributes": {"size": null, "type": "arrow"}}, {"key": "1566", "source": "515", "target": "1594", "attributes": {"size": null, "type": "arrow"}}, {"key": "1567", "source": "515", "target": "1595", "attributes": {"size": null, "type": "arrow"}}, {"key": "1568", "source": "515", "target": "1596", "attributes": {"size": null, "type": "arrow"}}, {"key": "1569", "source": "515", "target": "1597", "attributes": {"size": null, "type": "arrow"}}, {"key": "1570", "source": "515", "target": "1598", "attributes": {"size": null, "type": "arrow"}}, {"key": "1571", "source": "515", "target": "1599", "attributes": {"size": null, "type": "arrow"}}, {"key": "1572", "source": "515", "target": "1184", "attributes": {"size": null, "type": "arrow"}}, {"key": "1573", "source": "515", "target": "1453", "attributes": {"size": null, "type": "arrow"}}, {"key": "1574", "source": "515", "target": "1454", "attributes": {"size": null, "type": "arrow"}}, {"key": "1575", "source": "515", "target": "1455", "attributes": {"size": null, "type": "arrow"}}, {"key": "1576", "source": "515", "target": "1456", "attributes": {"size": null, "type": "arrow"}}, {"key": "1577", "source": "515", "target": "1457", "attributes": {"size": null, "type": "arrow"}}, {"key": "1578", "source": "515", "target": "1458", "attributes": {"size": null, "type": "arrow"}}, {"key": "1579", "source": "515", "target": "1459", "attributes": {"size": null, "type": "arrow"}}, {"key": "1580", "source": "515", "target": "1460", "attributes": {"size": null, "type": "arrow"}}, {"key": "1581", "source": "515", "target": "1461", "attributes": {"size": null, "type": "arrow"}}, {"key": "1582", "source": "515", "target": "1462", "attributes": {"size": null, "type": "arrow"}}, {"key": "1583", "source": "515", "target": "1463", "attributes": {"size": null, "type": "arrow"}}, {"key": "1584", "source": "515", "target": "1464", "attributes": {"size": null, "type": "arrow"}}, {"key": "1585", "source": "515", "target": "1465", "attributes": {"size": null, "type": "arrow"}}, {"key": "1586", "source": "515", "target": "1466", "attributes": {"size": null, "type": "arrow"}}, {"key": "1587", "source": "515", "target": "1467", "attributes": {"size": null, "type": "arrow"}}, {"key": "1588", "source": "515", "target": "1468", "attributes": {"size": null, "type": "arrow"}}, {"key": "1589", "source": "515", "target": "1469", "attributes": {"size": null, "type": "arrow"}}, {"key": "1590", "source": "515", "target": "1470", "attributes": {"size": null, "type": "arrow"}}, {"key": "1591", "source": "515", "target": "1471", "attributes": {"size": null, "type": "arrow"}}, {"key": "1592", "source": "515", "target": "1472", "attributes": {"size": null, "type": "arrow"}}, {"key": "1593", "source": "515", "target": "1473", "attributes": {"size": null, "type": "arrow"}}, {"key": "1594", "source": "515", "target": "1474", "attributes": {"size": null, "type": "arrow"}}, {"key": "1595", "source": "515", "target": "1475", "attributes": {"size": null, "type": "arrow"}}, {"key": "1596", "source": "515", "target": "1476", "attributes": {"size": null, "type": "arrow"}}, {"key": "1597", "source": "1600", "target": "1601", "attributes": {"size": null, "type": "arrow"}}, {"key": "1598", "source": "1602", "target": "1605", "attributes": {"size": null, "type": "arrow"}}, {"key": "1599", "source": "1602", "target": "1606", "attributes": {"size": null, "type": "arrow"}}, {"key": "1600", "source": "1602", "target": "1607", "attributes": {"size": null, "type": "arrow"}}, {"key": "1601", "source": "1602", "target": "1608", "attributes": {"size": null, "type": "arrow"}}, {"key": "1602", "source": "1602", "target": "1609", "attributes": {"size": null, "type": "arrow"}}, {"key": "1603", "source": "1602", "target": "1610", "attributes": {"size": null, "type": "arrow"}}, {"key": "1604", "source": "1602", "target": "1611", "attributes": {"size": null, "type": "arrow"}}, {"key": "1605", "source": "1602", "target": "1612", "attributes": {"size": null, "type": "arrow"}}, {"key": "1606", "source": "1602", "target": "1613", "attributes": {"size": null, "type": "arrow"}}, {"key": "1607", "source": "1602", "target": "1614", "attributes": {"size": null, "type": "arrow"}}, {"key": "1608", "source": "1602", "target": "1615", "attributes": {"size": null, "type": "arrow"}}, {"key": "1609", "source": "1602", "target": "1616", "attributes": {"size": null, "type": "arrow"}}, {"key": "1610", "source": "1602", "target": "1617", "attributes": {"size": null, "type": "arrow"}}, {"key": "1611", "source": "1602", "target": "1618", "attributes": {"size": null, "type": "arrow"}}, {"key": "1612", "source": "1602", "target": "1603", "attributes": {"size": null, "type": "arrow"}}, {"key": "1613", "source": "1602", "target": "1604", "attributes": {"size": null, "type": "arrow"}}, {"key": "1614", "source": "1619", "target": "1620", "attributes": {"size": null, "type": "arrow"}}, {"key": "1615", "source": "1619", "target": "1621", "attributes": {"size": null, "type": "arrow"}}, {"key": "1616", "source": "1619", "target": "1622", "attributes": {"size": null, "type": "arrow"}}, {"key": "1617", "source": "1619", "target": "1623", "attributes": {"size": null, "type": "arrow"}}, {"key": "1618", "source": "1619", "target": "1624", "attributes": {"size": null, "type": "arrow"}}, {"key": "1619", "source": "1619", "target": "1625", "attributes": {"size": null, "type": "arrow"}}, {"key": "1620", "source": "1619", "target": "1626", "attributes": {"size": null, "type": "arrow"}}, {"key": "1621", "source": "1619", "target": "1627", "attributes": {"size": null, "type": "arrow"}}, {"key": "1622", "source": "1628", "target": "1630", "attributes": {"size": null, "type": "arrow"}}, {"key": "1623", "source": "1628", "target": "1629", "attributes": {"size": null, "type": "arrow"}}, {"key": "1624", "source": "1631", "target": "910", "attributes": {"size": null, "type": "arrow"}}, {"key": "1625", "source": "1631", "target": "1024", "attributes": {"size": null, "type": "arrow"}}, {"key": "1626", "source": "1631", "target": "1632", "attributes": {"size": null, "type": "arrow"}}, {"key": "1627", "source": "1631", "target": "1633", "attributes": {"size": null, "type": "arrow"}}, {"key": "1628", "source": "1631", "target": "1634", "attributes": {"size": null, "type": "arrow"}}, {"key": "1629", "source": "1631", "target": "1635", "attributes": {"size": null, "type": "arrow"}}, {"key": "1630", "source": "1631", "target": "1636", "attributes": {"size": null, "type": "arrow"}}, {"key": "1631", "source": "1631", "target": "1637", "attributes": {"size": null, "type": "arrow"}}, {"key": "1632", "source": "1631", "target": "1638", "attributes": {"size": null, "type": "arrow"}}, {"key": "1633", "source": "1631", "target": "1639", "attributes": {"size": null, "type": "arrow"}}, {"key": "1634", "source": "1631", "target": "1640", "attributes": {"size": null, "type": "arrow"}}, {"key": "1635", "source": "1631", "target": "1641", "attributes": {"size": null, "type": "arrow"}}, {"key": "1636", "source": "1631", "target": "1642", "attributes": {"size": null, "type": "arrow"}}, {"key": "1637", "source": "1631", "target": "1643", "attributes": {"size": null, "type": "arrow"}}, {"key": "1638", "source": "1631", "target": "1644", "attributes": {"size": null, "type": "arrow"}}, {"key": "1639", "source": "1631", "target": "1645", "attributes": {"size": null, "type": "arrow"}}, {"key": "1640", "source": "1631", "target": "1646", "attributes": {"size": null, "type": "arrow"}}, {"key": "1641", "source": "1631", "target": "1647", "attributes": {"size": null, "type": "arrow"}}, {"key": "1642", "source": "1631", "target": "1648", "attributes": {"size": null, "type": "arrow"}}, {"key": "1643", "source": "1631", "target": "1649", "attributes": {"size": null, "type": "arrow"}}, {"key": "1644", "source": "1631", "target": "1650", "attributes": {"size": null, "type": "arrow"}}, {"key": "1645", "source": "1631", "target": "1651", "attributes": {"size": null, "type": "arrow"}}, {"key": "1646", "source": "1631", "target": "1652", "attributes": {"size": null, "type": "arrow"}}, {"key": "1647", "source": "1631", "target": "1653", "attributes": {"size": null, "type": "arrow"}}, {"key": "1648", "source": "1631", "target": "1415", "attributes": {"size": null, "type": "arrow"}}, {"key": "1649", "source": "1654", "target": "1655", "attributes": {"size": null, "type": "arrow"}}, {"key": "1650", "source": "1654", "target": "1656", "attributes": {"size": null, "type": "arrow"}}, {"key": "1651", "source": "1654", "target": "1657", "attributes": {"size": null, "type": "arrow"}}, {"key": "1652", "source": "1654", "target": "1658", "attributes": {"size": null, "type": "arrow"}}, {"key": "1653", "source": "1654", "target": "734", "attributes": {"size": null, "type": "arrow"}}, {"key": "1654", "source": "1654", "target": "1659", "attributes": {"size": null, "type": "arrow"}}, {"key": "1655", "source": "1654", "target": "1660", "attributes": {"size": null, "type": "arrow"}}, {"key": "1656", "source": "1654", "target": "1661", "attributes": {"size": null, "type": "arrow"}}, {"key": "1657", "source": "1654", "target": "1662", "attributes": {"size": null, "type": "arrow"}}, {"key": "1658", "source": "1654", "target": "350", "attributes": {"size": null, "type": "arrow"}}, {"key": "1659", "source": "1654", "target": "1663", "attributes": {"size": null, "type": "arrow"}}, {"key": "1660", "source": "1654", "target": "1664", "attributes": {"size": null, "type": "arrow"}}, {"key": "1661", "source": "1654", "target": "1665", "attributes": {"size": null, "type": "arrow"}}, {"key": "1662", "source": "1654", "target": "1666", "attributes": {"size": null, "type": "arrow"}}, {"key": "1663", "source": "1654", "target": "1667", "attributes": {"size": null, "type": "arrow"}}, {"key": "1664", "source": "1668", "target": "713", "attributes": {"size": null, "type": "arrow"}}, {"key": "1665", "source": "1668", "target": "1669", "attributes": {"size": null, "type": "arrow"}}, {"key": "1666", "source": "1668", "target": "1670", "attributes": {"size": null, "type": "arrow"}}, {"key": "1667", "source": "1668", "target": "1671", "attributes": {"size": null, "type": "arrow"}}, {"key": "1668", "source": "1668", "target": "1672", "attributes": {"size": null, "type": "arrow"}}, {"key": "1669", "source": "1668", "target": "1673", "attributes": {"size": null, "type": "arrow"}}, {"key": "1670", "source": "1668", "target": "1674", "attributes": {"size": null, "type": "arrow"}}, {"key": "1671", "source": "1668", "target": "1675", "attributes": {"size": null, "type": "arrow"}}, {"key": "1672", "source": "1668", "target": "1676", "attributes": {"size": null, "type": "arrow"}}, {"key": "1673", "source": "1668", "target": "1677", "attributes": {"size": null, "type": "arrow"}}, {"key": "1674", "source": "1668", "target": "1678", "attributes": {"size": null, "type": "arrow"}}, {"key": "1675", "source": "1668", "target": "1679", "attributes": {"size": null, "type": "arrow"}}, {"key": "1676", "source": "1668", "target": "1680", "attributes": {"size": null, "type": "arrow"}}, {"key": "1677", "source": "1668", "target": "1681", "attributes": {"size": null, "type": "arrow"}}, {"key": "1678", "source": "1668", "target": "1682", "attributes": {"size": null, "type": "arrow"}}, {"key": "1679", "source": "1668", "target": "1683", "attributes": {"size": null, "type": "arrow"}}, {"key": "1680", "source": "1668", "target": "1684", "attributes": {"size": null, "type": "arrow"}}, {"key": "1681", "source": "1668", "target": "1685", "attributes": {"size": null, "type": "arrow"}}, {"key": "1682", "source": "1668", "target": "1686", "attributes": {"size": null, "type": "arrow"}}, {"key": "1683", "source": "1668", "target": "1687", "attributes": {"size": null, "type": "arrow"}}, {"key": "1684", "source": "1668", "target": "1688", "attributes": {"size": null, "type": "arrow"}}, {"key": "1685", "source": "1668", "target": "1689", "attributes": {"size": null, "type": "arrow"}}, {"key": "1686", "source": "1668", "target": "1690", "attributes": {"size": null, "type": "arrow"}}, {"key": "1687", "source": "1668", "target": "1691", "attributes": {"size": null, "type": "arrow"}}, {"key": "1688", "source": "1668", "target": "1692", "attributes": {"size": null, "type": "arrow"}}, {"key": "1689", "source": "1668", "target": "1693", "attributes": {"size": null, "type": "arrow"}}, {"key": "1690", "source": "1668", "target": "1694", "attributes": {"size": null, "type": "arrow"}}, {"key": "1691", "source": "1668", "target": "1695", "attributes": {"size": null, "type": "arrow"}}, {"key": "1692", "source": "1668", "target": "1696", "attributes": {"size": null, "type": "arrow"}}, {"key": "1693", "source": "1668", "target": "1697", "attributes": {"size": null, "type": "arrow"}}, {"key": "1694", "source": "1668", "target": "1698", "attributes": {"size": null, "type": "arrow"}}, {"key": "1695", "source": "1668", "target": "1699", "attributes": {"size": null, "type": "arrow"}}, {"key": "1696", "source": "1668", "target": "1700", "attributes": {"size": null, "type": "arrow"}}, {"key": "1697", "source": "1668", "target": "1701", "attributes": {"size": null, "type": "arrow"}}, {"key": "1698", "source": "1668", "target": "1702", "attributes": {"size": null, "type": "arrow"}}, {"key": "1699", "source": "1668", "target": "1703", "attributes": {"size": null, "type": "arrow"}}, {"key": "1700", "source": "1668", "target": "1704", "attributes": {"size": null, "type": "arrow"}}, {"key": "1701", "source": "1668", "target": "1705", "attributes": {"size": null, "type": "arrow"}}, {"key": "1702", "source": "1668", "target": "1706", "attributes": {"size": null, "type": "arrow"}}, {"key": "1703", "source": "1668", "target": "1707", "attributes": {"size": null, "type": "arrow"}}, {"key": "1704", "source": "1668", "target": "1708", "attributes": {"size": null, "type": "arrow"}}, {"key": "1705", "source": "1668", "target": "1709", "attributes": {"size": null, "type": "arrow"}}, {"key": "1706", "source": "1668", "target": "1710", "attributes": {"size": null, "type": "arrow"}}, {"key": "1707", "source": "1668", "target": "1711", "attributes": {"size": null, "type": "arrow"}}, {"key": "1708", "source": "1668", "target": "1712", "attributes": {"size": null, "type": "arrow"}}, {"key": "1709", "source": "1668", "target": "1713", "attributes": {"size": null, "type": "arrow"}}, {"key": "1710", "source": "1668", "target": "1714", "attributes": {"size": null, "type": "arrow"}}, {"key": "1711", "source": "1668", "target": "1715", "attributes": {"size": null, "type": "arrow"}}, {"key": "1712", "source": "1716", "target": "1719", "attributes": {"size": null, "type": "arrow"}}, {"key": "1713", "source": "1716", "target": "1720", "attributes": {"size": null, "type": "arrow"}}, {"key": "1714", "source": "1716", "target": "1717", "attributes": {"size": null, "type": "arrow"}}, {"key": "1715", "source": "1716", "target": "1718", "attributes": {"size": null, "type": "arrow"}}, {"key": "1716", "source": "1721", "target": "1975", "attributes": {"size": null, "type": "arrow"}}, {"key": "1717", "source": "1721", "target": "1976", "attributes": {"size": null, "type": "arrow"}}, {"key": "1718", "source": "1721", "target": "1977", "attributes": {"size": null, "type": "arrow"}}, {"key": "1719", "source": "1721", "target": "1978", "attributes": {"size": null, "type": "arrow"}}, {"key": "1720", "source": "1721", "target": "1979", "attributes": {"size": null, "type": "arrow"}}, {"key": "1721", "source": "1721", "target": "1980", "attributes": {"size": null, "type": "arrow"}}, {"key": "1722", "source": "1721", "target": "1981", "attributes": {"size": null, "type": "arrow"}}, {"key": "1723", "source": "1721", "target": "1021", "attributes": {"size": null, "type": "arrow"}}, {"key": "1724", "source": "1721", "target": "1982", "attributes": {"size": null, "type": "arrow"}}, {"key": "1725", "source": "1721", "target": "1983", "attributes": {"size": null, "type": "arrow"}}, {"key": "1726", "source": "1721", "target": "1984", "attributes": {"size": null, "type": "arrow"}}, {"key": "1727", "source": "1721", "target": "1985", "attributes": {"size": null, "type": "arrow"}}, {"key": "1728", "source": "1721", "target": "1986", "attributes": {"size": null, "type": "arrow"}}, {"key": "1729", "source": "1721", "target": "1987", "attributes": {"size": null, "type": "arrow"}}, {"key": "1730", "source": "1721", "target": "1988", "attributes": {"size": null, "type": "arrow"}}, {"key": "1731", "source": "1721", "target": "1989", "attributes": {"size": null, "type": "arrow"}}, {"key": "1732", "source": "1721", "target": "1990", "attributes": {"size": null, "type": "arrow"}}, {"key": "1733", "source": "1721", "target": "1991", "attributes": {"size": null, "type": "arrow"}}, {"key": "1734", "source": "1721", "target": "1992", "attributes": {"size": null, "type": "arrow"}}, {"key": "1735", "source": "1721", "target": "1993", "attributes": {"size": null, "type": "arrow"}}, {"key": "1736", "source": "1721", "target": "1994", "attributes": {"size": null, "type": "arrow"}}, {"key": "1737", "source": "1721", "target": "916", "attributes": {"size": null, "type": "arrow"}}, {"key": "1738", "source": "1721", "target": "355", "attributes": {"size": null, "type": "arrow"}}, {"key": "1739", "source": "1721", "target": "1722", "attributes": {"size": null, "type": "arrow"}}, {"key": "1740", "source": "1721", "target": "1723", "attributes": {"size": null, "type": "arrow"}}, {"key": "1741", "source": "1721", "target": "1724", "attributes": {"size": null, "type": "arrow"}}, {"key": "1742", "source": "1721", "target": "1725", "attributes": {"size": null, "type": "arrow"}}, {"key": "1743", "source": "1721", "target": "1726", "attributes": {"size": null, "type": "arrow"}}, {"key": "1744", "source": "1721", "target": "1727", "attributes": {"size": null, "type": "arrow"}}, {"key": "1745", "source": "1721", "target": "1728", "attributes": {"size": null, "type": "arrow"}}, {"key": "1746", "source": "1721", "target": "1729", "attributes": {"size": null, "type": "arrow"}}, {"key": "1747", "source": "1721", "target": "1730", "attributes": {"size": null, "type": "arrow"}}, {"key": "1748", "source": "1721", "target": "1731", "attributes": {"size": null, "type": "arrow"}}, {"key": "1749", "source": "1721", "target": "1732", "attributes": {"size": null, "type": "arrow"}}, {"key": "1750", "source": "1721", "target": "1733", "attributes": {"size": null, "type": "arrow"}}, {"key": "1751", "source": "1721", "target": "1734", "attributes": {"size": null, "type": "arrow"}}, {"key": "1752", "source": "1721", "target": "1735", "attributes": {"size": null, "type": "arrow"}}, {"key": "1753", "source": "1721", "target": "1736", "attributes": {"size": null, "type": "arrow"}}, {"key": "1754", "source": "1721", "target": "1737", "attributes": {"size": null, "type": "arrow"}}, {"key": "1755", "source": "1721", "target": "1738", "attributes": {"size": null, "type": "arrow"}}, {"key": "1756", "source": "1721", "target": "1739", "attributes": {"size": null, "type": "arrow"}}, {"key": "1757", "source": "1721", "target": "1740", "attributes": {"size": null, "type": "arrow"}}, {"key": "1758", "source": "1721", "target": "1741", "attributes": {"size": null, "type": "arrow"}}, {"key": "1759", "source": "1721", "target": "1742", "attributes": {"size": null, "type": "arrow"}}, {"key": "1760", "source": "1721", "target": "1743", "attributes": {"size": null, "type": "arrow"}}, {"key": "1761", "source": "1721", "target": "1744", "attributes": {"size": null, "type": "arrow"}}, {"key": "1762", "source": "1721", "target": "1745", "attributes": {"size": null, "type": "arrow"}}, {"key": "1763", "source": "1721", "target": "1746", "attributes": {"size": null, "type": "arrow"}}, {"key": "1764", "source": "1721", "target": "1747", "attributes": {"size": null, "type": "arrow"}}, {"key": "1765", "source": "1721", "target": "1748", "attributes": {"size": null, "type": "arrow"}}, {"key": "1766", "source": "1721", "target": "1749", "attributes": {"size": null, "type": "arrow"}}, {"key": "1767", "source": "1721", "target": "1750", "attributes": {"size": null, "type": "arrow"}}, {"key": "1768", "source": "1721", "target": "1751", "attributes": {"size": null, "type": "arrow"}}, {"key": "1769", "source": "1721", "target": "1752", "attributes": {"size": null, "type": "arrow"}}, {"key": "1770", "source": "1721", "target": "1753", "attributes": {"size": null, "type": "arrow"}}, {"key": "1771", "source": "1721", "target": "1754", "attributes": {"size": null, "type": "arrow"}}, {"key": "1772", "source": "1721", "target": "1755", "attributes": {"size": null, "type": "arrow"}}, {"key": "1773", "source": "1721", "target": "1756", "attributes": {"size": null, "type": "arrow"}}, {"key": "1774", "source": "1721", "target": "1757", "attributes": {"size": null, "type": "arrow"}}, {"key": "1775", "source": "1721", "target": "1758", "attributes": {"size": null, "type": "arrow"}}, {"key": "1776", "source": "1721", "target": "1759", "attributes": {"size": null, "type": "arrow"}}, {"key": "1777", "source": "1721", "target": "1760", "attributes": {"size": null, "type": "arrow"}}, {"key": "1778", "source": "1721", "target": "1761", "attributes": {"size": null, "type": "arrow"}}, {"key": "1779", "source": "1721", "target": "1762", "attributes": {"size": null, "type": "arrow"}}, {"key": "1780", "source": "1721", "target": "1763", "attributes": {"size": null, "type": "arrow"}}, {"key": "1781", "source": "1721", "target": "1764", "attributes": {"size": null, "type": "arrow"}}, {"key": "1782", "source": "1721", "target": "1765", "attributes": {"size": null, "type": "arrow"}}, {"key": "1783", "source": "1721", "target": "1766", "attributes": {"size": null, "type": "arrow"}}, {"key": "1784", "source": "1721", "target": "1767", "attributes": {"size": null, "type": "arrow"}}, {"key": "1785", "source": "1721", "target": "1768", "attributes": {"size": null, "type": "arrow"}}, {"key": "1786", "source": "1721", "target": "1769", "attributes": {"size": null, "type": "arrow"}}, {"key": "1787", "source": "1721", "target": "1770", "attributes": {"size": null, "type": "arrow"}}, {"key": "1788", "source": "1721", "target": "1771", "attributes": {"size": null, "type": "arrow"}}, {"key": "1789", "source": "1721", "target": "1772", "attributes": {"size": null, "type": "arrow"}}, {"key": "1790", "source": "1721", "target": "1773", "attributes": {"size": null, "type": "arrow"}}, {"key": "1791", "source": "1721", "target": "1774", "attributes": {"size": null, "type": "arrow"}}, {"key": "1792", "source": "1721", "target": "1775", "attributes": {"size": null, "type": "arrow"}}, {"key": "1793", "source": "1721", "target": "1776", "attributes": {"size": null, "type": "arrow"}}, {"key": "1794", "source": "1721", "target": "1777", "attributes": {"size": null, "type": "arrow"}}, {"key": "1795", "source": "1721", "target": "1778", "attributes": {"size": null, "type": "arrow"}}, {"key": "1796", "source": "1721", "target": "1779", "attributes": {"size": null, "type": "arrow"}}, {"key": "1797", "source": "1721", "target": "1780", "attributes": {"size": null, "type": "arrow"}}, {"key": "1798", "source": "1721", "target": "1781", "attributes": {"size": null, "type": "arrow"}}, {"key": "1799", "source": "1721", "target": "1782", "attributes": {"size": null, "type": "arrow"}}, {"key": "1800", "source": "1721", "target": "1783", "attributes": {"size": null, "type": "arrow"}}, {"key": "1801", "source": "1721", "target": "1784", "attributes": {"size": null, "type": "arrow"}}, {"key": "1802", "source": "1721", "target": "1785", "attributes": {"size": null, "type": "arrow"}}, {"key": "1803", "source": "1721", "target": "1786", "attributes": {"size": null, "type": "arrow"}}, {"key": "1804", "source": "1721", "target": "1787", "attributes": {"size": null, "type": "arrow"}}, {"key": "1805", "source": "1721", "target": "1788", "attributes": {"size": null, "type": "arrow"}}, {"key": "1806", "source": "1721", "target": "1789", "attributes": {"size": null, "type": "arrow"}}, {"key": "1807", "source": "1721", "target": "1790", "attributes": {"size": null, "type": "arrow"}}, {"key": "1808", "source": "1721", "target": "1791", "attributes": {"size": null, "type": "arrow"}}, {"key": "1809", "source": "1721", "target": "1792", "attributes": {"size": null, "type": "arrow"}}, {"key": "1810", "source": "1721", "target": "1793", "attributes": {"size": null, "type": "arrow"}}, {"key": "1811", "source": "1721", "target": "1794", "attributes": {"size": null, "type": "arrow"}}, {"key": "1812", "source": "1721", "target": "1795", "attributes": {"size": null, "type": "arrow"}}, {"key": "1813", "source": "1721", "target": "1796", "attributes": {"size": null, "type": "arrow"}}, {"key": "1814", "source": "1721", "target": "1797", "attributes": {"size": null, "type": "arrow"}}, {"key": "1815", "source": "1721", "target": "1798", "attributes": {"size": null, "type": "arrow"}}, {"key": "1816", "source": "1721", "target": "1799", "attributes": {"size": null, "type": "arrow"}}, {"key": "1817", "source": "1721", "target": "1800", "attributes": {"size": null, "type": "arrow"}}, {"key": "1818", "source": "1721", "target": "1801", "attributes": {"size": null, "type": "arrow"}}, {"key": "1819", "source": "1721", "target": "1802", "attributes": {"size": null, "type": "arrow"}}, {"key": "1820", "source": "1721", "target": "1803", "attributes": {"size": null, "type": "arrow"}}, {"key": "1821", "source": "1721", "target": "1804", "attributes": {"size": null, "type": "arrow"}}, {"key": "1822", "source": "1721", "target": "1805", "attributes": {"size": null, "type": "arrow"}}, {"key": "1823", "source": "1721", "target": "1806", "attributes": {"size": null, "type": "arrow"}}, {"key": "1824", "source": "1721", "target": "1807", "attributes": {"size": null, "type": "arrow"}}, {"key": "1825", "source": "1721", "target": "1808", "attributes": {"size": null, "type": "arrow"}}, {"key": "1826", "source": "1721", "target": "1809", "attributes": {"size": null, "type": "arrow"}}, {"key": "1827", "source": "1721", "target": "1810", "attributes": {"size": null, "type": "arrow"}}, {"key": "1828", "source": "1721", "target": "1811", "attributes": {"size": null, "type": "arrow"}}, {"key": "1829", "source": "1721", "target": "1812", "attributes": {"size": null, "type": "arrow"}}, {"key": "1830", "source": "1721", "target": "1813", "attributes": {"size": null, "type": "arrow"}}, {"key": "1831", "source": "1721", "target": "1814", "attributes": {"size": null, "type": "arrow"}}, {"key": "1832", "source": "1721", "target": "1815", "attributes": {"size": null, "type": "arrow"}}, {"key": "1833", "source": "1721", "target": "1816", "attributes": {"size": null, "type": "arrow"}}, {"key": "1834", "source": "1721", "target": "1817", "attributes": {"size": null, "type": "arrow"}}, {"key": "1835", "source": "1721", "target": "1818", "attributes": {"size": null, "type": "arrow"}}, {"key": "1836", "source": "1721", "target": "1819", "attributes": {"size": null, "type": "arrow"}}, {"key": "1837", "source": "1721", "target": "1820", "attributes": {"size": null, "type": "arrow"}}, {"key": "1838", "source": "1721", "target": "1821", "attributes": {"size": null, "type": "arrow"}}, {"key": "1839", "source": "1721", "target": "1822", "attributes": {"size": null, "type": "arrow"}}, {"key": "1840", "source": "1721", "target": "1823", "attributes": {"size": null, "type": "arrow"}}, {"key": "1841", "source": "1721", "target": "1824", "attributes": {"size": null, "type": "arrow"}}, {"key": "1842", "source": "1721", "target": "1825", "attributes": {"size": null, "type": "arrow"}}, {"key": "1843", "source": "1721", "target": "1826", "attributes": {"size": null, "type": "arrow"}}, {"key": "1844", "source": "1721", "target": "1827", "attributes": {"size": null, "type": "arrow"}}, {"key": "1845", "source": "1721", "target": "1828", "attributes": {"size": null, "type": "arrow"}}, {"key": "1846", "source": "1721", "target": "1829", "attributes": {"size": null, "type": "arrow"}}, {"key": "1847", "source": "1721", "target": "1830", "attributes": {"size": null, "type": "arrow"}}, {"key": "1848", "source": "1721", "target": "1831", "attributes": {"size": null, "type": "arrow"}}, {"key": "1849", "source": "1721", "target": "1832", "attributes": {"size": null, "type": "arrow"}}, {"key": "1850", "source": "1721", "target": "1833", "attributes": {"size": null, "type": "arrow"}}, {"key": "1851", "source": "1721", "target": "1834", "attributes": {"size": null, "type": "arrow"}}, {"key": "1852", "source": "1721", "target": "1835", "attributes": {"size": null, "type": "arrow"}}, {"key": "1853", "source": "1721", "target": "1836", "attributes": {"size": null, "type": "arrow"}}, {"key": "1854", "source": "1721", "target": "1837", "attributes": {"size": null, "type": "arrow"}}, {"key": "1855", "source": "1721", "target": "1838", "attributes": {"size": null, "type": "arrow"}}, {"key": "1856", "source": "1721", "target": "1839", "attributes": {"size": null, "type": "arrow"}}, {"key": "1857", "source": "1721", "target": "1840", "attributes": {"size": null, "type": "arrow"}}, {"key": "1858", "source": "1721", "target": "1841", "attributes": {"size": null, "type": "arrow"}}, {"key": "1859", "source": "1721", "target": "1842", "attributes": {"size": null, "type": "arrow"}}, {"key": "1860", "source": "1721", "target": "1843", "attributes": {"size": null, "type": "arrow"}}, {"key": "1861", "source": "1721", "target": "1844", "attributes": {"size": null, "type": "arrow"}}, {"key": "1862", "source": "1721", "target": "1845", "attributes": {"size": null, "type": "arrow"}}, {"key": "1863", "source": "1721", "target": "1846", "attributes": {"size": null, "type": "arrow"}}, {"key": "1864", "source": "1721", "target": "1847", "attributes": {"size": null, "type": "arrow"}}, {"key": "1865", "source": "1721", "target": "1848", "attributes": {"size": null, "type": "arrow"}}, {"key": "1866", "source": "1721", "target": "1849", "attributes": {"size": null, "type": "arrow"}}, {"key": "1867", "source": "1721", "target": "1850", "attributes": {"size": null, "type": "arrow"}}, {"key": "1868", "source": "1721", "target": "1851", "attributes": {"size": null, "type": "arrow"}}, {"key": "1869", "source": "1721", "target": "1852", "attributes": {"size": null, "type": "arrow"}}, {"key": "1870", "source": "1721", "target": "1853", "attributes": {"size": null, "type": "arrow"}}, {"key": "1871", "source": "1721", "target": "1854", "attributes": {"size": null, "type": "arrow"}}, {"key": "1872", "source": "1721", "target": "1855", "attributes": {"size": null, "type": "arrow"}}, {"key": "1873", "source": "1721", "target": "1856", "attributes": {"size": null, "type": "arrow"}}, {"key": "1874", "source": "1721", "target": "1857", "attributes": {"size": null, "type": "arrow"}}, {"key": "1875", "source": "1721", "target": "1858", "attributes": {"size": null, "type": "arrow"}}, {"key": "1876", "source": "1721", "target": "1859", "attributes": {"size": null, "type": "arrow"}}, {"key": "1877", "source": "1721", "target": "1860", "attributes": {"size": null, "type": "arrow"}}, {"key": "1878", "source": "1721", "target": "1861", "attributes": {"size": null, "type": "arrow"}}, {"key": "1879", "source": "1721", "target": "1862", "attributes": {"size": null, "type": "arrow"}}, {"key": "1880", "source": "1721", "target": "1863", "attributes": {"size": null, "type": "arrow"}}, {"key": "1881", "source": "1721", "target": "1864", "attributes": {"size": null, "type": "arrow"}}, {"key": "1882", "source": "1721", "target": "1865", "attributes": {"size": null, "type": "arrow"}}, {"key": "1883", "source": "1721", "target": "1866", "attributes": {"size": null, "type": "arrow"}}, {"key": "1884", "source": "1721", "target": "1867", "attributes": {"size": null, "type": "arrow"}}, {"key": "1885", "source": "1721", "target": "1868", "attributes": {"size": null, "type": "arrow"}}, {"key": "1886", "source": "1721", "target": "1869", "attributes": {"size": null, "type": "arrow"}}, {"key": "1887", "source": "1721", "target": "1870", "attributes": {"size": null, "type": "arrow"}}, {"key": "1888", "source": "1721", "target": "1871", "attributes": {"size": null, "type": "arrow"}}, {"key": "1889", "source": "1721", "target": "1872", "attributes": {"size": null, "type": "arrow"}}, {"key": "1890", "source": "1721", "target": "1873", "attributes": {"size": null, "type": "arrow"}}, {"key": "1891", "source": "1721", "target": "1874", "attributes": {"size": null, "type": "arrow"}}, {"key": "1892", "source": "1721", "target": "1875", "attributes": {"size": null, "type": "arrow"}}, {"key": "1893", "source": "1721", "target": "1876", "attributes": {"size": null, "type": "arrow"}}, {"key": "1894", "source": "1721", "target": "1877", "attributes": {"size": null, "type": "arrow"}}, {"key": "1895", "source": "1721", "target": "1878", "attributes": {"size": null, "type": "arrow"}}, {"key": "1896", "source": "1721", "target": "1879", "attributes": {"size": null, "type": "arrow"}}, {"key": "1897", "source": "1721", "target": "1880", "attributes": {"size": null, "type": "arrow"}}, {"key": "1898", "source": "1721", "target": "1881", "attributes": {"size": null, "type": "arrow"}}, {"key": "1899", "source": "1721", "target": "1882", "attributes": {"size": null, "type": "arrow"}}, {"key": "1900", "source": "1721", "target": "1883", "attributes": {"size": null, "type": "arrow"}}, {"key": "1901", "source": "1721", "target": "1884", "attributes": {"size": null, "type": "arrow"}}, {"key": "1902", "source": "1721", "target": "1885", "attributes": {"size": null, "type": "arrow"}}, {"key": "1903", "source": "1721", "target": "1886", "attributes": {"size": null, "type": "arrow"}}, {"key": "1904", "source": "1721", "target": "1887", "attributes": {"size": null, "type": "arrow"}}, {"key": "1905", "source": "1721", "target": "1888", "attributes": {"size": null, "type": "arrow"}}, {"key": "1906", "source": "1721", "target": "1889", "attributes": {"size": null, "type": "arrow"}}, {"key": "1907", "source": "1721", "target": "1890", "attributes": {"size": null, "type": "arrow"}}, {"key": "1908", "source": "1721", "target": "1891", "attributes": {"size": null, "type": "arrow"}}, {"key": "1909", "source": "1721", "target": "1892", "attributes": {"size": null, "type": "arrow"}}, {"key": "1910", "source": "1721", "target": "1893", "attributes": {"size": null, "type": "arrow"}}, {"key": "1911", "source": "1721", "target": "1894", "attributes": {"size": null, "type": "arrow"}}, {"key": "1912", "source": "1721", "target": "1895", "attributes": {"size": null, "type": "arrow"}}, {"key": "1913", "source": "1721", "target": "1896", "attributes": {"size": null, "type": "arrow"}}, {"key": "1914", "source": "1721", "target": "1897", "attributes": {"size": null, "type": "arrow"}}, {"key": "1915", "source": "1721", "target": "1898", "attributes": {"size": null, "type": "arrow"}}, {"key": "1916", "source": "1721", "target": "1899", "attributes": {"size": null, "type": "arrow"}}, {"key": "1917", "source": "1721", "target": "1900", "attributes": {"size": null, "type": "arrow"}}, {"key": "1918", "source": "1721", "target": "1901", "attributes": {"size": null, "type": "arrow"}}, {"key": "1919", "source": "1721", "target": "1902", "attributes": {"size": null, "type": "arrow"}}, {"key": "1920", "source": "1721", "target": "1903", "attributes": {"size": null, "type": "arrow"}}, {"key": "1921", "source": "1721", "target": "1904", "attributes": {"size": null, "type": "arrow"}}, {"key": "1922", "source": "1721", "target": "1905", "attributes": {"size": null, "type": "arrow"}}, {"key": "1923", "source": "1721", "target": "1906", "attributes": {"size": null, "type": "arrow"}}, {"key": "1924", "source": "1721", "target": "1907", "attributes": {"size": null, "type": "arrow"}}, {"key": "1925", "source": "1721", "target": "1908", "attributes": {"size": null, "type": "arrow"}}, {"key": "1926", "source": "1721", "target": "1909", "attributes": {"size": null, "type": "arrow"}}, {"key": "1927", "source": "1721", "target": "1910", "attributes": {"size": null, "type": "arrow"}}, {"key": "1928", "source": "1721", "target": "1911", "attributes": {"size": null, "type": "arrow"}}, {"key": "1929", "source": "1721", "target": "1912", "attributes": {"size": null, "type": "arrow"}}, {"key": "1930", "source": "1721", "target": "1913", "attributes": {"size": null, "type": "arrow"}}, {"key": "1931", "source": "1721", "target": "1914", "attributes": {"size": null, "type": "arrow"}}, {"key": "1932", "source": "1721", "target": "1915", "attributes": {"size": null, "type": "arrow"}}, {"key": "1933", "source": "1721", "target": "1916", "attributes": {"size": null, "type": "arrow"}}, {"key": "1934", "source": "1721", "target": "1917", "attributes": {"size": null, "type": "arrow"}}, {"key": "1935", "source": "1721", "target": "1918", "attributes": {"size": null, "type": "arrow"}}, {"key": "1936", "source": "1721", "target": "1919", "attributes": {"size": null, "type": "arrow"}}, {"key": "1937", "source": "1721", "target": "1920", "attributes": {"size": null, "type": "arrow"}}, {"key": "1938", "source": "1721", "target": "1921", "attributes": {"size": null, "type": "arrow"}}, {"key": "1939", "source": "1721", "target": "1922", "attributes": {"size": null, "type": "arrow"}}, {"key": "1940", "source": "1721", "target": "1923", "attributes": {"size": null, "type": "arrow"}}, {"key": "1941", "source": "1721", "target": "1924", "attributes": {"size": null, "type": "arrow"}}, {"key": "1942", "source": "1721", "target": "1925", "attributes": {"size": null, "type": "arrow"}}, {"key": "1943", "source": "1721", "target": "1926", "attributes": {"size": null, "type": "arrow"}}, {"key": "1944", "source": "1721", "target": "1927", "attributes": {"size": null, "type": "arrow"}}, {"key": "1945", "source": "1721", "target": "1928", "attributes": {"size": null, "type": "arrow"}}, {"key": "1946", "source": "1721", "target": "1929", "attributes": {"size": null, "type": "arrow"}}, {"key": "1947", "source": "1721", "target": "1930", "attributes": {"size": null, "type": "arrow"}}, {"key": "1948", "source": "1721", "target": "1931", "attributes": {"size": null, "type": "arrow"}}, {"key": "1949", "source": "1721", "target": "1932", "attributes": {"size": null, "type": "arrow"}}, {"key": "1950", "source": "1721", "target": "1933", "attributes": {"size": null, "type": "arrow"}}, {"key": "1951", "source": "1721", "target": "1934", "attributes": {"size": null, "type": "arrow"}}, {"key": "1952", "source": "1721", "target": "1935", "attributes": {"size": null, "type": "arrow"}}, {"key": "1953", "source": "1721", "target": "1936", "attributes": {"size": null, "type": "arrow"}}, {"key": "1954", "source": "1721", "target": "1937", "attributes": {"size": null, "type": "arrow"}}, {"key": "1955", "source": "1721", "target": "1938", "attributes": {"size": null, "type": "arrow"}}, {"key": "1956", "source": "1721", "target": "1939", "attributes": {"size": null, "type": "arrow"}}, {"key": "1957", "source": "1721", "target": "1940", "attributes": {"size": null, "type": "arrow"}}, {"key": "1958", "source": "1721", "target": "1941", "attributes": {"size": null, "type": "arrow"}}, {"key": "1959", "source": "1721", "target": "1942", "attributes": {"size": null, "type": "arrow"}}, {"key": "1960", "source": "1721", "target": "1943", "attributes": {"size": null, "type": "arrow"}}, {"key": "1961", "source": "1721", "target": "1944", "attributes": {"size": null, "type": "arrow"}}, {"key": "1962", "source": "1721", "target": "1945", "attributes": {"size": null, "type": "arrow"}}, {"key": "1963", "source": "1721", "target": "1946", "attributes": {"size": null, "type": "arrow"}}, {"key": "1964", "source": "1721", "target": "1947", "attributes": {"size": null, "type": "arrow"}}, {"key": "1965", "source": "1721", "target": "1948", "attributes": {"size": null, "type": "arrow"}}, {"key": "1966", "source": "1721", "target": "1949", "attributes": {"size": null, "type": "arrow"}}, {"key": "1967", "source": "1721", "target": "1950", "attributes": {"size": null, "type": "arrow"}}, {"key": "1968", "source": "1721", "target": "1951", "attributes": {"size": null, "type": "arrow"}}, {"key": "1969", "source": "1721", "target": "1952", "attributes": {"size": null, "type": "arrow"}}, {"key": "1970", "source": "1721", "target": "1953", "attributes": {"size": null, "type": "arrow"}}, {"key": "1971", "source": "1721", "target": "1954", "attributes": {"size": null, "type": "arrow"}}, {"key": "1972", "source": "1721", "target": "1955", "attributes": {"size": null, "type": "arrow"}}, {"key": "1973", "source": "1721", "target": "1956", "attributes": {"size": null, "type": "arrow"}}, {"key": "1974", "source": "1721", "target": "1957", "attributes": {"size": null, "type": "arrow"}}, {"key": "1975", "source": "1721", "target": "1958", "attributes": {"size": null, "type": "arrow"}}, {"key": "1976", "source": "1721", "target": "1959", "attributes": {"size": null, "type": "arrow"}}, {"key": "1977", "source": "1721", "target": "1960", "attributes": {"size": null, "type": "arrow"}}, {"key": "1978", "source": "1721", "target": "1961", "attributes": {"size": null, "type": "arrow"}}, {"key": "1979", "source": "1721", "target": "1962", "attributes": {"size": null, "type": "arrow"}}, {"key": "1980", "source": "1721", "target": "1963", "attributes": {"size": null, "type": "arrow"}}, {"key": "1981", "source": "1721", "target": "1964", "attributes": {"size": null, "type": "arrow"}}, {"key": "1982", "source": "1721", "target": "1965", "attributes": {"size": null, "type": "arrow"}}, {"key": "1983", "source": "1721", "target": "1966", "attributes": {"size": null, "type": "arrow"}}, {"key": "1984", "source": "1721", "target": "1967", "attributes": {"size": null, "type": "arrow"}}, {"key": "1985", "source": "1721", "target": "1968", "attributes": {"size": null, "type": "arrow"}}, {"key": "1986", "source": "1721", "target": "1969", "attributes": {"size": null, "type": "arrow"}}, {"key": "1987", "source": "1721", "target": "1970", "attributes": {"size": null, "type": "arrow"}}, {"key": "1988", "source": "1721", "target": "1971", "attributes": {"size": null, "type": "arrow"}}, {"key": "1989", "source": "1721", "target": "1972", "attributes": {"size": null, "type": "arrow"}}, {"key": "1990", "source": "1721", "target": "1973", "attributes": {"size": null, "type": "arrow"}}, {"key": "1991", "source": "1721", "target": "1974", "attributes": {"size": null, "type": "arrow"}}]}